<SEC-DOCUMENT>0001213900-22-047496.txt : 20220812
<SEC-HEADER>0001213900-22-047496.hdr.sgml : 20220812
<ACCEPTANCE-DATETIME>20220812170131
ACCESSION NUMBER:		0001213900-22-047496
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		50
CONFORMED PERIOD OF REPORT:	20220630
FILED AS OF DATE:		20220812
DATE AS OF CHANGE:		20220812

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Actinium Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001388320
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				880378336
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36374
		FILM NUMBER:		221161054

	BUSINESS ADDRESS:	
		STREET 1:		275 MADISON AVENUE, 7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016
		BUSINESS PHONE:		646-677-3875

	MAIL ADDRESS:	
		STREET 1:		275 MADISON AVENUE, 7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cactus Ventures, Inc.
		DATE OF NAME CHANGE:	20070130
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>f10q0622_actiniumpharma.htm
<DESCRIPTION>QUARTERLY REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Aug 12 02:15:32 UTC 2022 -->
<html xmlns:atnm="http://actiniumpharmaceuticals.com/20220630" xmlns:compsci="http://compsciresources.com" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:pf0="http://fasb.org/srt/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:xml="http://www.w3.org/XML/1998/namespace"><head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type" />
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNITED
STATES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Washington,
D.C. 20549</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORM
<ix:nonNumeric contextRef="c0" name="dei:DocumentType">10-Q</ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Mark
One)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonNumeric><b>&#160;&#160;&#160;&#160;QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the quarterly period ended <b><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate">June 30, <ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus">2022</ix:nonNumeric></ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">or</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric><b>&#160;&#160;&#160;&#160;TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the transition period from __________ to __________</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
File Number: <ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber"><b>001-36374</b></ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ACTINIUM
PHARMACEUTICALS, INC.</b></span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; border-bottom: black 1.5pt solid; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Delaware</b></span></ix:nonNumeric></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; border-bottom: black 1.5pt solid; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityTaxIdentificationNumber"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>74-2963609</b></span></ix:nonNumeric></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or Other Jurisdiction of<br/> Incorporation or Organization)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S. Employer<br/> Identification No.)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-bottom: black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>275 Madison Ave, 7<sup>th</sup> Floor</b></span></ix:nonNumeric></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown">New York</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:EntityAddressStateOrProvince">NY</ix:nonNumeric></b></span></p></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10016</b></span></ix:nonNumeric></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of Principal Executive Offices)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="c0" name="dei:CityAreaCode">(646)</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:LocalPhoneNumber">677-3870</ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant&#8217;s
Telephone Number, Including Area Code)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
registered pursuant to Section&#160;12(b) of the Act:</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title of each class</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading Symbol</b>&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of exchange on which registered</b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:Security12bTitle"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common stock, par value $0.001</b></span></ix:nonNumeric></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:TradingSymbol"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ATNM</b></span></ix:nonNumeric></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="c0" name="dei:SecurityExchangeName">NYSE</ix:nonNumeric> American</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. &#9746;&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric>&#160;&#160;&#160;&#160;&#160;No&#160;&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). &#9746;&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric>&#160;&#160;&#160;&#160;&#160;No&#160;&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company,
or an emerging growth company. &#160;See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller
reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; "> <td style="font: 10pt Times New Roman, Times, Serif; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; "> <td style="font: 10pt Times New Roman, Times, Serif"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer</span></ix:nonNumeric></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:EntitySmallBusiness"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></ix:nonNumeric></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; "> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric>&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards, provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). &#9744;&#160;Yes&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric>&#160;No</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Indicate the number of shares
outstanding of each of the issuer&#8217;s classes of common stock, as of August 12, 2022: <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares">25,184,654</ix:nonFraction></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Actinium
Pharmaceuticals, Inc.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Table
of Contents</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INDEX</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td colspan="2" style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">Page</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#a_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
    I &#8211; FINANCIAL INFORMATION</b></span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 81%"><a href="#a_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    Statements</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#a_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&#8217;s
    Discussion and Analysis of Financial Condition and Results of Operations</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#a_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quantitative
    and Qualitative Disclosures About Market Risk</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#a_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controls
    and Procedures</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#a_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
    II &#8211; OTHER INFORMATION</b></span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#a_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal
    Proceedings</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">30</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#a_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
    Factors</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#a_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unregistered
    Sales of Equity Securities and Use of Proceeds</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#a_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Defaults
    Upon Senior Securities</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#a_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mine
    Safety Disclosures</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#a_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    Information</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#a_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#a_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>


</div><!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="a_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
I - FINANCIAL INFORMATION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
1. &#160;FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared by the Company and are unaudited. In the opinion of management, all
adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position at June 30, 2022 and
December 31, 2021, and the results of operations and cash flows for the three and six months ended June 30, 2022 and 2021, respectively,
have been made. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting
principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these financial statements
be read in conjunction with the financial statements and notes thereto included in the Company&#8217;s audited financial statements for
the year ended December 31, 2021 in the Company&#8217;s Annual Report on Form 10-K. The results of operations for the three and six months
ended June 30, 2022 are not necessarily indicative of the operating results for the full year.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Actinium
Pharmaceuticals, Inc.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Condensed
Consolidated Balance Sheets</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(In
thousands, except share and per share data)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">(Unaudited)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">(Audited)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">Assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">Current Assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 0.25in">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd">116,330</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd">77,829</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashCurrent" scale="3" unitRef="usd">392</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashCurrent" scale="3" unitRef="usd">392</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Security deposit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SecurityDeposit" scale="3" unitRef="usd">50</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SecurityDeposit" scale="3" unitRef="usd">50</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Prepaid expenses and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd">1,525</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd">1,478</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 27pt">Total Current Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd">118,297</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd">79,749</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Property and equipment, net of accumulated depreciation of $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd">395</ix:nonFraction> and $<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd">335</ix:nonFraction></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd">557</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd">340</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Security deposit &#8211; long term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepositsAssetsNoncurrent" scale="3" unitRef="usd">299</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-0">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Operating leases right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd">2,629</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd">241</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Finance leases right-of-use assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" unitRef="usd">18</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" unitRef="usd">58</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total Assets</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd">121,800</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd">80,388</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center; text-indent: -9pt; padding-left: 9pt">Liabilities and Stockholders&#8217; Equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Current Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableCurrent" scale="3" unitRef="usd">5,767</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableCurrent" scale="3" unitRef="usd">5,535</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Other revenue deferred&#8211; current liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" unitRef="usd">204</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" unitRef="usd">998</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Operating leases current liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd">292</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd">245</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Finance leases current liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" unitRef="usd">19</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" unitRef="usd">62</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 27pt">Total Current Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd">6,282</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd">6,840</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">&#160;&#160;&#160;&#160;Long-term license revenue deferred</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenue" scale="3" unitRef="usd">35,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">&#160;&#160;&#160;&#160;Long-term operating leases obligations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" unitRef="usd">2,335</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-2">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">&#160;&#160;&#160;&#160;Long-term finance leases obligations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="atnm:LongtermFinanceLeaseObligationsNoncurrent" scale="3" unitRef="usd">2</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="atnm:LongtermFinanceLeaseObligationsNoncurrent" scale="3" unitRef="usd">3</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Total Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd">43,619</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd">6,843</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Commitments and contingencies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-3">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-4">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Stockholders&#8217; Equity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Preferred stock, $<ix:nonFraction contextRef="c2" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares"><ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares">50,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-5">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-6">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Common stock, $<ix:nonFraction contextRef="c2" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares"><ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">1,000,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">24,870,623</ix:nonFraction></ix:nonFraction> and <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">22,143,974</ix:nonFraction></ix:nonFraction> shares issued and outstanding, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd">25</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd">22</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd">346,800</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd">329,271</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd">268,644</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd">255,748</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Total Stockholders&#8217; Equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">78,181</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">73,545</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total Liabilities and Stockholders&#8217; Equity</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd">121,800</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd">80,388</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to the condensed consolidated financial statements.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 4; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Actinium
Pharmaceuticals, Inc.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Condensed
Consolidated Statements of Operations</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(In
thousands, except share and per share data)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the<br/> Three Months Ended<br/> June&#160;30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the<br/> Six Months Ended<br/> June&#160;30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Revenue</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 0.25in">Revenue</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-7">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-8">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-9">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-10">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 52%; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Other revenue</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SubleaseIncome" scale="3" unitRef="usd">45</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SubleaseIncome" scale="3" unitRef="usd">266</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SubleaseIncome" scale="3" unitRef="usd">985</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SubleaseIncome" scale="3" unitRef="usd">888</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Total revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd">45</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd">266</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd">985</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd">888</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Research and development, net of reimbursements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd">4,662</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd">3,631</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd">9,031</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd">7,907</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">3,233</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">1,710</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">4,968</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">3,428</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd">7,895</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd">5,341</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd">13,999</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd">11,335</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Loss from operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd">7,850</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd">5,075</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd">13,014</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd">10,447</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Other income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Interest income - net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNet" scale="3" unitRef="usd">83</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNet" scale="3" unitRef="usd">54</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNet" scale="3" unitRef="usd">118</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNet" scale="3" unitRef="usd">106</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Total other income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" unitRef="usd">83</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" unitRef="usd">54</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" unitRef="usd">118</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" unitRef="usd">106</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Net loss</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">7,767</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">5,021</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">12,896</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">10,341</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"><div style="-sec-ix-hidden: hidden-fact-14; -sec-ix-hidden: hidden-fact-13; -sec-ix-hidden: hidden-fact-12; -sec-ix-hidden: hidden-fact-11">Net loss per common share &#8211; basic and diluted</div></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">0.33</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">0.25</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">0.56</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">0.54</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"><div style="-sec-ix-hidden: hidden-fact-18; -sec-ix-hidden: hidden-fact-17; -sec-ix-hidden: hidden-fact-16; -sec-ix-hidden: hidden-fact-15">Weighted average common shares &#160;outstanding &#8211; basic and diluted</div></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">23,731,886</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">20,231,278</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">22,942,317</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">19,308,487</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to the condensed consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>


</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Actinium
Pharmaceuticals, Inc.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Condensed
Consolidated Statement of Changes in Stockholders&#8217; Equity </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the Three and Six Months Ended June 30, 2022</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(In
thousands, except share amounts)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Additional <br/> Paid-In</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Stockholders&#8217;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Equity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold">Balance, January 1, 2022</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">22,143,974</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd">22</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd">329,271</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd">255,748</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd">73,545</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-19">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" unitRef="usd">421</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-20">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" unitRef="usd">421</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-21">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-22">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">5,129</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">5,129</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt">Balance, March 31, 2022</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">22,143,974</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd">22</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c15" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd">329,692</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd">260,877</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c17" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd">68,837</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-23">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" unitRef="usd">425</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-24">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" unitRef="usd">425</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Sale of common stock, net of issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares">2,726,649</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" unitRef="usd">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" unitRef="usd">16,683</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-25">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" unitRef="usd">16,686</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-26">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-27">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">7,767</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">7,767</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Balance, June 30, 2022</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">24,870,623</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd">25</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd">346,800</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c23" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd">268,644</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd">78,181</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to the condensed consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 6; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Actinium
Pharmaceuticals, Inc.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Condensed
Consolidated Statement of Changes in Stockholders&#8217; Equity</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the Three and Six Months Ended June 30, 2021</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(In
thousands, except share amounts)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Additional <br/> Paid-In</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Stockholders&#8217;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Equity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold; text-indent: -9pt; padding-left: 9pt">Balance, January 1, 2021</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">17,532,893</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c24" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd">18</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd">292,275</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd">230,974</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd">61,319</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-28">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" unitRef="usd">376</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-29">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" unitRef="usd">376</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Sale of common stock, net of costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">1,712,745</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c28" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">14,360</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">14,361</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-31">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-32">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c30" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">5,320</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">5,320</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-indent: -9pt; padding-left: 9pt">Balance, March 31, 2021</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">19,245,638</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c32" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd">19</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c33" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd">307,011</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd">236,294</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd">70,736</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c36" decimals="0" format="ixt:num-dot-decimal" name="atnm:StockIssuedDuringPeriodSharesIssuanceOfCommonStockFromExerciseOfPrefundedWarrants" scale="0" unitRef="shares">8,705</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" unitRef="usd">459</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" unitRef="usd">459</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Sale of common stock, net of issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c36" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares">1,835,688</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c36" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" unitRef="usd">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" unitRef="usd">14,317</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" unitRef="usd">14,319</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Exercise of stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c36" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares">900</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd">6</ix:nonFraction></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd">6</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">5,021</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">5,021</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Balance, June 30, 2021</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c39" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">21,090,931</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd">21</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c40" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd">321,793</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c41" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd">241,315</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c42" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd">80,499</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to the condensed consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Actinium
Pharmaceuticals, Inc.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Condensed
Consolidated Statements of Cash Flows</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(In
thousands)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the<br/> Six Months Ended<br/> June&#160;30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Cash Flows From Operating Activities:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 0.25in">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">12,896</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">10,341</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd">846</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd">835</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 27pt">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd">317</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd">254</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" unitRef="usd">47</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" sign="-" unitRef="usd">106</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Payment of security deposit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInSecurityDeposits" scale="3" sign="-" unitRef="usd">299</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" unitRef="usd">232</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" sign="-" unitRef="usd">913</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Other revenue deferred&#8211; current liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" sign="-" unitRef="usd">794</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Long-term license revenue deferred</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" unitRef="usd">35,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Operating lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="atnm:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" sign="-" unitRef="usd">222</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="atnm:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" sign="-" unitRef="usd">167</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Net Cash Provided By/Used In Operating Activities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" unitRef="usd">22,137</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd">10,226</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Cash Flows Used In Investing Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Purchase of property and equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd">277</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd">65</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Net Cash Used In Investing Activities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" sign="-" unitRef="usd">277</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" sign="-" unitRef="usd">65</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Cash Flows From Financing Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Payments on finance leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" unitRef="usd">45</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" unitRef="usd">42</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 0.25in">Sales of shares of common stock, net of costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="atnm:SalesOfSharesOfCommonStockNetOfCosts" scale="3" unitRef="usd">16,686</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="atnm:SalesOfSharesOfCommonStockNetOfCosts" scale="3" unitRef="usd">28,680</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Proceeds from exercise of stock options</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" unitRef="usd">6</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Net Cash Provided By Financing Activities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd">16,641</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd">28,644</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Net change in cash, cash equivalents, and restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" unitRef="usd">38,501</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" unitRef="usd">18,353</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Cash, cash equivalents, and restricted cash at beginning of period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd">78,221</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd">63,999</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Cash, cash equivalents, and restricted cash at end of period</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd">116,722</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c42" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd">82,352</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Supplemental disclosure of cash flow information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Cash paid for interest</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Cash paid for income taxes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to the condensed consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Actinium
Pharmaceuticals, Inc.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Condensed Consolidated Financial Statements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1 - Description of Business and Summary of Significant Accounting Policies</b>&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_2" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="atnm:NatureOfBusinessPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Nature of Business -</b> Actinium
Pharmaceuticals, Inc. (the &#8220;Company&#8221; or &#8220;Actinium&#8221;) is a clinical-stage, biopharmaceutical company focused on
developing and potentially commercializing targeted radiotherapies for patients with unmet needs. The Company applies its proprietary
technology platform consisting of over 195 patents and patent applications, know-how and clinical experience in approximately 600 patients
to develop novel therapies for blood cancer and solid tumor indications. Its clinical and preclinical development programs utilize multiple
isotopes including Actinium-225, Iodine-131 and Lutetium-177 directed at multiple validated cancer targets including CD45, CD33, CD38,
CD47, HER2 and HER3 for targeted conditioning prior to cell and gene therapies including bone marrow transplant and cancer therapeutics
as single agents or in combination with other therapeutic modalities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_3" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
of Presentation - </b>The accompanying unaudited condensed consolidated financial statements and related notes have been prepared in
accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for condensed financial
information, and pursuant to the rules and regulations of the United States Securities and Exchange Commission (the &#8220;SEC&#8221;)
with respect to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required
by U.S. GAAP for complete financial statements. The unaudited condensed consolidated financial statements reflect all adjustments (consisting
of normal recurring adjustments) which are, in the opinion of management, necessary for a fair statement of the results for the condensed
periods presented. Condensed results are not necessarily indicative of the results for the full year. These unaudited condensed consolidated
financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in
the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_4" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ConsolidationPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principles
of Consolidation -</b> The basis of consolidation is unchanged from the disclosure in the Company&#8217;s Notes to the Consolidated Financial
Statements section in its Report on Form 10-K for the year ended December 31, 2021. The unaudited condensed consolidated financial statements
include the Company&#8217;s accounts and those of the Company&#8217;s wholly owned subsidiaries.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_5" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_4"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:UseOfEstimates"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use
of Estimates </b>- The preparation of these unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated
financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_6" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_5"><ix:nonNumeric contextRef="c0" continuedAt="_PandemicOnFinancialStatements-c0_cont_1" escape="true" name="atnm:PandemicOnFinancialStatements"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Impact
of COVID&#8211;19 Pandemic on Financial Statements - </b>The global health crisis caused by the novel coronavirus (&#8220;COVID-19&#8221;)
pandemic and its resurgences has and may continue to negatively impact global economic activity, which, despite progress in vaccination
efforts, remains uncertain and cannot be predicted with confidence. In addition, the Omicron variants of COVID-19, including subvariants
BA.4 and BA.5, which appear to be the most transmissible variants to date, have spread globally. The full impact of the Omicron variants,
or any subsequent variants, cannot be predicted at this time, and could depend on numerous factors, including vaccination rates among
the population, the effectiveness of COVID-19 vaccines against the Omicron variants and subsequent variants and the response by governmental
bodies and regulators.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_7" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_6"><ix:continuation continuedAt="_PandemicOnFinancialStatements-c0_cont_2" id="_PandemicOnFinancialStatements-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
countries around the world have continued to impose quarantines and restrictions on travel and mass gatherings to slow the spread of
the virus. Accordingly, the Company&#8217;s ability to continue to operate its business may also be limited. Such events may result in
a period of business, supply and drug product manufacturing disruption, and in reduced operations, any of which could materially affect
the Company&#8217;s business, financial condition and results of operations. In response to COVID-19, the Company implemented hybrid
working for its office-based staff, while its research staff has been actively working in its laboratory throughout the pandemic and
thus far, has not experienced a significant disruption or delay in its operations as it relates to the clinical development, preclinical
research or drug production of its drug candidates.&#160;A continuation or worsening of the levels of market disruption and volatility
seen in the recent past could have an adverse effect on the Company&#8217;s ability to access capital, which could in the future negatively
affect the Company&#8217;s liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially
affect the Company&#8217;s business and the value of the Company&#8217;s common stock.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_8" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_7"><ix:continuation continuedAt="_PandemicOnFinancialStatements-c0_cont_3" id="_PandemicOnFinancialStatements-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
COVID-19 may result in delays in receiving approvals from local and foreign regulatory authorities, delays in necessary interactions
with IRB&#8217;s or Institutional Review Boards, local and foreign regulators, ethics committees and other important agencies and contractors
due to limitations in employee resources or forced furlough of government employees.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_9" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_8"><ix:continuation id="_PandemicOnFinancialStatements-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, COVID-19 has not had a financial impact on the Company. The Company continues to monitor the impacts of COVID-19 on the global
economy and on its business operations. However, at this time, it is difficult to predict how long the potential operational impacts
of COVID-19 will last or to what degree further disruption might impact the Company&#8217;s operations and financial results.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;&#160;</b></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_10" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_9"><ix:nonNumeric contextRef="c0" continuedAt="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash,
Cash Equivalents and Restricted Cash -</b> The Company considers all highly liquid accounts with original maturities of three months
or less to be cash equivalents. Balances held by the Company are typically in excess of Federal Deposit Insurance Corporation insured
limits.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_11" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_10"><ix:continuation continuedAt="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_2" id="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of cash, cash equivalents and restricted cash at June 30, 2022 and December 31, 2021:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_12" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_11"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"><ix:continuation continuedAt="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_3" id="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_2"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" unitRef="usd">116,330</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" unitRef="usd">77,829</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Restricted cash</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherRestrictedAssetsCurrent" scale="3" unitRef="usd">392</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherRestrictedAssetsCurrent" scale="3" unitRef="usd">392</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Cash, cash equivalents and restricted cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" scale="3" unitRef="usd">116,772</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" scale="3" unitRef="usd">78,221</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p></ix:continuation></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_13" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_12"><ix:continuation id="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
cash relates to a certificate of deposit held as collateral for a letter of credit issued in connection with the Company&#8217;s lease
for corporate office space.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_14" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_13"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Leases
</b>&#8211; The Company has operating and finance leases for corporate office space, office equipment and furniture located at the corporate
office space. Leases with an initial term of 12 months or less are not recorded on the balance sheet; lease expense for these leases
is recognized on a straight-line basis over the lease term. The Company entered into a lease for corporate office space effective June
1, 2022 and paid a security deposit to the landlord. A certificate of deposit will be provided as collateral for a letter of credit to
be issued with this new office space during 2022 and at that time, the security deposit will be returned to the Company.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_15" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_14"><ix:nonNumeric contextRef="c0" continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:RevenueRecognitionPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Revenue
Recognition </b>- The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) Topic 606, <i>Revenue From
Contracts With Customers</i> (&#8220;ASC 606&#8221;). Under ASC 606, an entity recognizes revenue when its customer obtains control of
promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods
or services. To determine revenue recognition for arrangements within the scope of ASC 606, the entity performs the following five steps:
(i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction
price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract;
and (v) recognize revenue as the entity satisfies a performance obligation. The Company only applies the five-step model to contracts
when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers
to the customer.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_16" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_15"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_2" id="_RevenueRecognitionPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses whether the promised goods
or services promised within each contract are distinct and, therefore, represent a separate performance obligation.&#160;Goods and services
that are determined not to be distinct are combined with other promised goods and services until a distinct bundle is identified. In
determining whether goods or services are distinct, the Company evaluates certain criteria, including whether (i)&#160;the customer can
benefit from the good or service either on its own or together with other resources that are readily available to the customer (capable
of being distinct) and (ii)&#160;the good or service is separately identifiable from other goods or services in the contract (distinct
in the context of the contract).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; ">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; "></p><div>

</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_17" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_16"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_3" id="_RevenueRecognitionPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company then determines the transaction price, which is the amount of consideration it expects to be entitled from a customer in exchange
for the promised goods or services for each performance obligation and recognizes the associated revenue as each performance obligation
is satisfied. The Company&#8217;s estimate of the transaction price for each contract includes all variable consideration to which it
expects to be entitled. Variable consideration includes payments in the form of collaboration milestone payments. If an arrangement includes
collaboration milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates
the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue
reversal would not occur, the associated milestone value is included in the transaction price.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_18" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_17"><ix:continuation id="_RevenueRecognitionPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
606 requires the Company to allocate the arrangement consideration on a relative standalone selling price basis for each performance
obligation after determining the transaction price of the contract and identifying the performance obligations to which that amount should
be allocated. The relative standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised
good or service separately to a customer. The Company then recognizes as revenue the amount of the transaction price that is allocated
to the respective performance obligation as each performance obligation is satisfied, either at a point in time or over time, and if
over time, recognition is based on the use of an output or input method.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_19" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_18"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:CollaborativeArrangementAccountingPolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Collaborative
Arrangements - </b>The Company follows the accounting guidance for collaboration agreements with third parties, which requires that certain
transactions between the Company and collaborators be recorded in its consolidated statements of operations and comprehensive loss on
either a gross basis or net basis, depending on the characteristics of the collaborative relationship, and requires enhanced disclosure
of collaborative relationships. The Company evaluates its collaboration agreements for proper classification in its consolidated statements
of operations and comprehensive loss based on the nature of the underlying activity. When the Company has concluded that it has a customer
relationship with one of its collaborators, the Company follows the guidance of ASC 606<i>.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p></ix:nonNumeric></ix:continuation><div>

</div><div>



</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_20" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_19"><ix:nonNumeric contextRef="c0" escape="true" name="atnm:GrantRevenuePolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Grant Revenue <i>&#8211; </i></b>The
Company has a grant from a government-sponsored entity for research and development related activities that provides for payments for
reimbursed costs, which includes overhead and general and administrative costs as well as an administrative fee. The Company recognizes
revenue from grants as it performs services and all conditions are met under this arrangement. Associated expenses are recognized when
incurred as research and development expense. Revenue and related expenses are presented gross in the consolidated statements of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_21" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_20"><ix:nonNumeric contextRef="c0" continuedAt="_LicenseRevenueTextBlock-c0_cont_1" escape="true" name="atnm:LicenseRevenueTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>License Revenue <i>&#8211;
</i></b>The Company entered into a product licensing agreement whereby the Company allowed a third party to commercialize a certain product
in specified territories using the Company&#8217;s trademarks. The terms of this arrangement includes payment to the Company for a combination
of one or more of the following: upfront license fees; development, regulatory and sales-based milestone payments; and royalties on net
sales of licensed products. The Company uses its judgment to determine whether milestones or other variable consideration should be included
in the transaction price.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_22" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_21"><ix:continuation continuedAt="_LicenseRevenueTextBlock-c0_cont_2" id="_LicenseRevenueTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Upfront
license fees</i>: If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance
obligations identified in the arrangement, the Company will recognize revenue from upfront license fees allocated to the license when
the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled
with other promises, the Company determines whether the combined performance obligation is satisfied over time or at a point in time.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_23" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_22"><ix:continuation continuedAt="_LicenseRevenueTextBlock-c0_cont_3" id="_LicenseRevenueTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Development,
regulatory or commercial milestone payments</i>: At the inception of each arrangement that includes payments based on the achievement
of certain development, regulatory and sales-based or commercial events, the Company evaluates whether the milestones are considered
probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it
is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price.
Milestone payments that are not within the Company&#8217;s or the licensee&#8217;s control, such as regulatory approvals, are not considered
probable of being achieved until regulatory approval is received. At the end of each subsequent reporting period, the Company will re-evaluate
the probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust the Company&#8217;s
estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis and recorded as part of license
revenue during the period of adjustment.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_24" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_23"><ix:continuation continuedAt="_LicenseRevenueTextBlock-c0_cont_4" id="_LicenseRevenueTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Sales-based
milestone payments and royalties</i>: For arrangements that include sales-based royalties, including milestone payments based on the
volume of sales, the Company will determine whether the license is deemed to be the predominant item to which the royalties or sales-based
milestones relate and if such is the case, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii)
when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_25" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_24"><ix:continuation id="_LicenseRevenueTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upfront
payments and fees may require deferral of revenue recognition to a future period until the Company performs its obligations under these
arrangements or when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur or when
the uncertainty associated with any variable consideration is subsequently resolved. Amounts payable to the Company are recorded as accounts
receivable when the Company&#8217;s right to consideration is unconditional.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_26" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_25"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and Development Costs -</b> Research and development costs are expensed as incurred. These costs include the costs of manufacturing drug
product, the costs of clinical trials, costs of employees and associated overhead, and depreciation and amortization costs related to
facilities and equipment. Research and development reimbursements are recorded by the Company as a reduction of research and development
costs.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_27" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_26"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:CompensationRelatedCostsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share-Based
Payments -</b> The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing
model. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee
is required to provide service in exchange for the award. The Company accounts for forfeitures of stock options as they occur.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_28" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_27"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><b>Net
Loss Per Common Share</b> - Basic loss per common share is computed by dividing the net loss available to common stockholders by the
weighted average number of shares of common stock outstanding during the reporting period. For periods of net loss, diluted loss per
share is calculated similarly to basic loss per share because the impact of all potential dilutive common shares is anti-dilutive. For
the three months ended June 30, 2022 and 2021, the Company&#8217;s potentially dilutive shares, which include outstanding common stock
options and warrants, have not been included in the computation of diluted net loss per share as the result would have been anti-dilutive.</ix:nonNumeric></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_29" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_28"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c43" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">1,431</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">859</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c45" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">2,053</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c46" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">2,114</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">3,484</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">2,973</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_30" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_29"><ix:nonNumeric contextRef="c0" continuedAt="_Accountingstandardsrecentlyissuedpolicytextblock-c0_cont_1" escape="true" name="atnm:Accountingstandardsrecentlyissuedpolicytextblock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recently
Adopted Accounting Pronouncements &#8211; </b>In May 2021, FASB issued ASU 2021-04, <i>Earnings Per Share (topic 260), Debt &#8212; Modifications
and Extinguishments (Subtopic 470-50), Compensation &#8211; Stock Compensation (Topic 718) and Derivatives and Hedging &#8211; Contracts
in an Entity&#8217;s Own Equity (Subtopic 815-40) &#8211; Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding
Equity-Classified Written Call Options</i>, which provides guidance of a modification or an exchange of a freestanding equity-classified
written call option that remains equity classified after modification or exchange as (1) an adjustment to equity and, if so, the related
earnings per share (EPS) effects, if any, or (2) an expense and, if so, the manner and pattern of recognition. The amendments in this
ASU are effective January 1, 2022, including interim periods. The Company adopted this standard effective January 1, 2022 and the standard
did not have a material effect on the Company&#8217;s financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_31" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_30"><ix:continuation id="_Accountingstandardsrecentlyissuedpolicytextblock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2021, the FASB issued ASU 2021-10, <i>Government Assistance (Topic 832), Disclosures by Business Entities about Government Assistance</i>,
which provides guidance on disclosure requirements to entities other than not-for-profit entities about transaction with a government
that are accounted for by applying a grant or contribution accounting model by analogy. ASU 2021-10 requires an entity to make annual
disclosures related to (1) the nature of the transactions and the related accounting policy used to account for the government transactions,
(2) quantification and disclosure of amounts related to the government transactions included in balance sheet and income statement financial
statement line items, and (3) significant terms and conditions of the government transactions, including commitments and contingencies.
The amendments of ASU 2021-10 are effective January 1, 2022, including interim periods. The Company adopted this standard effective January
1, 2022, and the standard did not have a material impact on the Company&#8217;s financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_31"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recently
Issued Accounting Pronouncements &#8211; </b>In October 2021, FASB issued ASU 2021-08, <i>Business Combinations (Topic 805), Account
for Contract Assets and Contract Liabilities from Contracts with Customers</i>, which provides guidance on accounting for contract assets
and contract liabilities acquired in a business combination in accordance with ASC 606. To achieve this, an acquirer may assess how the
acquiree applied ASC 606 to determine what to record for the acquired revenue contracts. Generally, this should result in an acquirer
recognizing and measuring the acquired contract assets and contract liabilities consistent with how they were recognized and measured
in the acquiree&#8217;s financial statements. The amendments of ASU 2021-08 are effective January 1, 2023, including interim periods.
Early adoption is permitted, including adoption in an interim period. The Company will evaluate the impact of ASU 2021-08 on any future
business combinations the Company may enter in the future.</span></p></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 - Commitments and Contingencies</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 15, 2012, the Company entered into a license and sponsored research agreement with Fred Hutchinson Cancer Research Center (&#8220;FHCRC&#8221;)
to build upon previous and ongoing clinical trials with apamistamab (licensed antibody). FHCRC has completed both a Phase 1 and Phase
2 clinical trial with apamistamab. The Company has been granted exclusive rights to the antibody and related master cell bank developed
by FHCRC. A milestone payment of $<ix:nonFraction contextRef="c47" decimals="-6" format="ixt:num-dot-decimal" name="atnm:MilestonePayment" scale="6" unitRef="usd">1</ix:nonFraction> million will be due to FHCRC upon U.S. Food and Drug Administration (&#8220;FDA&#8221;) approval
of the first drug utilizing the licensed antibody. <ix:nonNumeric contextRef="c47" name="atnm:DescriptionOfRoyaltyPaymentToRelatedParty">Upon commercial sale of the drug, royalty payments of 2% of net sales will be due
to FHCRC.</ix:nonNumeric>&#160;</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_LeasesTextBlock-c0_cont_1" escape="true" name="atnm:LeasesTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
3 - Leases </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_LeasesTextBlock-c0_cont_2" id="_LeasesTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company entered into a
lease for corporate office space, effective June 1, 2022. As of June 30, 2022, the Company has <ix:nonFraction contextRef="c0" decimals="0" format="ixt-sec:numwordsen" name="atnm:NumberOfOperatingLease" scale="0" unitRef="pure">two</ix:nonFraction> operating leases for corporate office
space and <ix:nonFraction contextRef="c0" decimals="0" format="ixt-sec:numwordsen" name="atnm:NumberOfFinanceLease" scale="0" unitRef="pure">two</ix:nonFraction> finance leases for office equipment and furniture located in <ix:nonFraction contextRef="c0" decimals="0" format="ixt-sec:numwordsen" name="atnm:AdditionSpaceForOperatingLease" scale="0" unitRef="pure">one</ix:nonFraction> of the corporate office spaces. In addition, the Company
has auxiliary corporate office space that it rents on a month-to-month basis; this rental is accounted for as an operating lease with
the same term as the Company&#8217;s main office.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_LeasesTextBlock-c0_cont_3" id="_LeasesTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of lease expense are as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LeasesTextBlock-c0_cont_4" id="_LeasesTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LeaseCostTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June&#160;30,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June&#160;30,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June&#160;30,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June&#160;30,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Operating lease expense</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="3" unitRef="usd">141</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="3" unitRef="usd">93</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="3" unitRef="usd">234</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="3" unitRef="usd">186</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Finance lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Amortization of right-to-use assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" unitRef="usd">20</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" unitRef="usd">21</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" unitRef="usd">41</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" unitRef="usd">41</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Interest on lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseInterestExpense" scale="3" unitRef="usd">1</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseInterestExpense" scale="3" unitRef="usd">2</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseInterestExpense" scale="3" unitRef="usd">2</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseInterestExpense" scale="3" unitRef="usd">5</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total finance lease cost</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" unitRef="usd">21</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" unitRef="usd">23</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" unitRef="usd">43</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" unitRef="usd">46</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_LeasesTextBlock-c0_cont_5" id="_LeasesTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental
cash flow information related to leases are as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LeasesTextBlock-c0_cont_6" id="_LeasesTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash
flow information:</b></span></p></ix:continuation><div>

</div><ix:continuation continuedAt="_LeasesTextBlock-c0_cont_7" id="_LeasesTextBlock-c0_cont_6"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June&#160;30,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June&#160;30,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cash paid for amounts included in the measurement of lease liabilities:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Operating cash flow use from operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" unitRef="usd">239</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" unitRef="usd">188</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Operating cash flow use from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" unitRef="usd">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" unitRef="usd">5</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Financing cash flow use from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" unitRef="usd">45</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" unitRef="usd">42</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Non-cash activity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Right-of-use assets obtained in exchange for lease obligations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" unitRef="usd">2,605</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Finance Leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_LeasesTextBlock-c0_cont_8" id="_LeasesTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
average remaining lease terms are as follows at June 30, 2022:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LeasesTextBlock-c0_cont_9" id="_LeasesTextBlock-c0_cont_8"><ix:nonNumeric contextRef="c0" escape="true" name="atnm:ScheduleOrDescriptionOfWeightedAverageTerm"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; ">
    <td>Weighted average remaining lease term:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center"><ix:nonNumeric contextRef="c2" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">5.0</ix:nonNumeric> years</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Finance Leases</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c2" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1">0.5</ix:nonNumeric> year</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_LeasesTextBlock-c0_cont_10" id="_LeasesTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the interest rate implicit in the leases was not readily determinable at the time that the leases were evaluated, the Company used its
incremental borrowing rate based on the information available in determining the present value of lease payments. The Company&#8217;s
incremental borrowing rate was based on the term of the lease, the economic environment of the lease and reflect the rate the Company
would have had to pay to borrow on a secured basis. Below is information on the weighted average discount rates used at the time that
the leases were evaluated:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LeasesTextBlock-c0_cont_11" id="_LeasesTextBlock-c0_cont_10"><ix:nonNumeric contextRef="c0" escape="true" name="atnm:ScheduleOfWeightedAverageDiscountRate"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>Weighted average discount rates:</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><ix:nonFraction contextRef="c2" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure">4.8</ix:nonFraction>%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Finance Leases</td><td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure">8.0</ix:nonFraction>%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_LeasesTextBlock-c0_cont_12" id="_LeasesTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maturities
of lease liabilities are as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;&#160;&#160;</b></span></p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_LeasesTextBlock-c0_cont_12"><ix:nonNumeric contextRef="c0" escape="true" name="atnm:OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)<br/> Year ending December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Operating <br/> Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Finance <br/> Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 76%">2022 (excluding six months ended June 30, 2022)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" scale="3" unitRef="usd">113</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" scale="3" unitRef="usd">17</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" scale="3" unitRef="usd">606</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" scale="3" unitRef="usd">5</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" scale="3" unitRef="usd">618</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" scale="3" unitRef="usd">630</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" scale="3" unitRef="usd">643</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">2027</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" scale="3" unitRef="usd">380</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" unitRef="usd">2,990</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" unitRef="usd">22</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="atnm:PaymentWithImputedInterestPremium" scale="3" sign="-" unitRef="usd">363</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" name="atnm:PaymentWithImputedInterestPremium" scale="3" sign="-" unitRef="usd">1</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Present value of lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="atnm:MaturitiesOfLeaseLiabilities" scale="3" unitRef="usd">2,627</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" name="atnm:MaturitiesOfLeaseLiabilities" scale="3" unitRef="usd">21</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_OtherRevenueTextBlock-c0_cont_1" escape="true" name="atnm:OtherRevenueTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4 &#8211; Other revenue </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_OtherRevenueTextBlock-c0_cont_2" id="_OtherRevenueTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determined that certain collaborations with a third party are within the scope of ASC 606. The collaboration agreement is made
up of multiple modules related to various research activities. The Company identified a single performance obligation to provide research
services within each module for which the Company receives monetary consideration. The third party can choose to proceed with each module
or can terminate the agreement at any time. The Company recognizes revenue for each module on a straight-line basis over the expected
module period. Revenue for succeeding modules is not recognized until all contingencies are resolved, inclusive of the third party&#8217;s
ability to terminate the module. Other revenue recognized during the three months and six months ended June 30, 2022 was $<ix:nonFraction contextRef="c4" decimals="-5" format="ixt:num-dot-decimal" name="atnm:RecognitionOfDeferredRevenue1" scale="6" unitRef="usd">0.0</ix:nonFraction> million
and $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="atnm:RecognitionOfDeferredRevenue1" scale="6" unitRef="usd">0.9</ix:nonFraction> million, respectively, and for the three months and six months ended June 30, 2021 was $<ix:nonFraction contextRef="c5" decimals="-5" format="ixt:num-dot-decimal" name="atnm:RecognitionOfDeferredRevenue1" scale="6" unitRef="usd">0.3</ix:nonFraction> million and $<ix:nonFraction contextRef="c6" decimals="-5" format="ixt:num-dot-decimal" name="atnm:RecognitionOfDeferredRevenue1" scale="6" unitRef="usd">0.9</ix:nonFraction> million, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OtherRevenueTextBlock-c0_cont_3" id="_OtherRevenueTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has a grant from a government-sponsored entity for research and development related activities that provide for payments for
reimbursed costs, which includes overhead and general and administrative costs as well as an administrative fee. The Company recognizes
revenue from grants as it performs services under this arrangement. Associated expenses are recognized when incurred as research and
development expense. Other revenue recognized during the three months and six months ended June 30, 2022 was $<ix:nonFraction contextRef="c4" decimals="-5" format="ixt:num-dot-decimal" name="atnm:RevenueRecognized" scale="6" unitRef="usd">0.0</ix:nonFraction> million and $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="atnm:RevenueRecognized" scale="6" unitRef="usd">0.1</ix:nonFraction> million,
respectively. There was no other revenue recognized from a grant from a government-sponsored entity during the six months ended June
30, 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_OtherRevenueTextBlock-c0_cont_4" id="_OtherRevenueTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 7, 2022, the Company
entered into a license and supply agreement (the &#8220;License Agreement&#8221;) with Immedica Pharma AB (&#8220;Immedica&#8221;), pursuant
to which Immedica licensed the exclusive product rights for commercialization of Iomab-B (I-131 apamistamab) in the European Economic
Area, Middle East and North Africa (EUMENA) including Algeria, Andorra, Bahrain, Cyprus, Egypt, Iran, Iraq, Israel, Jordan, Kuwait, Lebanon,
Libya, Monaco, Morocco, Oman, Palestine, Qatar, San Marino, Saudi Arabia, Switzerland, Syria, Tunisia, Turkey, the United Arab Emirates,
the United Kingdom, the Vatican City and Yemen. Upon signing, the Company was entitled to an upfront payment of $<ix:nonFraction contextRef="c50" decimals="-6" format="ixt:num-dot-decimal" name="atnm:UpfrontPayment" scale="6" unitRef="usd">35</ix:nonFraction> million from Immedica,
which was received in May 2022. Under the terms of the License Agreement, the Company is eligible to receive regulatory and commercial
milestone payments and is entitled to receive royalties in the mid-20 percent range on net sales of the product in certain countries that
may result from the License Agreement. The Company will continue to be responsible for certain clinical development activities and the
manufacturing of Iomab-B and will retain commercialization rights in the U.S. and rest of the world.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>
</div><div>

</div><ix:continuation id="_OtherRevenueTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s contract liabilities
are recorded within Other revenue deferred &#8211; current liability or Long-term license revenue deferred in its condensed consolidated
balance sheets depending on the short-term or long-term nature of the payments to be recognized. The Company&#8217;s contract liabilities
primarily consist of advanced payments from licensees. Other revenue deferred &#8211; current liability was $<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueCurrent" scale="6" unitRef="usd">0.2</ix:nonFraction> million at June 30, 2022
and $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueCurrent" scale="6" unitRef="usd">0.9</ix:nonFraction> million at December 31, 2021. Long-term license revenue deferred was $<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="atnm:LongtermLicenseRevenueDeferred" scale="6" unitRef="usd">35.0</ix:nonFraction> million at June 30, 2022; there was no long-term license
revenue deferred at December 31, 2021. This deferred revenue will be recognized upon EU regulatory approval of Iomab B.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5 - Equity&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020 the Company entered into the Capital on Demand&#8482; Sales Agreement with JonesTrading Institutional Services LLC, or JonesTrading,
pursuant to which the Company may sell, from time to time, through or to JonesTrading, up to an aggregate of $<ix:nonFraction contextRef="c51" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" unitRef="usd">200</ix:nonFraction> million of its common
stock. Shares of common stock are offered pursuant to a shelf registration statement on Form S-3 filed with the SEC on August 7, 2020.
As of December 31, 2021, the Company had sold <ix:nonFraction contextRef="c52" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="6" unitRef="shares">6.7</ix:nonFraction> million shares of common stock, resulting in gross proceeds of $<ix:nonFraction contextRef="c52" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" unitRef="usd">59.1</ix:nonFraction> million and net
proceeds of $<ix:nonFraction contextRef="c52" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" unitRef="usd">57.0</ix:nonFraction> million. For the six months ended June 30, 2022, the Company sold <ix:nonFraction contextRef="c53" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="6" unitRef="shares">2.7</ix:nonFraction> million shares of common stock, resulting in
gross proceeds of $<ix:nonFraction contextRef="c53" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" unitRef="usd">17.2</ix:nonFraction> million and net proceeds of $<ix:nonFraction contextRef="c53" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" unitRef="usd">16.7</ix:nonFraction> million. For the six months ended June 30, 2021, the Company sold <ix:nonFraction contextRef="c54" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="6" unitRef="shares">3.5</ix:nonFraction> million
shares of common stock, resulting in gross proceeds of $<ix:nonFraction contextRef="c54" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" unitRef="usd">29.6</ix:nonFraction> million and net proceeds of $<ix:nonFraction contextRef="c54" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" unitRef="usd">28.7</ix:nonFraction> million.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_3" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 28, 2022, the Company entered into an Amendment and Restated Capital on Demand&#8482; Sales Agreement (the &#8220;A&amp;R Sales
Agreement&#8221;) with JonesTrading and B. Riley Securities, Inc. (&#8220;B. Riley Securities&#8221;). The A&amp;R Sales Agreement modifies
the original Capital on Demand&#8482; Sales Agreement to include B. Riley Securities as an additional sales agent thereunder.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_4" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock
Options</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_5" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of stock option activity for the six months ended June 30, 2022:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_6" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_5"><ix:nonNumeric contextRef="c59" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number&#160;of<br/> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Exercise <br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Term <br/> (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 53%">Outstanding, January 1, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">1,362</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">12.45</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">8.69</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares">120</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">5.23</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" unitRef="shares">51</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">8.89</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Outstanding, June 30, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">1,431</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">11.97</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1">8.36</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Exercisable, June 30, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares">473</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">22.19</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">7.07</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;</span></p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_7" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" name="atnm:PurchaseOfCommonStockDescription">During
the six months ended June 30, 2022, the Company granted new employees options to purchase 120 thousand shares of common stock with an
exercise price ranging from $<ix:nonFraction contextRef="c55" decimals="2" format="ixt:num-dot-decimal" name="atnm:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight" scale="0" unitRef="usdPershares">5.20</ix:nonFraction> to $<ix:nonFraction contextRef="c56" decimals="2" format="ixt:num-dot-decimal" name="atnm:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight" scale="0" unitRef="usdPershares">5.93</ix:nonFraction> per share, a term of <ix:nonNumeric contextRef="c57" format="ixt-sec:duryear" name="atnm:StockOptionTerm">10</ix:nonNumeric> years, and a vesting period of <ix:nonNumeric contextRef="c57" format="ixt-sec:duryear" name="atnm:VestingPeriodOfStockOption">4</ix:nonNumeric> years.</ix:nonNumeric>&#160;The options have an aggregated
fair value of $<ix:nonFraction contextRef="c57" decimals="-6" format="ixt:num-dot-decimal" name="atnm:AggregateFairValue" scale="6" unitRef="usd">442</ix:nonFraction> thousand that was calculated using the Black-Scholes option-pricing model. <ix:nonNumeric contextRef="c57" name="atnm:StockOptionDescription">Variables used in the Black-Scholes option-pricing
model include: (1) discount rate range from 1.52% to 3.03% (2) expected life of 6 years, (3) expected volatility range from 78.8% to
79.9%, and (4) zero expected dividends.</ix:nonNumeric></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_8" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair values of all options issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation
expense at June 30, 2022 was $<ix:nonFraction contextRef="c57" decimals="-5" format="ixt:num-dot-decimal" name="atnm:UnrecognizedCompensationExpense" scale="6" unitRef="usd">4.4</ix:nonFraction> million related to unvested options, which is expected to be expensed over a weighted average of <ix:nonNumeric contextRef="c57" format="ixt-sec:duryear" name="atnm:WeightedAverageTerm">3.0</ix:nonNumeric>
years. During the six months ended June 30, 2022 and 2021, the Company recorded compensation expense related to stock options of $<ix:nonFraction contextRef="c57" decimals="-5" format="ixt:num-dot-decimal" name="atnm:CompensationExpenseRelatedToStockOptions" scale="6" unitRef="usd">0.8</ix:nonFraction>
million and $<ix:nonFraction contextRef="c58" decimals="-5" format="ixt:num-dot-decimal" name="atnm:CompensationExpenseRelatedToStockOptions" scale="6" unitRef="usd">0.7</ix:nonFraction> million, respectively. &#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_9" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_10" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
is a summary of warrant activity for the six months ended June 30, 2022:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_10"><ix:nonNumeric contextRef="c60" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Exercise <br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Term <br/> (in&#160;years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 53%">Outstanding, January 1, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c61" decimals="0" format="ixt:num-dot-decimal" name="atnm:NumberOfWarrantsOutstandings" scale="0" unitRef="shares">2,112</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c61" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">20.52</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center"><ix:nonNumeric contextRef="c60" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">1.76</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c61" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="3" unitRef="usd">276</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Cancelled/Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c60" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" sign="-" unitRef="shares">59</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c60" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">3.62</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Outstanding, June 30, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c62" decimals="0" format="ixt:num-dot-decimal" name="atnm:NumberOfWarrantsOutstandings" scale="0" unitRef="shares">2,053</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c62" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">21.01</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: center"><ix:nonNumeric contextRef="c60" format="ixt-sec:duryear" name="atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms">1.32</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Exercisable, June 30, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c62" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares">2,049</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c62" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">20.57</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: center"><ix:nonNumeric contextRef="c60" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">1.31</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SubsequentEventsTextBlock-c0_cont_1" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6 &#8211; Subsequent Event</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c0_cont_2" id="_SubsequentEventsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
June 30, 2022, the Company has sold <ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="atnm:SharesOfCommonStockValue" scale="6" unitRef="usd">0.3</ix:nonFraction> million shares of common stock under its A&amp;R Sales Agreement, resulting in net proceeds of
$<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="atnm:NetProceeds" scale="6" unitRef="usd">1.4</ix:nonFraction> million.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_SubsequentEventsTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 2, 2022, warrants to purchase an aggregate of <ix:nonFraction contextRef="c63" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRepurchaseOfWarrants" scale="6" unitRef="usd">0.6</ix:nonFraction> million shares of common stock expired. These warrants were issued on August
2, 2017, when the Company completed an underwritten offering of <ix:nonFraction contextRef="c64" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredOfferingCosts" scale="6" unitRef="usd">0.7</ix:nonFraction> million shares of its common stock and warrants to purchase an aggregate
of <ix:nonFraction contextRef="c65" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRepurchaseOfWarrants" scale="6" unitRef="usd">0.6</ix:nonFraction> million shares of its common stock at a price of $<ix:nonFraction contextRef="c64" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares">22.50</ix:nonFraction> per share and related warrant. The warrants were exercisable for a period
of <ix:nonNumeric contextRef="c64" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm">5</ix:nonNumeric> years at an exercise price of $<ix:nonFraction contextRef="c64" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">31.50</ix:nonFraction> per share. As of August 12, 2022, the Company has <ix:nonFraction contextRef="c66" decimals="-5" format="ixt:num-dot-decimal" name="atnm:NumberOfShares" scale="6" unitRef="shares">1.4</ix:nonFraction> million warrants outstanding.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="a_003"></a></div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
2. &#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORWARD-LOOKING
STATEMENT NOTICE</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Form 10-Q contains certain forward-looking statements. For this purpose, any statements contained in this Form 10-Q that are not statements
of historical fact may be deemed to be forward-looking statements. &#160;Without limiting the foregoing, words such as &#8220;may,&#8221;
&#8220;will,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;estimate&#8221; or &#8220;continue&#8221;
or comparable terminology are intended to identify forward-looking statements. &#160;These statements by their nature involve substantial
risks and uncertainties, and actual results may differ materially depending on a variety of factors, many of which are not within our
control. &#160;These factors include but are not limited to economic conditions generally and in the industries in which we may participate;
competition within our chosen industry, including competition from much larger competitors; technological advances and failure to successfully
develop business relationships.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description
of Business</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Actinium Pharmaceuticals, Inc.
is a clinical-stage, biopharmaceutical company applying its proprietary platform technology and deep understanding of radiobiology to
the development of novel targeted radiotherapies for patients with unmet needs. Our targeted radiotherapies combine the cell-killing ability
of radiation via a radioisotope payload with a targeting agent, such as a monoclonal antibody, to deliver radiation in a precise manner
inside the body to specific, targeted cells, to potentially achieve greater efficacy with lower toxicity than with external beam radiation.
They also enable a broader usage of radiation than external beam radiation as they can be used in the treatment of both solid tumors and
blood cancers, which generally cannot be treated with external radiation given their diffuse nature. Our clinical pipeline is focused
on targeting the antigens CD45 and CD33, both of which are expressed in multiple hematologic cancers, which are known to be highly sensitive
to radiation. Our clinical programs are focused on two primary areas: (1) targeted conditioning prior to a bone marrow transplant (&#8220;BMT&#8221;),
adoptive cell therapy (&#8220;ACT&#8221;) such as CAR-T or gene therapy with Iomab-B and (2) targeted radiotherapy combinations with Actimab-A
and other therapeutic agents. Our product development strategy is actively informed by clinical data with Iomab-B and Actimab-A in approximately
600 patients, including our ongoing Pivotal Phase 3 SIERRA trial, which completed its targeted enrollment of 150 patients in the third
quarter of 2021, with the last patient receiving their BMT in the fourth quarter of 2021. Our clinical pipeline has emanated from our
Antibody Warhead Enabling (&#8220;AWE&#8221;) technology platform, which is protected by over 195 issued and pending patents, trade secrets
and know-how that we are applying to the development of targeted radiotherapies for blood and solid tumor indications, independently and
with collaborators. Ongoing collaborations include a research partnership with Astellas Pharma, Inc. (&#8220;Astellas&#8221;) focused
on the development of theranostics, which enable the diagnosis and treatment, for solid tumor indications, a collaboration with EpicentRx,
Inc, focused on a novel CD47 immunotherapy targeted radiotherapy combination, leveraging EpicentRx&#8217;s RRx-001, that is being studied
in a Phase 3 trial in non-small cell lung cancer, with our clinical stage Actimab-A in AML models, and a collaboration with AVEO Oncology,
focused on developing a HER3 targeting ARC or Antibody Radiation Conjugate for solid tumors leveraging with their clinical stage antibody.
We are also utilizing our AWE technology platform to advance our research objectives focused on developing next-generation targeted radiotherapies
with our expanded research and development organization and research laboratories leveraging our drug development experience.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Targeted
Conditioning</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the best of our knowledge, we are advancing the most advanced multi-target, multi-indication, clinical-stage pipeline for targeted conditioning.
Our targeted conditioning agents are intended to potentially enable improved access and outcomes to cell-based therapies with curative
potential, including BMT, ACT and gene therapy. Conditioning in the context of BMT, ACT or gene therapy is the act of depleting certain
blood and immune-forming cells, including bone marrow stem cells and, in some cases, cancer cells prior to transplanting new cells into
a patient. Currently, conditioning is accomplished using a combination of cytotoxic chemotherapeutic agents and external radiation. These
non-targeted conditioning regimens are highly toxic and may prevent a patient from receiving a potentially curative therapy and hinder
outcomes. We believe our targeted conditioning agents have the potential to increase patient access and outcomes by way of their ability
to selectively deplete targeted cells while sparing normal healthy cells, resulting in potentially lower systemic and off-target toxicities.
We use our ARCs both at high isotope dose levels to achieve myeloablation, which fully depletes bone marrow stem cells and at lower isotope
dose levels to achieve lymphodepletion, which spares bone marrow stem cells from depletion. In addition, dosing may be titrated downward
from myeloablative doses to achieve partial myeloablation, which may be appropriate for certain gene therapy programs.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CD45
Targeted Conditioning Program</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Iomab-B
(I-131 apamistamab), our lead candidate and targeted conditioning agent is comprised of the anti-CD45 monoclonal antibody known as apamistamab
(formerly BC8) and the radioisotope Iodine-131 (&#8220;I-131&#8221;). CD45 is an antigen expressed on leukemia, lymphoma and myeloma
cancer cells, as well as nucleated immune cells including bone marrow stem cells, but is not expressed outside of the hematopoietic,
or blood forming, system. This unique expression on blood cancer and immune cells enables simultaneous depletion of both cell types,
making CD45 an optimal antigen for targeted conditioning applications. CD45 is a cell surface antigen with an average expression of 200,000
copies per cell, however, it only internalizes at a rate of 10-15%. We believe our ARC approach is the most effective method to target
CD45 positive cells, as the radioisotope payload linear energy transfer can readily ablate a targeted cell without requiring payload
internalization like an antibody drug conjugate or without relying on biological effector function processes like a naked antibody. Furthermore,
since CD45 expression level varies from low to high antigen density as the immune cells become more terminally differentiated, we can
selectively condition depending on the therapeutic application, from full myeloablation to transient lymphodepletion, by adjusting the
dose or intensity of the I-131 isotope payload. Full myeloablation can be achieved with high doses of I-131, as its energy pathlength
and crossfire effect can penetrate into bone marrow niches to target and deplete blood and immune system forming bone marrow stem cells.
Myeloablation is applicable to autologous or allogeneic BMT and to autologous gene-edited or modified therapies that can reconstitute
a patient&#8217;s blood and immune systems. Alternatively, low doses of I-131 can be transiently lymphodepleting and spare a patient&#8217;s
bone marrow stem cells, which we believe is ideal for ACT applications such as CAR-T. We intend to develop our CD45 targeted conditioning
program for BMT, ACT and gene therapy applications for malignant and non-malignant diseases and believe that multiple radioisotopes beyond
I-131 may be utilized including alpha and beta emitters.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Iomab-B
uses high doses of I-131 to achieve myeloablative conditioning prior to a BMT. Iomab-B is currently being studied in the pivotal Phase
3 Study of Iomab-B in Elderly Relapsed or Refractory AML (&#8220;SIERRA&#8221;), clinical trial for targeted conditioning prior to an
allogeneic BMT for patients with active, relapsed or refractory (&#8220;r/r&#8221;) Acute Myeloid Leukemia, (&#8220;AML&#8221;), who
are age 55 or older. Enrollment of the planned 150 patients in the SIERRA trial was completed in the third quarter of 2021 with the last
patient receiving their BMT in the fourth quarter of 2021. Patients with active, r/r AML are not normally considered eligible for BMT
and the SIERRA trial is the only randomized Phase 3 trial to offer BMT as a treatment option for this patient population. The SIERRA
trial compares outcomes of patients randomized to receive Iomab-B and a BMT (the &#8220;study arm&#8221;) to those patients randomized
to receive physician&#8217;s choice of salvage therapy (the &#8220;control arm&#8221;). The control arm is also defined as conventional
care, as no standard of care exists for this patient population and includes over 20 agents that may be used as single agents or in combination
including venetoclax, a targeted Bcl-2 inhibitor, Midostaurin and Sorafenib, targeted FLT3 inhibitors, hypomethylating agents and cytotoxic
chemotherapies. Patients who fail to achieve a Complete Remission (&#8220;CR&#8221;) on the control arm are ineligible to proceed to
a BMT, but the trial design permits these patients to &#8220;cross over&#8221; to receive the study arm treatment if they meet the eligibility
criteria. The primary endpoint of the SIERRA trial is durable Complete Remission (&#8220;dCR&#8221;) of 180 days and the secondary endpoint
is Overall Survival (&#8220;OS&#8221;). When the crossover patients receive Iomab-B and BMT, they have not achieved remission with their
salvage therapy and are considered to be failures for the primary endpoint of the study. The SIERRA trial recruited patients at 24 sites
in the United States and Canada, which includes many of the leading BMT sites based on volume.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
approved, we expect our initial commercial launch would target the leading 50-100 BMT and medical centers that perform the vast majority
of BMTs in the United States. In the European Union (&#8220;EU&#8221;), we received favorable feedback from the European Medicines Agency
(&#8220;EMA&#8221;) via their scientific advice program that the trial design, primary endpoint and planned statistical analysis from
the SIERRA trial are acceptable as the basis for a Marketing Authorization Application, or MAA. Additionally, the EMA commented that
it does not anticipate the need for further standalone preclinical toxicology or safety studies. Overall, transplant procedures in the
EU are approximately fifty percent higher than in the United States with a similar market dynamic, with a majority of BMT volume being
conducted in a concentrated number of leading medical centers. In April 2022, we entered into a license and supply agreement with Immedica
Pharma AB, or Immedica, pursuant to which Immedica licensed the exclusive product rights for commercialization of Iomab-B in the European
Economic Area, Middle East and North Africa. including Algeria, Andorra, Bahrain, Cyprus, Egypt, Iran, Iraq, Israel, Jordan, Kuwait,
Lebanon, Libya. Monaco, Morocco, Oman, Palestine, Qatar, San Marino, Saudi Arabia, Switzerland, Syria, Tunisia, Turkey, the United Arab
Emirates, the United Kingdom, the Vatican City and Yemen. Upon signing, we were entitled to an upfront payment of $35 million from Immedica,
which we received in May 2022. Under the terms of the agreement, we are eligible to receive regulatory and commercial milestone payments
and we are entitled to receive royalties in the mid-20 percent range on net sales of the product in certain countries that may result
from the License Agreement. We will continue to be responsible for certain clinical development activities and the manufacturing of Iomab-B
and will retain commercialization rights in the U.S. and rest of the world.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Data
from full patient enrollment in the SIERRA trial (153 patients), was presented at the Transplantation &amp; Cellular Therapy (TCT) Tandem
Meetings of ASTCT and CIBMTR, the combined annual meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and
the Center for International Blood &amp; Marrow Transplant Research (CIBMTR) in April 2022. The data presented includes rates of BMT
access and engraftment, 100-day non-relapse transplant-related mortality (100-day TRM) and adverse events, which has been reported from
interim analyses conducted at 25%, 50%, 75% and 100% of patient enrollment pursuant to the study protocol. The data presented at ASH
highlighted that 100% of patients (66/66) on the study arm that received a therapeutic dose of Iomab-B received a BMT, with a median
time to BMT of 30 days, and all patients achieved neutrophil and platelet engraftment in a median time of 18 days despite a high median
blast count of 30%. On the control arm, only 18% of patients (14/77) achieved remission after salvage therapy, and then received a BMT
with a median time to BMT of 67 days and median blast count of 20%. Of the 82% of patients failing to achieve a complete remission (&#8220;CR&#8221;)
with conventional care (63/77), 40 patients were eligible and elected to cross over to receive Iomab-B followed by transplant. These
patients are considered as having failed the primary endpoint of the study. All crossover patients who received the therapeutic dose
of Iomab-B (40/40) received a BMT, with a median time to BMT of 24 days and they achieved engraftment in a median time of 19 days despite
high median blast count of 35% at time of crossover. It was also reported that 100-day TRM of the study or Iomab-B arm was 09% (6/65)
of patients that received a BMT compared to 14% of patients (2/14) who received a BMT after salvage therapy on the control arm. The universal
engraftment rate and low 100-day TRM rate of the Iomab-B arm resulted in 59 patients potentially evaluable for the primary endpoint compared
to 12 patients in the control arm, an approximate five times difference. At each of the interim analyses throughout the SIERRA trial,
this approximate five times difference has been consistent in favor of the Iomab-B arm as a result of higher rates of BMT engraftment
and lower rates of 100-day TRM. Top-line data for the primary endpoint of durable Complete Remission is expected to be presented in the
fourth quarter of 2022 based on the current status of the data collection and data query process with certain SIERRA trial sites. We
believe topline data from SIERRA will support the submission of a Biologics License Application (&#8220;BLA&#8221;) with the FDA, which
we expect to file in the first half of 2023.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Iomab-ACT program is intended for targeted conditioning prior to ACT or gene therapy and uses the same I-131-apamistamab construct as
Iomab-B at varying doses. At lower doses of one-eighth to one-sixth of the myeloablative dose, it is applicable for lymphodepletion prior
to CAR-T or certain gene therapy applications where stem cell myeloablation is not necessary. At higher doses it is applicable for gene
therapy applications where stem cell myeloablation is necessary.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe our Iomab-ACT program is highly differentiated when compared to Fludarabine and Cyclophosphamide (&#8220;Flu/Cy&#8221;) or other
chemotherapy-based regimens that are used as the standard of practice today for lymphodepletion prior to CAR-T. CD45 is an antigen expressed
on certain immune cell types that are relevant to the mechanism of CAR-T therapies including lymphocytes, regulatory T-cells and macrophages
that have been associated with clinical responses that may limit the safety, efficacy and durability of response of these CAR-T therapies
including cytokine release syndrome (&#8220;CRS&#8221;) and neurotoxicity. Some of these limitations may be attributable to the chemotherapy-based
conditioning agents that are being used prior to CAR-T therapies. Preclinical data supporting the rational for our Iomab-ACT program
was presented at multiple medical conferences in 2019. Unlike chemotherapy, Iomab-ACT is targeted in nature and, due to this CD45-directed
targeting, we expect we can improve CAR-T cell expansion, potentially resulting in responses that are more durable, but also resulting
in reduced CAR-T related toxicities. Importantly, we expect the Iomab-ACT program construct to enable lymphodepletion through a single-dose,
outpatient administration versus Flu/Cy or other chemotherapy-based lymphodepletion regimens that can require multiple infusion cycles
over several days. Because of this potentially superior profile, the Iomab-ACT construct could result in improved access to CAR-T therapy
and better outcomes.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are studying Iomab-ACT in a clinical collaboration with Memorial Sloan Kettering Cancer Center (&#8220;MSKCC&#8221;) for targeted conditioning
prior to administration of MSKCC&#8217;s 19-28z CD19 targeting CAR-T in patients with relapsed or refractory B-cell acute lymphoblastic
leukemia (&#8220;ALL&#8221;) or diffuse large B-cell lymphoma (&#8220;DLBCL&#8221;). We received grant funding from the National Institute
of Health (&#8220;NIH&#8221;) to fund this trial with MSKCC being a co-recipient on this grant. This is a first of its kind study to
use an ARC-based conditioning regimen with CAR-T therapy. The hypothesized rationale for this study is that Iomab-ACT will exert an anti-tumor
effect on the chemotherapy-refractory B-ALL cells that are sensitive to radiation resulting in reduced disease burden and simultaneously
deplete CD45 expressing immune cells implicated in CAR-T related toxicities, resulting in an optimal homeostatic environment for the
CAR-T cells. Results with MSKCC&#8217;s 19-28z CD-19 CAR-T in 53 patients with r/r B-ALL published in the New England Journal of Medicine
reported complete remissions in 83% (44/53) of patients, which compares favorably to standard chemotherapy regimens that have complete
remission rates of 18% - 45% in this patient population. Median event-free survival (&#8220;EFS&#8221;) was 6.1 months and median overall
survival (&#8220;OS&#8221;) was 12.9 months at a median follow up period of 29 months (range 1 &#8211; 65 months). There was a 26% (14/53)
rate of Grade 3 or greater CRS and a 42% rate of Grade 3 or 4 neurotoxicity reported. The study will evaluate the feasibility of using
an ARC-based conditioning regimen with CAR-T therapy and will evaluate safety measures including incidence of CRS and neurotoxicity and
efficacy measures including responses and survival outcomes. We expect proof of concept data from this study in the second half of 2022.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we are working in collaboration with the University of California Davis to utilize Iomab-ACT conditioning with a novel anti-HIV
autologous gene therapy. We continue to identify additional gene therapies for which Iomab-ACT can be used for targeted conditioning
with the goal of collaborating with multiple academic or industry developers to establish Iomab-ACT as a non-chemotherapy universal targeted
conditioning solution.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;<b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CD33
Program: Combinations and Therapeutics </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
CD33 program is evaluating the clinical utility of Actimab-A, comprised of the anti-CD33 mAb lintuzumab linked to the potent alpha-emitting
radioisotope Actinium-225 (&#8220;Ac-225&#8221;). CD33 is expressed in the majority of patients with AML and myelodysplastic syndrome
(&#8220;MDS&#8221;) as well as approximately one-third of patients with multiple myeloma. Ac-225 emits four alpha particles and can kill
a cell with one alpha-particle hit, making it one of the most powerful cell-killing agents with no know resistance mechanism to the double
strand DNA breaks it can cause. We source Ac-225 from the Department of Energy&#8217;s Oak Ridge National Laboratory.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
CD33 development program is driven by data obtained from over one hundred fifty treated patients, including results from a Phase 1/2
trial that studied Actimab-A as a single agent at multiple dose levels in 58 patients with newly diagnosed AML, which was completed in
2018, as well as trials studying Actimab-A in combination with other agents.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that radiation delivered internally via a targeting moiety can be synergistic when used in combination with chemotherapy, targeted
agents and immunotherapy based on mechanistic rationales supported by our own clinical data, preclinical research and scientific and
clinical evidence in the literature. We have prioritized our efforts and resources in favor of combination trials for our CD33 program
development strategy rather than single agent trials at this time as we believe Actimab-A can be a backbone therapy in AML when combined
with other therapeutic modalities. Our CD33 development program encompasses the following ongoing trials:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">Actimab
-A Combination Trials</span>:</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Actimab-A
+ CLAG-M </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
combination of Actimab-A with CLAG-M has been studied in a Phase 1 combination trial that was conducted in collaboration with the Medical
College of Wisconsin (&#8220;MCW&#8221;) in patients age 18 and above with r/r AML who are fit for intensive therapy. Patient enrollment
was completed in November 2021. CLAG-M (cladribine, cytarabine, filgrastim and mitoxantrone) is a salvage chemotherapy regimen that produced
a 55% remission rate in patients with r/r AML in a previous study conducted by MCW that compared outcomes of patients receiving either
CLAG-M, MEC or CLAG salvage therapy regimens. Data from the Phase 1 combination trial of Actimab-A + CLAG-M were presented at ASH in
December 2021. After completion of dose-escalation in the Phase 1 trial, the recommended Phase 2 dose was determined to be 0.75 &#181;Ci/kg
of Actimab-A. 3 patients were enrolled in the 0.75 &#181;Ci/kg dose cohort, which had a 100% remission rate comprised of 1 complete
remission (&#8220;CR&#8221;) and 2 complete remissions with incomplete platelet recovery (&#8220;CRp&#8221;), there were no dose limiting
toxicities (&#8220;DLTs&#8221;) or 30-day mortality reported. Overall, a 67% (12/18) overall response rate (&#8220;ORR&#8221;) was reported
across all dose cohorts (0.25 &#8211; 1.0 &#181;Ci/kg) and remissions were achieved in every dose cohort including the 0.25 and 0.50
&#181;Ci/kg doses of Actimab-A, which have been shown to be subtherapeutic as a single agent. In addition, there was a 72% minimal residual
disease (&#8220;MRD&#8221;) negativity rate, which compares favorably to the 39% MRD negativity rate reported by MCW with CLAG-M alone.
This study enrolled patients who previously failed Venetoclax, a targeted Bcl-2 inhibitor, and efficacy was similar in patients Venetoclax
na&#239;ve and those that previously failed Venetoclax, with a 60% response rate in previous Venetoclax failures. We are working to develop
a regulatory and development pathway for the Actimab-A CLAG-M combination and will be evaluating potential registration enabling strategies.
In addition, we believe this Actimab-A + CLAG-M combination study has provided proof of principle that the addition of Actimab-A to other
AML therapies can lead to well-tolerated regimens with improved responses, which supports our Actimab-A backbone therapy in AML strategy.</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Actimab-A
+ Venetoclax</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also conducting a Phase 1/2 Actimab-A combination trial with the Bcl-2 inhibitor Venetoclax in fit and unfit patients age 18 and
above with relapsed or refractory AML. This multi-center trial is being led by UCLA Medical Center. This combination is supported by
mechanistic evidence in preclinical studies using Venetoclax -resistant AML tumor cell lines. In these models, we have demonstrated that
Actimab-A can deplete Mcl-1 and Bcl-XL, two proteins implicated in mediating resistance to Venetoclax, in addition to causing potentially
lethal double-stranded DNA breaks in these CD33 expressing cells. Furthermore, in vivo studies in animal models of Venetoclax-resistant
AML demonstrated robust tumor regression and improved survival in cohorts receiving the Actimab-A Venetoclax combination compared to
Venetoclax alone. The rationale for this clinical study is that the addition of Actimab-A will; 1) have a direct anti-tumor effect via
double-stranded DNA breaks and 2) deplete Mcl-1 and Bcl-XL making the AML cells more susceptible to Venetoclax. Updated data from the
Phase 1 dose escalation portion of this study was presented at ASH in December 2021 from three dose cohorts of 0.50, 0.75 and 1.0 &#181;Ci/kg
of Actimab-A in a total of 12 patients. 50% of patients received Venetoclax therapy prior to enrollment on the Actimab-A combination
trial. And 67% of patients had poor risk cytogenetics, of which, 3 had a TP53 mutation, which is associate with poorer response rates
and survival outcomes. Of the patients with a TP53 mutation, 67% achieved a remission including a patient that achieved a CR who remained
in follow-up 230 days (~7.5 months) at the time of data cutoff for ASH. The combination of Actimab-A with Venetoclax was reported to
be well-tolerated with no 30-day mortality. The data to date support advancing to the Phase 2 portion of the trial and we expect to provide
an update on the development strategy after the Phase 1 dose finding portion of the trial is complete and the recommended Phase 2 dose
is determined.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to these ongoing trials, we actively seek and evaluate additional modalities and agents that can be the basis for Actimab-A
therapeutic combinations such as the CD47 immunotherapy magrolimab combinations we announced at the Society for Immunotherapy of Cancer
(&#8220;SITC&#8221;) in November 2021 to leverage our clinical experience, supply chain and AWE technology platform.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CD47
Based ARC Combinations in Solid Tumors and Blood Cancers</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CD47
is a macrophage checkpoint that is upregulated in multiple cancers including blood cancers such as AML and MDS as well as solid tumors.
CD47 acts as a &#8220;don&#8217;t eat me&#8221; signal on cancer cells to suppress phagocytosis and evade detection and destruction by
the immune system. It has become an immunotherapy target of significant interest with multiple biopharmaceutical companies actively developing
CD47 targeting agents across a wide range of oncology and hematology indications. CD47 targeting agents have shown limited efficacy as
single agent monotherapies in AML/MDS or solid tumors, which has led to combinations such as with hypomethylating agents in AML/MDS.
We hypothesized that targeted radiotherapy via ARCs could synergize with CD47 targeting agents via the direct cytotoxic and immunogenic
effect of ARCs without overlapping toxicities. To explore this synergy and the potential to improve patient outcomes and we have initiated
a program in AML with our Actimab-A ARC, consistent with our strategy to establish Actimab-A as a backbone AML therapy, and in solid
tumors with a HER2 and HER3 targeting ARCs, which emanated from our AWE technology platform. To our knowledge, these are the first and
only ARC-based targeted radiotherapy combinations with CD47 immunotherapy. Data from the novel HER2 magrolimab combination was presented
at the 36<sup>th</sup> Annual SITC Meeting in April 2022 and at the HER3 magrolimab combination was presented American Association for
Cancer Research (&#8220;AACR&#8221;) Annual Meeting in April 2022 that showed a significant increase in tumor control compared to magrolimab
alone in preclinical non-small cell lung cancer (&#8220;NSCLC&#8221;)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
most advanced CD47 development programs are being studied in patients with AML and MDS. Leveraging our clinical experience with Actimab-A
in these indications we have begun studying Actimab-A with the anti-CD47 antibody immunotherapy magrolimab, which is owned by Gilead
Sciences, Inc., in preclinical models of AML. In preclinical models, it was shown that in multiple AML cell lines, the combination of
Actimab-A with magrolimab led to increased phagocytosis of AML cells compared to magrolimab alone. Our studies also demonstrated that
AML cell lines exposed to Actimab-A had an upregulation of calreticulin, which is a pro-phagocytic or &#8220;eat me&#8221; signal, which
we hypothesize makes Actimab-A potentially synergistic with magrolimab and other anti-CD47 antibodies. The Actimab-A and magrolimab combination
showed a significant increase in survival compared to Actimab-A alone in a disseminated AML animal tumor model. We intend to continue
to study preclinically this combination with the goal of advancing to human clinical trials.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2022, we announced a research collaboration with EpicentRx that will evaluate Actimab-A in combination with EpicentRx&#8217;s
RRx-001in AML. EpicentRx&#8217;s RRx-001, currently under investigation in a Phase 3 trial for Small Cell Lung Cancer and in other oncology
and non-oncology indications, is a versatile next generation small molecule immunotherapeutic that targets the CD47-SIRP&#945; axis
and the NLRP3 inflammasome&#160;to alter the tumor microenvironment and optimize immune response. This collaboration will explore the
mechanistic synergy of RRx-001&#8217;s CD47&#8211;SIRP&#945; downregulation with Actinium&#8217;s targeted radiotherapy calreticulin
upregulation to increase the immune detection and destruction of cancer cells. Preclinical experiments have begun exploring this combination
in AML models. We intend to leverage our experience with CD47 targeting agents such as magrolimab in this collaboration. Based on Actimab-A
and RRx-001 both being clinical-stage assets, we believe there is a potentially faster pathway to clinical trials with this novel combination,
particularly if the preclinical safety and efficacy profile are in line with what was observed with Actimab-A and magrolimab.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Antibody
Warhead Enabling Technology Platform</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our proprietary AWE technology
platform is supported by intellectual property, know-how and trade secrets that cover the generation, development, methods of use and
manufacture of targeted radiotherapies and certain of their components. Our AWE technology patent portfolio presently includes 45 patent
families comprised of over 195 issued patents and pending patent applications, of which 12 are issued and 39 are pending in the United
States, and 145 are issued or pending internationally. The effective lives of the issued patents in our portfolio, or patents that may
issue from the pending applications in our portfolio, ranges from expirations between 2024 and 2043. Our technology enables the direct
labeling, or conjugation and labeling, of a biomolecular targeting agent to a radionuclide warhead and its development and use as a therapeutic
regimen for the treatment of diseases such as cancer. Our AWE intellectual property covers various methods of use in multiple diseases,
including indication, dose and scheduling, radionuclide warhead, and therapeutic combinations. We have particular expertise in utilizing
the alpha emitting isotope Ac-225 including clinical experience in treating approximately 150 patients with our alpha-emitter-based therapies,
&#8220;gold standard&#8221; linker technology and 5 issued patents in the United States and 49 patents internationally related to the
manufacturing or Ac-225 in a cyclotron, which we believe has the potential to produce higher quantities of Ac-225 than currently utilized
methods.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research is focused on applying our AWE technology platform to the development of radiation conjugates and to execute on research collaborations.
Our R&amp;D efforts employ a multidisciplinary approach leveraging our team&#8217;s knowledge and experience in cancer cell biology,
radiochemistry, radiation sciences, immunology and oncology drug development. We intend to focus on generating targeted radiotherapies
using our existing intellectual property, evaluating assets for in-licensing to complement our existing clinical pipeline and securing
collaborations and partnerships with biopharmaceutical companies. By adding research and development capabilities to our clinical development
and clinical supply chain capabilities, we seek to enable the rapid translation of radiotherapies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
AWE technology platform is being utilized in our ongoing research collaboration with Astellas to arm select targeting agents owned by
Astellas with the alpha-emitting radioisotope Ac-225 for the development of theranostics for solid tumor indications, which combine the
ability of radioisotopes to be used for both diagnostic and therapeutic purposes.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also utilized AWE to create a HER2-targeting radiotherapy using the antibody Trastuzumab with either Ac-225 or Lu-177 radioisotopes to
study in combination with magrolimab for solid tumors. Anti-CD47 monotherapies, such as magrolimab, have not shown meaningful responses
in clinical studies in solid tumors. We hypothesized that radiation directed at HER2 expressing cells would upregulate cell surface calreticulin,
a pro-phagocytic &#8220;eat me&#8221; signal, that when combined with an anti-CD47 blockade therapy would enhance antitumor activity.
Data from this combination was presented at the Annual Meeting of the Society for Immunotherapy for Cancer in November 2021. In vitro
studies showed that immunogenicity, determined by binding to HER2 expressing cells, remained intact after radiolabeling Trastuzumab with
Ac-225 or Lu-177. In multiple cells lines radiolabeled Trastuzumab increased cell surface calreticulin and the combination with magrolimab
increased phagocytosis. The combination of the Ac-225 or Lu-117 Trastuzumab with magrolimab slowed tumor growth in animal models of solid
tumors compared to either the radiolabeled Trastuzumab or magrolimab as single agents. We are continuing to evaluate this combination
in additional tumor models, and we intend to continue to study this combination with the goal of advancing to human clinical trials.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also collaborating with AVEO Oncology (&#8220;AVEO&#8221;) to develop a targeted radiotherapy against ErbB3, also known as HER3,
with the Ac-225 isotope for solid tumor indications. HER3 is overexpressed in several solid tumor indications with high unmet needs,
including colorectal, gastric, head and neck, breast, ovarian, melanoma, prostate and bladder cancers with HER3 agents under development
demonstrating activity in preclinical and clinical studies. To our knowledge, this is the first HER3 targeting radiotherapy in development.
AVEO is developing high affinity antibodies including HER3 targeting AV-203, which has demonstrated preclinical activity across a number
of solid tumor indications and was studied in a Phase 1 open-label trial in patients with advanced solid tumors where it was found to
be safe and generally well tolerated. In April 2022, we presented data at the AACR Annual Meeting showing potent tumor cell cytotoxicity,
enhanced antitumor effects and significantly improved survival with an Ac-225 radiolabeled HER3 antibody compared to a naked HER3 antibody
in a preclinical NSCLC model. We believe these preliminary results support our collaboration with AVEO and given that AV-203 has clinical
safety data, a potentially accelerated regulatory pathway to clinical studies with an Ac-225 HER3 targeted radiotherapy.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Developments</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Impact
of COVID&#8211;19 Pandemic</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The global health crisis caused by the novel coronavirus COVID-19 pandemic
and its resurgences has and may continue to negatively impact global economic activity, which, despite progress in vaccination efforts,
remains uncertain and cannot be predicted with confidence. In addition, the Omicron variants of COVID-19, including subvariants BA.4 and
BA.5, which appear to be the most transmissible variants to date, have spread globally. The full impact of the Omicron variants, or any
subsequent variants, cannot be predicted at this time, and could depend on numerous factors, including vaccination rates among the population,
the effectiveness of COVID-19 vaccines against the Omicron variants and the response by governmental bodies and regulators. Given the
ongoing and dynamic nature of the circumstances, it is difficult to predict the impact of the COVID-19 pandemic on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
countries around the world have continued to impose quarantines and restrictions on travel and mass gatherings to slow the spread of
the virus. Accordingly, our ability to continue to operate our business may also be limited. Such events may result in a period of business,
supply and drug product manufacturing disruption, and in reduced operations, any of which could materially affect our business, financial
condition and results of operations. In response to COVID-19, we implemented hybrid working for our office-based staff, while our research
staff has been actively working in our laboratory throughout the pandemic and thus far have not experienced a significant disruption
or delay in our operations as it relates to the clinical development, preclinical research or manufacturing of our drug candidates. Such
government-imposed precautionary measures may have been relaxed in certain countries or states, but there is no assurance that more strict
measures will be put in place again due to a resurgence in COVID-19 cases, including those involving new variants of the coronavirus,
which may be more contagious and deadly than prior strains. Therefore, the COVID-19 pandemic may continue to affect our operation, may
further divert the attention and efforts of the medical community to coping with COVID-19 and disrupt the marketplace in which we operate
and may have a material adverse effect on our operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
continuation or worsening of the levels of market disruption and volatility seen in the recent past could have an adverse effect on our
ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting
from the spread of COVID-19 could materially affect our business and the value of our common stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe our earlier stage CD33 clinical trials will continue to recruit and enroll patients given the acute nature of relapsed or refractory
AML. The continuation of the pandemic could adversely affect our planned clinical trial operations, including our ability to conduct
the trials on the expected timelines and recruit and retain patients and principal investigators and site staff who, as healthcare providers,
may have heightened exposure to COVID-19 if their geography is impacted by the pandemic. Further, the continuation and/or resurgence
of the COVID-19 pandemic could result in delays in our clinical trials due to prioritization of hospital resources toward the pandemic,
restrictions in travel, potential unwillingness of patients to enroll in trials at this time, or the inability of patients to comply
with clinical trial protocols if quarantines or travel restrictions impede patient movement or interrupt healthcare services. In addition,
we rely on independent clinical investigators, contract research organizations and other third-party service providers to assist us in
managing, monitoring and otherwise carrying out our preclinical studies and clinical trials, and the pandemic may affect their ability
to devote sufficient time and resources to our programs or to travel to sites to perform work for us, which may result in delays or hinder
our ability to collect data from our clinical trials.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
COVID-19 may result in delays in receiving approvals from local and foreign regulatory authorities, delays in necessary interactions
with IRB&#8217;s or Institutional Review Boards, local and foreign regulators, ethics committees and other important agencies and contractors
due to limitations in employee resources or forced furlough of government employees.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, COVID-19 has not had a financial impact on our company. We continue to monitor the impacts of COVID-19 on the global economy and
on our business operations. Although we expect that vaccinations for COVID-19 will continue to improve conditions, the ultimate impact
from COVID-19 on our business operations and financial results during 2022 will depend on, among other things, the ultimate severity
and scope of the pandemic, including the new variants of the virus, the pace at which governmental and private travel restrictions and
public concerns about public gatherings will ease, the rate at which historically large increases in unemployment rates will decrease,
if at all, and whether, and the speed with which the economy recovers. We are not able to fully quantify the impact that these factors
will have on our financial results during 2022 and beyond.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>


</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations &#8211; Three Months Ended June 30, 2022 Compared to Three Months Ended June 30, 2021</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth, for the periods indicated, data derived from our statements of operations:&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For&#160;the<br/> Three&#160;Months&#160;Ended<br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Revenue:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Revenue</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Other revenue</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">45</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">266</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Total revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">45</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">266</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Research and development, net of reimbursements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,662</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,631</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,233</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,710</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,895</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,341</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Interest income &#8211; net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">83</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">54</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Total other income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">83</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">54</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Net loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(7,767</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(5,021</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Revenue</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recorded no commercial revenue for the three months ended June 30, 2022 and June 30, 2021.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
revenue</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
determined that certain collaborations with a third-party are within the scope of Topic ASC 606, <i>Revenue Recognition from Contracts
with Customers, </i>or ASC 606. The collaboration agreement is made up of multiple modules related to various research activities. While
the third party has the option to terminate the agreement at the conclusion of any module, we identified a single performance obligation
to provide research services within each module for which we receive monetary consideration. Other revenue recognized during the three
months ended June 30, 2022 and June 30, 2021 was $45 thousand and $0.3 million respectively.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and development, net of reimbursements</b>&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development expenses of $4.7 million for the three months
ended June 30, 2022 increased $1.1 million from $3.6 million for the three months ended June 30, 2021. Higher expenses related to increased
compensation of $0.5 million, resulting from increased compensation expenses and higher expenses due to an increase in the number of employees
and increased research activities at our laboratory space.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General
and administrative</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses of $3.2 million for the three months ended June 30, 2022 increased $1.5 million from $1.7 million for the
three months ended June 30, 2021. The increase was primarily attributable to increased compensation of $0.8 million, higher professional
fees and consulting fees including recruitment costs, and higher legal fees.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
income</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
income is comprised of net interest income in both reporting periods. The amount for the three months ended June 30, 2022 of $83 thousand
increased from $54 thousand for the three months ended June 30, 2021 due to a higher average balance.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net
loss</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss of $7.8 million for the three months ended June 30, 2022 increased by $2.8 million from $5.0 million for the three months ended
June 30, 2021, due to the increases in research and development expenses and general and administrative expenses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations &#8211; Six Months Ended June 30, 2022 Compared to Six Months Ended June 30, 2021</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth, for the periods indicated, data derived from our statements of operations:&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For&#160;the<br/> Six&#160;Months&#160;Ended<br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Revenue:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Revenue</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Other revenue</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">985</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">888</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Total revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">985</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">888</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Research and development, net of reimbursements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,031</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,907</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,968</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,428</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,999</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,335</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Interest income &#8211; net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">118</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">106</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Total other income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">118</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">106</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Net loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(12,896</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(10,341</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Revenue</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recorded no commercial revenue for the six months ended June 30, 2022 and June 30, 2021.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
revenue</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
determined that certain collaborations with a third-party are within the scope of ASC 606. The collaboration agreement is made up of
multiple modules related to various research activities. While the third party has the option to terminate the agreement at the conclusion
of any module, we identified a single performance obligation to provide research services within each module for which we receive monetary
consideration. Other revenue recognized during the six months ended June 30, 2022 and June 30, 2021 was $0.9 million and $0.9 million
respectively.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
National Institutes of Health awarded us a Small Business Technology Transfer cost reimbursable grant to support a clinical collaboration
with Memorial Sloan Kettering Cancer Center, or MSK, to study Iomab-ACT for targeted conditioning to achieve lymphodepletion prior to
administration of a CD19-targeted CAR T-cell therapy developed at MSK. We recognized other revenue during the six months ended June 30,
2022 of $0.1 million.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and development, net of reimbursements</b>&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses of $9.0 million for the six months ended June 30, 2022 increased $1.1 million from $7.9 million for the six
months ended June 30, 2021. The increase was due to higher expenses related to our research activities at our laboratory space and government
grant program and increased compensation of $0.5 million.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General
and administrative</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses of $5.0 million for the six months ended June 30, 2022 increased $1.6 million from $3.4 million for the six
months ended June 30, 2021. The increase was primarily attributable to increased compensation of $0.8 million, higher professional fees
and consulting fees including recruitment costs, and higher legal fees.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
income</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Other income is comprised of net
interest income in both reporting periods. The amount for the six months ended June 30, 2022 of $0.1 million was unchanged from the prior-year
period.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net
loss</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss of $12.9 million for the six months ended June 30, 2022 increased by $2.6 million from $10.3 million for the six months ended June
30, 2021, due to the increases in research and development expenses and general and administrative expenses. &#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Capital Resources</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historically,
we have financed our operations primarily through sales of shares of our stock. The following tables sets forth selected cash flow information
for the periods indicated:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For&#160;the<br/> Six&#160;Months&#160;Ended<br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Cash provided by/used in operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">22,137</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(10,226</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Cash used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(277</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(65</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,641</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">28,644</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Net&#160;change in cash, cash equivalents and restricted cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">38,501</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">18,353</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash provided by operating
activities for the six months ended June 30, 2022 of $22.1 million increased by $32.3 million from a use of funds of $10.2 million in
the prior-year period. This increase was due to the receipt of the $35.0 million up-front payment from Immedica.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in investing activities of $0.3 million for the six months ended June 30, 2022 and $0.1 million for the prior-year period are
primarily due to the acquisition of equipment for our laboratory.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash provided by financing
activities for the six months ended June 30, 2022 of $16.6 million and for the six months ended June 30, 2021 of $28.6 million was primarily
from the sale of shares of our common stock.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We entered into a lease for corporate office space effective June 1, 2022
and paid a security deposit to the landlord. The lease has a term of 5 years 2 months, with an expiration date of July 30, 2027, and a
current annual rate of $0.6 million. We are also responsible for certain other costs, such as insurance, taxes, utilities and maintenance.
In July, 2022 a certificate of deposit was provided as collateral for a letter of credit and the security deposit was returned.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020 we entered into a Capital on Demand&#8482; Sales Agreement with JonesTrading Institutional Services LLC, or JonesTrading,
pursuant to which we may sell, from time to time, through or to JonesTrading, up to an aggregate of $200 million of our common stock.
Shares of common stock are offered pursuant to our shelf registration statement on Form S-3 filed with the SEC on August 7, 2020. As
of December 31, 2021, we had sold 6.7 million shares of common stock, resulting in gross proceeds of $59.1 million and net proceeds of
$57.0 million. For the six months ended June 30, 2022, we sold 2.7 million shares of common stock, resulting in gross proceeds of $17.2
million and net proceeds of $16.7 million. For the six months ended June 30, 2021, we sold 3.5 million shares of common stock, resulting
in gross proceeds of $29.6 million and net proceeds of $28.7 million.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 28, 2022, we entered into an Amendment and Restated Capital on Demand&#8482; Sales Agreement, or the A&amp;R Sales Agreement, with
JonesTrading and B. Riley Securities, Inc., or B. Riley Securities. The A&amp;R Sales Agreement modifies the original Capital on Demand&#8482;
Sales Agreement to include B. Riley Securities as an additional sales agent thereunder.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of filing this report, we expect that our existing resources will be more than sufficient to fund our planned operations
for more than 12 months following the date of this report.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Policies and Use of Estimates</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management&#8217;s discussion and analysis of financial condition and results of operations is based on our consolidated financial statements,
which have been prepared in accordance with accounting principles generally accepted in the United States, (&#8220;GAAP&#8221;). The
preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities
and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements during the reporting periods.
These items are monitored and analyzed by us for changes in facts and circumstances, and material changes in these estimates could occur
in the future. We base our estimates on historical experience, known trends and events, and on various other factors that we believe
are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and
liabilities that are not readily apparent from other sources. Changes in estimates are reflected in reported results for the period in
which they become known. Actual results may differ materially from these estimates under different assumptions or conditions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
significant accounting policies are described in detail in the notes to our consolidated financial statements appearing in our Annual
Report filed on Form 10-K for the year ended December 31, 2021.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Revenue
Recognition </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognize revenue in accordance with ASC 606. Under ASC 606, we recognize revenue when our customer obtains control of promised goods
or services, in an amount that reflects the consideration that we expect to receive in exchange for those goods or services. To determine
revenue recognition for arrangements within the scope of ASC 606, we perform the following five steps: (i) identify the contract(s) with
a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration,
if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue as we satisfy a
performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration to
which we are entitled in exchange for the goods or services we transfer to the customer.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
contract inception, once the contract is determined to be within the scope of ASC 606, we assess whether the promised goods or services
promised within each contract are distinct and, therefore, represent a separate performance obligation.&#160;Goods and services that
are determined not to be distinct are combined with other promised goods and services until a distinct bundle is identified. In determining
whether goods or services are distinct, we evaluate certain criteria, including whether (i)&#160;the customer can benefit from the good
or service either on its own or together with other resources that are readily available to the customer (capable of being distinct)
and (ii)&#160;the good or service is separately identifiable from other goods or services in the contract (distinct in the context of
the contract).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
606 requires us to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation
after determining the transaction price of the contract and identifying the performance obligations to which that amount should be allocated.
The relative standalone selling price is defined in the new revenue standard as the price at which an entity would sell a promised good
or service separately to a customer. We then recognize as revenue the amount of the transaction price that is allocated to the respective
performance obligation as each performance obligation is satisfied, either at a point in time or over time, and if over time, recognition
is based on the use of an output or input method.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Collaborative
Arrangements </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
follow the accounting guidance for collaboration agreements, which requires that certain transactions between us and collaborators be
recorded in our consolidated statements of operations and comprehensive loss on either a gross basis or net basis, depending on the characteristics
of the collaborative relationship, and requires enhanced disclosure of collaborative relationships. We evaluate our collaboration agreements
for proper classification in our consolidated statements of operations and comprehensive loss based on the nature of the underlying activity.
When we conclude that we have a customer relationship with one of our collaborators, we follow the guidance of ASC 606<i>.</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>License
Revenue </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
entered into a product licensing agreement whereby we allowed a third party to commercialize a certain product in specified territories
using our trademarks. The terms of this arrangement includes payment to us for a combination of one or more of the following: upfront
license fees; development, regulatory and sales-based milestone payments; and royalties on net sales of licensed products. We use judgment
to determine whether milestones or other variable consideration should be included in the transaction price.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Upfront
license fees</i>: If the license to our intellectual property is determined to be distinct from the other performance obligations identified
in the arrangement, we will recognize revenue from upfront license fees allocated to the license when the license is transferred to the
licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, we determine
whether the combined performance obligation is satisfied over time or at a point in time.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Development,
regulatory or commercial milestone payments</i>: At the inception of each arrangement that includes payments based on the achievement
of certain development, regulatory and sales-based or commercial events, we evaluate whether the milestones are considered probable of
being achieved and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable
that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments
that are not within our or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of being achieved
until regulatory approval is received. At the end of each subsequent reporting period, we will re-evaluate the probability of achieving
such development and regulatory milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction
price. Any such adjustments are recorded on a cumulative catch-up basis and recorded as part of license revenues during the period of
adjustment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Sales-based
milestone payments and royalties</i>: For arrangements that include sales-based royalties, including milestone payments based on the
volume of sales, we will determine whether the license is deemed to be the predominant item to which the royalties or sales-based milestones
relate and if such is the case, we will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance
obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upfront
payments and fees may require deferral of revenue recognition to a future period until we perform our obligations under these arrangements
or when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty
associated with any variable consideration is subsequently resolved. Amounts payable to us are recorded as accounts receivable when our
right to consideration is unconditional.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and Development Costs</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed as incurred. These costs include the costs of manufacturing drug product, the costs of clinical trials,
costs of employees and associated overhead, and depreciation and amortization costs related to facilities and equipment. Research and
development reimbursements are recorded by us as a reduction of research and development costs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share-Based
Payments</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
estimate the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model. The fair value
determined represents the cost for the award and is recognized over the vesting period during which an employee is required to provide
service in exchange for the award. We account for forfeitures of stock options as they occur.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accounting
Standards Recently Adopted </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2021, FASB issued ASU 2021-04, <i>Earnings Per Share (topic 260), Debt &#8212; Modifications and Extinguishments (Subtopic 470-50),
Compensation &#8211; Stock Compensation (Topic 718) and Derivatives and Hedging &#8211; Contracts in an Entity&#8217;s Own Equity (Subtopic
815-40) &#8211; Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options</i>,
which provides guidance of a modification or an exchange of a freestanding equity-classified written call option that remains equity
classified after modification or exchange as (1) an adjustment to equity and, if so, the related earnings per share (EPS) effects, if
any, or (2) an expense and, if so, the manner and pattern of recognition. The amendments in this ASU are effective January 1, 2022, including
interim periods. We adopted this standard effective January 1, 2022 and the standard did not have a material effect on our financial
statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In November 2021, the FASB issued
ASU 2021-10, <i>Government Assistance (Topic 832), Disclosures by Business Entities about Government Assistance</i>, which provides guidance
on disclosure requirements to entities other than not-for-profit entities about transaction with a government that are accounted for by
applying a grant or contribution accounting model by analogy. ASU 2021-10 requires an entity to make annual disclosures related to (1)
the nature of the transactions and the related accounting policy used to account for the government transactions, (2) quantification and
disclosure of amounts related to the government transactions included in balance sheet and income statement financial statement line items,
and (3) significant terms and conditions of the government transactions, including commitments and contingencies. The amendments of ASU
2021-10 are effective January 1, 2022, including interim periods. We adopted this standard effective January 1, 2022 and the standard
did not have a material impact on our financial statements.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accounting
Standards Recently Issued</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2021, FASB issued ASU 2021-08, <i>Business Combinations (Topic 805), Account for Contract Assets and Contract Liabilities from
Contracts with Customers</i>, which provides guidance on accounting for contract assets and contract liabilities acquired in a business
combination in accordance ASC 606. To achieve this, an acquirer may assess how the acquiree applied ASC 606 to determine what to record
for the acquired revenue contracts. Generally, this should result in an acquirer recognizing and measuring the acquired contract assets
and contract liabilities consistent with how they were recognized and measured in the acquiree&#8217;s financial statements. The amendments
of ASU 2021-08 are effective January 1, 2023, including interim periods. Early adoption is permitted, including adoption in an interim
period. We will evaluate the impact of ASU 2021-08 on any future business combinations that we may enter in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Subsequent
Events</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
June 30, 2022, we have sold 0.3 million shares of common stock under our A&amp;R Sales Agreement, resulting in net proceeds of $1.4 million.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 2, 2022, warrants to purchase an aggregate of 0.6 million shares of common stock expired. These warrants were issued on August
2, 2017, when we completed an underwritten offering of 0.7 million shares of our common stock and warrants to purchase an aggregate of
0.6 million shares of our common stock at a price of $22.50 per share and related warrant. The warrants were exercisable for a period
of 5 years at an exercise price of $31.50 per share. As of August 12, 2022, we have 1.4 million warrants outstanding.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="a_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not currently exposed to significant market risk related to changes in interest rates. As of June 30, 2022, our cash equivalents
consisted primarily of short-term money market funds. Our primary exposure to market risk is interest rate sensitivity, which is affected
by changes in the general level of U.S. interest rates. Due to the short-term nature of the cash equivalents in our portfolio and the
low risk profile of our cash equivalents, an immediate 10% change in interest rates would not have a material effect on the fair market
value of our financial position or results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not currently exposed to significant market risk related to changes in foreign currency exchange rates. Our operations may be subject
to fluctuations in foreign currency exchange rates in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inflation
generally affects us by increasing our cost of labor and clinical trial costs. We do not believe that inflation had a material effect
on our business, financial condition or results of operations during the six months ended June 30, 2022 and 2021.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
4. CONTROLS AND PROCEDURES.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Evaluation
of Disclosure Controls and Procedures</i>. &#160;Under the supervision and with the participation of our management, including our principal
executive officer and principal financial and accounting officer, we conducted an evaluation of the effectiveness, as of June 30, 2022,
of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as
amended, or the Exchange Act. Based upon such evaluation, our principal executive officer and principal financial and accounting officer
have concluded that, as of June 30, 2022, our disclosure controls and procedures were effective to provide reasonable assurance that
the information we are required to disclose in our filings with the Securities and Exchange Commission, or SEC, under the Exchange Act
(i) is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms and (ii) accumulated
and communicated to our management, including our principal executive officer and principal financial and accounting officer, as appropriate
to allow timely decisions regarding required disclosure.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Changes
in Internal Control over Financial Reporting</i>. There were no changes in our system of internal controls over financial reporting during
the period covered by this report that has materially affected, or are reasonably likely to materially affect, our internal control over
financial reporting.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
II &#8211; OTHER INFORMATION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
1. LEGAL PROCEEDINGS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
1A. RISK FACTORS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>In
analyzing our company, you should consider carefully the following risk factors, together with all of the other information included
in this Quarterly Report on Form&#160;10-Q. Factors that could cause or contribute to differences in our actual results include those
discussed in the following subsection, as well as those discussed above in &#8220;Management&#8217;s Discussion and Analysis of Financial
Condition and Results of Operations&#8221; and in our Annual Report filed on Form 10-K for the year ended December 31, 2021. Each of
the following risk factors, either alone or taken together, could adversely affect our business, operating results and financial condition,
as well as adversely affect the value of an investment in our company. The risks and uncertainties described below are not the only ones
we face. Additional risks not currently known to us or other factors not perceived by us to present significant risks to our business
at this time also may impair our business operations.</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
of Risk Factors</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are providing the following summary of the risk factors contained in this Annual Report on Form 10-K to enhance the readability and accessibility
of our risk factor disclosures. We encourage you to carefully review the full risk factors contained in this Annual Report on Form 10-K
in their entirety for additional information regarding the material factors that make an investment in our securities speculative or
risky. These risks and uncertainties include, but are not limited to, the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are a clinical-stage company and have generated no revenue from commercial sales to date;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have incurred net losses in every year since our inception and anticipate that we will continue to incur net losses in the future;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we fail to obtain additional financing, we will be unable to continue or complete our product development and you will likely lose
    your entire investment;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are highly dependent on the success of Iomab-B and the SIERRA trial and we may not be able to complete the necessary clinical development
    or our development efforts may not result in the data necessary to receive regulatory approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    business could be adversely affected by the effects of health epidemics, including the global COVID-19 pandemic;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have not demonstrated that any of our products are safe and effective for any indication and will continue to expend substantial
    time and resources on clinical development before any of our current or future product candidates will be eligible for FDA approval,
    if ever;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    clinical trials may fail to demonstrate adequately the efficacy and safety of our product candidates, which would prevent or delay
    regulatory approval and commercialization;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preliminary,
    Interim, and &#8220;top-line&#8221; data from our clinical trials that we announce or publish from time to time may change as more
    patient data become available and are subject to audit and verification procedures that could result in material changes in the final
    data.;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare
                                            legislative reform measures intended to increase pressure to reduce prices of pharmaceutical
                                            products paid for by Medicare or, otherwise, affect the federal regulation of the U.S. healthcare
                                            system could have a material adverse effect our business, future revenue, if any, and results
                                            of operations;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties
    or meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval for or commercialize
    our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    currently depend on a single third-party manufacturer to produce our pre-clinical and clinical trial drug supplies. Any disruption
    in the operations of our current third-party manufacturer, or other third-party manufacturers we may engage in the future, could
    adversely affect our business and results of operations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent
    their regulatory approval, limit their commercial potential, or result in significant negative consequences;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    patent position is highly uncertain and involves complex legal and factual questions.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    use of hazardous materials, including radioactive and biological materials, in our research and development efforts imposes certain
    compliance costs on us and may subject us to liability for claims arising from the use or misuse of these materials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are highly dependent on our key personnel, and the demand for talent in the biotechnology industry is highly competitive;
    if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement or
    execute our business strategy;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
    provisions of our Certificate of Incorporation and Bylaws and Delaware law make it more difficult for a third party to acquire us
    and make a takeover more difficult to complete, even if such a transaction were in our stockholders&#8217; interest; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>Risks
Related to Our Business</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are a clinical-stage company and have generated no revenue from commercial sales to date. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage biopharmaceutical company with a limited operating history. We have no products approved for commercial sale and
have not generated any revenue from product sales to date. We will encounter risks and difficulties frequently experienced by early-stage
companies in rapidly evolving fields. If we do not address these risks successfully, our business will suffer.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have incurred net losses in every year since our inception and anticipate that we will continue to incur net losses in the future.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not profitable and have incurred losses in each period since our inception. As of June 30, 2022, and December 31, 2021, we had an
accumulated deficit of $268.6 million and $255.7 million, respectively. We reported a net loss of $12.9 million and $10.3 million for
the six months ended June 30, 2022, and 2021, respectively. We expect to continue to operate at a net loss as we continue our research
and development efforts, continue to conduct clinical trials and develop manufacturing, sales, marketing and distribution capabilities.
There can be no assurance that the products under development by us will be approved for sale in the United States or elsewhere. Furthermore,
there can be no assurance that if such products are approved, they will be successfully commercialized, which would have an adverse effect
on our business prospects, financial condition and results of operation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to obtain additional financing, we will be unable to continue or complete our product development and you will likely lose your
entire investment.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, we entered into the Capital on Demand&#8482; Sales Agreement with JonesTrading, pursuant to which we may sell, from time
to time, through or to JonesTrading, up to an aggregate of $200 million of our common stock. Shares of common stock are offered pursuant
to our shelf registration statement filed with the SEC on August 7, 2020. As of December 31, 2021, we had sold 6.7 million shares of
common stock, resulting in gross proceeds of $59.1 million and net proceeds of $57.0 million. For the six months ended June 30, 2022,
we sold 2.7 million shares of common stock, resulting in gross proceeds of $17.2 million and net proceeds of $16.7 million.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 28, 2022, we entered into an Amendment and Restated Capital on Demand&#8482; Sales Agreement, or the A&amp;R Sales Agreement, with
JonesTrading and B. Riley Securities, Inc., or B. Riley Securities. The A&amp;R Sales Agreement modifies the Original Capital on Demand&#8482;
Sales Agreement to include B. Riley Securities as an additional sales agent thereunder.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of filing this report, we expect that our existing resources will be more than sufficient to fund our planned operations
for more than 12 months following the date of this report.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business or operations may change in a manner that would consume available funds more rapidly than anticipated and substantial additional
funding may be required to maintain operations, fund expansion, develop new or enhanced products, acquire complementary products, business
or technologies or otherwise respond to competitive pressures and opportunities, such as a change in the regulatory environment or a
change in preferred cancer treatment modalities. However, we may not be able to secure funding when we need it or on favorable terms
or indeed on any terms. In addition, from time to time, we may not be able to secure enough capital in a timely enough manner which may
cause the generation of a going-concern opinion from our auditors which can and may impair our stock market valuation and also our ability
to finance on favorable terms or indeed on any terms.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
raise additional capital, we may in the future offer additional shares of our common stock or other securities convertible into or exchangeable
for our common stock. We cannot assure you that we will be able to sell shares or other securities in any other offering at a price per
share that is equal to or greater than the price per share paid by investors, and investors purchasing shares or other securities in
the future could have rights superior to existing stockholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we cannot raise adequate funds to satisfy our capital requirements, we will have to delay, scale back or eliminate our research and development
activities, clinical studies or future operations. We may also be required to obtain funds through arrangements with collaborators, which
arrangements may require us to relinquish rights to certain technologies or products that we otherwise would not consider relinquishing,
including rights to future product candidates or certain major geographic markets. We may further have to license our technology to others.
This could result in sharing revenues which we might otherwise have retained for ourselves. Any of these actions may harm our business,
financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amount of funding we will need depends on many factors, including the progress, timing and scope of our product development programs;
the progress, timing and scope of our preclinical studies and clinical trials; the time and cost necessary to obtain regulatory approvals;
the time and cost necessary to further develop manufacturing processes and arrange for contract manufacturing; our ability to enter into
and maintain collaborative, licensing and other commercial relationships; and our partners&#8217; commitment of time and resources to
the development and commercialization of our products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have limited access to the capital markets and even if we can raise additional funding, we may be required to do so on terms that are
dilutive to you.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have limited access to the capital markets to raise funds. The capital markets have been unpredictable in the recent past for radioisotope
and other oncology companies and unprofitable companies such as ours. In addition, it is generally difficult for development-stage companies
to raise capital under current market conditions. The amount of capital that a company such as ours is able to raise often depends on
variables that are beyond our control. As a result, we may not be able to secure financing on terms attractive to us, or at all. If we
are able to consummate a financing arrangement, the amount raised may not be sufficient to meet our future needs. If adequate funds are
not available on acceptable terms, or at all, our business, including our technology licenses, results of operations, financial condition
and our continued viability will be materially adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are highly dependent on the success of
Iomab-B and the SIERRA trial and we may not be able to complete the necessary clinical development or our development efforts may not
result in the data necessary to receive regulatory approval.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have completed patient
enrollment in the pivotal Phase 3 SIERRA trial (Study of Iomab-B in Elderly Relapsed or Refractory AML), a 153-patient multi-center randomized
trial that will compare outcomes of patients who receive Iomab-B and a BMT to those patients receiving physician&#8217;s choice of salvage
chemotherapy, defined as conventional care, as no standard of care exists for this patient population. The SIERRA trial may be unsuccessful
and fail to demonstrate a safety and efficacy profile that is necessary to receive favorable regulatory approval. Even if Iomab-B receives
favorable regulatory approval, we may not be successful in securing adequate reimbursement or establishing successful commercial operations.
Any or all of these factors could have a material adverse impact on our business and ability to continue operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be unable to establish sales, marketing
and commercial supply capabilities.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not currently have,
nor have we ever had, commercial sales and marketing capabilities. If any of our product candidates become approved, we would have to
build and establish these capabilities in order to commercialize our approved product candidates. The process of establishing commercial
capabilities will be expensive and time consuming. Even if we are successful in building sales and marketing capabilities, we may not
be successful in commercializing any of our product candidates. Any delays in commercialization or failure to successfully commercialize
any product candidate may have material adverse impacts on our business and ability to continue operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our business could be adversely affected
by the effects of health epidemics, including the global COVID-19 pandemic.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The global health crisis caused by the novel coronavirus COVID-19 pandemic
and its resurgences has and may continue to negatively impact global economic activity, which, despite progress in vaccination efforts,
remains uncertain and cannot be predicted with confidence. In addition, the Omicron variants of COVID-19, including subvariants BA.4 and
BA.5, which appear to be the most transmissible variants to date, have spread globally. The full impact of the Omicron variant, or any
subsequent variant, cannot be predicted at this time, and could depend on numerous factors, including vaccination rates among the population,
the effectiveness of COVID-19 vaccines against the Omicron variant and the response by governmental bodies and regulators. Given the ongoing
and dynamic nature of the circumstances, it is difficult to predict the impact of the COVID-19 pandemic on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many countries around the
world have continued to impose quarantines and restrictions on travel and mass gatherings to slow the spread of the virus. Accordingly,
our ability to continue to operate our business may also be limited. Such events may result in a period of business, supply and drug product
manufacturing disruption, and in reduced operations, any of which could materially affect our business, financial condition and results
of operations. In response to COVID-19, we implemented remote working and thus far have not experienced a significant disruption or delay
in our operations as it relates to the clinical development of our drug candidates. Such government-imposed precautionary measures may
have been relaxed in certain countries or states, but there is no assurance that more strict measures will be put in place again due to
a resurgence in COVID-19 cases, including those involving new variants of the coronavirus, which may be more contagious and deadly than
prior strains. Therefore, the COVID-19 pandemic may continue to affect our operation, may further divert the attention and efforts of
the medical community to coping with COVID-19 and disrupt the marketplace in which we operate and may have a material adverse effect on
our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A continuation or worsening
of the levels of market disruption and volatility seen in the recent past could have an adverse effect on our ability to access capital,
which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of
COVID-19 could materially affect our business and the value of our common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe our earlier stage
CD33 clinical trials will continue to recruit and enroll patients given the acute nature of relapsed or refractory AML. The continuation
of the pandemic could adversely affect our planned clinical trial operations, including our ability to conduct the trials on the expected
timelines and recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened
exposure to COVID-19 if their geography is impacted by the pandemic. Further, the continuation and/or resurgence of the COVID-19 pandemic
could result in delays in our clinical trials due to prioritization of hospital resources toward the pandemic, restrictions in travel,
potential unwillingness of patients to enroll in trials at this time, or the inability of patients to comply with clinical trial protocols
if quarantines or travel restrictions impede patient movement or interrupt healthcare services. In addition, we rely on independent clinical
investigators, contract research organizations and other third-party service providers to assist us in managing, monitoring and otherwise
carrying out our preclinical studies and clinical trials, and the pandemic may affect their ability to devote sufficient time and resources
to our programs or to travel to sites to perform work for us, which may result in delays or hinder our ability to collect data from our
clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, COVID-19 may
result in delays in receiving approvals from domestic and foreign regulatory authorities, delays in necessary interactions with Institutional
Review Boards (&#8220;IRBs&#8221;), domestic and foreign regulators, ethics committees and other important agencies and contractors due
to limitations in employee resources or forced furlough of government employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We continue to monitor the
impacts of COVID-19 on the global economy and on our business operations. However, the ultimate impact from COVID-19 on our business operations
and financial results during 2022 will depend on, among other things, the ultimate severity and scope of the pandemic, including the new
variants of the virus, the pace at which governmental and private travel restrictions and public concerns about public gatherings will
ease, the rate at which historically large increases in unemployment rates will decrease, if at all, and whether, and the speed with which
the economy recovers. We are not able to fully quantify the impact that these factors will have on our financial results during 2022 and
beyond.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our business is subject to cybersecurity
risks.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our operations are increasingly
dependent on information technologies and services. Threats to information technology systems associated with cybersecurity risks and
cyber incidents or attacks continue to grow, and include, among other things, storms and natural disasters, terrorist attacks, utility
outages, theft, viruses, phishing, malware, design defects, human error, and complications encountered as existing systems are maintained,
repaired, replaced, or upgraded. Risks associated with these threats include, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">theft or misappropriation of funds;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss, corruption, or misappropriation of intellectual property, or other proprietary, confidential or personally identifiable information (including supplier, clinical data or employee data);</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disruption or impairment of our and our business operations and safety procedures;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">damage to our reputation with our potential partners, patients and the market;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exposure to litigation; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased costs to prevent, respond to or mitigate cybersecurity events.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we utilize various
procedures and controls to mitigate our exposure to such risk, cybersecurity attacks and other cyber events are evolving and unpredictable.
Moreover, we have no control over the information technology systems of third parties conducting our clinical trials, our suppliers, and
others with which our systems may connect and communicate. As a result, the occurrence of a cyber incident could go unnoticed for a period
time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have cybersecurity insurance
coverage in the event we become subject to various cybersecurity attacks, however, we cannot ensure that it will be sufficient to cover
any particular losses we may experience as a result of such cyberattacks. Any cyber incident could have a material adverse effect on our
business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Regulation&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The FDA or comparable foreign regulatory
authorities may disagree with our regulatory plans and we may fail to obtain regulatory approval of our product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our products are subject to
rigorous regulation by the FDA and numerous other federal, state and foreign governmental authorities. The process of seeking regulatory
approval to market an antibody radiation-conjugate product is expensive and time-consuming, and, notwithstanding the effort and expense
incurred, approval is never guaranteed. If we are not successful in obtaining timely approval of our products from the FDA, we may never
be able to generate significant revenue and may be forced to cease operations. In particular, the FDA permits commercial distribution
of a new antibody radiation-conjugate product only after a BLA for the product has received FDA approval. The BLA process is costly, lengthy
and inherently uncertain. Any BLA filed by us will have to be supported by extensive data, including, but not limited to, technical, preclinical,
clinical trial, chemistry, manufacturing and controls (&#8220;CMC&#8221;) and labeling data, to demonstrate to the FDA&#8217;s satisfaction
the safety and efficacy of the product for its intended use. The lengthy approval process as well as the unpredictability of future clinical
trial results may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm
our business, results of operations and prospects. In addition, even if we were to obtain approval, regulatory authorities may approve
any of our product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for
our products, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate
with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate.
Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The approval process in the
United States and in other countries could result in unexpected and significant costs for us and consume management&#8217;s time and other
resources. The FDA and other foreign regulatory agencies could ask us to supplement our submissions, collect non-clinical data, conduct
additional clinical trials or engage in other time-consuming actions, or it could simply deny our applications. In addition, even if we
obtain approval to market our products in the United States or in other countries, the approval could be revoked, or other restrictions
imposed if post-market data demonstrates safety issues or lack of effectiveness. We cannot predict with certainty how, or when, the FDA
or other regulatory authorities will act. If we are unable to obtain the necessary regulatory approvals, our financial condition and cash
flow may be materially adversely affected, and our ability to grow domestically and internationally may be limited. Additionally, even
if we obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications that we
request. The Company&#8217;s products may not be approved for the specific indications that are most necessary or desirable for successful
commercialization or profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have not demonstrated that any of our
products are safe and effective for any indication and will continue to expend substantial time and resources on clinical development
before any of our current or future product candidates will be eligible for FDA approval, if ever.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect that a substantial
portion of our efforts and expenditures over the next few years will be devoted to development of our existing and contemplated biological
product candidates. Accordingly, our business currently depends heavily on the successful development, FDA approval, and commercialization
of such candidates, which may never receive FDA approval or be successfully commercialized even if FDA approval is received. The research,
testing, manufacturing, labeling, approval, sale, marketing, and distribution of our biological product candidates are, and will remain,
subject to extensive regulation by the FDA and other regulatory authorities in the United States and other countries, as applicable. We
are currently not permitted to market any of our current or future product candidates in the United States until we receive FDA approval
(of each) via the BLA process. To date, we have two product candidates in clinical development and have not-yet submitted a BLA for any
of our candidates and, for many such candidates, do not expect to be in a position to do so for the foreseeable future, as there are numerous
developmental steps that must be completed before we can prepare and submit a BLA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, the
FDA regulates pharmaceutical and biological product candidates under the FDCA and the Public Health Service Act (&#8220;PHSA&#8221;),
as well as their respective implementing regulations. Such products and product candidates are also subject to other federal, state, and
local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal,
state, local, and foreign statutes and regulations requires the expenditure of substantial time and financial resources. The process required
by the FDA before a drug or biological product may be marketed in the United States generally involves the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion of preclinical laboratory tests and animal studies in accordance with FDA&#8217;s good laboratory practices (&#8220;GLPs&#8221;) and applicable requirements for the humane use of laboratory animals or other applicable regulations;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission to the FDA of an Investigational New Drug (&#8220;IND&#8221;), which must become effective before human clinical trials in the United States may begin;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance of adequate and well-controlled human clinical trials in accordance with FDA&#8217;s IND regulations, GCPs, and any additional requirements for the protection of human research subjects and their health information, to establish the safety and efficacy of the proposed biological product for its intended use;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission to the FDA of a BLA for marketing approval that meets applicable requirements to ensure the continued safety, purity, and potency of the product that is the subject of the BLA based on results of preclinical testing and clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the biological product is produced, to assess compliance with cGMPs and assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s identity, strength, quality and purity;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential FDA audit of the nonclinical study and clinical trial sites that generated the data in support of the BLA; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA review and approval, or denial, of the BLA.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before testing any biological
product candidate in humans, the product candidate enters the preclinical testing stage. Preclinical tests include laboratory evaluations
of product chemistry, toxicity and formulation, as well as animal studies to assess the potential safety and activity of the product candidate.
The conduct of the preclinical tests must comply with federal regulations and requirements including GLPs. The clinical trial sponsor
must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data
or literature and a proposed clinical protocol, to the FDA as part of the IND. Some preclinical testing may continue even after the IND
is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns or questions regarding
the proposed clinical trials and places the trial on a clinical hold within that 30-day time period. In such a case, the IND sponsor and
the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may also impose clinical holds on a biological
product candidate at any time before or during clinical trials due to safety concerns or non-compliance. If the FDA imposes a clinical
hold, trials may not recommence without FDA authorization and then only under terms authorized by the FDA. Accordingly, we cannot be sure
that submission of an IND will result in the FDA allowing clinical trials to begin or that, for those that have already commenced under
an active IND, that issues will not arise that suspend or terminate such trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical trials involve the
administration of the biological product candidate to healthy volunteers or patients under the supervision of qualified investigators,
generally physicians not employed by or under the trial sponsor&#8217;s control. Clinical trials are conducted under protocols detailing,
among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, and the parameters
to be used to monitor subject safety, including stopping rules that assure a clinical trial will be stopped if certain adverse events
should occur. Each protocol and any amendments to the protocol must be submitted to the FDA as part of the IND. Clinical trials must be
conducted and monitored in accordance with the FDA&#8217;s regulations composing the GCP requirements, including the requirement that
all research subjects provide informed consent. Further, each clinical trial must be reviewed and approved by an independent institutional
review board, or IRB, at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting
the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical
trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the form and content of the informed
consent that must be signed by each clinical trial subject or his or her legal representative and must monitor the clinical trial until
completed. Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 1. The biological product is initially introduced into healthy human subjects and tested for safety. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in subjects.</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 2. The biological product is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 3. Clinical trials are undertaken to further evaluate dosage, clinical efficacy, potency, and safety in an expanded patient population at geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk to benefit ratio of the product and provide an adequate basis for product labeling.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Post-approval clinical trials,
sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These clinical trials are used to
gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow-up.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After the completion of clinical
trials of a biological product, FDA approval of a BLA must be obtained before commercial marketing of the biological product. The BLA
must include results of product development, laboratory and animal studies, human trials, information on the manufacture and composition
of the product, proposed labeling and other relevant information. The FDA may grant deferrals for submission of data, or full or partial
waivers. The testing and approval processes require substantial time and effort and there can be no assurance that the FDA will accept
the BLA for filing and, even if filed, that any approval will be granted on a timely basis, if at all. Before approving a BLA, the FDA
will inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing
processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required
specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure that the clinical
trials were conducted in compliance with IND trial requirements and GCP requirements. To assure cGMP and GCP compliance, an applicant
must incur significant expenditure of time, money and effort in the areas of training, record keeping, production, and quality control.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the submission
of relevant data and information, the FDA may ultimately decide that the BLA does not satisfy its regulatory criteria for approval and
deny approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret
the same data. Our product candidates are in the earliest stages of clinical development and, therefore, a long way from BLA submission.
We cannot predict with any certainty if or when we might submit a BLA for regulatory approval for our product candidates or whether any
such BLA will be approved by the FDA. Human clinical trials are very expensive and difficult to design and implement, in part because
they are subject to rigorous regulatory requirements. For example, the FDA may not agree with our proposed endpoints for any clinical
trial we propose, which may delay the commencement of our clinical trials. The clinical trial process is also lengthy and requires substantial
time and effort.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2015, the FDA
cleared our IND filing for Iomab-B and we have completed patient enrollment of a randomized, controlled, pivotal Phase 3 clinical trial
under such IND to study Iomab-B in patients 55 years of age or older with relapsed or refractory AML. Assuming the Phase 3 trial meets
its endpoints and there are no unexpected issues or delays, it is expected to form the basis for a BLA for Iomab-B for use in preparing
and conditioning AML patients for a BMT. Additionally, there are physician IND trials at the FHCRC that have been conducted or are currently
ongoing at FHCRC with Iomab-B (for other target indications) and the apamistamab antibody (formerly known as BC8) we licensed. And, we
have multiple Phase 1 and Phase 2 clinical trials ongoing and others that we have planned but not-yet commenced, for our other drug candidates
under our own sponsorship and multiple investigator-initiated trials ongoing. Except for Iomab-B (for patients with AML), we expect that
the clinical trials we need to conduct to be in a position to submit BLAs for our product candidates currently in-development will take,
at least, several years to complete. Moreover, failure can occur at any stage of the trials, and we could encounter problems that cause
us to abandon or repeat clinical trials. Also, the results of early preclinical and clinical testing may not be predictive of the results
of subsequent clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced
clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier studies. And, preclinical
and clinical data are often susceptible to multiple interpretations and analyses. Many companies that have believed their product candidates
performed satisfactorily in preclinical studies and clinical trials have, nonetheless, failed to obtain marketing approval of their products.
Success in preclinical testing and early clinical trials does not ensure that later clinical trials, which involve many more subjects,
and the results of later clinical trials may not replicate the results of prior clinical trials and preclinical testing. Any failure or
substantial delay in our product development plans may have a material adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may encounter substantial delays in our
clinical trials or may not be able to conduct our trials on the timelines we expect.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot predict whether
we will encounter problems with any of our ongoing or planned clinical trials that will cause us or regulatory authorities to delay, suspend,
or discontinue clinical trials or to delay the collection or analysis of data from ongoing clinical trials. Any of the following could
delay or disrupt the clinical development of our product candidates and potentially cause our product candidates to fail to receive regulatory
approval:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 19.95pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">conditions imposed on us by the FDA or comparable foreign authorities regarding the scope or design of our clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in receiving, or the inability to obtain, required approvals from IRBs or other reviewing entities at clinical sites selected for participation in our clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in enrolling patients into clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a lower than anticipated retention rate of patients in clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the need to repeat or discontinue clinical trials as a result of inconclusive or negative results or unforeseen complications in testing or because the results of later trials may not confirm positive results from earlier preclinical studies or clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inadequate supply, delays in distribution, deficient quality of, or inability to purchase or manufacture drug product, comparator drugs or other materials necessary to conduct our clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unfavorable FDA or other foreign regulatory inspection and review of a clinical trial site or records of any clinical or preclinical investigation;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">serious and unexpected drug-related side effects experienced by participants in our clinical trials, which may occur even if they were not observed in earlier trials or only observed in a limited number of participants;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a finding that the trial participants are being exposed to unacceptable health risks;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the placement by the FDA or a foreign regulatory authority of a clinical hold on a trial; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in obtaining regulatory agency authorization for the conduct of our clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays by us or third parties in the collection or analysis of data from our clinical trials; or</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays due to COVID-19 or a similar global health pandemic.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may suspend, or the FDA
or other applicable regulatory authorities may require us to suspend, clinical trials of a product candidate at any time if we or they
believe the patients participating in such clinical trials, or in independent third-party clinical trials for drugs based on similar technologies,
are being exposed to unacceptable health risks including but not limited to unacceptable or suboptimal factors related to toxicity, clinical
efficacy, imbalances in safety and efficacy profiles or for other reasons.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, individuals involved
with our clinical trials may serve as consultants to us from time to time and receive stock options or cash compensation in connection
with such services. If these relationships and any related compensation to the clinical investigator carrying out the study result in
perceived or actual conflicts of interest, or the FDA concludes that the financial relationship may have affected interpretation of the
study, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial
itself may be jeopardized. The delay, suspension or discontinuation of any of our clinical trials, or a delay in the analysis of clinical
data for our product candidates, for any of the foregoing reasons, could adversely affect our efforts to obtain regulatory approval for
and to commercialize our product candidates, increase our operating expenses and have a material adverse effect on our financial results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical trials may also be
delayed or terminated as a result of ambiguous or negative interim results. In addition, a clinical trial may be suspended or terminated
by us, the FDA, the IRBs at the sites where the IRBs are overseeing a trial, or a data safety monitoring board, or DSMB (Data Safety Monitoring
Board)/DMC (Data Monitoring Committee), overseeing the clinical trial at issue, or other regulatory authorities due to a number of factors,
including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 19.95pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inspection of the clinical trial operations or trial sites by the FDA or other regulatory authorities resulting in the imposition of a clinical hold;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">varying interpretation of data by the FDA or similar foreign regulatory authorities;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure to achieve primary or secondary endpoints or other failure to demonstrate efficacy;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unforeseen safety issues; or</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">lack of adequate funding to continue the clinical trial.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Modifications to our product candidates
may require federal approvals.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The BLA application is the
vehicle through which the company may formally propose that the FDA approve a new pharmaceutical for sale and marketing in the United
States. Once a particular product candidate receives FDA approval, expanded uses or uses in new indications of our products may require
additional human clinical trials and new regulatory approvals, including additional IND and BLA submissions and premarket approvals before
we can begin clinical development, and/or prior to marketing and sales. If the FDA requires new approvals for a particular use or indication,
we may be required to conduct additional clinical studies, which would require additional expenditures and harm our operating results.
If the products are already being used for these new indications, we may also be subject to significant enforcement actions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Conducting clinical trials
and obtaining approvals is a time-consuming process, and delays in obtaining required future approvals could adversely affect our ability
to introduce new or enhanced products in a timely manner, which in turn would have an adverse effect on our business prospects, financial
condition and results of operation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The FDA or comparable foreign regulatory
authorities may disagree with our regulatory plans, and we may fail to obtain regulatory approval of our product candidates. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2012, we acquired
rights to apamistamab, a clinical stage anti-CD45 monoclonal antibody with safety and efficacy data in more than 300 patients in need
of a BMT. Iomab-B is our product candidate that links I-131 to apamistamab that is being studied in the pivotal Phase 3 SIERRA trial.
Product candidates utilizing apamistamab would require BLA approval before they can be marketed in the United States. We are also evaluating
Iomab-ACT, which uses a lower dose I-131 for lymphodepletion prior to CAR-T or adoptive cell therapy. We are currently evaluating clinical
trials that would use our construct for lymphodepletion. Our lintuzumab-Ac-225 product candidate is also being studied in several Phase
1 trials under our sponsorship and investigator-initiated trials in patients with r/r AML. Product candidates utilizing the lintuzumab
antibody would require BLA approval before they can be marketed in the United States. We are in the early stages of evaluating other product
candidates consisting of conjugates of Ac-225 with human or humanized antibodies for pre-clinical and clinical development in other types
of cancer. The FDA may not approve these products for the indications that are necessary or desirable for successful commercialization.
The FDA may fail to approve any BLA we submit for new product candidates or for new intended uses or indications for approved products
or future product candidates. Failure to obtain FDA approval for our products in the proposed indications would have a material adverse
effect on our business prospects, financial condition and results of operations.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Clinical trials necessary to support approval
of our product candidates are time-consuming and expensive. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Initiating and completing
clinical trials necessary to support FDA approval of a BLA for Iomab-B, CD33 program candidates, and other product candidates, is a time-consuming
and expensive process, and the outcome is inherently uncertain. Moreover, the results of early clinical trials are not necessarily predictive
of future results, and any product candidate we advance into clinical trials may not have favorable results in later clinical trials.
We worked with the FDA to develop the SIERRA clinical trial to test the safety and efficacy of Iomab-B in patients with relapsed or refractory
AML who are age 55 and above prior to a BMT. This trial is designed to support a BLA filing for marketing approval by the FDA, pending
results from the trial. In addition to clinical data, a BLA filing encompasses preclinical, CMC, labeling and other information. Even
if the clinical data from the SIERRA trial is positive, there can be no assurances that the BLA filing we produce will meet all of the
FDA&#8217;s requirements or that they will not request additional information or studies, which may delay the FDA&#8217;s review or we
may not be able to produce. We have also worked with the FDA to develop a regulatory pathway for lintuzumab-Ac-225 in patients with high-risk
MDS that consists of a dose-confirming Phase 1 trial that can be followed by a randomized, controlled pivotal trial that could support
a BLA filing. To date, we have not initiated this clinical trial and we may never elect or be able to do so. There can be no assurance
that the data generated during the trial will meet our chosen safety and effectiveness endpoints or otherwise produce results that will
eventually support the filing or approval of a BLA. Even if the data from this trial are favorable, the data may not be predictive of
the results of any future clinical trials.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Preliminary, Interim, and &#8220;top-line&#8221;
data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject
to audit and verification procedures that could result in material changes in the final data.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, we may
publicly disclose preliminary, interim, and top-line data from our clinical trials, which is based on a preliminary analysis of then-available
data, and the results and related findings and conclusions are subject to change as more patient data become available or following a
more comprehensive review of the data related to the particular study or trial. For example, at the ASH annual meeting in December 2021
and TCT annual meeting in April 2022, we presented safety and feasibility data available at the time of data submission from 100% patient
enrollment from the SIERRA trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data,
and we may not have received or had the opportunity to fully and carefully evaluate all data. Our clinical trials may be open label studies
and certain of our clinical development and or operations staff may review interim or preliminary safety or efficacy data during routine
data collection, cleaning and analysis from time to time. Interim or preliminary results that we report may differ from future results
of the same studies, or different conclusions or considerations may qualify such results once additional data have been received and fully
evaluated. Preliminary, interim or top-line data also remain subject to audit and verification procedures that may result in the final
data being materially different from the top-line, interim or preliminary data we previously published. As a result, top-line, interim
and preliminary data should be viewed with caution until the final data are available.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, we may
also disclose interim data from our preclinical studies and clinical trials. Interim data from clinical trials that we may complete are
subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data
become available. Adverse differences between interim data and final data could significantly harm our business prospects. Further, disclosure
of interim data by us or by our competitors could result in volatility in the price of our common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, others, including
regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or
weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization
of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose
regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with
what we determine is material or otherwise appropriate information to include in our disclosure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the interim, top-line or
preliminary data that we report differ from final results, or if others, including regulatory authorities, disagree with the conclusions
reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating
results, prospects or financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our clinical trials may fail to demonstrate
adequately the efficacy and safety of our product candidates, which would prevent or delay regulatory approval and commercialization.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if our clinical trials
are completed as planned, we cannot be certain that their results will support our product candidate claims or that the FDA or foreign
authorities will agree with our conclusions regarding them. Success in pre-clinical studies and early clinical trials does not ensure
that later clinical trials will be successful, and we cannot be sure that the later trials will replicate the results of prior trials
and pre-clinical studies. The clinical trial process may fail to demonstrate that our product candidates are safe and effective for the
proposed indicated uses. If FDA concludes that the clinical trials for Iomab-B, Actimab-A, or any other product candidate for which we
might seek approval, have failed to demonstrate safety and effectiveness, we would not receive FDA approval to market that product candidate
in the United States for the indications sought. In addition, such an outcome could cause us to abandon the product candidate and might
delay development of others. Any delay or termination of our clinical trials will delay or preclude the filing of any submissions with
the FDA and, ultimately, our ability to commercialize our product candidates and generate revenues. It is also possible that patients
enrolled in clinical trials will experience adverse side effects that are not currently part of a product candidate&#8217;s profile.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The intellectual property related to antibodies
we have licensed has expired or likely expired.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The key patents related to the
humanized antibody, lintuzumab, which we use in our CD33 program product candidates have expired. It is generally possible that others
may be eventually able to use an antibody with the same sequence, and we will then need to rely on additional patent protection covering
alpha particle drug products comprising Ac-225. Our final drug construct, Actimab-A, consists of the lintuzumab antibody labeled with
the isotope Ac-225. We currently own issued and pending patents relating to methods of manufacturing Actimab-A, methods of treatment using
Actimab-A and production of the Ac-225 isotope. In addition, we possess trade secrets and know how related to the manufacturing and use
of isotopes. Any competing product based on the lintuzumab antibody is likely to require several years of development before achieving
our product candidate&#8217;s current status and may be subject to significant regulatory hurdles but such development by others is nevertheless
a possibility that could negatively impact our business in the future. We own 4 issued U.S. patents, 1 issued European patent (validated
as a national patent in several countries) and 1 issued Japanese patent that relate to the composition of our Iomab-B product candidate.
Several patent applications relating to Iomab-B are also pending in the U.S. and internationally. We have and may continue to file patents
related to Iomab-B that can provide barriers to entry but there is no certainty that these patents will be granted or such granting thereof
will adequately prevent others from seeking to replicate and use the apamistamab antibody or the construct. We have pending patents related
to radioimmunoconjugate composition, formulation administration, and methods of use in solid or liquid cancers. This subject matter includes
composition, administration, and methods of treatment for our product candidates Actimab-A and Iomab-B. Any competing product based on
the antibody used in Iomab-B is likely to require several years of development before achieving our product candidate&#8217;s current
status and may be subject to significant regulatory hurdles but such development by others is nevertheless a possibility that could negatively
impact our business in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our CD33 program clinical trials are testing
the same drug construct. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our CD33 program is comprised
of several clinical trials including investigator-initiated trials in AML that are studying the same drug construct consisting of lintuzumab-Ac-225.
Negative results from any of these trials could negatively impact our ability to enroll or complete our other trials studying lintzumab-Ac-225.
Additionally, negative outcomes including safety concerns, may result in the FDA discontinuing other trials utilizing lintuzumab-Ac-225.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be unable to obtain a sufficient
supply of isotopes to support clinical development or at commercial scale.&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Iodine-131 is a key component
of our Iomab-B drug candidate. We currently source medical grade I-131 from three suppliers including two leading global manufacturers.
Currently, there is sufficient supply of I-131 to advance our ongoing SIERRA clinical trial, support additional trials we may undertake
utilizing I-131 and for commercialization of Iomab-B. We continually evaluate I-131 manufacturers and suppliers and intend to have multiple
qualified suppliers prior to the commercial launch of Iomab-B. While we consider I-131 to be commoditized and obtainable through several
suppliers, there can be no guarantee that we will be able to secure I-131 or obtain I-131 on terms that are acceptable to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Actinium-225 is a key component
of our CD33 ARC program, AWE platform and other drug candidates that we might consider for development with the Ac-225 payload. There
are adequate quantities of Ac-225 available today to meet our current needs via our present supplier, the Department of Energy (&#8220;DOE&#8221;).
The current Ac-225 currently supplied to Actinium&#8217;s clinical trials from the DOE is derived from the natural decay of thorium-229
from so-called &#8216;thorium-cows&#8217; and is able to produce sufficient quantities that are several multiples of the amount of Ac-225
we require to supply our clinical programs through to early commercialization phase. The DOE is also producing Ac-225 from a recently
developed alternative route for Ac-225 production via a linear accelerator that is currently being evaluated by Actinium. Initial preclinical
and modelling results have indicated that the linear accelerator sourced Ac-225 does not impact labelling efficiency and expected distribution.
In accordance with representations made by the DOE, the capacity of Ac-225 from this route is expected to be sufficient to supply all
of Actinium&#8217;s pipeline and commercial Ac-225 needs and support new program expansion by not just Actinium but also other companies
that are developing Ac-225 based products. Additional routes of Ac-225 production are being pursued by the DOE including the generation
of new thorium cows and production via a cyclotron. The cyclotron production method for Ac-225 production leverages Actinium&#8217;s proprietary
technology and know-how and presents an additional path towards production of high-quality Ac-225 that would be able to satisfy commercial
needs. In addition, we are aware of at least six other government and non-government entities globally including the U.S., Canada, Russia,
Belgium, France and Japan that have, or expect to have ability to supply Ac-225 or equipment for its production within the timeframes
relevant to the potential first commercial approval of our Ac-225 ARC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our contract for supply of
Ac-225 from the DOE must be renewed annually and our current contract extends through the end of 2022. While we expect this contract will
continue to be renewed at the end of its term as it has since 2009, there can be no assurance that the DOE will renew the contract or
change its policies that allow for the sale of isotope to us. Failure to acquire sufficient quantities of medical grade Ac-225 would make
it impossible to effectively complete clinical trials and to commercialize any Ac-225 based drug candidates that we may develop and would
materially harm our business.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ability to conduct clinical
trials to advance our ARC drug candidates is dependent on our ability to obtain the radioisotopes I-131, Ac-225 and other isotopes we
may choose to utilize in the future. Currently, we are dependent on third party manufacturers and suppliers for our isotopes. These suppliers
may not perform their contracted services or may breach or terminate their agreements with us. Our suppliers are subject to regulations
and standards that are overseen by regulatory and government agencies and we have no control over our suppliers&#8217; compliance to these
standards. Failure to comply with regulations and standards may result in their inability to supply isotopes and could result in delays
in our clinical trials, which could have a negative impact on our business. We have developed intellectual property, know-how and trade
secrets related to the manufacturing process of Ac-225. While we have manufactured medical grade Ac-225 of a purity compared to the cyclotron
sourced material in the past, this activity was terminated due to operating cost reasons and we currently do not have experience in manufacturing
medical grade Ac-225 and may not obtain the resources necessary to establish our own manufacturing capabilities in future. Our inability
to build out and establish our own manufacturing facilities would require us to continue to rely on third party suppliers as we currently
do. However, based on our current third-party suppliers and potential future suppliers of Ac-225 we expect to have adequate isotope supply
to support our current ongoing clinical trials, current AWE program activities and commercialization should our drug candidates receive
approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we encounter difficulties enrolling patients
in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The timely completion of clinical
trials in accordance with their protocols depends on our ability to enroll a sufficient number of patients who remain in the trial until
its conclusion. We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the size and nature of the patient population;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the patient eligibility criteria defined in the protocol;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the size of the study population required for analysis of the trial&#8217;s primary endpoints;&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the proximity of patients to trial sites;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the design of the trial;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to recruit clinical trial investigators with the appropriate competencies and expertise;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competing clinical trials for similar or alternate therapeutic treatments;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinician&#8217;s and patients&#8217; perceptions as to the potential advantages and side effects of the product candidate being studied in relation to other available therapies;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to obtain and maintain patient consents; and </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the risk that patients enrolled in clinical trials will not complete a clinical trial.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, refractory patients,
which several of our trials are enrolling, participating in clinical trials are seriously and often terminally ill and therefore may not
complete the clinical trial due to reasons including comorbid conditions or occurrence of adverse medical events related or unrelated
to the investigational products, or death. Even if we are able to enroll a sufficient number of patients in our clinical trials, delays
in patient enrollment will result in increased costs or affect the timing of our planned trials, which could adversely affect our ability
to advance the development of our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>FDA may take actions that would prolong,
delay, suspend, or terminate clinical trials of our product candidates, which may delay or prevent us from commercializing our product
candidates on a timely basis.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There can be no assurance
that the data generated in our clinical trials will be acceptable to FDA or that if future modifications during the trial are necessary,
that any such modifications will be acceptable to FDA. Certain modifications to a clinical trial protocol made during the course of the
clinical trial have to be submitted to the FDA. This could result in the delay or halt of a clinical trial while the modification is evaluated.
In addition, depending on the quantity and nature of the changes made, FDA could take the position that some or all of the data generated
by the clinical trial is not usable because the same protocol was not used throughout the trial. This might require the enrollment of
additional subjects, which could result in the extension of the clinical trial and the FDA delaying approval of a product candidate. If
the FDA believes that its prior approval is required for a particular modification, it can delay or halt a clinical trial while it evaluates
additional information regarding the change.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 19.95pt">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any delay or termination of
our current or future clinical trials as a result of the risks summarized above, including delays in obtaining or maintaining required
approvals from IRBs, delays in patient enrollment, the failure of patients to continue to participate in a clinical trial, and delays
or termination of clinical trials as a result of protocol modifications or adverse events during the trials, may cause an increase in
costs and delays in the filing of any submissions with the FDA, delay the approval and commercialization of our product candidates or
result in the failure of the clinical trial, which could adversely affect our business, operating results and prospects. Lengthy delays
in the completion of our Iomab-B clinical trials would adversely affect our business and prospects and could cause us to cease operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have obtained orphan drug designation
from FDA for two of our current product candidates and intend to pursue such designation for other candidates and indications in the future,
but we may be unable to obtain such designations or to maintain the benefits associated with any orphan drug designations we have received
or may receive in the future.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have received orphan drug
designation for Iomab-B and lintuzumab-CD33 ARC for treatment of AML in both the United States and the EU. Under the Orphan Drug Act,
the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is a disease or condition
that affects fewer than 200,000 individuals in the United States, or if it affects more than 200,000 individuals in the United States,
there is no reasonable expectation that the cost of developing and making available a drug or biologic for this type of disease or condition
will be recovered from sales in the United States for that drug or biologic. Similarly, the EMA grants orphan drug designation to promote
the development of products that are intended for the diagnosis, prevention, or treatment of a life-threatening or chronically debilitating
condition affecting not more than five in 10,000 persons in the EU.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Orphan drug designation neither
shortens the development time or regulatory review time of a drug or biologic nor gives the drug or biologic any advantage in the regulatory
review or approval process. In the United States, orphan drug designation entitles a party to financial incentives, such as opportunities
for grant funding towards clinical trial costs, tax advantages, and application fee waivers. In addition, if a product candidate receives
the first FDA approval for the indication for which it has orphan designation, such product is entitled, upon approval, to seven years
of orphan-drug exclusivity, during which the FDA may not approve any other application to market the same drug for the same indication,
unless a subsequently approved product is clinically superior to orphan drug or where the manufacturer is unable to assure sufficient
product quantity in the applicable patient population. In the EU, orphan drug designation entitles a party to financial incentives such
as reduction of fees or fee waivers and ten years of market exclusivity following drug or biological product approval. This period may
be reduced to six years if the orphan drug designation criteria are no longer met, including where it is shown that the product is sufficiently
profitable not to justify maintenance of market exclusivity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if we obtain (or have
obtained) orphan drug designation for certain product candidates, we may not be the first to obtain marketing approval for such candidates
for the applicable indications due to the uncertainties inherent in the development of novel biologic products. And, an orphan drug candidate
may not receive orphan-drug exclusivity upon approval if such candidate is approved for a use that is broader than the indication for
which it received orphan designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines
that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product
to meet the needs of patients with the rare disease or condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Finally, even if we successfully
obtain orphan-drug exclusivity for an orphan drug candidate upon approval, such exclusivity may not effectively protect the product from
competition because (i) different drugs with different active moieties can be approved for the same condition; and (ii) the FDA or EMA
can also subsequently approve a subsequent product with the same active moiety and for the same indication as the orphan drug if the later-approved
drug if deemed clinically superior to the orphan drug.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Even if we receive regulatory approval of
our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any regulatory approvals that
we receive for our product candidates will require surveillance to monitor the safety and efficacy of the product candidate. The FDA may
also require a REMS in order to approve our product candidates, which could entail requirements for a medication guide, physician communication
plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization
tools. In addition, if the FDA or a comparable foreign regulatory authority approves our product candidates, the manufacturing processes,
labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our
product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety
and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and GCPs for any clinical trials
that we conduct post-approval. In addition, the FDA could require us to conduct another study to obtain additional safety or biomarker
information. Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity
or frequency, or with our third-party suppliers or manufacturing processes, or failure to comply with regulatory requirements, may result
in, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions on the marketing or manufacturing of our product candidates, withdrawal of the product from the market, or voluntary or mandatory product recalls;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 46; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines, warning letters or holds on clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of license approvals;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product seizure or detention, or refusal to permit the import or export of our product candidates; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions or the imposition of civil or criminal penalties.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA&#8217;s and other
regulatory authorities&#8217; policies may change, and additional government regulations may be enacted that could prevent, limit or delay
regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise
from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes
in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we
may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Coverage and reimbursement may be limited
or unavailable in certain market segments for our product candidates which could limit our sales of our product candidates, if approved.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The commercial success of
our product candidates in both domestic and international markets will be substantially dependent on whether third-party coverage and
reimbursement is available for patients that use our products. However, the availability of insurance coverage and reimbursement for newly
approved cancer therapies is uncertain, and therefore, third-party coverage may be particularly difficult to obtain even if our products
are approved by the FDA as safe and efficacious. Patients using existing approved therapies are generally reimbursed all or part of the
product cost by Medicare or other third-party payors. Medicare, Medicaid, health maintenance organizations and other third-party payors
are increasingly attempting to contain healthcare costs by limiting both coverage and the level of reimbursement of new drugs, and, as
a result, they may not cover or provide adequate payment for these products. Submission of applications for reimbursement approval generally
does not occur prior to the filing of a BLA for that product and may not be granted until many months after BLA approval. In order to
obtain coverage and reimbursement for these products, we or our commercialization partners may have to agree to a net sales price lower
than the net sales price we might charge in other sales channels. The continuing efforts of government and third-party payors to contain
or reduce the costs of healthcare may limit our revenue. Initial dependence on the commercial success of our products may make our revenues
particularly susceptible to any cost containment or reduction efforts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Healthcare legislative reform measures intended
to increase pressure to reduce prices of pharmaceutical products paid for by Medicare or, otherwise, affect the federal regulation of
the U.S. healthcare system could have a material adverse effect our business, future revenue, if any, and results of operations.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, there
have been a number of legislative and regulatory initiatives focused on containing the cost of healthcare. The Affordable Care Act, for
example, substantially changed the way healthcare is financed by both governmental and private insurers. The Affordable Care Act contains
a number of provisions that could impact our business and operations, primarily, once we obtain FDA approval to commercialize one of our
product candidates in the United States, if ever, and may also affect our operations in ways we cannot currently predict. Affordable Care
Act provisions that may affect our business include, among others, those governing enrollment in federal healthcare programs, reimbursement
changes, rules regarding prescription drug benefits under health insurance exchanges, expansion of the 340B program, expansion of state
Medicaid programs, fees and increased discount and rebate obligations, transparency and reporting requirements, and fraud and abuse enforcement.
Such changes may impact existing government healthcare programs, industry competition, formulary composition, and may result in the development
of new programs, including Medicare payment for performance initiatives, health technology assessments, and improvements to the physician
quality reporting system and feedback program.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There have been significant
ongoing judicial, administrative, executive, and legislative initiatives to modify, limit, replace, or repeal the Affordable Care Act.
For example, former President Trump issued several Executive Orders and other directives designed to delay the implementation of certain
provisions of the Affordable Care Act or otherwise circumvent some of the requirements for health insurance mandated by the Affordable
Care Act. Concurrently, Congress considered legislation that would repeal or replace all or part of the Affordable Care Act. While Congress
has not passed comprehensive repeal legislation, several bills affecting the implementation the Affordable Care Act have been passed.
For example, the Tax Cuts and Jobs Act of 2017 eliminated the Affordable Care Act provision requiring individuals to purchase and maintain
health coverage, or the &#8220;individual mandate,&#8221; by reducing the associated penalty to zero, beginning in 2019. In December 2018,
a district court in Texas held that the individual mandate is unconstitutional and that the rest of the Affordable Care Act is, therefore,
invalid. On appeal, the Fifth Circuit Court of Appeals affirmed the holding on the individual mandate but remanded the case back to the
lower court to reassess whether and how such holding affects the validity of the rest of the Affordable Care Act. The Fifth Circuit&#8217;s
decision on the individual mandate was appealed to the U.S. Supreme Court. On June 17, 2021, the Supreme Court held that the plaintiffs
(comprised of the state of Texas, as well as numerous other states and certain individuals) did not have standing to challenge the constitutionality
of the Affordable Care Act&#8217;s individual mandate and, accordingly, vacated the Fifth Circuit&#8217;s decision and instructed the
district court to dismiss the case. As a result, the Affordable Care Act will remain in-effect in its current form for the foreseeable
future; however, we cannot predict what additional challenges may arise in the future, the outcome thereof, or the impact any such actions
may have on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The adoption or implementation
of new or amended legislation at the federal or state level could affect our ability to obtain regulatory approval for any of our vaccine
candidates and the commercial viability of our future approved products, if any. We cannot predict the ultimate nature, timing, or effect
of any changes to the Affordable Care Act or other federal and state reform efforts, and there is no assurance that such efforts will
not adversely affect our future business and financial results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the Affordable
Care Act, there have been several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among
other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, and
reform government program reimbursement methodologies for drug products. Pharmaceutical product prices have been the focus of increased
scrutiny by the government, including certain state attorneys general, members of Congress and the United States Department of Justice.
State or federal healthcare reform measures or other social or political pressure to lower the cost of pharmaceutical products could have
a material adverse impact on our business, results of operations and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Biden administration also
introduced various measures in 2021 focusing on healthcare and drug pricing, in particular. For example, on January 28, 2021, President
Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through
the Affordable Care Act marketplace, which began on February 15, 2021, and remained open through August 15, 2021. The executive order
also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare,
including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements and policies that
create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the Affordable Care Act. On the legislative
front, the American Rescue Plan Act of 2021 was signed into law on March 11, 2021, which, in relevant part, eliminates the statutory Medicaid
drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source drugs and innovator multiple source
drugs, beginning January 1, 2024. And, in July 2021, the Biden administration released an executive order entitled, &#8220;Promoting Competition
in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response, on September 9, 2021, HHS released
a &#8220;Comprehensive Plan for Addressing High Drug Prices&#8221; that outlines principles for drug pricing reform and sets out a variety
of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these
principles. And, in November 2021, President Biden announced the &#8220;Prescription Drug Pricing Plan&#8221; as part of the Build Back
Better Act (H.R. 5376) passed by the House of Representatives on November 19, 2021, which aims to lower prescription drug pricing by,
among other things, allowing Medicare to negotiate prices for certain high-cost prescription drugs covered under Medicare Part D and Part
B after the drugs have been on the market for a certain number of years and imposing tax penalties on drug manufacturers that refuse to
negotiate pricing with Medicare or increase drug prices &#8220;faster than inflation.&#8221; If enacted, this bill could have a substantial
impact on our business, particularly once we have commercially available products on the U.S. market, if ever. In the coming years, additional
legislative and regulatory changes could be made to governmental health programs that could significantly impact pharmaceutical companies
and the potential success of our vaccine candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our relationships with customers, health
care professionals and third-party payors may be subject to applicable healthcare laws, which could expose us to penalties, including
administrative, civil or criminal penalties, damages, fines, imprisonment, exclusion from participation in federal healthcare programs
such as Medicare and Medicaid, reputational harm, the curtailment or restructuring of our operations and diminished future profits and
earnings.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Healthcare professionals and
third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing
approval. Our current and future arrangements with customers, healthcare professionals and third-party payors may expose us to broadly
applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships
through which we conduct research, market, sell and distribute any products for which we obtain marketing approval. Federal and state
healthcare laws and regulations that may affect our operations, directly or indirectly, include the following, among others:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal Anti-Kickback Statute, which prohibits persons and entities from, among other things, knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made under federal and state healthcare programs such as Medicare and Medicaid;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal false claims laws, including civil whistleblower or qui tam actions under the federal False Claims Act, which impose criminal and civil penalties against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, which imposes criminal and civil liability for, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters and also imposes obligations, including mandatory contractual terms, on covered entities, including certain healthcare providers, health plans, and healthcare clearinghouses, and their respective business associates that create, receive, maintain or transmit individually identifiable health information for or on behalf of the covered entity as well as their covered subcontractors, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal Civil Monetary Penalties Law, which prohibits, among other things, the offering or transfer of remuneration to a Medicare or state healthcare program beneficiary if the person knows or should know it is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state healthcare program, unless an exception applies;&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal Physician Payments Sunshine Act, created under the Affordable Care Act, and its implementing regulations, which requires certain manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually information related to certain payments or other transfers of value provided to physicians and any ownership and investment interests held by physicians or their immediate family members. Beginning in 2022, applicable manufacturers also will be required to report such information regarding payments and other transfers of value to physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists and certified nurse midwives during the previous year; and</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">analogous state laws and regulations, including (among others) state anti-kickback and false claims laws, which may apply to our business practices, including, but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the United States federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information and that require tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; state and local laws that require the registration of pharmaceutical sales representatives; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by federal law, thus complicating compliance efforts.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Efforts to comply with applicable
healthcare laws and regulations will involve substantial costs. Interpretations of standards of compliance under these laws and regulations
are rapidly changing and subject to varying interpretations and it is possible that governmental authorities will conclude that our business
practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare
laws and regulations. If our operations are found to be in violation of any of these laws or any other laws that may apply to us, we may
be subject to significant civil, criminal and administrative penalties, damages, fines, exclusion from government funded healthcare programs,
such as Medicare and Medicaid, reputational harm, imprisonment, additional reporting obligations and oversight (if we become subject to
a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws), and the curtailment or restructuring
of our operations, any of which could diminish our future profits or earnings. If any of the physicians or other providers or entities
with whom we expect to do business are found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative
sanctions, including exclusions from government funded healthcare programs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Third-party payors may not adequately reimburse
customers for any of our products that we may commercialize or promote and may impose coverage restrictions or limitations such as prior
authorizations and step edits that affect their use.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ability to commercialize
any product candidates successfully also will depend in part on the extent to which coverage and adequate reimbursement for these products
and related treatments will be available from government health programs, private health insurers, integrated delivery networks and other
third-party payors. Third-party payors decide which medications they will pay for and establish reimbursement levels. A significant trend
in the United States healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted
to control costs by limiting coverage and the amount of payment for particular medications. Increasingly, third-party payors are requiring
that drug companies provide predetermined discounts from list prices and are challenging the prices charged for medical products. Coverage
and reimbursement may not be available for any product that we commercialize and, if reimbursement is available, the level of reimbursement
may not be sufficient for commercial success. Coverage and reimbursement may impact the demand for, or the price of, any product candidate
for which we obtain marketing approval. If coverage and reimbursement is not available or is available only to limited levels, we may
not be able to successfully commercialize any product candidate for which we obtain marketing approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Obtaining reimbursement approval
for any product candidate for which we obtain marketing approval from any government or other third-party payor is a time-consuming and
costly process. There may be significant delays in obtaining coverage and adequate reimbursement for newly approved products. Moreover,
eligibility for coverage and reimbursement does not imply that any product will be paid for in all cases or at a rate that covers our
costs, including research, development, manufacture, sale and distribution. Even when a payor determines that a product that we may commercialize
or promote is eligible for reimbursement under its criteria, the payor may impose coverage limitations that preclude payment for some
uses that are approved by the FDA, or may impose restrictions, such as prior authorization requirements, or may simply deny coverage altogether.
Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent.
Coverage and reimbursement rates may vary according to the use of the drug and the medical circumstances under which it is used may be
based on reimbursement levels already set for lower cost products or procedures or may be incorporated into existing payments for other
services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private
payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices
than in the United States. Furthermore, the Centers for Medicare and Medicaid Services frequently change product descriptors, coverage
policies, product and service codes, payment methodologies and reimbursement values. Commercial third-party payors often rely upon Medicare
coverage policies and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain and maintain coverage
and profitable payment rates from both government-funded programs and private payors for any approved products that we develop could have
a material adverse effect on our operating results, our ability to raise capital needed to commercialize our approved products and our
overall financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Third Parties</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We rely on third parties to conduct our
clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines or comply with
regulatory requirements, we may not be able to obtain regulatory approval for or commercialize our product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not have the ability
to independently conduct our clinical trials for our product candidates and we must rely on third parties, such as contract research organizations,
medical institutions, clinical investigators and contract laboratories to conduct such trials. Our reliance on these third parties for
clinical development activities results in reduced control over these activities. Moreover, the FDA requires us to comply with regulations
and standards, commonly referred to as GCPs (good clinical practices), for conducting, recording and reporting the results of clinical
trials to assure that data and reported results are credible and accurate and that the trial participants are adequately protected. Our
reliance on third parties does not relieve us of these responsibilities and requirements. If we or any of our third-party contractors
fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable
foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot
assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials
complies with GCP regulations. In addition, our clinical trials must be conducted with product produced under current good manufacturing
practice, or (&#8220;cGMP&#8221;) regulations. Our failure to comply with these regulations may require us to repeat clinical trials,
which would delay the regulatory approval process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our consultants, contract
research organizations and other similar entities with which we are working do not successfully carry out their contractual duties, meet
expected deadlines, or comply with applicable regulations, we may be required to replace them. Although we believe that there are a number
of other third-party contractors we could engage to continue these activities, we may not be able to enter into arrangements with alternative
third-party contractors or to do so on commercially reasonable terms, which may result in a delay of our planned clinical trials and delayed
development of our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our third-party
contractors are not our employees, and except for remedies available to us under our agreements with such third-party contractors, we
cannot control whether or not they devote sufficient time and resources to our programs. If these third parties do not successfully carry
out their contractual duties or regulatory obligations or meet expected deadlines, or if the quality or accuracy of the data they obtain
is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our pre-clinical
development activities or clinical trials may be extended, delayed, suspended or terminated, and we may not be able to obtain regulatory
approval for, or successfully commercialize, our product candidates on a timely basis, if at all, and our business, operating results
and prospects would be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The antibodies we use in our targeted radiotherapy
product candidates may be subject to generic competition.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are not aware of any existing
or pending regulations or legislation that pertains to generic radiopharmaceutical products such as antibody radiation-conjugate product
candidates. Our product candidates are regulated by the FDA as biologic products and we intend to seek approval for these products pursuant
to the BLA pathway. The Biologics Price Competition and Innovation Act of 2009, or BPCIA, created an abbreviated pathway for the approval
of biosimilar and interchangeable biologic products. The abbreviated regulatory pathway establishes legal authority for the FDA to review
and approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on its similarity
to an existing brand product. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12 years after
the original branded product was approved under a BLA. The law is complex and is still being interpreted and implemented by the FDA. As
a result, its ultimate impact, implementation, and meaning are subject to uncertainty. Even if a biosimilar gets approved for one of the
antibodies that we use, the final constructs of our drug candidates consist of an antibody, radioisotope and in some cases a linker. Therefore,
we do not believe that the final drug product of our candidates can be subject to competition from a biosimilar as outlined in BPCIA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our product candidates may never achieve
market acceptance.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Iomab-B, CD33 program candidates
and future product candidates that we may develop may never gain market acceptance among physicians, patients and the medical community.
The degree of market acceptance of any of our products will depend on a number of factors, including the actual and perceived effectiveness
and reliability of the product; the results of any long-term clinical trials relating to use of the product; the availability, relative
cost and perceived advantages and disadvantages of alternative technologies; the degree to which treatments using the product are approved
for reimbursement by public and private insurers; the strength of our marketing and distribution infrastructure; and the level of education
and awareness among physicians and hospitals concerning the product.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that oncologists
and other physicians will not widely adopt a product candidate unless they determine, based on experience, clinical data, and published
peer-reviewed journal articles, that the use of that product candidate provides an effective alternative to other means of treating specific
cancers. Patient studies or clinical experience may indicate that treatment with our product candidates does not provide patients with
sufficient benefits in extension of life or quality of life. We believe that recommendations and support for the use of each product candidate
from influential physicians will be essential for widespread market acceptance. Our product candidates are still in the development stage
and it is premature to attempt to gain support from physicians at this time. We can provide no assurance that such support will ever be
obtained. If our product candidates do not receive such support from these physicians and from long-term data, physicians may not use
or continue to use, and hospitals may not purchase or continue to purchase, them.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Failure of Iomab-B, CD33 program
candidates or any of our other product candidates to significantly penetrate current or new markets would negatively impact our business
financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be subject to claims that our third-party
service providers, consultants or current or former employees have wrongfully used or disclosed confidential information of third parties.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have received confidential
and proprietary information from third parties. In addition, we employ individuals who were previously employed at other biotechnology
or pharmaceutical companies. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently
or otherwise used or disclosed confidential information of these third parties or our employees&#8217; former employers. Litigation may
be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial
cost and be a distraction to our management and employees.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We currently depend on single third-party
manufacturers to produce our pre-clinical and clinical trial drug supplies. Any disruption in the operations of our current third-party
manufacturers, or other third-party manufacturers we may engage in the future, could adversely affect our business and results of operations.
</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not currently operate
manufacturing facilities for pre-clinical or clinical production of any of our product candidates. We rely on third-party manufacturers
to supply, store, and distribute pre-clinical and clinical supply of the components of our drug product candidates including monoclonal
antibodies, linkers and radioisotopes, as well as the final construct which comprises our drug product candidates. We expect to continue
to depend on third-party manufacturers for the foreseeable future. Any performance failure on the part of our existing or future manufacturers
could delay clinical development, cause us to suspend or terminate development or delay or prohibit regulatory approval of our product
candidates or commercialization of any approved products. Further avenues of disruption to our clinical or eventual commercial supply
may also occur due to the sale, acquisition, business reprioritization, bankruptcy or other unforeseen circumstances that might occur
at any of our suppliers or contract manufacturing partners including an inability to come to terms on renewal of existing contracts or
new contracts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently rely on single
manufacturers to manufacture our pre-clinical and clinical trial drug supplies. With a view to maintaining business continuity we are
evaluating alternatives and second and even third sources of supply or manufacturing for our core suppliers and manufacturing partners,
however there can be no assurances that we will be able to identify such suppliers or partners and assuming we did, that we would be able
to enter into contracts that are on favorable terms or on terms that will enable sufficient supply to ensure business continuity and support
our growth plans.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our product candidates require
precise, high-quality manufacturing. Failure by our current contract manufacturer or other third-party manufacturers we may engage in
the future to achieve and maintain high manufacturing standards could result in patient injury or death, product recalls or withdrawals,
delays or failures in testing or delivery, cost overruns, or other problems that could seriously hurt our business. Contract manufacturers
may encounter difficulties involving production yields, quality control, and quality assurance. These manufacturers are subject to ongoing
periodic and unannounced inspections by the FDA and corresponding state and foreign agencies to ensure strict compliance with cGMPs and
other applicable government regulations and corresponding foreign standards; we do not have control over third-party manufacturers&#8217;
compliance with these regulations and standards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may elect to build or purchase
a manufacturing facility or facilities in the future to operate for the purposes of manufacturing our own products. We have never built,
owned or operated a manufacturing facility. There can be no assurances that we will be able to successfully accomplish this and in doing
so we may experience delays, cost overruns, or other problems that could seriously hurt our business. Even if we successfully build or
purchase a manufacturing facility, we may not realize the expected benefits of these efforts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We depend on vendors with
specialized operations, equipment and know-how to manufacture the respective components of our drug candidates. We have entered into manufacturing
and supply agreements with these third-parties, and in some instances, we have agreed that such vendor be the exclusive manufacturer and
supplier. If any of the third-parties we depend on encounter difficulties in their operations, fail to comply with required regulations
or breach their contractual obligations it may be difficult, or we may be unable to identify suitable alternative third-party manufacturers.
While we identify and evaluate third-party manufacturers from time to time, even if we do identify suitable alternative third-parties,
we may fail to reach agreement on contractual terms, it may be prohibitively expensive and there can be no assurance that we can successfully
complete technology transfer and development work necessary or complete the necessary work in a timely manner. Any of which could prevent
us from commencing manufacturing with third-parties which could cause delays or suspension of our clinical trials and pre-clinical work
that may have a negative impact on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, these third-party
contractors, whether foreign or domestic, may experience regulatory compliance difficulty, mechanical shutdowns, employee strikes, or
any other unforeseeable acts that may delay or limit production. Our inability to adequately establish, supervise and conduct (either
ourselves or through third parties) all aspects of the formulation and manufacturing processes, and the inability of third-party manufacturers
to consistently supply quality product when required would have a material adverse effect on our ability to develop or commercialize our
products. We have faced delays and risks associated with reliance on key third party manufacturers in the past and may be faced with such
delays and risks in the future. Any future manufacturing interruptions or related supply issues could have an adverse effect on our company,
including delays in clinical trials.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are successful in obtaining marketing
approval from the FDA and/or other regulatory agencies for any of our product candidates, we anticipate continued reliance on third-party
manufacturers.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, our product candidates
have been manufactured in small quantities for preclinical and clinical testing by third-party manufacturers. If the FDA or other regulatory
agencies approve any of our product candidates for commercial sale, we expect that we would continue to rely, at least initially, on third-party
specialized manufacturers to produce commercial quantities of approved products. These manufacturers may not be able to successfully increase
the manufacturing capacity for any approved product in a timely or economic manner, or at all. Significant scale-up of manufacturing may
require additional validation studies, which the FDA must review and approve. Scale-up for commercial product may require financial commitment
or investment by us, which we may not have sufficient capital for or may elect not to undertake. If third party manufacturers are unable
to successfully increase the manufacturing capacity for a product candidate, or we are unable to establish our own manufacturing capabilities,
the commercial launch of any approved products may be delayed or there may be a shortage in supply, which in turn could have a material
adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the facilities
used by our contract manufacturers to manufacture our product candidates must be approved by the FDA pursuant to inspections that will
be conducted after we submit a BLA to the FDA. We do not control the manufacturing process of, and are completely dependent on, our contract
manufacturing partners for compliance with cGMPs. If our contract manufacturers cannot successfully manufacture material that conforms
to our specifications and the strict regulatory requirements of the FDA or other regulatory authorities, they will not be able to secure
and/or maintain regulatory approval for their manufacturing facilities. If the FDA or a comparable foreign regulatory authority does not
approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need
to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for
or market our product candidates, if approved.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may have conflicts with our partners
that could delay or prevent the development or commercialization of our product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may have conflicts with
our partners, such as conflicts concerning the interpretation of preclinical or clinical data, the achievement of milestones, the interpretation
of contractual obligations, payments for services, development obligations or the ownership of intellectual property developed during
our collaboration. If any conflicts arise with any of our partners, such partner may act in a manner that is averse to our best interests.
Any such disagreement could result in one or more of the following, each of which could delay or prevent the development or commercialization
of our product candidates, and in turn prevent us from generating revenues: unwillingness on the part of a partner to pay us milestone
payments or royalties we believe are due under a collaboration; uncertainty regarding ownership of intellectual property rights arising
from our collaborative activities, which could prevent us from entering into additional collaborations; unwillingness by the partner to
cooperate in the development or manufacture of the product, including providing us with product data or materials; unwillingness on the
part of a partner to keep us informed regarding the progress of its development and commercialization activities or to permit public disclosure
of the results of those activities; initiating litigation or alternative dispute resolution options by either party to resolve the dispute;
or attempts by either party to terminate the agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If in the future we are unable to establish
U.S. or global sales and marketing capabilities or enter into agreements with third parties to sell and market our product candidates,
we may not be successful in commercializing our product candidates if they are approved and we may not be able to generate any revenue.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently do not have a
marketing or sales team for the marketing, sales and distribution of any of our product candidates that may receive regulatory approval.
In order to commercialize any product candidates after approval, we must build on a territory-by-territory basis marketing, sales, distribution,
managerial and other non-technical capabilities or make arrangements with third parties to perform these services, and we may not be successful
in doing so. If our product candidates receive regulatory approval, we may decide to establish an internal sales or marketing team with
technical expertise and supporting distribution capabilities to commercialize our product candidates, which will be expensive and time-consuming
and will require significant attention of our executive officers to manage. Any failure or delay in the development of our internal sales,
marketing and distribution capabilities would adversely impact the commercialization of any of our product candidates that we obtain approval
to market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin: 0pt 0">With respect to the commercialization of all or certain of our product
candidates, we may choose to collaborate, either globally or on a territory-by-territory basis, with third parties that have direct sales
forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales
force and distribution systems. In particular, we have and expect to continue to partner with third parties to commercialize Iomab-B outside
the United States. In April&#160;2022, we entered into a licensing agreement with Immedica, in which Immedica acquired the product rights
for commercialization of Iomab-B for certain territories outside the U.S. If we are unable to enter into or maintain such arrangements
when needed on acceptable terms, or at all, we may not be able to successfully commercialize any of our product candidates that receive
regulatory approval or any such commercialization may experience delays or limitations. If we are not successful in commercializing our
product candidates, either on our own or through collaborations with one or more third parties, our future product revenue will suffer
and we may incur significant additional losses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We face significant competition from other
biotechnology and pharmaceutical companies.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our product candidates face,
and will continue to face, intense competition from large pharmaceutical and biotechnology companies, as well as academic and research
institutions. We compete in an industry that is characterized by (i) rapid technological change, (ii) evolving industry standards, (iii)
emerging competition and (iv) new product introductions. Our competitors have existing products and technologies that will compete with
our product candidates and technologies and may develop and commercialize additional products and technologies that will compete with
our product candidates and technologies. Because several competing companies and institutions have greater financial resources than us,
they may be able to (i) provide broader services and product lines, (ii) make greater investments in research and development, or R&amp;D,
and (iii) carry on broader R&amp;D initiatives. Our competitors also have greater development capabilities than we do and have substantially
greater experience in undertaking preclinical and clinical testing of product candidates, obtaining regulatory approvals, and manufacturing
and marketing pharmaceutical products. They also have greater name recognition and better access to customers than us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our product candidates may cause undesirable
side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial
potential, or result in significant negative consequences. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Undesirable side effects caused
by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more
restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. The drug-related side
effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability
claims. Any of these occurrences may harm our business, financial condition and prospects significantly. Even if any of our product candidates
receives marketing approval, as greater numbers of patients use a product following its approval, an increase in the incidence of side
effects or the incidence of other post-approval problems that were not seen or anticipated during pre-approval clinical trials could result
in a number of potentially significant negative consequences, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory authorities may withdraw their approval of the product;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory authorities may require the addition of labeling statements, such as warnings or contraindications;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be required to change the way the product is administered, conduct additional clinical trials or change the labeling of the product;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may elect, or we may be required, to recall or withdraw product from the market;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we could be sued and held liable for harm caused to patients; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our reputation may suffer.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any of these events could
substantially increase the costs and expenses of developing, commercializing and marketing any such product candidates or could harm or
prevent sales of any approved products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We depend upon securing and protecting critical
intellectual property.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are dependent on obtaining
and maintaining patents, trade secrets, copyright and trademark protection of our technologies in the United States and other jurisdictions,
as well as successfully enforcing this intellectual property and defending this intellectual property against third-party challenges.
The degree of future protection of our proprietary rights is uncertain for product candidates that are currently in the early stages of
development because we cannot predict which of these product candidates will ultimately reach the commercial market or whether the commercial
versions of these product candidates will incorporate proprietary technologies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our patent position is highly uncertain
and involves complex legal and factual questions.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Accordingly, we cannot predict
the breadth of claims that may be allowed or enforced under our patents or in third-party patents. For example, we or our licensors might
not have been the first to make the inventions covered by each of our pending patent applications and issued patents; we or our licensors
might not have been the first to file patent applications for these inventions; others may independently develop similar or alternative
technologies or duplicate any of our technologies; it is possible that none of our pending patent applications or the pending patent applications
of our licensors will result in issued patents; our issued patents and issued patents of our licensors may not provide a basis for commercially
viable technologies, or may not provide us with any competitive advantages, or may be challenged and invalidated by third parties; and,
we may not develop additional proprietary technologies that are patentable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result, our owned and
licensed patents may not be valid, and we may not be able to obtain and enforce patents and to maintain trade secret protection for the
full commercial extent of our technology. The extent to which we are unable to do so could materially harm our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We or our licensors have applied
for and will continue to apply for patents for certain products. Such applications may not result in the issuance of any patents, and
any patents now held or that may be issued may not provide us with adequate protection from competition. Furthermore, it is possible that
patents issued or licensed to us may be challenged successfully. In that event, if we have a preferred competitive position because of
such patents, such preferred position would be lost. If we are unable to secure or to continue to maintain a preferred position, we could
become subject to competition from the sale of generic products. Failure to receive, inability to protect, or expiration of our patents
for medical use, manufacture, conjugation and labeling of Ac-225, the antibodies that we license from third parties, or subsequent related
filings, would adversely affect our business and operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Patents issued or licensed
to us may be infringed by the products or processes of others. The cost of enforcing our patent rights against infringers, if such enforcement
is required, could be significant, and we do not currently have the financial resources to fund such litigation. Further, such litigation
can go on for years and the time demands could interfere with our normal operations. There has been substantial litigation and other proceedings
regarding patent and other intellectual property rights in the pharmaceutical industry. We may become a party to patent litigation and
other proceedings. The cost to us of any patent litigation, even if resolved in our favor, could be substantial. Some of our competitors
may be able to sustain the costs of such litigation more effectively than we can because of their substantially greater financial resources.
Litigation may also absorb significant management time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unpatented trade secrets,
improvements, confidential know-how and continuing technological innovation are important to our scientific and commercial success. Although
we attempt to and will continue to attempt to protect our proprietary information through reliance on trade secret laws and the use of
confidentiality agreements with our partners, collaborators, employees and consultants and other appropriate means, these measures may
not effectively prevent disclosure of our proprietary information, and, in any event, others may develop independently, or obtain access
to, the same or similar information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain of our patent rights
are licensed to us by third parties. If we fail to comply with the terms of these license agreements, our rights to those patents may
be terminated, and we will be unable to conduct our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are found to be infringing on patents
or trade secrets owned by others, we may be forced to cease or alter our product development efforts, obtain a license to continue the
development or sale of our products, and/or pay damages.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our manufacturing processes
and potential products may violate proprietary rights of patents that have been or may be granted to competitors, universities or others,
or the trade secrets of those persons and entities. As the pharmaceutical industry expands and more patents are issued, the risk increases
that our processes and potential products may give rise to claims that they infringe the patents or trade secrets of others. These other
persons could bring legal actions against us claiming damages and seeking to enjoin clinical testing, manufacturing and marketing of the
affected product or process. If any of these actions are successful, in addition to any potential liability for damages, we could be required
to obtain a license in order to continue to conduct clinical tests, manufacture or market the affected product or use the affected process.
Required licenses may not be available on acceptable terms, if at all, and the results of litigation are uncertain. If we become involved
in litigation or other proceedings, it could consume a substantial portion of our financial resources and the efforts of our personnel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to infringement
or other intellectual property claims against us, we may become a party to other patent litigation or proceedings before regulatory agencies,
including post-grant review, inter parties review, interference or re-examination proceedings filed with the U.S. Patent and Trademark
Office (or similar proceedings before corresponding tribunals in other jurisdictions) that challenge our patent rights or the patent rights
of our licensors. The costs and efforts of defending our patents or enforcing our proprietary rights in post-issuance administrative proceedings
can be substantial and the outcome can be uncertain. An adverse determination in these proceedings could weaken or invalidate the patent
claims that cover our technology, which adverse determination could harm our business significantly and dissuade companies from collaborating
with us or permit third parties to directly compete with the same technology.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our ability to protect and enforce our patents
does not guarantee that we will secure the right to commercialize our patents.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A patent is a limited monopoly
right conferred upon an inventor, and his successors in title, in return for the making and disclosing of a new and non-obvious invention.
This monopoly is of limited duration but, while in force, allows the patent holder to prevent others from making and/or using its invention.
While a patent gives the holder this right to exclude others, it is not a license to commercialize the invention where other permissions
may be required for commercialization to occur. For example, a drug cannot be marketed without the appropriate authorization from the
FDA, regardless of the existence of a patent covering the product. Further, the invention, even if patented itself, cannot be commercialized
if it infringes the valid patent rights of another party.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We rely on confidentiality agreements to
protect our trade secrets. If these agreements are breached by our employees or other parties, our trade secrets may become known to our
competitors.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We rely on trade secrets that
we seek to protect through numerous measures, including non-compete and confidentiality agreements with our employees and other parties.
If these agreements are breached, our competitors may obtain and use our trade secrets to gain a competitive advantage over us. Any remedies
that may be available to us may not be adequate to protect our business or compensate us for the damaging disclosure. In addition, we
may have to expend resources to protect our interests from possible infringement by others. We have learned that a former employee violated
the non-compete provision of their employment agreement by working for a direct competitor. This employee, who had access to materials
containing proprietary information and trade secrets, may have been solicited, and until recently, pursuant to actions taken by Actinium,
was employed by a direct competitor. We intend to fully investigate this matter and, if appropriate, pursue litigation against all parties
that may be involved to protect our confidential information and trade secrets. &#160;&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We expect to expand our development and
regulatory capabilities and potentially implement sales, marketing and distribution capabilities, and, as a result, we may encounter difficulties
in managing our growth, which could disrupt our operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expect to experience significant growth in
the number of our employees and the scope of our operations, particularly in the areas of product candidate development, regulatory affairs
and, if any of our product candidates receives marketing approval, sales, marketing and distribution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently do not have a marketing or sales
team for the marketing, sales and distribution of any of our product candidates that are potentially able to obtain regulatory approval.
In order to commercialize any product candidates, we must build on a territory-by-territory basis marketing, sales, distribution, managerial
and other non-technical capabilities or make arrangements with third parties to perform these services, and we may not be successful in
doing so. If our product candidates receive regulatory approval, we intend to establish an internal sales or marketing team with technical
expertise and supporting distribution capabilities to commercialize our product candidates, which will be expensive and time consuming
and will require significant attention of our executive officers to manage. We will also have to compete with other pharmaceutical and
biotechnology companies to recruit, hire, train and retain marketing and sales personnel. Any failure or delay in the development of our
internal sales, marketing and distribution capabilities would adversely impact the commercialization of any of our product candidates
that we obtain approval to market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">To manage our anticipated future growth, we must continue to implement
and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified
personnel. Due to our limited financial resources and the limited experience of our management team in managing a public company with
such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified
personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources.
Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The use of hazardous materials, including
radioactive and biological materials, in our research and development efforts imposes certain compliance costs on us and may subject us
to liability for claims arising from the use or misuse of these materials.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research, development
and manufacturing activities involve the controlled use of hazardous materials, including chemicals, radioactive and biological materials,
such as radioactive isotopes. We are subject to federal, state, local and foreign environmental laws and regulations governing, among
other matters, the handling, storage, use and disposal of these materials and some waste products. We cannot completely eliminate the
risk of contamination or injury from these materials and we could be held liable for any damages that result, which could exceed our financial
resources. We currently maintain insurance coverage for injuries resulting from the hazardous materials we use; however, future claims
may exceed the amount of our coverage. Also, we do not have insurance coverage for pollution cleanup and removal. Currently the costs
of complying with such federal, state, local and foreign environmental regulations are not significant, and consist primarily of waste
disposal expenses. However, they could become expensive, and current or future environmental laws or regulations may impair our research,
development, production and commercialization efforts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may undertake international operations,
which will subject us to risks inherent with operations outside of the United States.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we do not have any
international operations at this time, we intend to seek market clearances in foreign markets that we believe will generate significant
opportunities. However, even with the cooperation of a commercialization partner, conducting drug development in foreign countries involves
inherent risks, including, but not limited to difficulties in staffing, funding and managing foreign operations; unexpected changes in
regulatory requirements; export restrictions; tariffs and other trade barriers; difficulties in protecting, acquiring, enforcing and litigating
intellectual property rights; fluctuations in currency exchange rates; and potentially adverse tax consequences.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we were to experience any
of the difficulties listed above, or any other difficulties, any international development activities and our overall financial condition
may suffer and cause us to reduce or discontinue our international development and registration efforts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are highly dependent on our key personnel,
and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our
business strategy. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our future operations and
successes depend in large part upon the continued service of key members of our senior management team whom we are highly dependent upon
to manage our business. If any member of our current senior management terminates his employment with us and we are unable to find a suitable
replacement quickly, the departure could have a material adverse effect on our business. An overall tightening and increasingly competitive
labor market has been observed in the U.S. employment market generally, especially in response to the COVID-19 pandemic. Specific to the
biotechnology industry in which we operate, there is significant demand and competition for highly specialized talent that we require.
A sustained labor shortage or increased turnover rates within our employee base, caused by the COVID-19 pandemic, as a result of general
macroeconomic factors, or due to dynamics within our industry, could lead to increased costs, such as increased wage rates to attract
and retain employees, and could negatively affect our ability to efficiently conduct our clinical development, R&amp;D, business development
and potential regulatory and commercial activities. If we are unable to hire and retain employees capable of performing at a high-level,
or if mitigation measures we may take to respond to a decrease in labor availability, have unintended negative effects, our business could
be adversely affected. An overall labor shortage, lack of skilled labor, increased turnover or labor inflation, caused by the COVID-19
pandemic, general macroeconomic factors or as a result of biotechnology industry dynamics could have a material adverse impact on our
operations, results of operations, liquidity or cash flows.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our future success also depends
on our ability to identify, attract, hire or engage, retain and motivate other well-qualified managerial, technical, clinical and regulatory
personnel. This activity is likely to create additional demands on the time and attention of our senior management personnel as they identify,
hire, and train external and internal candidates to fill the sizable number of positions required to execute our business plans including
submit a BLA and build a commercial organization. The market for talent in our industry is very competitive. Many of the other biopharmaceutical
companies we compete against for qualified personnel have greater financial and other resources, more favorable risk profiles and a longer
operating history in the biopharmaceutical industry than we do. They also may provide more diverse opportunities and better chances for
career advancement. Some of these opportunities may be more appealing to high-quality candidates than what we have to offer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is particularly difficult
to recruit and hire new employees during the COVID-19 pandemic as conducting interviews remotely makes it more difficult to ensure we
are recruiting and hiring high-quality employees, and the uncertainty created by the COVID-19 pandemic makes it less likely potential
candidates will be willing to leave a stable job to explore a new opportunity. There can be no assurance that such professionals will
be available in the market, or that we will be able to retain existing professionals or meet or continue to meet their compensation requirements.
Furthermore, the cost base in relation to such compensation, which may include equity compensation, may increase significantly, which
could have a material adverse effect on us. Failure to establish and maintain an effective management team and workforce could adversely
affect our ability to operate, grow and manage our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Managing our growth as we expand operations
may strain our resources.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect to need to grow
rapidly in order to support additional, larger, and potentially international, pivotal clinical trials of our product candidates as well
as potential commercial operations, which will place a significant strain on our financial, managerial and operational resources. In order
to achieve and manage growth effectively, we must continue to improve and expand our operational and financial management capabilities.
Moreover, we will need to increase staffing and to train, motivate and manage our employees. All of these activities will increase our
expenses and may require us to raise additional capital sooner than expected. Failure to manage growth effectively could materially harm
our business, financial condition or results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may expand our business through the acquisition
of rights to new product candidates that could disrupt our business, harm our financial condition and may also dilute current stockholders&#8217;
ownership interests in our company.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business strategy includes
expanding our products and capabilities, and we may seek acquisitions of product candidates, antibodies or technologies to do so. Acquisitions
involve numerous risks, including substantial cash expenditures; potentially dilutive issuance of equity securities; incurrence of debt
and contingent liabilities, some of which may be difficult or impossible to identify at the time of acquisition; difficulties in assimilating
acquired technologies or the operations of the acquired companies; diverting our management&#8217;s attention away from other business
concerns; risks of entering markets in which we have limited or no direct experience; and the potential loss of our key employees or key
employees of the acquired companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We can make no assurances
that any acquisition will result in short-term or long-term benefits to us. We may incorrectly judge the value or worth of an acquired
product, company or business. In addition, our future success would depend in part on our ability to manage the rapid growth associated
with some of these acquisitions. We cannot assure that we will be able to make the combination of our business with that of acquired products,
businesses or companies work or be successful. Furthermore, the development or expansion of our business or any acquired products, business
or companies may require a substantial capital investment by us. We may not have these necessary funds, or they might not be available
to us on acceptable terms or at all. We may also seek to raise funds by selling shares of our preferred or common stock, which could dilute
each current stockholder&#8217;s ownership interest in the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Risks Related to Ownership of Our Common
Stock</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The sale of securities by us in any equity
or debt financing could result in dilution to our existing stockholders and have a material adverse effect on our earnings.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have financed our operations
primarily through sales of stock and warrants. It is likely that during the next twelve months we will seek to raise additional capital
through the sales of stock and warrants in order to expand our level of operations to continue our research and development efforts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any sale of common stock by
us in a future offering could result in dilution to our existing stockholders as a direct result of our issuance of additional shares
of our capital stock. In addition, our business strategy may include expansion through internal growth or by establishing strategic relationships
with targeted customers and vendors. In order to do so, or to finance the cost of our other activities, we may issue additional equity
securities that could dilute our stockholders&#8217; stock ownership. We may also assume additional debt and incur impairment losses related
to goodwill and other tangible assets if we acquire another company and this could negatively impact our earnings and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our common stock is subject to price volatility
which could lead to losses by stockholders and potential costly security litigation.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The trading volume of our
common stock has been and may continue to be extremely limited and sporadic. We expect the market price of our common stock to fluctuate
substantially due to a variety of factors, including market perception of our ability to achieve our planned growth, quarterly operating
results of other companies in the same industry, trading volume in our common stock, changes in general conditions in the economy and
the financial markets or other developments affecting our competitors or us. This volatility has had a significant effect on the market
price of securities issued by many companies for reasons unrelated to their operating performance and could have the same effect on our
common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The trading price of our common
stock may be highly volatile and could fluctuate in response to factors such as:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual or anticipated variations in our operating results;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements of developments by us or our competitors;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing of IND and/or BLA approval, the completion and/or results of our clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory actions regarding our products;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adoption of new accounting standards affecting our industry;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions or departures of key personnel;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">introduction of new products by us or our competitors;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales of our common stock or other securities in the open market; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other events or factors, many of which are beyond our control.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The stock market is subject
to significant price and volume fluctuations. Moreover, the COVID-19 pandemic has resulted in significant financial market volatility
and uncertainty in recent months. In the past, following periods of volatility in the market price of a company&#8217;s securities, securities
class action litigation has often been initiated against such a company. Litigation initiated against us, whether or not successful, could
result in substantial costs and diversion of our management&#8217;s attention and our resources, which could harm our business and financial
condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We do not intend to pay dividends on our
common stock, so any returns will be determined by the value of our common stock.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never declared or
paid any cash dividends on our common stock. For the foreseeable future, it is expected that earnings, if any, generated from our operations
will be used to finance the growth of our business, and that no dividends will be paid to holders of our common stock. As a result, the
success of an investment in our common stock will depend upon any future appreciation in its value. There is no guarantee that our common
stock will appreciate in value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Certain provisions of our Certificate of
Incorporation and Bylaws and Delaware law make it more difficult for a third party to acquire us and make a takeover more difficult to
complete, even if such a transaction were in our stockholders&#8217; interest.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Provisions of our certificate
of incorporation and bylaws may delay or discourage transactions involving an actual or potential change in our control or change in our
management, including transactions in which stockholders might otherwise receive a premium for their shares, or transactions that our
stockholders might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the price of our stock.
Among other things, the certificate of incorporation and bylaws:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide that the authorized number of directors may be changed by resolution of the board of directors; </span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide
    that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative
    vote of a majority of directors then in office, even if less than a quorum; </span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">divide the board of directors into three classes; and</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide notice in writing in a timely manner, and meet specific requirements as to the form and content of a stockholder&#8217;s notice.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we are governed
by Section 203 of the Delaware General Corporation Law. In general, Section 203 prohibits a public Delaware corporation from engaging
in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a period of three years after the date of the
transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner.
A &#8220;business combination&#8221; includes mergers, asset sales or other transactions resulting in a financial benefit to the stockholder.
An &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns, or within three years, did own,
15% or more of the corporation&#8217;s outstanding voting stock. These provisions may have the effect of delaying, deferring or preventing
a change in our control.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Compliance with the reporting requirements
of federal securities laws can be expensive.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to the information
and reporting requirements of the Exchange Act and other federal securities laws, and the compliance obligations of the Sarbanes-Oxley
Act. The costs of preparing and filing annual and quarterly reports and other information with the Securities and Exchange Commission
and furnishing audited reports to stockholders are substantial. In addition, we will incur substantial expenses in connection with the
preparation of registration statements and related documents with respect any offerings of our common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 60; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Failure to establish and maintain adequate
finance infrastructure and accounting systems and controls could impair our ability to comply with the financial reporting and internal
controls requirements for publicly traded companies.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a public company, we operate
in an increasingly demanding regulatory environment, including with respect to more complex accounting rules. Company responsibilities
required by the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act, include establishing and maintaining corporate oversight
and adequate internal control over financial reporting and disclosure controls and procedures. Effective internal controls are necessary
for us to produce reliable financial reports and are important to help prevent financial fraud.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our compliance with Section
404 of the Sarbanes-Oxley Act requires that we incur substantial accounting expense and expend significant management efforts. We complied
with Section 404 at December 31, 2021 and 2020 and while our testing did not reveal any material weaknesses in our internal controls,
any material weaknesses in our internal controls in the future would be required us to remediate in a timely manner so as to be able to
comply with the requirements of Section 404 each year. If we are not able to comply with the requirements of Section 404 in a timely manner
each year, we could be subject to sanctions or investigations by the SEC, NYSE American or other regulatory authorities which would require
additional financial and management resources and could adversely affect the market price of our common stock. Furthermore, if we cannot
provide reliable financial reports or prevent fraud, our business and results of operations could be harmed, and investors could lose
confidence in our reported financial information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If securities or industry analysts do not
publish research or publish inaccurate or unfavorable research about our business, the price of our common stock and trading volume could
decline.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The trading market for our
common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. Multiple
securities and industry analysts currently cover us. If one or more of the analysts downgrade our common stock or publish inaccurate or
unfavorable research about our business, the price of our common stock would likely decline. If one or more of these analysts cease coverage
of us or fail to publish reports on us regularly, demand for our common stock could decrease, which could cause the price of our common
stock and trading volume to decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our amended and restated&#160;bylaws, as
amended,&#160;designate the U.S.&#160;federal&#160;district courts as the&#160;exclusive forum&#160;for the resolution of any complaint
asserting a cause of action arising under the Securities Act of 1933, as amended. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our amended and restated&#160;bylaws,
as amended,&#160;provide that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the
United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities
Act of 1933, as amended. In addition, our amended and restated bylaws, as amended, state that any person purchasing or otherwise acquiring
any interest in our security shall be deemed to have notice of and to have consented to such provision. Such choice of forum provision
may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors,
officers or other employees, which may discourage such lawsuits, if successful, might benefit our stockholders. Stockholders who do bring
a claim in the federal district courts of the United States of America could face additional litigation costs in pursuing any such claim.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><div><a id="a_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 3. DEFAULTS UPON SENIOR SECURITIES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 4. MINE SAFETY DISCLOSURES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 5. OTHER INFORMATION.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 61; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_013"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 6. EXHIBITS </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Copies of the following documents
are included as exhibits to this report pursuant to Item 601 of Regulation S-K.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 9%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit&#160;No.</b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 90%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390013001911/f8k041113ex3i_actinium.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Incorporation of Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.1 of the Company&#8217;s Form 8-K filed with the SEC on April 17, 2013).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390014000604/fs12014ex3v_actinium.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to Certificate of Incorporation, as amended, filed January 7, 2014 (incorporated by reference to Exhibit 3.5 to Form S-1 filed on January 31, 2014).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390014000688/f8k020314ex3i_actinium.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to Certificate of Incorporation, as amended, filed February 3, 2014. (incorporated by reference to Exhibit 3.1 to Form 8-K filed on February 7, 2014).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390015001553/f8k022615ex3i_actinium.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to Certificate of Incorporation, as amended, filed on February 26, 2015 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on March 4, 2015).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390018002270/f8k022618ex3-1_actinium.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to Certificate of Incorporation, as amended, filed on February 26, 2018 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on February 26, 2018).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390019004269/f10k2018ex3-7_actinium.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to Certificate of Incorporation, as amended, filed on March 6, 2019 (incorporated by reference to Exhibit 3.7 to Form 10-K filed on March 15, 2019).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390020015104/ea123121ex3-1_actiniumpharma.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to Certificate of Incorporation, as amended, filed on June 16, 2020 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on June 16, 2020).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.8</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390020022322/ea125571ex3-1_actinium.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to Certificate of Incorporation, as amended, filed on August 10, 2020 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on August 14, 2020).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.9</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390018010603/f10q0618ex3-1_actinium.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Bylaws, dated August 8, 2018 (incorporated by reference to Exhibit 3.1 to Form 10-Q filed on August 9, 2018).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.10</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390020011052/ea121342ex3-1_actinium.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to Amended and Restated Bylaws, dated May 7, 2020 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on May 5, 2020).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>

<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1+&#8224;*</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: justify; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="f10q0622ex10-1_actinium.htm">Exclusive License and Supply Agreement, dated April&#160;7, 2022, between Immedica Pharma AB and Actinium Pharmaceuticals, Inc.</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="f10q0622ex10-2_actinium.htm">Sublease Agreement, dated April 28, 2022, between ABN AMRO HOLDINGS USA LLC and Actinium Pharmaceuticals, Inc.</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>

<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: justify; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="f10q0622ex31-1_actinium.htm">Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="f10q0622ex31-2_actinium.htm">Certification of the Principal Financial and Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1**</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="f10q0622ex32-1_actinium.htm">Certification of the Chief Executive Officer pursuant to U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2**</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="f10q0622ex32-2_actinium.htm">Certification of the Principal Financial and Accounting Officer pursuant to U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS&#160;&#160;*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Instance Document</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH&#160;*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Schema Document</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL&#160;*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Calculation Linkbase Document</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF&#160;*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Definition Linkbase Document</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB *</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Label Linkbase Document </span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE *</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Presentation Linkbase Document</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed herewith.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furnished herewith. </span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">#</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates a management contract or compensatory plan or arrangement.</span></td></tr>
  </table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">+</td><td style="text-align: justify">Certain of the schedules (and similar attachments) to this
Exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5) of Regulation S-K under the Securities Act of 1933, as amended,
because they do not contain information material to an investment or voting decision and that information is not otherwise disclosed
in the Exhibit or the disclosure document. The registrant hereby agrees to furnish a copy of all omitted schedules (or similar attachments)
to the SEC upon its request.</td>
</tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">&#8224;</td><td style="text-align: justify">Portions of this exhibit have been omitted pursuant to Item
601(b)(10)(iv) of Regulation S-K under the Securities Act of 1933, as amended, because they are both (i) not material and (ii) the type
that the registrant treats as private or confidential. A copy of the omitted portions will be furnished to the SEC upon its request.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 62; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ACTINIUM PHARMACEUTICALS, INC.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 37%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: August 12, 2022</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/ Sandesh Seth</i></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandesh Seth</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman and Chief Executive Officer<br/>
(Duly Authorized Officer and<br/>
Principal Executive Officer)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/ Steve O&#8217;Loughlin</i></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steve O&#8217;Loughlin</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Duly Authorized Officer and<br/>
Principal Financial and Accounting Officer)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">61</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0in; margin-bottom: 0in; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonFraction contextRef="c3" id="hidden-fact-0" name="us-gaap:DepositsAssetsNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-1" name="us-gaap:DeferredRevenue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-2" name="us-gaap:FinanceLeaseLiabilityNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-3" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-4" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-5" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-6" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-7" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-8" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-9" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-10" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" decimals="2" id="hidden-fact-11" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">0.25</ix:nonFraction>
<ix:nonFraction contextRef="c4" decimals="2" id="hidden-fact-12" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">0.33</ix:nonFraction>
<ix:nonFraction contextRef="c6" decimals="2" id="hidden-fact-13" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">0.54</ix:nonFraction>
<ix:nonFraction contextRef="c0" decimals="2" id="hidden-fact-14" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">0.56</ix:nonFraction>
<ix:nonFraction contextRef="c6" decimals="0" id="hidden-fact-15" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">19308487</ix:nonFraction>
<ix:nonFraction contextRef="c5" decimals="0" id="hidden-fact-16" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">20231278</ix:nonFraction>
<ix:nonFraction contextRef="c0" decimals="0" id="hidden-fact-17" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">22942317</ix:nonFraction>
<ix:nonFraction contextRef="c4" decimals="0" id="hidden-fact-18" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">23731886</ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-19" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-20" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-21" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-22" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-23" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-24" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-25" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-26" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-27" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-28" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-29" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-30" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-31" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c29" id="hidden-fact-32" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-33" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c38" id="hidden-fact-34" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c38" id="hidden-fact-35" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-36" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c38" id="hidden-fact-37" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-38" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c37" id="hidden-fact-39" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-40" name="us-gaap:IncreaseDecreaseInSecurityDeposits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-41" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-42" name="us-gaap:IncreaseDecreaseInDeferredRevenue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-43" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-44" name="us-gaap:InterestPaidNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-45" name="us-gaap:InterestPaidNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-46" name="us-gaap:IncomeTaxesPaid" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-47" name="us-gaap:IncomeTaxesPaid" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-48" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-49" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-50" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c49" id="hidden-fact-51" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c49" id="hidden-fact-52" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c49" id="hidden-fact-53" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c49" id="hidden-fact-54" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-55" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-56" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-57" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c60" id="hidden-fact-58" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c60" id="hidden-fact-59" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c60" id="hidden-fact-60" name="atnm:NumberOfSharesExercised1" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c60" id="hidden-fact-61" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c62" id="hidden-fact-62" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c62" id="hidden-fact-63" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus">Q2</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey">0001388320</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="atnm-20220630.xsd" xlink:type="simple"></link:schemaRef></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><xbrli:context id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-08-12</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb5nsTZF1hxsII3StF2nMaFie2WjubTneMhItBwoNuKpVkBjepuDGZJv0uAY/2011DiRxFwSK8IV5mRgvGfHwlBphcd0S/9cahV/vLA5QTpMuHsLSaekfOQE+nOwFp1gLwGaIR82N4BdA/qqO+LqocFMcsLb+CKpnMLguXk/dClIuZ4s7bLRTp12jwSERaIqdwlwSSuibmDawK3f+WdTJs5DUhfVfZs+dFqVCilfiUjhg==] CSR-->
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2012-05-16</xbrli:startDate>
    <xbrli:endDate>2012-06-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="atnm:LeaseAxis">atnm:OperatingLeaseLiabilitiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="atnm:LeaseAxis">atnm:FinanceLeaseLiabilitiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2022-04-07</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-08-03</xbrli:startDate>
    <xbrli:endDate>2020-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">atnm:StocksOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-08-02</xbrli:startDate>
    <xbrli:endDate>2017-08-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2017-08-02</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-08-02</xbrli:startDate>
    <xbrli:endDate>2017-08-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-08-01</xbrli:startDate>
    <xbrli:endDate>2022-08-12</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:unit id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>f10q0622ex10-1_actinium.htm
<DESCRIPTION>EXCLUSIVE LICENSE AND SUPPLY AGREEMENT, DATED APRIL 7, 2022, BETWEEN IMMEDICA PHARMA AB AND ACTINIUM PHARMACEUTICALS INC
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CERTAIN CONFIDENTIAL INFORMATION MARKED BY [*]
HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS
AS PRIVATE OR CONFIDENTIAL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXCLUSIVE LICENSE AND SUPPLY AGREEMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS EXCLUSIVE LICENSE AND
SUPPLY AGREEMENT <B>(&ldquo;Agreement&rdquo;) </B>is made effective as of the 7th day of April, 2022 (the <B>&ldquo;Effective Date&rdquo;),
</B>by and between Immedica Pharma AB, a corporation organized and existing under the laws of Sweden with registration number, 556835-6322
and offices at Norrtullsgatan 15, SE 113 29 Stockholm, Sweden <B>(&ldquo;IMMEDICA&rdquo;) </B>and Actinium Pharmaceuticals, Inc., a corporation
organized and existing under the laws of Delaware and with offices at 275 Madison Avenue, 7th Floor, New York, NY 10016, U.S.A. <B>(&ldquo;LICENSOR&rdquo;).
</B>IMMEDICA and LICENSOR may, from time-to-time, be individually referred to as a <B>&ldquo;Party&rdquo; </B>and collectively referred
to as the <B>&ldquo;Parties&rdquo;.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RECITALS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">WHEREAS, LICENSOR Controls the Licensed Technology
(hereinafter defined); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">WHEREAS, IMMEDICA wishes to obtain, and LICENSOR
wishes to grant, certain licenses under the Licensed Technology on the terms and conditions set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.6pt; text-align: justify; text-indent: 36.1pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">NOW, THEREFORE,
in consideration of the mutual agreements and covenants set forth herein and other good and valuable consideration, the receipt and sufficiency
of which the Parties hereby acknowledge, the Parties, intending to be legally bound hereby, agree to the foregoing and as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.65pt; text-indent: -36.2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.</TD><TD><B>DEFINITIONS</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.6pt; text-indent: -36.9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.1.</TD><TD><B>&ldquo;Additional Clinical Studies&rdquo; </B>has the meaning given in Section 4.2.1.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.6pt; text-indent: -36.9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.2.</TD><TD><B>&ldquo;Additional Indication Study&rdquo; </B>has the meaning given in Section 4.2.2.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.35pt; text-indent: -36.65pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.3.</TD><TD><B>&ldquo;Additional Product&rdquo; </B>has the meaning given in Section 2.4.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.6pt; text-align: justify; text-indent: -36.9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.4.</TD><TD STYLE="text-align: justify"><B>&ldquo;Affiliate&rdquo; </B>means, with respect to a Party, any Person that controls, is controlled
by, or is under common control with that Party. For the purpose of this definition, <B>&ldquo;control&rdquo; </B>shall refer to: (a)&nbsp;the
possession, directly or indirectly, of the power to direct the management or policies of an entity, whether through the ownership of voting
securities, by contract or otherwise, or (b) the ownership, directly or indirectly, of fifty percent (50%) or more of the voting securities
of such entity.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.8pt; text-align: justify; text-indent: -37.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.5.</TD><TD STYLE="text-align: justify"><B>&ldquo;Applicable Laws&rdquo; </B>means all applicable laws, statutes, rules, regulations and guidelines,
including, without limitation, all applicable standards or guidelines promulgated by any Regulatory Authority, including to the extent
applicable, GLP, GCP and GMP.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.1pt; text-indent: -36.15pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.6.</TD><TD><B>&ldquo;AML&rdquo; </B>means Acute Myeloid Lukemia.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.8pt; text-align: justify; text-indent: -36.8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.8pt; text-align: justify; text-indent: -36.8pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.8pt; text-align: justify; text-indent: -36.8pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.7.</TD><TD STYLE="text-align: justify"><B>&ldquo;Business Day&rdquo; </B>means any day other than a Saturday, a Sunday or a day on which commercial
banks located in New York, NY, U.S.A. or Sweden are authorized or required by law to remain closed.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 43pt; text-align: justify; text-indent: -37.05pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.8.</TD><TD STYLE="text-align: justify"><B>&ldquo;Calendar Quarter&rdquo; </B>means each period of three (3) consecutive months ending on March
31, June 30, September 30, or December 31.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.85pt; text-align: justify; text-indent: -36.9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.9.</TD><TD STYLE="text-align: justify"><B>&ldquo;Calendar Year&rdquo; </B>means the period of twelve (12) consecutive months corresponding to
the calendar year commencing on the first day of January and ending on the last day of December, and each successive twelve (12) month
period thereafter.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.9pt; text-align: justify; text-indent: -36.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.10.</TD><TD STYLE="text-align: justify"><B>&ldquo;Claims&rdquo; </B>means collectively, any and all Third Party demands, claims, actions and proceedings
(whether criminal or civil, in contract, tort or otherwise) for losses, damages, liabilities, costs and expenses (including reasonable
attorneys&rsquo; fees).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.9pt; text-align: justify; text-indent: -36.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.11.</TD><TD STYLE="text-align: justify"><B>&ldquo;Clinical Studies&rdquo; </B>means any study in which human subjects are dosed or treated with
a drug or biological product, whether approved or investigational and including paediatric studies and investigator sponsored studies.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.9pt; text-align: justify; text-indent: -36.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.12.</TD><TD STYLE="text-align: justify"><B>&ldquo;Commercialize&rdquo; or &ldquo;Commercialization&rdquo; </B>means any and all activities related
to pre-marketing, launching, marketing, promotion (including advertising and detailing), serialization, bidding and listing, pricing and
reimbursement, distribution, storage, handling, offering for sale, selling, having sold, importing, having imported, exporting, having
exported, distributing, having distributed, supplying for named patient use, providing customer service and support, conducting medical
affairs, conducting post-marketing safety surveillance and reporting of or otherwise commercializing or exploiting the Product. <B>&ldquo;Commercializing&rdquo;
</B>has the correlative meaning.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.9pt; text-align: justify; text-indent: -36.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.13.</TD><TD STYLE="text-align: justify"><B>&ldquo;Commercially Reasonable Efforts&rdquo; </B>means that level of efforts that a similarly situated
biopharmaceutical company would normally use, in the exercise of its prudent scientific and business judgment, for the development and/or
commercialization of a comparable pharmaceutical product for a similar patient population at a similar stage of its development or commercialization,
taking into account all relevant scientific, commercial, business and other factors, including issues of safety and efficacy, expected
and approved product labeling, expected and actual cost and time to develop, expected and actual profitability, the nature and extent
of expected and actual market exclusivity (including patent coverage and regulatory exclusivity), the expected likelihood of marketing
approval, and the expected and actual amounts of marketing and promotional expenditures required. Commercially Reasonable Efforts shall
be determined on a country-by-country basis and it is anticipated that the level of effort and resources that constitute &ldquo;Commercially
Reasonable Efforts&rdquo; with respect to a particular country will change over time.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.9pt; text-align: justify; text-indent: -36.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.14.</TD><TD STYLE="text-align: justify"><B>&ldquo;Control&rdquo; or &ldquo;Controlled&rdquo; </B>means, with respect to any Intellectual Property
Rights, the legal authority or right (whether by ownership, license or otherwise) of a Party to grant the applicable access to, or a license
or a sublicense of or under, such Intellectual Property Rights to the other Party without breaching the terms of any agreement with a
Third Party existing as of the Effective Date, or at such later time as such Party first acquires rights to such subject matter.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.9pt; text-align: justify; text-indent: -36.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.9pt; text-align: justify; text-indent: -36.6pt"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.9pt; text-align: justify; text-indent: -36.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.15.</TD><TD STYLE="text-align: justify"><B>&ldquo;Cover&rdquo; </B>means, with respect to a compound, product, technology, process or method,
that in the absence of ownership of or a license granted under a Valid Claim, the Manufacture, use, offer for sale, sale or importation
of such product or the practice of such technology, process or method would infringe such Valid Claim (or, in the case of a Valid Claim
that has not yet issued, would infringe such Valid Claim if it were to issue as then being prosecuted). <B>&ldquo;Covered by&rdquo; </B>has
the correlative meaning.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.9pt; text-align: justify; text-indent: -36.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.16.</TD><TD STYLE="text-align: justify"><B>&ldquo;Develop&rdquo; or &ldquo;Development&rdquo; </B>means to conduct any and all non-clinical and
clinical research and development activities, including non-clinical development, toxicology, pharmacology, statistical analysis, Clinical
Studies (including pre- and post-approval studies), regulatory affairs, and regulatory activities pertaining to designing and carrying
out clinical studies and all activities necessary to obtain Regulatory Approval.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.9pt; text-align: justify; text-indent: -36.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.17.</TD><TD STYLE="text-align: justify"><B>&ldquo;EMA&rdquo; </B>means the European Medicines Agency or any successor agency thereto.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.9pt; text-indent: -36.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.18.</TD><TD><B>&ldquo;Executive Officers&rdquo; </B>means with respect to each Party, the chief executive officer of such Party or another senior
officer designated by such chief executive officer.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.1pt; text-align: justify; text-indent: -37.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.19.</TD><TD STYLE="text-align: justify"><B>&ldquo;Existing Agreements&rdquo; </B>means the [*].</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.15pt; text-align: justify; text-indent: -37.2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.20.</TD><TD STYLE="text-align: justify"><B>&ldquo;Facility&rdquo; or &ldquo;Facilities&rdquo; </B>shall mean the following GMP manufacturing facilities
utilized by LICENSOR or its Third Party contract manufacturers in the manufacture of the Product: [*].</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.4pt; text-align: justify; text-indent: -37.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.21.</TD><TD STYLE="text-align: justify"><B>&ldquo;FDA&rdquo; </B>shall mean the United States Food and Drug Administration, or any successor agency
thereto.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.6pt; text-indent: -36.65pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.22.</TD><TD><B>&ldquo;FDCA&rdquo; </B>shall mean the U.S. Federal Food, Drug and Cosmetic Act.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.6pt; text-indent: -36.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.23.</TD><TD><B>&ldquo;Fees&rdquo; </B>means collectively, the upfront payment, all Milestone Payments, and Royalties.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.4pt; text-align: justify; text-indent: -37.2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.24.</TD><TD STYLE="text-align: justify"><B>&ldquo;Field&rdquo; </B>means all uses in humans including the treatment of AML, bone marrow transplant
conditioning, non-myeloablative conditioning, and lymphodepletion.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.4pt; text-align: justify; text-indent: -37.2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.25.</TD><TD STYLE="text-align: justify"><B>&ldquo;First Commercial Sale&rdquo; </B>means, on a country-by-country basis, the first sale for use,
or consumption, by the general public of the Product following receipt of all Regulatory Approvals for such Product in such country in
the Territory.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.8pt; text-indent: -36.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.26.</TD><TD><B>&ldquo;Force Majeure Event&rdquo; </B>has the meaning set out in Section 19.5.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -37.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.27.</TD><TD STYLE="text-align: justify"><B>&ldquo;Good Clinical Practice&rdquo; or &ldquo;GCP&rdquo; </B>means the current standards for clinical
studies for pharmaceuticals, as set forth in the ICH guidelines and applicable regulations promulgated thereunder, as amended from time
to time, and such standards of good clinical practice as are required by the European Union, to the extent such standards are not less
stringent than United States Good Clinical Practice.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.6pt; text-align: justify; text-indent: -37.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.6pt; text-align: justify; text-indent: -37.1pt"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.6pt; text-align: justify; text-indent: -37.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.28.</TD><TD STYLE="text-align: justify"><B>&ldquo;Good Laboratory Practice&rdquo; or &ldquo;GLP&rdquo; </B>means the current standards for laboratory
activities for pharmaceuticals, as set forth in the FDA&rsquo;s Good Laboratory Practice regulations or the Good Laboratory Practice principles
of the Organization for Economic Co-Operation and Development, as amended from time to time, and such standards of good laboratory practice
as are required by the European Union, to the extent such standards are not less stringent than United States Good Laboratory Practice.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.6pt; text-align: justify; text-indent: -36.9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.29.</TD><TD STYLE="text-align: justify"><B>&ldquo;Good Manufacturing Practice&rdquo; or &ldquo;GMP&rdquo; </B>shall mean current good manufacturing
practice and standards as provided for (and as amended from time to time) in the Current Good Manufacturing Practice Regulations of the
U.S. Code of Federal Regulations Title 21 (21 CPR &sect;&sect; 210, 211, 601 and 610) and the most recent approved edition of European
Commission Directives applicable to the production of pharmaceutical products, as interpreted by the ICH Harmonized Tripartite Guideline,
and related regulations or guidance documents subsequently established by any applicable governmental or regulatory authority in the United
States or European Union.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.8pt; text-indent: -37.15pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.30.</TD><TD><B>&ldquo;Housemarks&rdquo; </B>shall mean the trade name Actinium Pharmaceuticals, Inc.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.9pt; text-align: justify; text-indent: -36.95pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.31.</TD><TD STYLE="text-align: justify"><B>&ldquo;lomab-B&rdquo; </B>means the pharmaceutical product known by that name comprising a CD45 directed
monoclonal antibody known as apamistamab linked to Iodine-131.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.9pt; text-align: justify; text-indent: -36.95pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.32.</TD><TD STYLE="text-align: justify"><B>&ldquo;Intellectual Property Rights&rdquo; </B>means all trade secrets, Know-How, copyrights, patents
and other patent rights, trademarks, moral rights, service marks, industrial designs, mask works, integrated circuit topographies, confidential
information, trade names, goodwill and any and all other intellectual property or proprietary rights now known or hereafter recognized
in any jurisdiction, whether registered or unregistered, and including rights in any application for any of the foregoing.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.1pt; text-align: justify; text-indent: -36.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.33.</TD><TD STYLE="text-align: justify"><B>&ldquo;Know-How&rdquo; </B>means all technical, scientific and other know-how and information, trade
secrets, knowledge, technology, means, methods, processes, practices, formulas, instructions, skills, techniques, procedures, ideas, technical
assistance, designs, drawings, assembly procedures, computer programs, apparatuses, specifications, data, results and other material,
including manufacturing procedures, test procedures, and purification and isolation techniques in written, electronic or any other form,
and all other discoveries, developments, inventions (whether or not patented or patentable), and tangible embodiments of any of the foregoing,
in each case that is not generally known to the public.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.05pt; text-align: justify; text-indent: -36.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.34.</TD><TD STYLE="text-align: justify"><B>&ldquo;Licensed Know-How&rdquo; </B>means all Know-How Controlled by LICENSOR or any of its Affiliates
as of the Effective Date or during the term of this Agreement that is necessary or useful for seeking and obtaining Regulatory Approval
for the Product in the Field in the Territory or for the Development or Commercialization of the Product in the Field in the Territory.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.05pt; text-align: justify; text-indent: -36.2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.35.</TD><TD STYLE="text-align: justify"><B>&ldquo;Licensed Patents&rdquo; </B>means: (a) the patents and patent applications listed in <U>Schedule
A,</U> (b) all Patent Rights that claim priority to the patents or patent applications described in subsection (a), and (c) any other
Patent Rights Controlled by the LICENSOR or any of its Affiliates as of the Effective Date or during the term of this Agreement that Cover
the Development or Commercialization of a Product or that claim Licensed Know-How (including in each case all related Patent Rights as
described in clauses (a)-(e) of Section 1.43 below).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.7pt; text-indent: -35.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.7pt; text-indent: -35.9pt"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.7pt; text-indent: -35.9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.36.</TD><TD><B>&ldquo;Licensed Technology&rdquo; </B>means collectively, the Licensed Patents and Licensed Know-How.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.35pt; text-align: justify; text-indent: -36.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.37.</TD><TD STYLE="text-align: justify"><B>&ldquo;Manufacture&rdquo; and &ldquo;Manufacturing&rdquo; </B>means all activities related to the synthesis,
making, production, processing, purifying, formulating, filling, finishing, packaging, labeling and shipping of any Product, or any intermediate
thereof, including process development, process qualification and validation, scale-up, pre-clinical, clinical and commercial production
and analytic development, product characterization, stability testing, quality assurance, and quality control. <B>&ldquo;Manufactured&rdquo;
</B>has the correlative meaning.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.45pt; text-align: justify; text-indent: -36.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.38.</TD><TD STYLE="text-align: justify"><B>&ldquo;Manufacturing Agreements&rdquo; </B>means those agreements entered into by or on behalf of the
LICENSOR or its Affiliates which relate to the manufacture of the Product or any part thereof, which is to be, or which has been, supplied
to IMMEDICA under this Agreement, including the associated drug substance and drug product manufacturing agreements. At the Effective
Date, the Manufacturing Agreements include (a) the Manufacturing Services Agreement, dated [*], between LICENSOR and [*], (b) the Agreement
for Services, dated [*], between LICENSOR and [*] and (c) the Radiochemical Supply Agreement, dated [*], between LICENSOR and [*].</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.9pt; text-align: justify; text-indent: -36.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.39.</TD><TD STYLE="text-align: justify"><B>&ldquo;Materials&rdquo; </B>shall mean, excipients and solvents and other chemicals and other raw materials
(including the CD45 directed monoclonal antibody known as apamistamab) and components, packaging and shipping materials (including vials)
and other materials and supplies reasonably necessary to perform the Services.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.15pt; text-indent: -35.65pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.40.</TD><TD><B>&ldquo;Milestone&rdquo; </B>means each milestone as set forth in <U>Schedule B</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 43.1pt; text-align: justify; text-indent: -37.2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.41.</TD><TD STYLE="text-align: justify"><B>&ldquo;Milestone Payment&rdquo; </B>has the meaning set out in Section 6.1.2.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.15pt; text-align: justify; text-indent: -36.9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.42.</TD><TD STYLE="text-align: justify"><B>&ldquo;Net Sales&rdquo; </B>means the sales revenues received by or on behalf ofIMMEDICA and its Affiliates
and Sublicensees for sales of the Product to Third Parties, less the following deductions if and to the extent they are included in the
gross invoiced sales price of the Product or otherwise incurred by IMMEDICA and its Affiliates or Sublicensees with respect to the sale
of the Product: (a) rebates, quantity and cash discounts, and other usual and customary discounts to customers, (b) Taxes (but excluding,
for the avoidance of doubt, income taxes paid or payable by IMMEDICA, its Affiliates and Sublicensees with respect to such sales) and
any other duties paid, absorbed or allowed which are directly related to the sale of the Product, (c) credits, allowances, discounts and
rebates, and chargebacks for spoiled, damaged, out-dated, recalled, rejected or returned Product, (d) actual freight and insurance costs
incurred in transporting the Product to customers, (e) discounts or rebates or other payments required by Applicable Law, including any
governmental special medical assistance programs, and (f) customs duties, surcharges and other governmental charges and rebates incurred
in connection with the exportation or importation of the Product . Subsections (a) through (f) shall be collectively referred to as <B>&ldquo;Deductions&rdquo;.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The following principles shall apply in the calculation
of Net Sales:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.6pt; text-align: justify; text-indent: -37.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.42.1.</TD><TD STYLE="text-align: justify">The provision of the Product at no charge for the purpose of conducting pre-clinical or clinical research,
or as donations or the like or as &ldquo;treatment IND sales&rdquo;, &ldquo;named patient sales&rdquo;, &ldquo;compassionate use sales&rdquo;,
or pursuant to any expanded access programs, or any equivalent sales, in each case shall not be deemed to be included in Net Sales.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.75pt; text-align: justify; text-indent: -37pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.42.2.</TD><TD STYLE="text-align: justify">Transfers of Product between IMMEDICA and its Affiliates and/or Sublicensees shall not be treated as Net
Sales for the purposes of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.75pt; text-align: justify; text-indent: -37pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.42.3.</TD><TD STYLE="text-align: justify">Unless otherwise specified herein, Net Sales shall be calculated in accordance with IMMEDICA&rsquo;s,
or its Affiliate&rsquo;s or Sublicensees&rsquo;s applicable accounting practices generally and consistently applied.</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.75pt; text-align: justify; text-indent: -37pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.75pt; text-align: justify; text-indent: -37pt"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.75pt; text-align: justify; text-indent: -37pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.43</TD><TD STYLE="text-align: justify"><B>&ldquo;Other Product&rdquo; </B>has the meaning given in Section 2.4.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.6pt; text-align: justify; text-indent: -37pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.44</TD><TD STYLE="text-align: justify"><B>&ldquo;Patent Rights&rdquo; </B>means with respect to any patents or patent applications, any and all
(a) patents issuing from such patent applications, (b) substitutions, divisionals, renewals, continuations or continuations-in-part (only
to the extent of claims that are entitled to the priority date of the parent application); (c) patents of addition, restorations, extensions,
supplementary protection certificates, registration or confinnation patents, patents resulting from post-grant proceedings, re-issues
and re-examinations; (d) other patents or patent applications claiming and entitled to claim priority to (i) such patents and patent applications
and any patent or patent application specified in (a), (b) or (c), or (ii) any patent or patent application from which such patents and
patent applications or a patent or patent application specified in (a), (b) or (c) claims and is entitled to claim priority; (d) all rights
of priority attendant to such patents and patent applications and any of the patents and patent applications listed in (a) through (d);
and (e) in each case of such patents and patent applications and of the patents and patent applications described in (a) through (d),
including all counterparts and foreign equivalents thereof filed in any country, territory or jurisdiction in the world.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.6pt; text-align: justify; text-indent: -37pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.45</TD><TD STYLE="text-align: justify"><B>&ldquo;Person&rdquo; </B>means an individual, corporation, partnership, limited liability company,
trust, business trust, association, joint stock company, joint venture, pool, syndicate, sole proprietorship, unincorporated organization,
governmental authority or any other form of entity not specifically listed herein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.6pt; text-align: justify; text-indent: -37pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.46</TD><TD STYLE="text-align: justify"><B>&ldquo;Phase III Clinical Trial&rdquo; </B>means the phase III clinical study of the Product titled
&ldquo;Iomab-B (131-I apamistamab)&rdquo; having ClinicalTrials.gov identifier NCT02665065 having the official title of A Multicenter,
Pivotal Phase 3 Study of <B>Iomab-B </B>Prior to Allogeneic Hematopoietic Cell Transplant Versus Conventional Care in Older Subjects With
Active, Relapsed or Refractory Acute Myeloid Leukemia (AML).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.6pt; text-align: justify; text-indent: -37pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.47</TD><TD STYLE="text-align: justify"><B>&ldquo;Product&rdquo; </B>means any pharmaceutical product containing, incorporating or comprising
<B>1311- </B>apamistamab (including the product currently known as Iomab-B both dosimetric and therapeutics doses and the product currently
known as Iomab-Act), irrespective of salt form or excipients, in any formulation, mode of administration, presentation or dosage form.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.6pt; text-align: justify; text-indent: -37pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.48</TD><TD STYLE="text-align: justify"><B>&ldquo;Product Trademark&rdquo; </B>any trademark used exclusively in relation to the Products in the
Territory.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.6pt; text-align: justify; text-indent: -37pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.49</TD><TD STYLE="text-align: justify"><B>&ldquo;Protocol&rdquo; </B>means sponsor protocol number 8, as such protocol may be amended from time
to time by LICENSOR after discussion at the JSC.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.6pt; text-indent: -37pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.50</TD><TD><B>&ldquo;Quality Agreement&rdquo; </B>has the meaning set forth in Section 7.3.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.6pt; text-align: justify; text-indent: -37pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.51</TD><TD STYLE="text-align: justify"><B>&ldquo;Regulatory Approval&rdquo; </B>means, with respect to the Product in any country or jurisdiction,
any approval (including where required, pricing and reimbursement approvals), registration, license or authorization that is required
by the applicable Regulatory Authority to market and sell the Product in such country or jurisdiction and including any orphan drug designations
or similar rights.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.6pt; text-align: justify; text-indent: -37pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.52</TD><TD STYLE="text-align: justify"><B>&ldquo;Regulatory Authority&rdquo; </B>means the EMA or any governmental agency or authority responsible
for granting Regulatory Approvals for the Product in any country or jurisdiction in the Territory.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.6pt; text-align: justify; text-indent: -37pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.53</TD><TD STYLE="text-align: justify"><B>&ldquo;Regulatory Filings&rdquo; </B>means, with respect to the Product, any submission to a Regulatory
Authority of any appropriate regulatory application, including, without limitation, any submission to a regulatory advisory board, any
marketing authorization application, any application for orphan drug designation, and any supplement or amendment thereto. As used herein,
&ldquo;Regulatory Filings&rdquo; also includes all correspondence with any Regulatory Authority (and their agents) regarding Product,
including all submissions, meeting minutes, reports and other items submitted to a Regulatory Authority by or under authority of a Party,
its Affiliates or its Sublicensees with respect to a Product, or the Development, Manufacture or Commercialization thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.6pt; text-indent: -37pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.6pt; text-indent: -37pt"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.6pt; text-indent: -37pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.54</TD><TD><B>&ldquo;Royalties&rdquo; </B>has the meaning set out in Section 6.1.3.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.6pt; text-align: justify; text-indent: -37pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.55</TD><TD STYLE="text-align: justify"><B>&ldquo;Services&rdquo; </B>shall mean the commercial Manufacture of Product to be performed by the
LICENSOR under this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.6pt; text-align: justify; text-indent: -37pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.56</TD><TD STYLE="text-align: justify"><B>&ldquo;Specifications&rdquo; </B>shall mean the specifications for Manufacturing the Product ready
for use, including without limitation all regulatory, manufacturing, quality control and quality assurance procedures, processes, practices,
standards instructions and other attributes for the Product as set forth on <U>Schedule C</U>, as such specifications may be amended by
the Parties due to new data with approval from Regulatory Authority or due to other regulatory requirements, from time to time.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.6pt; text-align: justify; text-indent: -37pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.57</TD><TD STYLE="text-align: justify"><B>&ldquo;Sublicense&rdquo; </B>means a written agreement appointing a Sublicensee.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.6pt; text-align: justify; text-indent: -37pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.58</TD><TD STYLE="text-align: justify"><B>&ldquo;Sublicensee&rdquo; </B>means any Third Party to which IMMEDICA has delegated substantially all
of its rights and obligations under this Agreement with respect to any jurisdiction(s) in the Territory, including all of the following:
(i) the exclusive (even as to IMMEDICA) right to purchase Product from LICENSOR (directly or indirectly via IMMEDICA) for sale or use
in such jurisdiction(s), (ii) the exclusive (even as to IMMEDICA) right to seek or hold Regulatory Approval (other than where such Regulatory
Approval is to be held on behalf of IMMEDICA) for the Product in such jurisdiction(s); (iii) the exclusive right (even as to IMMEDICA)
to set the price of the Product in such jurisdiction(s); and (iv) the obligation to Commercialize the Product in such jurisdiction(s).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.6pt; text-align: justify; text-indent: -37pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.59</TD><TD STYLE="text-align: justify"><B>&ldquo;Supply Failure&rdquo; </B>means a failure by LICENSOR to supply at least [*]% of the Product
ordered by IMMEDICA under this Agreement in two Calendar Quarters in any Calendar Year.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.6pt; text-indent: -37pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.60</TD><TD><B>&ldquo;Target&rdquo; </B>means [*].</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.6pt; text-indent: -37pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.61</TD><TD><B>&ldquo;Taxes&rdquo; </B>has the meaning set forth in Section 6.3.1.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.6pt; text-align: justify; text-indent: -37pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.62</TD><TD STYLE="text-align: justify"><B>&ldquo;Territory&rdquo; </B>means the current members states of the European Economic Area (together
with any country that becomes a member of the European Economic Area), Algeria, Andorra, Bahrain, Cyprus, Egypt, Iran, Iraq, Israel, Jordan,
Kuwait, Lebanon, Libya. Monaco, Morocco, Oman, Palestine, Qatar, San Marino, Saudi Arabia, Switzerland, Syria, Tunisia, Turkey, the United
Arab Emirates, the United Kingdom, the Vatican City and Yemen. For the avoidance of doubt, if a country ceases to be a member state of
the European Economic Area then, notwithstanding such cessation, such country shall remain part of the Territory</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.6pt; text-indent: -37pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.63</TD><TD><B>&ldquo;Third Party&rdquo; </B>means any Person other than a Party or an Affiliate of a Party</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.6pt; text-align: justify; text-indent: -37pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.64</TD><TD STYLE="text-align: justify"><B>&ldquo;Valid Claim&rdquo; </B>means either: (a) a claim of an issued and unexpired Patent Right, which
has not been permanently revoked or declared unenforceable or invalid by an unreversed and unappealable or unreversed and unappealed decision
of a court or other appropriate body of competent jurisdiction, or (b) a claim of a pending application for a Patent Right, which claim:
(i)&nbsp;is within [*] from its earliest priority date and was filed and is being prosecuted in good faith and has not been abandoned
or finally disallowed without the possibility of appeal or refiling of such application and (ii) has not been admitted to be invalid or
unenforceable through reissue, reexamination, or disclaimer and which is not subject to an interference claim.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.55pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.55pt"><FONT STYLE="font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.55pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-weight: normal">2.</FONT></TD><TD STYLE="text-align: justify">LICENSE GRANT</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-indent: -37.15pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">2.1.</TD><TD><B>License Grant.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.9pt; text-align: justify; text-indent: -37.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
<TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">2.1.1.</FONT></TD><TD STYLE="text-align: justify"><B>Licensed Technology. </B>Subject to the terms and conditions of this Agreement, LICENSOR hereby grants
to IMMEDICA an exclusive, royalty-bearing right and license with the right to grant Sublicenses, as provided in Section 2.2, under the
Licensed Technology to Develop and Commercialize the Product in the Field within the Territory. Such license shall not include a license
to Manufacture the Product unless IMMEDICA takes over responsibility for Manufacture in accordance with Section 7.8.5 provided that IMMEDICA
shall be entitled to carry out QP release of and to import the Product. IMMEDICA shall not itself or through or with any Third Party,
conduct or facilitate any research or Development directly related to the Product outside of the Territory without LICENSOR&rsquo;s prior
written consent.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 80.1pt; text-align: justify; text-indent: -37.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
<TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">2.1.2.</FONT></TD><TD STYLE="text-align: justify"><B>Trademarks. </B>LICENSOR grants to IMMEDICA an exclusive right and license to use all (i) Product Trademarks
owned or Controlled by LICENSOR or its Affiliates and the Housemarks to the extent that the Housemarks are applied by LICENSOR to the
Product or its packaging, in each case in connection with the Commercialization of the Product in the Field within the Territory. All
marks, whether registered or unregistered, used in connection with the Products must be approved, in writing, by the LICENSOR prior to
use in the Territory which approval will not be unreasonably withheld, conditioned or delayed.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.85pt; text-align: justify; text-indent: -36.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">2.2.</TD><TD STYLE="text-align: justify"><B>Sublicense Rights. </B>IMMEDICA may grant a Sublicense of the rights granted to it by LICENSOR under
this Agreement only with LICENSOR&rsquo;s prior written consent, and subject to the following requirements:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1in; text-align: justify; text-indent: -37.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">2.2.1.</FONT></TD><TD STYLE="text-align: justify">Any such Sublicenses shall be subject to and consistent with the terms and conditions of this Agreement,
including, without limitation, with respect to confidentiality, record keeping obligations and audit rights;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.15pt; text-align: justify; text-indent: -37.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">2.2.2.</FONT></TD><TD STYLE="text-align: justify">Unless otherwise agreed by the LICENSOR and IMMEDICA, IMMEDICA shall act as the representative of its
Sublicensees for purposes of exercising rights under Section 7 of this Agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.15pt; text-align: justify; text-indent: -37.05pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">2.2.3.</FONT></TD><TD STYLE="text-align: justify">IMMEDICA shall remain responsible for the payment to LICENSOR of all Milestone Payments and Royalties
payable with respect to Net Sales of Products made by such Sublicensees;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.3pt; text-align: justify; text-indent: -37.25pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">2.2.4.</FONT></TD><TD STYLE="text-align: justify">IMMEDICA shall remain liable for the actions and omissions of each Sublicensee; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78.9pt; text-align: justify; text-indent: -36.85pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">2.2.5.</FONT></TD><TD STYLE="text-align: justify">IMMEDICA shall furnish to LICENSOR an accurate and complete copy of each Sublicense agreement with a Third
Party and each amendment thereto prior to execution, provided that any such copy may be redacted to remove any commercially sensitive
or financial terms, or terms which do not relate to the Product.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41pt; text-align: justify; text-indent: 0.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.05pt">In addition IMMEDICA
may also appoint distributors, wholesalers or appoint any Third Party to provide services including sales, logistics and/or regulatory
services, all of which shall not be considered Sublicensees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.85pt; text-align: justify; text-indent: -41.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.85pt; text-align: justify; text-indent: -41.85pt"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.85pt; text-align: justify; text-indent: -41.85pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">2.3.</TD><TD STYLE="text-align: justify"><B>Retained Rights. </B>IMMEDICA acknowledges and agrees that LICENSOR retains (i) the right to make,
have made, and export the Product under the terms of this Agreement, (ii)&nbsp;subject to Section 4.2.2, the right to make, have made
and use the Product for internal research purposes within the Field in the Territory, provided such reservation of rights expressly excludes
(a) the right to conduct Clinical Studies using the Product in the Territory other than those expressly permitted under this Agreement
or as otherwise agreed by the Parties in writing, (b) the right to apply for or to seek Regulatory Approval for the Product in the Territory,
and (c) the right to Commercialize the Product in the Territory, and (iii) the right to make, have made, use and export the Product for
any and all purposes outside of the Territory.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.85pt; text-align: justify; text-indent: -41.85pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">2.4.</TD><TD STYLE="text-align: justify"><B>Additional Products. </B>If during the term of this Agreement (i) LICENSOR or its Affiliate Develops
or Commercializes either alone or with a Third Party and or (ii) LICENSOR or its Affiliate acquires the right to Develop and Commercialize
in the Territory, any other product comprising an antibody, or another biological therapeutic molecule, conjugated or linked with or otherwise
administered with a radioisotope directed to the Target in the Field and such product obtains Regulatory Approval in any country in an
indication for which the Product has also obtained Regulatory Approval in a country in the Territory or for which an application for Regulatory
Approval has been submitted in a country in the Territory <B>(&ldquo;Additional Product&rdquo;) </B>it shall promptly notify IMMEDICA
in writing. IMMEDICA shall have the right within [*] of receiving any such notice to request that LICENSOR shall provide such information
as IMMEDICA shall reasonably request to enable IMMEDICA to assess the Additional Product. IMMEDICA shall have a period of [*], commencing
on its receipt from LICENSOR of the information requested by IMMEDICA, to notify LICENSOR if IMMEDICA wishes to include the Additional
Product under the terms of this Agreement. If IMMEDICA notifies LICENSOR that it does wish to include the Additional Product under the
terms of this Agreement, then from the date of IMMEDICA&rsquo;s notice, the terms of this Agreement shall apply to such Additional Product
including the provisions of Section 6.1 (other than Section 6.1.1) and the Parties shall agree in good faith any necessary amendments
to the terms of this Agreement. If during the term of this Agreement (i) LICENSOR or its Affiliate Develops or Commercializes either alone
or with a Third Party and or (ii)&nbsp;LICENSOR or its Affiliate acquires the right to Develop and Commercialize in the Territory, any
other product comprising an antibody, or another biological therapeutic molecule, conjugated or linked with or otherwise administered
with a radioisotope directed to the Target in the Field in an indication for which the Product has not obtained Regulatory Approval in
a country in the Territory or for which an application for Regulatory Approval has not been submitted in a country in the Territory <B>(&ldquo;Other
Product&rdquo;) </B>LICENSOR shall promptly notify IMMEDICA in writing. If LICENSOR or its Affiliate is proposing to outlicense, sell
or otherwise transfer the right to Develop and or Commercialize such Other Product in the Territory to a Third Party LICENSOR shall notify
IMMEDICA in writing and shall grant IMMEDICA for a period of [*], commencing on the date of IMMEDICA&rsquo;s receipt of such notice, the
first right to negotiate in good faith the terms of an agreement pursuant to which IMMEDICA would be granted the right to Develop and
Commercialize such Other Product in the Territory. During such [*] period LICENSOR and its Affiliates will not discuss with or grant any
Third Party any right to Develop and or Commercialize the Other Product in the Territory.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.1pt; text-align: justify; text-indent: -36.9pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.1pt; text-align: justify; text-indent: -36.9pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">2.5.</TD><TD STYLE="text-align: justify"><B>Territory Exclusivity. </B>LICENSOR shall not and shall ensure that its Affiliates shall not during
the term of this Agreement directly or indirectly (i) grant to a Third Party any rights to Commercialize the Product in the Territory
for use in the Field or (ii) supply Product to a Third Party (other than Sublicensees if requested by IMMEDICA) for any such purpose.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt; text-align: justify; text-indent: -36.8pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">2.6.</TD><TD STYLE="text-align: justify"><B>No Additional Rights. </B>Nothing in this Agreement shall be construed to confer any rights upon IMMEDICA
by implication, estoppel, or otherwise as to any technology or Intellectual Property Rights of LICENSOR or its Affiliates other than the
Licensed Technology.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.35pt; text-indent: -36.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.35pt; text-indent: -36.1pt"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.35pt; text-indent: -36.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">3.</TD><TD><B>GOVERNANCE</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.05pt; text-align: justify; text-indent: -36.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">3.1.</TD><TD STYLE="text-align: justify"><B>Alliance Managers. </B>Within [*] after the Effective Date, each Party shall appoint and notify the
other Party of the identity of a representative having the appropriate qualifications, including a general understanding of pharmaceutical
development and commercialization issues, to act as its alliance manager under this Agreement (the <B>&ldquo;Alliance Manager&rdquo;).
</B>The Alliance Managers shall serve as the primary contact points between the Parties for the purpose of providing each Party with information
on the progress and results of the Development and Commercialization of the Product in the Field in the Territory. The Alliance Managers
shall also be primarily responsible for facilitating the flow of information and otherwise promoting communication, coordination and collaboration
between the Parties with respect to the Product and its Manufacture. Each Party may replace its Alliance Manager with a new representative
having the appropriate qualifications at any time upon written notice to the other Party.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.15pt; text-indent: -36.9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">3.2.</TD><TD><B>Joint Steering Committee.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.6pt; text-align: justify; text-indent: -37.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.2.1.</TD><TD STYLE="text-align: justify"><B>JSC Formation and Role. </B>Within [*] after the Effective Date, the Parties shall establish a joint
steering committee (the <B>&ldquo;Joint Steering Committee&rdquo; or &ldquo;JSC&rdquo;) </B>for the overall coordination and oversight
of the Parties&rsquo; activities under this Agreement. The role of the JSC shall be to:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 114.5pt; text-align: justify; text-indent: -36.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">review and discuss the overall strategy for the Development and Commercialization of the Product in the
Territory;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 114.5pt; text-align: justify; text-indent: -36.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">monitor and discuss the performance and results of the Phase III Clinical Trial and all other Clinical
Studies performed by or on behalf of the LICENSOR pursuant to Section&nbsp;4.2.1;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 111.45pt; text-align: justify; text-indent: -35.65pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">discuss any Clinical Study using the Product in the Territory proposed by either Party including proposed
investigator sponsored studies and any post Regulatory Approval studies aimed at generating real life data with regard to the Product;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 111.35pt; text-align: justify; text-indent: -35.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify">review and discuss the Marketing Plan, including the use of any and all Product Trademarks in connection
with the Products in the Territory, and any proposed amendments or revisions thereto;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 111.45pt; text-align: justify; text-indent: -35.65pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(e)</TD><TD STYLE="text-align: justify">monitor performance of this Agreement as well as progress of the Commercialization activities compared
to the goals defined in the Marketing Plan;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 111.5pt; text-align: justify; text-indent: -35.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(f)</TD><TD STYLE="text-align: justify">act as the point of escalation for issues that cannot be resolved otherwise;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 111.55pt; text-align: justify; text-indent: -35.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(g)</TD><TD STYLE="text-align: justify">discuss label expansion for additional patient population or indications;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 111.55pt; text-align: justify; text-indent: -35.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(h)</TD><TD STYLE="text-align: justify">coordinate the audit of any LICENSOR suppliers and subcontractors relevant to the Product in the Territory,
as further detailed in Section&nbsp;7.2.2;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 111.25pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(i)</TD><TD STYLE="text-align: justify">discuss, as applicable, the monitoring of performance under the Manufacturing Agreements, and discuss
any proposal by LICENSOR to enter into new agreements with Third Parties relating to the Manufacture of the Product during the term of
this Agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 111.45pt; text-align: justify; text-indent: -35.85pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(j)</TD><TD STYLE="text-align: justify">discuss any proposal by LICENSOR to enter into a new agreement with a Third Party relating to the Manufacture
of the Products or any proposal to amend the Manufacturing Agreements as further described in Section 12.7;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 111.5pt; text-align: justify; text-indent: -35.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(k)</TD><TD STYLE="text-align: justify">establish sub-committees that may have separate member composition from the JSC with mutually acceptable
charters and defined responsibilities to manage key workstreams related to the Parties&rsquo; activities under this Agreement, including
but not limited to Development and Commercial sub-committees;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 111.5pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify">act as a forum for the Parties to exchange information about the LICENSOR&rsquo;s Development and Commercialization
activities in respect of the Product outside the Territory and about IMMEDICA&rsquo;s Commercialization activities in respect of the Product
in the Territory;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 111.8pt; text-align: justify; text-indent: -35.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(m)</FONT></TD><TD STYLE="text-align: justify">establish a mechanism for dealing with the on-line presence for the Product inside and outside the Territory
in compliance with Applicable Law; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 111.7pt; text-align: justify; text-indent: -35.65pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(n)</FONT></TD><TD STYLE="text-align: justify">perform such other functions as appropriate to further the purposes of this Agreement, as expressly set
forth in this Agreement or as determined by the Parties in writing.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.6pt; text-align: justify; text-indent: -36.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.6pt; text-align: justify; text-indent: -36.6pt"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.6pt; text-align: justify; text-indent: -36.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.2.2.</TD><TD STYLE="text-align: justify"><B>Members. </B>The JSC shall be comprised of an equal number of representatives from each Party. Each
Party&rsquo; s representatives shall be officers or employees of such Party or its Affiliate having sufficient seniority within the applicable
Party to make decisions arising within the scope of the JSC&rsquo;s responsibilities. Each Party shall initially appoint three (3) representatives
to the JSC. Each Party may replace its representatives at any time upon written notice to the other Party. Each Party shall appoint one
(1) of its representatives on the JSC to act as the co-chairperson of JSC. The role of the co-chairpersons shall be to preside at the
JSC meetings, but the co-chairpersons shall have no additional powers or rights beyond those held by other JSC representatives. Unless
otherwise agreed by the Parties, the Alliance Managers from both Parties shall be non- voting members of the JSC.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 64.05pt; text-align: justify; text-indent: -36.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.2.3.</TD><TD STYLE="text-align: justify"><B>Meetings. </B>The JSC shall hold meetings on a [*] basis during the term of this Agreement for so long
as the JSC exists, unless the Parties mutually agree to a different frequency for such meetings. Either Party may also call a special
meeting of the JSC in the event such Party reasonably believes that a significant matter must be addressed prior to the next regularly
scheduled meeting and, reasonably in advance of such special meeting, such Party shall provide the JSC with materials adequate to enable
an informed discussion. Reasonably in advance of each JSC meeting, the Alliance Managers (or their designees), on an alternating basis,
shall prepare and circulate an agenda for such meeting; provided that either Party may propose additional topics to be included on such
agenda, either prior to or in the course of such meeting. The JSC may meet in person, by videoconference or by teleconference. No action
taken at a JSC meeting shall be effective unless at least one (1) representative of each Party is present or participating in such meeting.
The Alliance Managers (or their designees), on an alternating basis, shall be responsible for preparing reasonably detailed written minutes
of each JSC meeting and shall send draft meeting minutes to each representative of the JSC for review. The Parties shall agree on meeting
minutes promptly, but in any event no later than [*] following receipt thereof; provided that, if the Parties cannot agree as to the content
of the meeting minutes by such timeframe, such minutes shall be finalized to reflect any areas of disagreement. Each Party may invite,
in addition to its JSC representatives, any number of employees (including employees of Affiliates) and, with the prior written consent
of the other Party, not to be unreasonably withheld, any number of Third Parties, to attend JSC meetings as non-voting participants, provided
that, prior to attending such meetings, such Third Party participants shall be bound by written obligations of confidentiality and non-use
consistent with those contained in this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 65.05pt; text-align: justify; text-indent: -36.85pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.2.4.</TD><TD STYLE="text-align: justify"><B>Decision Making and Escalation. </B>The JSC shall strive to seek consensus in its actions and decision-making
process, and all decisions by the JSC shall be made by unanimous agreement, with each Party&rsquo;s representatives having collectively
one (1) vote in all decisions. If the Parties&rsquo; representatives on the JSC, after reasonable discussion and good faith consideration
of each Party&rsquo;s opinions, cannot reach agreement on a matter within the JSC&rsquo;s responsibilities within [*] after the JSC has
met and attempted to agree on such matter (or such other period as the Parties may agree upon in writing), then such disagreement shall
be referred to the Parties&rsquo; respective Executive Officers for resolution. Any final decision that the Executive Officers mutually
agree to in writing shall be conclusive and binding on the Parties. If the Executive Officers cannot reach agreement on a matter within
[*] after such matter has been referred to them by the JSC (or such other period as the Executive Officers may agree upon in writing),
then IMMEDICA shall have the tie-breaking vote, and the decision of IMMEDICA&rsquo;s Executive Officer shall be final and binding on the
Parties, with respect to any matter concerning Regulatory Approval in the Territory, or safety of the Product in the Territory or Commercialization
in the Territory, including regarding the adaptation and localisation of the global marketing and brand strategy for the Product in the
Territory, or, subject to Section 4.3.7, pricing strategy, launch sequencing, reference pricing and importation and distribution matters
in each case with respect to the Product in the Territory, except that LICENSOR shall have the tie-breaking vote, and the decision of
LICENSOR&rsquo;s Executive Officer shall be final and binding on the Parties, with respect to any matter that will have a material adverse
impact on (a) the global safety profile of the Product, (b)&nbsp;the procurement or maintenance of any Regulatory Approval in any country
or jurisdiction outside of the Territory, (c) changes to the Protocol, and (d) subject to the provisions of Section&nbsp;4.2, matters
concerning the Development Activities of LICENSOR, including the Clinical Studies carried out by LICENSOR in the Territory in accordance
with the terms of this Agreement and all decisions regarding whether or not LICENSOR will conduct Additional Clinical Studies and Additional
Indication Studies involving the Product.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78.55pt; text-align: justify; text-indent: -36.4pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78.55pt; text-align: justify; text-indent: -36.4pt"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78.55pt; text-align: justify; text-indent: -36.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.2.5.</TD><TD STYLE="text-align: justify"><B>Limitations of JSC Authority. </B>Notwithstanding the foregoing, neither the JSC nor the Party with
final decision-making authority as set forth in Section&nbsp;3.2.4 shall have the authority to: (a) modify or amend the terms and conditions
of this Agreement; (b) waive or determine either Party&rsquo;s compliance with this Agreement; (c) decide any issue in a manner that would
conflict with the express terms and conditions of this Agreement; or (d) obligate either Party to violate Applicable Laws or incur any
material liabilities or payment obligations.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78.2pt; text-align: justify; text-indent: -36.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.2.6.</TD><TD STYLE="text-align: justify"><B>Discontinuation of the JSC. </B>The activities to be performed by the JSC shall solely relate to governance
under this Agreement, and are not intended to be or involve the delivery of services. The JSC shall continue to exist until the Parties
mutually agree to disband the JSC, but in any event the JSC shall be automatically disbanded effective upon the expiration or termination
of this Agreement. Once the JSC is disbanded, it shall have no further obligations under this Agreement and, thereafter, the Alliance
Managers shall be responsible for the exchange of information under this Agreement and the decisions of the Alliance Managers shall be
decisions as between the Parties (but, with final decision-making authority to continue to be in accordance with Section 3.2.4), subject
to the other terms and conditions of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-indent: -35.2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35pt">4.</TD><TD><B>TRANSFER OF LICENSED KNOW-HOW, DEVELOPMENT AND COMMERCIALIZATION</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -36.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36.5pt">4.1.</TD><TD><B>Transfer of Licensed Know-How</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78.2pt; text-indent: -36.55pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt"><B>4.1.1.</B></FONT></TD><TD><B>Intentionally Omitted.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify; text-indent: -36.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">4.1.2.</FONT></TD><TD STYLE="text-align: justify"><B>Ongoing Transfer. </B>LICENSOR shall, and shall use diligent efforts to cause any contractors to, promptly
transfer to IMMEDICA (or, in the case of contractors, to promptly grant to IMMEDICA a right of reference with respect thereto, if applicable),
from time to time during the term of this Agreement, Licensed Know-How that is necessary or useful for the Development or Commercialization
of the Product in the Field in the Territory as contemplated in this Agreement, including for the purposes of preparing, filing, and maintaining
any Regulatory Approvals in accordance with Section 5.2, to the extent that it has not previously been provided to IMMEDICA hereunder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.85pt; text-align: justify; text-indent: -36.15pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">4.1.3.</FONT></TD><TD STYLE="text-align: justify"><B>Cooperation. </B>The Parties will cooperate and reasonably agree upon formats and procedures to facilitate
the orderly and efficient exchange of the Licensed Know-How in accordance with this Section&nbsp;4.1. Without limiting the foregoing,
the LICENSOR shall provide all such items in electronic form to the extent the same exists in electronic form and shall provide copies
and an opportunity to inspect (and copy) original versions for all other materials comprising such Licensed Know-How (including for example,
original patient report forms and other original source data). It is understood that all Licensed Know-How shall be made available to
IMMEDICA in English. Upon request by IMMEDICA, the LICENSOR shall, and shall use diligent efforts to cause any contractors (including
any contract manufacturers) to, reasonably cooperate with and assist IMMEDICA, at LICENSOR&rsquo;s cost, as may be necessary or desirable
in order to allow IMMEDICA to understand the Licensed Know-How and to utilize the Licensed Know-How for the purposes contemplated in this
Agreement. Notwithstanding the foregoing, if during the term of this Agreement the Parties agree to transfer responsibility for Manufacturing
the Product to IMMEDICA at IMMEDICA&rsquo;s request, any reasonable costs of LICENSOR associated with the transfer of the Manufacturing
process for the Product to IMMEDICA shall be reimbursed by IMMEDICA, without prejudice to the provisions of Section&nbsp;7.8.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.4pt; text-indent: -37.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.4pt; text-indent: -37.45pt"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.4pt; text-indent: -37.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37.4pt">4.2.</TD><TD><B>Development.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.45pt; text-align: justify; text-indent: -36.9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">4.2.1.</TD><TD STYLE="text-align: justify">Unless otherwise agreed by the Parties, and except as otherwise provided in this Section 4.2.1 and Section
4.2.3, the LICENSOR shall be solely responsible for the performance of, and all costs relating to, the Development of the Product in the
Territory, including the Phase III Clinical Trial. LICENSOR will use Commercially Reasonable Efforts to continue the on-going Phase III
Clinical Trial in the manner outlined within the Protocol. If any further Clinical Studies are required by a Regulatory Authority in order
to obtain or maintain a Regulatory Approval for the Product (including complying with any paediatric investigation plan or carrying out
any post approval safety or efficacy studies) for active, relapsed or refractory AML in patients aged 55 and older (or any variation to
the foregoing agreed with a Regulatory Authority) in the Territory (<B>&ldquo;Additional Clinical Studies&rdquo;</B>), the Parties shall
discuss such required Clinical Studies at the JSC. If the reasonably estimated costs of carrying out such Clinical Studies is less than
[*] the LICENSOR shall carry out such Clinical Studies at its cost as soon as reasonably practicable. If the reasonably estimated costs
of carrying out Additional Clinical Studies is more than [*] the Parties shall discuss in good faith and agree how such Clinical Study
should be carried out and how the costs of such Clinical Study in excess of [*] should be shared between the Parties, provided that LICENSOR
shall not be obligated to perform any such Clinical Study in the absence of agreement between the Parties. Unless otherwise agreed by
the Parties, any such Clinical Study shall be designed to include no more than the minimum number of subjects required by the applicable
Regulatory Authority. Subject to the foregoing, the LICENSOR shall not, and shall not assist, enable or authorize any Affiliate or Third
Party to, undertake any Clinical Study of the Product within the Territory in active, relapsed or refractory AML in patients aged 55 and
older (or any variation to the foregoing agreed with a Regulatory Authority) or any other indication that has obtained Regulatory Approval
in the Territory without the prior written consent of IMMEDICA, which consent shall not be unreasonably withheld, conditioned or delayed.
Any protocol for such proposed Clinical Study within the Territory shall be subject to the prior written approval of IMMEDICA, which approval
shall not be unreasonably withheld, conditioned or delayed.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 80.6pt; text-align: justify; text-indent: -0.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.1pt">LICENSOR shall
provide the JSC with quarterly reports on the status and progress of all such Development activities. Upon completion of each
Clinical Study (including all Additional Indication Studies) relating to the Product, LICENSOR shall provide the JSC with a final
clinical study report, including all raw data LICENSOR receives or has a right to receive in respect of such Clinical Study.
LICENSOR shall use diligent and reasonable efforts to provide to IMMEDICA all other Product-related data and information requested
by any Regulatory Authority. In addition, the LICENSOR shall, promptly upon filing, provide a complete and accurate copy of all
material Regulatory Filings for the Product submitted to the US Food and Drug Administration for review by IMMEDICA. Subject to the
provision of the data and information by the LICENSOR set out in this Section 4.2.1, and notwithstanding anything to the contrary in
this Section 4.2.1, IMMEDICA shall bear all responsibility and expense for filing all Regulatory Filings in the Territory in
IMMEDICA&rsquo;s name and obtaining Regulatory Approval for the Product in the Territory. IMMEDICA will undertake such activities at
its sole expense and shall provide to LICENSOR reports regarding IMMEDICA&rsquo;s progress within [*] following the expiration of
each Calendar Year. In addition, IMMEDICA shall, promptly upon filing, provide a complete and accurate copy of all material
Regulatory Filings (excluding any Regulatory Filings relating to pricing and reimbursement in the Territory) for the Product
submitted to Regulatory Authorities in the Territory for review by LICENSOR. IMMEDICA shall provide to LICENSOR copies of all
pricing and reimbursement approvals obtained by IMMEDICA for the Product in the Territory. If the JSC approves any investigator
sponsored Clinical Studies to be conducted in the Territory IMMEDICA shall be responsible for entering into any agreements with the
applicable investigators for such approved studies. Such agreements will be substantially based on a template agreement that will be
reviewed and approved by the JSC. Upon completion of each such Clinical Study relating to the Product, IMMEDICA shall provide the
JSC with a final clinical study report, including all raw data (in relation to raw data for interventional studies but not raw data
for non- interventional studies) IMMEDICA receives or has a right to receive in respect of such Clinical Study. IMMEDICA shall use
diligent and reasonable efforts to provide to LICENSOR all other Product-related data and information in the possession or control
of IMMEDICA requested by any regulatory authority outside the Territory in relation to the Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.05pt; text-align: justify; text-indent: -36.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">4.2.2.</TD><TD STYLE="text-align: justify"><B>Development in new indications by LICENSOR inside the Territory. </B>If the LICENSOR or any Affiliate
or Third Party authorized by the LICENSOR intends to conduct a Clinical Study for the Product in the Territory for an indication in addition
to active, relapsed or refractory AML in patients aged 55 and older (including complying with any paediatric investigation plan) or any
other indication that has, at the relevant date, not been granted Regulatory Approval in the Territory <B>(&ldquo;Additional Indication
Study&rdquo;), </B>the LICENSOR shall provide prior written notice thereof, together with a copy of the proposed protocol for such Additional
Indication Study, to IMMEDICA. The LICENSOR shall provide IMMEDICA a reasonable opportunity to comment on any such proposed protocol and
consider in good faith (but without any obligation to incorporate or adopt) any comments provided by IMMEDICA within [*] after delivery
of the proposed protocol to IMMEDICA. Subject to the foregoing provisions LICENSOR shall be entitled to carry out Additional Indication
Studies in the Territory.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.55pt; text-align: justify; text-indent: -36.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.55pt; text-align: justify; text-indent: -36.6pt"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.55pt; text-align: justify; text-indent: -36.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">4.2.3.</TD><TD STYLE="text-align: justify"><B>Development by IMMEDICA. </B>IMMEDICA shall be responsible for carrying out, at IMMEDICA&rsquo;s sole
cost, all observational studies, registers and health economic studies in relation to the Product in Territory (except any post marketing
studies required to obtain or maintain a Regulatory Approval for the Product which studies shall be the responsibility of the LICENSOR)
and shall keep LICENSOR regularly informed through the JSC with regard to any such studies that it conducts. Upon completion of each such
study, IMMEDICA shall provide the JSC with a final study report, including all raw data (in relation to raw data for interventional studies
but not raw data for non-interventional studies) IMMEDICA receives or obtains, has a right to receive or obtain, in respect of such study.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.8pt; text-align: justify; text-indent: -36.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">4.2.4.</TD><TD STYLE="text-align: justify"><B>Co-Operation. </B>Each Party will keep the other Party reasonably informed through the JSC as to its
regulatory strategy for obtaining regulatory approval of the Product, in the case of the LICENSOR outside the Territory and in the case
of IMMEDICA inside the Territory. The LICENSOR may inform its licensees outside the Territory of IMMEDICA&rsquo;s Development activities
in respect of the Product in the Territory solely for the purpose of the Development and Commercialization of the Product in such licensees&rsquo;
respective territory outside the Territory. Each Party shall cooperate as reasonably requested by the other Party in an effort to ensure
that the Parties&rsquo; Development activities, as they relate to obtaining regulatory approval of the Product are coordinated worldwide,
provided however that this shall not be interpreted or construed as limiting IMMEDICA&rsquo;s and the LICENSOR&rsquo;s rights and obligations
under this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.6pt; text-align: justify; text-indent: -36.85pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">4.2.5.</TD><TD STYLE="text-align: justify">The Parties shall each ensure that they comply with all Applicable Laws with respect to the performance
of their obligations hereunder and in the performance of all Clinical Studies relating to the Product.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.6pt; text-align: justify; text-indent: -37.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">4.2.6.</TD><TD STYLE="text-align: justify"><B>Prohibition on Development of Competing Products. </B>IMMEDICA shall not, during the term of this Agreement,
Develop or Commercialize any pharmaceutical product for conditioning treatment, inside or outside the Territory, itself or through or
with a Third-Party, that competes with an indication approved under a Regulatory Approval for the Product, except upon the prior written
consent of the LICENSOR.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.6pt; text-align: justify; text-indent: -37.2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37.05pt">4.3.</TD><TD STYLE="text-align: justify"><B>Commercialization. </B>IMMEDICA shall be solely responsible for the Commercialization of the Product
in the Territory. IMMEDICA will undertake such activities at its sole expense.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.8pt; text-align: justify; text-indent: -37.05pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">4.3.1.</TD><TD STYLE="text-align: justify"><B>Marketing Plan. </B>No later than [*] before the expected launch of the Product in the Territory IMMEDICA
will prepare an initial marketing plan for the Product <B>(&ldquo;Marketing Plan&rdquo;) </B>according to IMMEDICA&rsquo;s marketing planning
process, but will include at a minimum, medical education and communication, brand strategy, brand positioning, key messages, public relations,
access, and reimbursement, sales and distribution strategies. The LICENSOR will notify IMMEDICA of LICENSOR&rsquo;s global marketing strategy
for the Product on an annual basis. Such strategy shall include medical education and communication, brand strategy, brand positioning,
key messages, public relations, access, and reimbursement, sales and distribution strategies.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 80.05pt; text-align: justify; text-indent: -37.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">4.3.2.</TD><TD STYLE="text-align: justify"><B>Review and Comment on Marketing Plan. </B>IMMEDICA will submit the final draft of the initial and any
materially updated Marketing Plan to LICENSOR, via the JSC, for review and comment. LICENSOR will provide comments on such draft to the
JSC within [*] after receipt. The JSC shall meet to review the Marketing Plan and any comments provided by LICENSOR, and IMMEDICA will
reasonably consider such comments, prior to finalization and implementation of the Marketing Plan. Notwithstanding anything herein to
the contrary, if LICENSOR notifies IMMEDICA that the Marketing Plan conflicts with LICENSOR&rsquo;s global commercialization strategy,
IMMEDICA shall not finalize and implement the Marketing Plan until such conflict is resolved to the satisfaction of both Parties.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 80.25pt; text-align: justify; text-indent: -37.25pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 80.25pt; text-align: justify; text-indent: -37.25pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">4.3.3.</TD><TD STYLE="text-align: justify"><B>Diligence Obligations. </B>IMMEDICA shall itself, or through its Affiliates or Sublicensees, use Commercially
Reasonable Efforts to Commercialize the Product in the Territory, including using Commercially Reasonable Efforts to perform the activities
set forth under each Marketing Plan. All efforts of IMMEDICA&rsquo;s Affiliates and Sublicensees will be considered efforts of IMMEDICA
for the purpose of determining IMMEDICA&rsquo;s compliance with its obligations under this Section 4.3.3.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 80.35pt; text-align: justify; text-indent: -37.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 80.35pt; text-align: justify; text-indent: -37.35pt"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 80.35pt; text-align: justify; text-indent: -37.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">4.3.4.</TD><TD STYLE="text-align: justify"><B>Shipment and Policing of Product Outside the Territory. </B>IMMEDICA may not deliver or tender (or
cause to be delivered or tendered) any Product outside of the Territory. If IMMEDICA becomes aware that any customer of the Product in
the Territory (including a distributor, wholesaler or health group) is reselling or distributing any quantities of the Product acquired
from IMMEDICA outside the Territory, then IMMEDICA shall notify LICENSOR in writing and take reasonable steps to cause such customer to
cease reselling or distributing the Product outside the Territory. If IMMEDICA receives any order from a prospective purchaser located
outside the Territory, IMMEDICA shall not accept any such orders and shall promptly inform LICENSOR of such order(s).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.45pt; text-align: justify; text-indent: -37pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">4.3.5.</TD><TD STYLE="text-align: justify"><B>Shipment and Policing of Product Inside the Territory. </B>Except with respect to the delivery of Product
for use in connection with Clinical Studies in the Territory and sales of the Product by LICENSOR to IMMEDICA under this Agreement, the
LICENSOR may not deliver or tender (or cause to be delivered or tendered) any Product inside the Territory. If the LICENSOR becomes aware
that any customer of the Product outside of the Territory (including a distributor, wholesaler or health group) is reselling or distributing
any quantities of the Product inside the Territory, then the LICENSOR shall notify IMMEDICA in writing and take reasonable steps to cause
such customer to cease reselling or distributing the Product in the Territory. If the LICENSOR receives any order from a prospective purchaser
located inside the Territory, the LICENSOR shall not accept any such orders and shall provide prompt written notice of such order(s) to
IMMEDICA.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.6pt; text-align: justify; text-indent: -36.9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">4.3.6.</TD><TD STYLE="text-align: justify"><B>Labeling and Artwork. </B>Cutter guides (technical drawings of the Artwork mock-ups) will be provided
by LICENSOR to IMMEDICA. IMMEDICA shall be responsible for updating the cutter guides and the creation of printer ready labeling mock-ups
in the Territory according to local regulations and guidelines. In the event that IMMEDICA proposes changes to the labeling or packaging
of the Product, it shall provide LICENSOR with justification for the proposed change, revised mock-ups for printing and clear timelines
for the implementation of such updates The actual cost of implementing such change will be at IMMEDICA&rsquo;s sole cost and expense,
including any materials made obsolete by IMMEDICA&rsquo;s changes to the artwork, unless such change was requested by the LICENSOR, in
which case such cost and expense shall be at the LICENSOR&rsquo;s sole cost and expense. All labeling, artwork, packaging and proposed
changes thereto shall at all times comply with Applicable Laws.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.9pt; text-align: justify; text-indent: -36.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">4.3.7.</TD><TD STYLE="text-align: justify"><B>Pricing and Reimbursement. </B>IMMEDICA shall be solely responsible for all pricing and reimbursement
matters relating to the Product in the Territory including all related discussions with Regulatory Authorities including relevant pricing
and reimbursement bodies; provided that if IMMEDICA supplies the Product in the Territory at a price that would cause the LICENSOR to
incur a loss on its fully burdened cost of Manufacture of the Product as notified to IMMEDICA prior to the date of any such supply, IMMEDICA
shall reimburse LICENSOR for any such shortfall. Notwithstanding the foregoing sentence, if approved by the JSC, IMMEDICA shall be entitled
to provide Product at no charge for the purpose of any investigator sponsored Clinical Studies conducted in the Territory with the JSC&rsquo;s
prior approval, or as donations or the like or as &ldquo;treatment IND sales&rdquo;, &ldquo;named patient sales&rdquo;, &ldquo;compassionate
use sales&rdquo;, or pursuant to any expanded access programs, or any equivalent; provided that the quantities of Product provided at
no charge do not exceed the quantities approved by the JSC for such purpose. IMMEDICA will reimburse LICENSOR for any Product supplied
that exceeds quantities approved by the JSC for such purpose. Each Party shall promptly provide to the other Party a copy of any cost
effectiveness model and/or value dossier developed by such Party relating to a Product for the other Party&rsquo;s review.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.9pt; text-align: justify; text-indent: -36.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">4.3.8.</TD><TD STYLE="text-align: justify"><B>Co-Operation. </B>Each Party will keep the other Party reasonably informed through the JSC as to its
Development and Commercialization activities in respect of the Product, in the case of the LICENSOR outside the Territory and in the case
of IMMEDICA inside the Territory. The LICENSOR may inform its licensees outside the Territory of IMMEDICA&rsquo;s Commercialization activities
in respect of the Product in the Territory solely for the purpose of the Development and Commercialization of the Product in such licensees&rsquo;
respective territory outside the Territory. The will keep IMMEDICA informed of its own and such licensee&rsquo;s Development and Commercialization
activities in respect of the Product solely for the purpose of IMMEDICA&rsquo;s Commercialization of the Product in the Territory. Each
Party shall cooperate as reasonably requested by the other Party in an effort to ensure that the Development and Commercialization of
the Product is coordinated worldwide, provided however that this shall not be interpreted or construed as limiting IMMEDICA&rsquo;s and
the LICENSOR&rsquo;s rights and obligations under this Agreement. The Parties will cooperate in good faith with regard to agreeing on
matters that relate to the Product inside and outside the Territory such as attendance at international conferences. LICENSOR shall ensure
that LICENSOR&rsquo;s, its Sublicensees&rsquo; and/or Affiliates&rsquo; engagement with healthcare professionals in relation to the Product
is in accordance with the Applicable Law in the country in the Territory where such healthcare professional is normally located and IMMEDICA
shall ensure that IMMEDICA&rsquo;s, its Sublicensees&rsquo; and/or Affiliates&rsquo; engagement with healthcare professionals in relation
to the Product is in accordance with the Applicable Law in the country outside the Territory where such healthcare professional is normally
located. Each Party shall keep the other reasonably informed with regard to such matters provided that this obligation shall not require
the Parties to keep each other informed in relation to incidental or immaterial interactions with healthcare professionals at international
conferences.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">5.</FONT></TD><TD>REGULATORY MATTERS</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">5.1.</TD><TD STYLE="text-align: justify"><B>Marketing Authorization Holder. </B>Subject to IMMEDICA&rsquo;s obligations upon termination pursuant
to Section 15.6, IMMEDICA shall be the holder and owner of all Regulatory Approvals in the Territory. Promptly and in any event within
[*] of the Effective Date, LICENSOR shall assign the Orphan Drug Designation for the Product in the Territory to IMMEDICA.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">5.2.</TD><TD STYLE="text-align: justify"><B>Maintenance of Marketing Authorizations. </B>With respect to the Product, IMMEDICA shall have the right,
at its sole discretion and cost and expense, to prepare, file and maintain such Regulatory Approvals in the Territory throughout the term
of this Agreement including obtaining any variations or renewals thereof. Without limiting the foregoing, IMMEDICA shall be responsible
for filing and shall use its Commercially Reasonable Efforts to file the marketing authorization application for the Product with the
EMA. LICENSOR shall provide IMMEDICA with all information in the possession or control of LICENSOR or its Affiliates or licensees or assignees
of the Product outside the Territory reasonably required by IMMEDICA to prepare, file and maintain any such application and any Regulatory
Approval including any filings for Regulatory Approval for the Product made by or on behalf of LICENSOR, its Affiliates or its licensees
or assignees outside the Territory. LICENSOR shall also, at no cost to IMMEDICA (as long as such costs are reasonable), make reasonably
available its personnel and subject matter experts with the knowledge of the Development of the Product to consult with IMMEDICA and to
provide reasonable assistance in a timely manner to IMMEDICA in connection with any of the foregoing, including but not limited to supporting
IMMEDICA&rsquo;s preparation of the EU marketing authorization application for the Product (through the provision of documentation for
and attendance at pre-submission meetings with EMA as relevant) and supporting Il&rsquo;v1MEDICA with respect to the EMA assessment of
the application and any questions raised by the EMA including attending meetings with the EMA to answer any such questions.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36.7pt">5.3.</TD><TD STYLE="text-align: justify"><B>Interaction with Regulatory Authorities. </B>After the Effective Date, each Party shall provide to
the other Party a copy of any material correspondence or materials that it receives from or submits to a Regulatory Authority or any material
decision made by a Regulatory Authority regarding, in each case, the Product, in respect of IMMEDICA, in the Territory and, in respect
of LICENSOR, outside of the Territory. LICENSOR shall use reasonable efforts to cause that its licensees or assignees in relation to the
Product outside the Territory to provide such information as is required by Section 5.2 above and this Section 5.3 to LICENSOR to enable
LICENSOR to comply with its obligations. If such correspondence received by a Party is not in English, then such copy will include a summary
in English of all material matters addressed thereby. IMMEDICA shall provide reasonable advance written notice to LICENSOR of all material
meetings, conferences, or calls with Regulatory Authorities concerning the Product (excluding meetings, conferences, or calls with Regulatory
Authorities relating to pricing and reimbursement of the Product), and LICENSOR shall be permitted to have appropriate representatives
attend all such meetings, conferences, or calls to the extent permitted by Applicable Law. IMMEDICA shall provide LICENSOR with copies
of any materials relating to any material regulatory matter relating to the Product (excluding materials relating to pricing and reimbursement)
and, when reasonably practicable, shall provide copies of any documents to be presented to any Regulatory Authority in respect of such
matters prior to their presentation thereto. In addition, during the term of the Agreement and with respect to all Product supplied and
purchased under this Agreement, after the termination of this Agreement, each Party shall promptly (and in any case within [*]) notify
the other Party of any information it receives regarding any threatened or pending action, inspection or communication by or from a concerned
Regulatory Authority which may affect the safety or efficacy claims of the Product or the continued marketing of the Product. Upon receipt
of such information, the Parties shall consult with each other in an effort to arrive at a mutually acceptable procedure for taking appropriate
action. The materials to be provided under this Section 5.3 with respect to material interactions with any Regulatory Authority will be
forwarded to the other Party promptly after receipt.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36.65pt">5.4.</TD><TD STYLE="text-align: justify"><B>Right of Reference. </B>Subject to the terms and conditions set forth in this Agreement, (i)&nbsp;LICENSOR
hereby grants to IMMEDICA a fully paid, exclusive right and license to reference any Regulatory Approvals Controlled by LICENSOR or its
Affiliates for the Product outside the Territory for the purpose of obtaining Regulatory Approval of the Product in one or more countries
in the Territory, and (ii)&nbsp;IMMEDICA hereby grants to LICENSOR, its Affiliates and its licensees a fully paid, exclusive right and
license to reference any Regulatory Approvals Controlled by IMMEDICA or its Affiliates or Sublicensees for Product inside the Territory
for the purpose of obtaining Regulatory Approval of the Product in one or more countries outside the Territory; provided that if the exercise
of the right of reference under this Section&nbsp;5.4(i) triggers any inspection or audit of LICENSOR (or its Affiliates or licensees
outside the Territory) then IMMEDICA will reimburse LICENSOR (or its Affiliates or licensees outside the Territory) for the costs incurred
by LICENSOR (or its Affiliates or licensees outside the Territory) in respect of such inspection or audit; and provided further that if
the exercise of the right of reference under this Section&nbsp;5.4(ii) triggers any inspection or audit of IMMEDICA then LICENSOR will
reimburse IMMEDICA for the costs incurred by IMMEDICA in respect of such inspection or audit.</TD></TR></TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36.7pt">5.5.</TD><TD STYLE="text-align: justify"><B>Pharmacovigilance. </B>The LICENSOR will be responsible for managing the global safety database for
the Product. Within [*] after the Effective Date, the Parties shall enter into a pharmacovigilance agreement pursuant to which the Parties
will mutually exchange adverse events or other safety data within and outside of the Territory as required for each Party to fulfill the
relevant requirements in accordance with Applicable Law. IMMEDICA may maintain its own safety database for the Product for safety data
collection, evaluation and reporting as well as for purposes of safety surveillance, risk management as required in the Territory. The
LICENSOR shall provide information on individual case safety reports from the global safety database for the Product to IMMEDICA to be
further specified in the pharmacovigilance agreement. The Parties shall mutually maintain a procedure for reconciliation of safety data
between the safety databases of the Parties. As between the Parties: (a)&nbsp;IMMEDICA shall be responsible for the pharmacovigilance
surveillance, risk management and timely reporting of adverse drug reactions/experiences, and safety data relating to the Product to the
appropriate Regulatory Authorities in the Territory in accordance Applicable Law in the Territory; and (b)&nbsp;LICENSOR or its licensee(s)
shall be responsible for the pharmacovigilance surveillance, risk management and timely reporting of adverse drug reactions/experiences,
and safety data relating to the Product to the appropriate Regulatory Authorities outside the Territory, in each case in accordance with
Applicable Laws. The Parties shall cooperate with each other with respect to their respective pharmacovigilance responsibilities and any
safety related changes to the Product label or other additional pharmacovigilance or risk minimization activities.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36.75pt">5.6.</TD><TD STYLE="text-align: justify"><B>Promotional Materials. </B>IMMEDICA shall be responsible for developing the promotional materials for
use in Commercializing the Product in the Territory in accordance with Applicable Law and shall ensure that such materials are consistent
with LICENSOR&rsquo;s global marketing strategy for the Product as notified to IMMEDICA in accordance with Section 4.3.1. If IMMEDICA
proposes to use promotional materials that deviate significantly from any such global marketing strategy such materials will be submitted
to LICENSOR for review and approval prior to use. IMMEDICA shall own all rights in any promotional materials it creates. IMMEDICA shall
deliver copies of all promotional materials it creates for the Product to the LICENSOR prior to distribution or use.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36.4pt">5.7.</TD><TD STYLE="text-align: justify"><B>Medical Inquiries. </B>Following grant of the first Regulatory Approval for the Product in the Territory
IMMEDICA will be responsible for handling all medical questions or inquiries in respect of the Product in the Territory. The LICENSOR
shall promptly forward any and all medical questions or inquiries which it receives in respect of the Product in the Territory to IMMEDICA
in accordance with Applicable Laws. The LICENSOR shall be responsible for handling all medical questions or inquries in respect of the
Product outside of the Territory. IMMEDICA shall promptly forward any and all medical questions or inquiries which it receives in respect
of the Product outside the Territory to the LICENSOR in accordance with Applicable Laws. The Parties shall cooperate and establish the
procedures reasonably necessary (such as periodic meetings via teleconference or videoconference) to ensure the consistency and correctness
of the medical information provided by the Parties.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt">6.</TD><TD><B>PAYMENT TERMS</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36.7pt">6.1.</TD><TD><B>Payment Terms .</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">6.1.1.</TD><TD STYLE="text-align: justify"><B>Upfront Payment. </B>IMMEDICA shall pay to LICENSOR an upfront payment as set forth in <U>Schedule
B</U> within [*] of the Effective Date, subject to the receipt of the applicable invoice from the LICENSOR.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">6.1.2.</TD><TD STYLE="text-align: justify"><B>Milestone Payments. </B>IMMEDICA shall notify LICENSOR [*] upon achievement of each Milestone. IMMEDICA
shall pay to LICENSOR each applicable milestone payment set forth in <U>Schedule B</U> (each, a <B>&ldquo;Milestone Payment&rdquo;) </B>within
[*] after the achievement of such Milestone is notified to LICENSOR, subject to the receipt of the applicable invoice from the LICENSOR.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">6.1.3.</TD><TD STYLE="text-align: justify"><B>Royalty Payments. </B>On a country-by-country basis, from the date of First Commercial Sale in such
country in the Territory, and for the remainder of the term of this Agreement, IMMEDICA shall pay to LICENSOR the royalties set forth
in <U>Schedule&nbsp;B</U> (collectively, <B>&ldquo;Royalties&rdquo;) </B>within [*] following the expiration of each Calendar Quarter.
All payments shall be accompanied by a report that includes for the applicable Calendar Quarter the following information on a country-by-country
basis: (a) gross sales of Product in United States Dollars (including any foreign exchange rates employed); (b) Net Sales of Product (including
any foreign exchange rates employed); (c) Deductions taken from gross sales (by category as set forth in the definition of Net Sales)
to arrive at the Net Sales calculation (including any foreign exchange rates employed); and (d)&nbsp;the Royalties payable to LICENSOR
in United States Dollars and in Euros (&euro;) (including any foreign exchange rates employed).</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">6.1.4.</TD><TD STYLE="text-align: justify"><B>Other Payments. </B>IMMEDICA shall pay to LICENSOR any other amounts due under this Agreement within
[*] following receipt of invoice, subject to the receipt of the applicable invoice from the LICENSOR.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">6.1.5.</TD><TD STYLE="text-align: justify"><B>Late Payments. </B>Any late payments shall bear interest, to the extent permitted by law, at [*] above
the Euribor three months rate of interest on the date payment is due.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">6.1.6.</TD><TD STYLE="text-align: justify"><B>Payments under Existing Agreements. </B>LICENSOR shall be responsible for making all payments of any
sums due under the Existing Agreements to the applicable counterparty to the agreement in respect of the activities conducted under this
Agreement including any milestone or royalty payments.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36.5pt">6.2.</TD><TD><B>Payment Method.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">6.2.1.</TD><TD STYLE="text-align: justify">For the purpose of calculating any sales milestone payment threshold expressed in Euros, any Net Sales
that are received by IMMEDICA in currencies other than Euros shall be converted into Euros at the average (mean) monthly closing prevailing
foreign exchange rate published by the European Central Bank (or any other qualified source that is acceptable to both Parties) during
the applicable Calendar Quarter in which such amounts were booked, or for periods less than a Calendar Quarter, the average (mean) prevailing
foreign exchange rate published by the European Central Bank during such period.</TD></TR></TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">6.2.2.</TD><TD STYLE="text-align: justify">All payments from IMMEDICA to LICENSOR shall be made in US Dollars. For the purpose of calculating Royalties
and Milestone Payments not expressed in US Dollars, Net Sales and Milestone Payments shall be converted into US Dollars at the average
(mean) daily closing prevailing foreign exchange rate published by the European Central Bank (or any other qualified source that is acceptable
to both Parties) (a) in the case of Royalties, during the applicable Calendar Quarter in which such Royalty is payable; and (b) in the
case of Milestone Payments, on the date the Milestone triggering such Milestone Payment is achieved. Each such payment shall be made by
wire transfer to the credit of such bank account as may be designated by LICENSOR in writing to IMMEDICA. Any payment which falls due
on a date which is not a Business Day may be made on the next succeeding Business Day.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36.35pt">6.3.</TD><TD><B>Taxes.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">6.3.1.</TD><TD STYLE="text-align: justify">It is understood and agreed between the Parties that any amounts payable by IMMEDICA to LICENSOR hereunder
are exclusive of any and all applicable sales, use, VAT, GST, excise, property, and other taxes, levies, duties or fees (collectively,
<B>&ldquo;Taxes&rdquo;). </B>IMMEDICA shall be responsible for billing and collection from its customers and remitting to the appropriate
taxing authority any and all Taxes which it is required to collect or remit. Each Party will be responsible for their own income and property
taxes.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">6.3.2.</TD><TD STYLE="text-align: justify">If IMMEDICA is required to make a payment to LICENSOR subject to a deduction of tax or withholding tax
(a <B>&ldquo;Withholding Tax Requirement&rdquo;), </B>then to the extent such amounts are deducted, withheld and paid by or on behalf
of IMMEDICA to the appropriate taxing authority, such amounts shall be treated for all purposes of this Agreement as having been paid
to the LICENSOR. IMMEDICA shall provide LICENSOR with official receipts issued by the appropriate governmental agency to IMMEDICA.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">6.3.3.</TD><TD STYLE="text-align: justify">The Parties agree to cooperate and produce on a timely basis any tax forms or reports and any other documentation
required to prove treaty eligibility (which may vary depending on the applicable country), reasonably requested by the other Party in
connection with any payment made by IMMEDICA to LICENSOR under this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36.05pt">7.</TD><TD><B>MANUFACTURE AND SUPPLY</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">7.1.</TD><TD STYLE="text-align: justify"><B>Purchase and Sale of Product. </B>During the term of this Agreement and in accordance with the terms
and conditions set forth herein, (a) the LICENSOR shall have Product Manufactured and sell and deliver to IMMEDICA Product packaged and
labeled and ready for use; and (b) IMMEDICA shall order, purchase, and take delivery of [*] exclusively from the LICENSOR. For the avoidance
of doubt, other than the serialization of the Product (which as at the Effective Date the Parties agree is not required), the foregoing
does not operate to grant any license to IMMEDICA to Manufacture or have Manufactured the Product.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37.25pt">7.2.</TD><TD><B>Manufacturing Standards and Practices.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">7.2.1.</TD><TD STYLE="text-align: justify">The LICENSOR shall have Product Manufactured for IMMEDICA at the Facility in accordance with the Specifications,
GMP, all Applicable Laws, the Quality Agreement and the terms and conditions of this Agreement. LICENSOR shall consult with IMMEDICA prior
to any change to the Facility that would impact the Regulatory Approval for the Product in the Territory (including any change that would
require a variation of the Regulatory Approval). LICENSOR shall provide notice and rationale of any such change to IMMEDICA as promptly
as practicable to allow IMMEDICA to file and seek approval of any variation or amendment to a Regulatory Approval before such change is
implemented. Justification for the proposed changes as well as any updated sections to the Regulatory Dossier Module 3 (CMC) documentation
required to support such variation will be provided to IMMEDICA by LICENSOR at LICENSOR&rsquo;s expense. The Specifications will not be
amended or modified unless agreed by both Parties in writing. If any Regulatory Authority requires a change to the Specifications or if
any such change is required by a change in Applicable Law the Parties will discuss and agree how to implement such change. LICENSOR shall,
and shall use reasonable efforts to cause its Third Party suppliers to, support IMMEDICA in gathering any information and data (including
through carrying out stability studies) required for IMMEDICA to fullfil its obligation to submit such regulatory variations, or fullfil
obligations associated with such variations (including &lsquo;Post approval commitments&rsquo;). IMMEDICA shall pay the filing fee associated
with any application by IMMEDICA for a variation to a Regulatory Approval for the Product in the Territory. Any other costs, fees or expenses
incurred as a result of having to file an application for a variation as a result of such a change in the Facility or change to the Specifications
or a requirement of a Regulatory Authority shall be borne by (i) IMMEDICA if such variation is required as a result of a request from
IMMEDICA, a change or requirement of a Regulatory Authority in the Territory or a change in Applicable Laws in the Territory and (ii)
in all other cases shall be borne by LICENSOR. For clarity, except as otherwise required to comply with Applicable Laws, until such time
as a variation is approved by the applicable Regulatory Authority LICENSOR shall continue to supply the Product to IMMEDICA in accordance
with the unamended Specification and Regulatory Approval.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">7.2.2.</TD><TD STYLE="text-align: justify">IMMEDICA shall have the right, at its sole expense, to audit the LICENSOR for compliance with Applicable
Laws, GMP and the terms of the Quality Agreement on reasonable prior written notice during normal business hours and not more than [*]
in each Calendar Year. In addition, and subject to reasonable confidentiality obligations, IMMEDICA shall have the right, at its sole
expense, to join with LICENSOR during its annual audit of LICENSOR&rsquo;s suppliers and subcontractors for compliance with Applicable
Laws, GMP and the terms of the Quality Agreement and any for-cause audits and audits required by Applicable Law. The LICENSOR shall co-operate
in good faith in scheduling, attending at and assisting in all IMMEDICA audits. To assist in such scheduling arrangements, the LICENSOR
shall notify IMMEDICA at least [*] in advance (or, in the case of for-cause audits, as soon as reasonably practicable) in the event that
the LICENSOR intends to conduct any audit at any suppliers or subcontractors and, if so desired by IMMEDICA, the LICENSOR shall use its
reasonable efforts to allow IMMEDICA to attend and fully participate in such audit. In the event that IMMEDICA audits a LICENSOR supplier
or subcontractor, the LICENSOR has the right to be on site during the audit and act as an observer between IMMEDICA and such supplier
or subcontractor. The LICENSOR may charge its reasonable costs and expenses for such attendance if such audit takes place more than [*]
per year, unless IMMEDICA identifies a material defect in the LICENSOR&rsquo;s or any subcontractor&rsquo;s or supplier&rsquo;s performance
of its obligations under this Agreement, justifying an audit. If IMMEDICA or its representatives notify the LICENSOR of any defects in
the LICENSOR&rsquo;s or any subcontractor&rsquo;s or supplier&rsquo;s performance of its obligations under this Agreement, including non-compliance
with any Applicable Laws, the LICENSOR shall correct, or cause its suppliers or subcontractors to correct, the defects as soon as practicable
at the LICENSOR&rsquo;s expense and shall provide such evidence as IMMEDICA may reasonably request that such defects have been remedied.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">7.2.3.</TD><TD STYLE="text-align: justify">The LICENSOR shall provide IMMEDICA with certificates of analysis for all Product supplied hereunder based
upon a reference standard established by the LICENSOR and reasonably acceptable to IMMEDICA.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">7.2.4.</TD><TD STYLE="text-align: justify">Upon the reasonable request of IMMEDICA following the release and shipment of any Product supplied under
this Agreement, the LICENSOR shall provide IMMEDICA with such information, including analytical and manufacturing documentation, batch
records for Product and stability data, in each case requested by IMMEDICA regarding quality control of such Product. Without limiting
the foregoing obligations, IMMEDICA acknowledges and agrees that IMMEDICA is responsible for the final disposition and release of Product
in the Territory.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">7.2.5.</TD><TD STYLE="text-align: justify">All information disclosed or obtained pursuant to this Section 7.2 shall constitute Confidential Information
of the LICENSOR.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36.25pt">7.3.</TD><TD STYLE="text-align: justify"><B>Quality Assurance. </B>Within [*] of the Effective Date, the Parties shall enter into a quality assurance
agreement for the Product (the <B>&ldquo;Quality Agreement&rdquo;). </B>The Quality Agreement shall address the standard quality terms
of supply and relevant other terms, including, terms relating to specifications, product warranties, quality testing, storage, shipment,
labelling, quality controls and regulatory matters.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36.25pt">7.4.</TD><TD STYLE="text-align: justify"><B>Materials. </B>Unless otherwise agreed to in writing by the Parties, the LICENSOR shall be responsible
at its expense for obtaining all Materials in reasonable quantities consistent with the LICENSOR&rsquo;s supply obligations under the
then-current purchase order, on timelines that enable the LICENSOR to meet its delivery and supply obligations under all applicable purchase
orders and this Agreement, taking into account the forecast demand for Product as reflected in the most recent Forecast.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36.7pt">7.5.</TD><TD STYLE="text-align: justify"><B>Handling and Storage. </B>The LICENSOR shall and shall cause its suppliers and subcontractors to handle
and store the Product and the Materials for the Product pursuant to GMP and otherwise in a commercially reasonable manner and in accordance
with, as applicable (a) the Specifications, (b) Applicable Laws, including GMP, and (c) the terms of the Quality Agreement. LICENSOR shall
and shall cause its suppliers and subcontractors to comply with such other practices and procedures mutually agreed upon in writing between
the LICENSOR by IMMEDICA.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37.15pt">7.6.</TD><TD STYLE="text-align: justify"><B>Packaging and Labeling. </B>As between the Parties, LICENSOR shall be solely responsible for packaging
and labeling the Product for sale and distribution in the Territory. IMMEDICA shall be responsible for providing to LICENSOR artwork for
the packaging to be applied to the Product by LICENSOR.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36.95pt">7.7.</TD><TD><B>Forecasts and Orders.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">7.7.1.</FONT></TD><TD STYLE="text-align: justify">Not less than [*] prior to the first day of each Calendar Quarter (commencing with the first Calendar
Quarter in which IMMEDICA orders Product from the LICENSOR hereunder), IMMEDICA shall prepare and provide the LICENSOR with a written
forecast of its good faith estimated requirements for Product for each of [*] (each a <B>&ldquo;Forecast</B>&rdquo;). IMMEDICA shall not
increase or decrease the quantity estimated for [*] of each Forecast from the quantity estimated for such periods in the previous Forecast.
The quantities estimated for all subsequent Calendar Quarters of each Forecast shall be non-binding, and for planning purposes only. By
way of example, if IMMEDICA issues a forecast on [*], [*] shall be binding on the Parties and the forecasts for [*] shall not be binding
on the Parties. In addition, IMMEDICA will provide on a country-by-country basis its good faith estimated number of patients to be treated
in the Forecast for the purposes of LICENSOR providing dosimetric doses of the Product. LICENSOR will supply dosimetric doses based on
such Forecast of the Product in a manner it reasonably believes most efficient, provided however, it will ensure that dosimetric doses
are supplied to all identified patients in accordance with the terms of this Agreement. Therapeutic doses of the Product will be supplied
on a per patient basis pursuant to the terms of this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">7.7.2.</FONT></TD><TD STYLE="text-align: justify">The LICENSOR shall be required to supply the quantity of Product ordered by IMMEDICA under this Section
7.7 in any Calendar Quarter up to the quantity forecasted for the [*] of the most recent Forecast in a manner that is reasonably practical
given the nature of the Product. If IMMEDICA&rsquo;s orders in any Calendar Quarter exceed the quantity forecasted for the [*] of the
most recent Forecast, the LICENSOR shall use commercially reasonable efforts to supply such excess. The LICENSOR shall use commercially
reasonable efforts to meet IMMEDICA&rsquo;s delivery requirements specified in accordance with Section 7.7.3. In the event of a shortfall,
the LICENSOR shall promptly inform IMMEDICA and use Commercially Reasonable Efforts to apportion Product among IMMEDICA, the LICENSOR,
and its other customers on a [*] according to their respective forecasts for the relevant period provided always that such forecasts were
proposed in good faith. The LICENSOR shall not give priority of supply to its requirements or its licensees requirements for the Product
outside the Territory.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">7.7.3.</FONT></TD><TD STYLE="text-align: justify">IMMEDICA shall make all purchases under this Section 7.7 by submitting firm purchase orders to the LICENSOR.
On a [*] basis, IMMEDICA shall submit such purchase order in writing in a form reasonably acceptable to the LICENSOR, and shall specify
the quantity of Product ordered, the place of delivery and the required delivery date therefor, which shall not be less than [*] from
after the date of such purchase order. On a continual basis, IMMEDICA shall inform LICENSOR as soon as practical of identified potential
patient and when a dosimetric dose of Product has been administered. Except as otherwise expressly provided in this Agreement, the LICENSOR
shall be paid for its supply of the Product via the royalty paid by IMMEDICA under Section 6.1.3.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">7.7.4.</FONT></TD><TD STYLE="text-align: justify">During the Term of this Agreement, to the extent that IMMEDICA orders a quantity of Product that is
                                                                                                       less than the quantity specified in the binding [*] of the Forecasts provided under Section 7.7.1, IMMEDICA shall refund
                                                                                                       LICENSOR&rsquo;s wasted out-of pocket costs of buying iodine 131 and/or reserving non- cancellable manufacturing slots to
                                                                                                       manufacture Product that was not subsequently ordered, subject to the provision by LICENSOR of appropoirate evidence of such costs
                                                                                                       and to the extent that such iodine 131 or such manufacturing slots cannot be reused or cancelled by LICENSOR.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36.3pt">7.8.</TD><TD><B>Delivery and Acceptance.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">7.8.1.</FONT></TD><TD STYLE="text-align: justify">All Product supplied under this Agreement shall be shipped [*] (Incoterms 2020) to the destination port
designated by IMMEDICA in its purchase order, which shall be in the European Union. Any change in the location of delivery shall require
the consent of both Parties, such consent not to be unreasonably withheld or delayed. Title to the Product purchased by IMMEDICA hereunder
shall pass to IMMEDICA upon delivery at the destination port. IMMEDICA shall be responsible for import duties, import clearance and acting
as the importer for such Product.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">7.8.2.</FONT></TD><TD STYLE="text-align: justify">The LICENSOR shall insure the Products during transit. The LICENSOR and IMMEDICA shall cooperate to ensure
all import clearances and other taxes, duties and formalities are paid and in place prior to delivery.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">7.8.3.</FONT></TD><TD STYLE="text-align: justify">During the term of this Agreement, the LICENSOR agrees and undertakes to maintain a minimum stock of the
Materials required to Manufacture the Product with the exception of 131-1 radioisotope equal to the amount required to Manufacture or
have Manufactured [*] supply of Product for the Territory in accordance with the most recent Forecast.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">7.8.4.</FONT></TD><TD STYLE="text-align: justify">If
the LICENSOR, at any time during the Manufacturing process, becomes aware that for any reason the LICENSOR will not be able to deliver
to IMMEDICA the agreed quantity of conforming Product on the agreed delivery date in accordance with the terms of any purchase order
or this Agreement (a <B>&ldquo;Delay&rdquo;), </B>or any Delay is likely to occur (an <B>&ldquo;Anticipated Delay&rdquo;), </B>then the
LICENSOR shall use its reasonable efforts to minimize, cure or overcome such Delay and/or Anticipated Delay as soon as reasonably possible.
Promptly upon the LICENSOR first becoming aware of any Delay or Anticipated Delay, it shall notify the JSC and the IMMEDICA Alliance
Manager of such fact in writing. The JSC shall convene a meeting as soon as reasonably possible following such notice, to consider what
steps should be taken to avoid or mitigate such Delay and/or Anticipated Delay and to develop a plan to avoid any Delay occurring, in
the event of an Anticipated Delay, to mitigate the effects of any Delay and how to prevent any Delay and/or Anticipated Delay from occurring
in the future, including the appointment of a Third Party Manufacturer or the allocation of more capacity to the Manufacture of Products
for IMMEDICA. In the event that a Third Party Manufacturer is appointed, the costs of the associated technology transfer shall be borne
solely by the LIC: NSOR and shall be subject to the agreement of a high-level plan for the full and complete transfer of the relevant
manufacturing Know- How and technology to such Third Party Manufacturer. In the event of an issue at the Facility, or a supply shortage
of the Product affecting IMMEDICA and/or the LICENSOR, its Affiliates and other licensees and Sublicensees, then the LICENSOR shall ensure
that IMMEDICA receives a fair and reasonable <I>pro rata </I>share of any Product based on the quantities of Product included in purchase
orders placed in the last Calendar Year before such Facility issue or supply shortage occurred.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">7.8.5.</FONT></TD><TD STYLE="text-align: justify">In the event of a Supply Failure or a Bankruptcy Event in relation to the LICENSOR all licenses granted
under this Agreement shall automatically include a right for IMMEDICA to Manufacture, or have Manufactured, the Product, including both
the drug product and drug substance, and IMMEDICA is hereby authorized to contract with any party to the Manufacturing Agreements or any
other Third Parties for the purposes of such Manufacture, provided always that this shall be without prejudice to the LICENSOR&rsquo;s
right to receive royalties under Section&nbsp;6.1.3. In the event that IMMEDICA undertakes Manufacture of the Product under this Section
7.8.5 (either itself or through an Affiliate or a Third Party) the LICENSOR will on request from IMMEDICA and at the LICENSOR&rsquo;S
own cost promptly conduct a technology transfer to IMMEDICA, its AFFILIATE or appointed Third Party supplier (as directed by IMMEDICA)
to enable IMMEDICA to Manufacture or have Manufactured the Product. In addition if any Supply Failure results from a breach of any agreement
between LICENSOR and a Third Party contract manufacturer of the Product IMMEDICA shall have the right to cure such breach on behalf of
LICENSOR and LICENSOR shall reimburse IMMEDICA for all costs and, expenses incurred and compensation paid by IMMEDICA in connection with
curing such breach.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36.8pt">7.9.</TD><TD><B>Defective Product.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">7.9.1.</TD><TD STYLE="text-align: justify">If a shipment of Product or any portion thereof is not in conformance with the Specifications, Applicable
Law, GMP, the terms of the Quality Agreement or does not have specific activity required in accordance with the calculated therapeutic
dose level when received by IMMEDICA or its agents at premises controlled by IMMEDICA, <B>(&ldquo;Defective Product&rdquo;) </B>then IMMEDICA
shall have the right to reject such shipment of Product if the entire shipment is nonconforming, or the portion thereof that fails to
so conform, as the case may be. IMMEDICA shall give notice to the LICENSOR of its rejection hereunder, as soon as practical after IMMEDICA&rsquo;s
physical receipt of such shipment in premises controlled by IMMEDICA, specifying the grounds for such rejection. LICENSOR will not be
responsible for any Defective Product as a result of transport delays or Product mishandling in each case caused by IMMEDICA or its agents.
If LICENSOR has to replace Defective Product as a result of transport delays or Product mishandling caused by IMMEDICA or its agents,
IMMEDICA shall reimburse LICENSOR for its fully burdened cost of Manufacture and supply of the replacement Product. Notwithstanding the
foregoing, and solely until the expiration of the shelf-life for the applicable Product, in the event of any Defective Product which was
not obvious on receipt of such shipment, IMMEDICA shall have [*] after becoming aware of such Defective Product to notify the LICENSOR.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">7.9.2.</TD><TD STYLE="text-align: justify">IMMEDICA&rsquo;s grounds for rejection shall be conclusive unless the LICENSOR notifies IMMEDICA, within
[*] of receipt by the LICENSOR of the notice of rejection, that it disagrees with such grounds. In the event of such a notice by the LICENSOR,
representative samples of the Defective Product in question shall be submitted to a mutually acceptable independent laboratory or consultant
(if not a laboratory analysis issue) for analysis or review, the costs of which shall be paid by the Party that is determined by the independent
laboratory or consultant to have been incorrect in its determination of whether the applicable Product should be rejected.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">7.9.3.</TD><TD STYLE="text-align: justify">In the event of any Defective Product, at IMMEDICA&rsquo;s sole discretion, the LICENSOR shall either,
at the election of IMMEDICA: (i) replace such Defective Product, as soon as possible, and in any event within [*] after receipt of notice
of rejection thereof, or (ii) reimburse IMMEDICA for any out-of-pocket costs incurred by IMMEDICA associated with the Defective Product
(including all labeling and packaging costs, handling costs and transportation costs).</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36.45pt">7.10.</TD><TD><B>Product Recall.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">7.10.1.</TD><TD STYLE="text-align: justify">If either Party becomes aware of information about distributed Product indicating that it may be non-conforming
with respect to the Specifications, Applicable Law, GMP, or the terms of the Quality Agreement, or that there is potential adulteration,
misbranding and/or any potential issues regarding safety or effectiveness with respect to the Product, it shall promptly serve written
notice to that effect on the other Party. If such issue relates to a Defective Product, the LICENSOR shall initiate an investigation and
assessment of such circumstances and shall provide IMMEDICA a written report of its findings and any proposed course of action to remedy
such issue.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">7.10.2.</TD><TD STYLE="text-align: justify">In the event: (i) any Regulatory Authority or other national government authority issues a request, directive
or order that Product be recalled; (ii) a court of competent jurisdiction orders such a recall; or (iii) IMMEDICA reasonably determines
that Product should be recalled, the Parties shall take all appropriate corrective actions, and shall cooperate in any governmental investigations
surrounding the recall. In the event the LICENSOR reasonably determines that Product should be recalled, the LICENSOR shall provide notice
to IMMEDICA including all relevant information that supports such determination. Upon receipt of any such notice, IMMEDICA shall promptly
initiate a Product recall. IMMEDICA will have the responsibility for all communications with Regulatory Authorities in the Territory and
customers regarding any recall of Product in the Field. The LICENSOR will give IMMEDICA any assistance that IMMEDICA may reasonably request
to handle any recall.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">7.10.3.</TD><TD STYLE="text-align: justify">In the event that such recall results from a Defective Product that was a Defective Product at the time
of delivery of the Product, including the breach of the LICENSOR&rsquo; s express warranties under Section 7.11, or the LICENSOR&rsquo;s
negligence, recklessness or willful misconduct (a &ldquo;LICENSOR Caused Recall&rdquo;), the LICENSOR shall at IMMEDICA&rsquo;s option,
promptly replace the quantity of Products that were recalled at no cost to IMMEDICA, or reimburse IMMEDICA for any out-of-pocket costs
incurred by IMMEDICA associated with the Products that were recalled (including all labeling and packaging costs, handling costs and transportation
costs). In the event that IMMEDICA elects to have the recalled Product replaced, the LICENSOR shall replace such Product as soon as possible.
In the event that IMMEDICA elects to be reimbursed for out-of-pocket costs associated with the recalled Products, the LICENSOR shall reimburse
IMMEDICA within [*] of receipt of request from IMMEDICA for reimbursement. In addition, the LICENSOR agrees that it shall be responsible
for the expenses of any such LICENSOR Caused recall. For purposes of this Agreement, the expenses of the recall shall include the expenses
of notification, and destruction or return of the recalled Product, and any costs associated with the distribution of the replacement
Product. In the event that the recall was not a LICENSOR Caused Recall, then to the extent such recall affects Products in the Territory
in the Field, the LICENSOR shall not be responsible for the expenses of the recall or for replacing or reimbursing the relevant Products.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36.6pt">7.11.</TD><TD><B>Supply Specific Representations and Warranties</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">7.11.1.</TD><TD STYLE="text-align: justify"><B>Services. </B>The LICENSOR represents, warrants and covenants that: (a) it shall perform all Services
in a professional manner, with due care and in accordance with industry standards; and (b) it shall perform all Services in accordance
with: (i) Applicable Laws; (ii) GMP; and (iii) the terms and conditions of this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">7.11.2.</TD><TD STYLE="text-align: justify"><B>Product Warranties. </B>The LICENSOR warrants and covenants that all Product delivered to IMMEDICA
pursuant to this Agreement shall conform with the Specificiations and the certificate of analysis, and shall be Manufactured in accordance
with GMP and in compliance with Applicable Laws.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36.05pt">8.</TD><TD><B>RECORDS; AUDIT RIGHTS; INSPECTIONS</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36.75pt">8.1.</TD><TD><B>Records.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">8.1.1.</TD><TD STYLE="text-align: justify"><B>IMMEDICA&rsquo;s Records. </B>IMMEDICA shall maintain, and cause its Affiliates and Sublicensees to
maintain, accurate financial books and records pertaining to the sale of the Product by IMMEDICA, its Affiliates and its Sublicensees,
as applicable, including any and all calculations of the applicable Fees (collectively, <B>&ldquo;Relevant Records&rdquo;). </B>IMMEDICA
shall maintain the Relevant Records for the longer of: (a) the period of time required by Applicable Law, or (b)&nbsp;[*] following the
end of the Calendar Year to which such books and records pertain.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">8.1.2.</TD><TD STYLE="text-align: justify"><B>The LICENSOR&rsquo;s Records. </B>The LICENSOR shall maintain, and cause its Affiliates and subcontractors
to maintain, at the LICENSOR&rsquo;s cost, complete and accurate records related to the performance of LICENSOR&rsquo;s obligations under
this Agreement, including in relation to all Services and Clinical Studies and any costs that LICENSOR incurs that are to be reimbursed
by IMMEDICA (the <B>&ldquo;LICENSOR Records&rdquo;). </B>LICENSOR shall provide IMMEDICA reasonable access to the LICENSOR Records upon
the written request of IMMEDICA. Such access shall be requested in writing at least [*] in advance, and shall be conducted during the
LICENSOR&rsquo;s normal business hours and otherwise in manner that minimizes any interference to the LICENSOR&rsquo;s business operations.
The LICENSOR shall retain the LICENSOR Records, together with samples representing each batch of the Product delivered to IMMEDICA under
this Agreement for at least [*] for LICENSOR Records and [*] after expiration of shelf-life for samples in each case from the shipment
of the relevant batch of Product to IMMEDICA or such longer period as required by Applicable Laws.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37.1pt">8.2.</TD><TD><B>Audit Rights.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">8.2.1.</TD><TD STYLE="text-align: justify"><B>Audit Request. </B>LICENSOR shall have the right during the term of this Agreement and for [*] thereafter
to engage, at its own expense, an independent auditor reasonably acceptable to IMMEDICA to examine the Relevant Records from time-to-time,
but no more frequently than [*], as may be necessary to verify the amounts reported by IMMEDICA and IMMEDICA&rsquo;s compliance with the
terms of this Agreement. Such audit shall be requested in writing at least [*] in advance, and shall be conducted during IMMEDICA&rsquo;s
normal business hours and otherwise in manner that minimizes any interference to IMMEDICA&rsquo;s business operations. Such audits may
not (i)&nbsp;be conducted for any Calendar Year ending more than [*] prior to the date of such request, (ii)&nbsp;be conducted more than
[*] in any Calendar Year or (iii)&nbsp;be [*] for any Calendar Quarter.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">8.2.2.</TD><TD STYLE="text-align: justify"><B>Audit Fees and Expenses. </B>Upon completion of any audit pursuant to Section&nbsp;8.2.1, the independent
auditor shall provide to the Parties a copy of its audit report disclosing any issues or discrepancies identified. LICENSOR shall bear
any and all fees and expenses it may incur in connection with any such audit of the Relevant Records; provided, however, in the event
an audit reveals an underpayment by IMMEDICA of more than [*] as to the period subject to the audit, IMMEDICA shall reimburse LICENSOR
for the reasonable and documented fees and expenses charged by such independent auditor in connection with such audit.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">8.2.3.</TD><TD STYLE="text-align: justify"><B>Payment of Deficiency. </B>If any audit establishes that IMMEDICA underpaid any amounts due to LICENSOR
under this Agreement, then IMMEDICA shall pay LICENSOR any such deficiency, plus interest calculated in accordance with Section&nbsp;6.1.5
from the date on which the payment was originally due, within [*] after receipt of written notice thereof. In the event such audit establishes
that amounts were overpaid by IMMEDICA during such period, the amount of such overpayment plus interest calculated in accordance with
Section&nbsp;6.1.5 shall be credited against future amounts owed by IMMEDICA provided always that in the event an audit is conducted within
the last [*] of the Term, such amount will be repaid to IMMEDICA.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">8.2.4.</TD><TD STYLE="text-align: justify"><B>Confidential Financial Information. </B>The LICENSOR shall treat all financial information subject
to review under this Section 8 as confidential and shall cause its independent auditor to retain all such financial information in confidence
on terms no less restrictive than those applicable to the LICENSOR under Section 11 below.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">8.3.</TD><TD><B>Inspections.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">8.3.1.</TD><TD STYLE="text-align: justify">Each Party shall promptly notify the other Party of any regulatory inspections that may impact the other
Party&rsquo;s rights or obligations under this Agreement. The LICENSOR shall provide all reasonable co-operation to any inspection by
any Regulatory Authority responsible for the approval of the Product in the Territory and shall facilitate reasonable access to the Facility
and all LICENSOR Records. Unless not permitted by such Regulatory Authority, in the event of an inspection at the LICENSOR&rsquo;s premises
or the Facility, IMMEDICA shall have the right (subject to Section 8.3.4 with respect to any Facility owned or controlled by a Third Party)
to have a representative present during the portion of the inspection that involves the Product.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">8.3.2.</TD><TD STYLE="text-align: justify">The LICENSOR shall, unless not permitted to do so by the Regulatory Authority, forward to IMMEDICA copies
of any and all correspondence from and with any Regulatory Authority responsible for the approval of the Product in the Territory. To
the extent the Product is implicated in regulatory inspection findings, the LICENSOR will provide a draft of the pertinent responses to
IMMEDICA for review and comment prior to submission to the relevant Regulatory Authority responsible for the approval of the Product in
the Territory; provided that the inspected entity is responsible for all responses to observations made by a Regulatory Authority and
is not obligated to modify responses based upon IMMEDICA&rsquo;s comments.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">8.3.3.</TD><TD STYLE="text-align: justify">. The LICENSOR shall promptly, and in any event within [*], after the LICENSOR becomes aware notify IMMEDICA
in writing of any written observation, violation or deficiency noted, by a Regulatory Authority responsible for the approval of the Product
in the Territory, following an inspection which related to or which may affect the Product or activities undertaken pursuant to this Agreement.
The LICENSOR shall promptly rectify, and shall use reasonable efforts to cause its manufacturers to rectify, any such violation or deficiency
at the LICENSOR&rsquo;s sole cost and expense.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">8.3.4.</TD><TD STYLE="text-align: justify">Where any part of the Manufacturing process is undertaken by a Third Party on behalf of the LICENSOR,
LICENSOR shall procure that such Third Party shall comply with the obligations set out in this Section 8.3. In respect of IMMEDICA&rsquo;
s right to have a representative present during an inspection pursuant to Section&nbsp;8.3.1, LICENSOR&rsquo;s obligation will be to use
its reasonable efforts to allow IMMEDICA to attend such inspection.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36.5pt">9.</TD><TD><B>INTELLECTUAL PROPERTY RIGHTS</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37.05pt">9.1.</TD><TD STYLE="text-align: justify"><B>Pre-existing </B>IP. Each Party shall retain all rights, title and interests in and to any Intellectual
Property Rights that are owned, licensed or sublicensed by such Party prior to or independent of this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36.85pt">9.2.</TD><TD STYLE="text-align: justify"><B>Ownership of Inventions. </B>Inventorship of inventions shall be determined in accordance with the
rules of inventorship under U.S. patent laws. As between the Parties, IMMEDICA (or its Affiliate) shall solely own all inventions made
solely by IMMEDICA personnel, and the LICENSOR (or its Affiliate) shall solely own all inventions made solely by personnel of the LICENSOR.
The Parties (or their respective Affiliates) shall jointly own all inventions made jointly by personnel of both IMMEDICA and the LICENSOR;
provided that, subject to the rights and licenses granted under and the restrictions set forth in this Agreement, each Party may practice
and exploit any such joint invention and/or any jointly owned Patent Rights to the extent such practice and exploitation does not infringe
the Intellectual Property Rights of the other Party, including, without limitation, in connection with its development, manufacture and/or
commercialization of products, without the consent of, or a duty of accounting to, the other Party, and each Party hereby waives any right
it may have under applicable law to require such consent or accounting.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37.25pt">9.3.</TD><TD STYLE="text-align: justify"><B>License of Developed </B>IP. Any Patent Rights that are conceived, developed or reduced to practice
by or on behalf of IMMEDICA as a direct result of the performance of its activities under this Agreement are, to the extent they are Controlled
by IMMEDICA <B>(&ldquo;Developed IP</B>&rdquo;), hereby licensed to the LICENSOR on a non-exclusive, fully paid-up basis, for the sole
and limited purpose of the Development, Manufacture, and Commercialization of the Product in all territories and countries of the world
other than the Territory (provided that after any termination of this Agreement, the foregoing license shall be worldwide).</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37.5pt">9.4.</TD><TD STYLE="text-align: justify"><B>Recording of License. </B>If either Party considers it advisable to record IMMEDICA as a licensee or
&ldquo;registered user&rdquo; of any of the Licensed Technology under local law, the other Party shall do all such acts and sign or have
signed all such documents as are reasonably proper and necessary to secure such recordation and for any changes thereof in the future.
In such event, the relevant Party is responsible for recording this Agreement or a document reflecting this Agreement&rsquo;s contents
with any applicable governmental authority and for all associated recordation fees and related costs and expenses. Upon termination of
IMMEDICA&rsquo;s rights under this Agreement, either Party may at any time thereafter apply for cancellation of the record of IMMEDICA
as a licensee (in the case of LICENSOR, upon written notice to IMMEDICA).</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37.4pt">9.5.</TD><TD><B>Patent and Trademark Prosecution.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">9.5.1.</TD><TD STYLE="text-align: justify"><B>Patent and Trademark Prosecution and Maintenance. </B>Subject to IMMEDICA&rsquo;s rights set forth
in Section&nbsp;9.5.3 and Section&nbsp;9.5.4, the LICENSOR will be responsible for filing, prosecuting (including in connection with any
reexaminations, oppositions and the like), defending and maintaining the Licensed Patents and all Product Trademarks in all countries
in the Territory in LICENSOR&rsquo;s name at LICENSOR&rsquo;s own cost and expense.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><B>9.5.2.</B></TD><TD><B>Assistance.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify">The LICENSOR shall inform IMMEDICA as to the prosecution and maintenance and defence of the Licensed Patents
and Product Trademarks in the Territory prior to any deadline, submission to or action with any patent or trademark office, and shall
furnish to IMMEDICA copies of all relevant drafts and documents of such Licensed Patents or relating to the Product trademarks reasonably
in advance of such consultation. The LICENSOR shall provide to IMMEDICA copies of all patent office and trademark submissions and correspondence
relevant to such Licensed Patents and Product Trademarks within a reasonable amount of time following submission or receipt thereof by
the LICENSOR. The LICENSOR shall consider in good faith any reasonable and timely comments provided by IMMEDICA in connection with the
prosecution and maintenance and defence of such Licensed Patents and Product Trademarks. LICENSOR will discuss and agree with IMMEDICA
any proposal to opt-in or opt-out of the proposed Unified Patent Court system should that come into effect or to designate a Licensed
Patent as a Unitary Patent.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify">IMMEDICA will provide reasonable assistance to LICENSOR, at LICENSOR&rsquo;s expense, in connection with
the filing, prosecution and maintenance and defence of such Licensed Patents and Product Trademarks, where such assistance shall include
providing access to relevant persons and executing all documentation reasonably requested by LICENSOR.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">(c)</FONT></TD><TD STYLE="text-align: justify">As reasonably requested by LICENSOR in writing and at LICENSOR&rsquo;s expense, IMMEDICA shall cooperate
in obtaining patent term restoration (under, but not limited to, the Drug Price Competition and Patent Term Restoration Act), supplementary
protection certificates or their equivalents, and patent term extensions with respect to the Licensed Patents in Europe.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">9.5.3.</TD><TD STYLE="text-align: justify"><B>Failure to Prosecute or Maintain. </B>In the event LICENSOR elects to forgo filing, prosecution or
maintenance or defence of any of the Licensed Patents or Product Trademarks in any country in the Territory, LICENSOR shall promptly notify
IMMEDICA of such election, but in any event at least [*] prior to any filing or payment due date, or any other due date that requires
action <B>(&ldquo;Election Notice&rdquo;). </B>Upon receipt of an Election Notice, IMMEDICA shall be entitled, upon written notice to
LICENSOR, at its sole discretion and expense, to file or to continue the prosecution or maintenance of such Licensed Patent or Product
Trademarks in such country in LICENSOR&rsquo;s name using counsel of its own choice and at its own expense, provided that IMMEDICA shall
keep the LICENSOR reasonably informed as to the material actions taken with regard to the prosecution and maintenance and defence of such
Licensed Patents and Product Trademarks in the Territory. The LICENSOR shall cooperate with IMMEDICA to transfer the prosecution and maintenance
of such Licensed Patent and Product Trademarks, together with all relevant documentation and the file wrapper, to IMMEDICA. If requested
by IMMEDICA, the LICENSOR shall ensure that the LICENSOR&rsquo;s patent or trademark attorney liaises with IMMEDICA&rsquo;s patent attorney
to ensure a smooth and complete transfer of prosecution and maintenance obligations.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">9.5.4.</TD><TD STYLE="text-align: justify"><B>Trademarks.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"></TD><TD STYLE="text-align: justify">The Parties recognize the importance of having a coordinated global approach to the use of
                                                                                trademarks in relation to the Product and to that end and to the extent reasonably possible in accordance with Appl: able Law agree
                                                                                to use the same trademarks on Product inside the Territory and outside the Territory. LICENSOR in consultation with IMMEDICA, shall
                                                                                be responsible for the creation, filing, registration, and prosecution and maintenance of the Product Trademarks in the Territory.
                                                                                LICENSOR, in consultation with IMMEDICA, shall undertake the searching and clearance of all potential Product Trademarks within the
                                                                                Territory as soon as reasonably possible following the Effective Date. If LICENSOR fails to apply for trademarks for the Product
                                                                                within the Territory reasonably in advance of IMMEDICA&rsquo;S intended launch of the Product in the Territory IMMEDICA shall be
                                                                                free to do so and shall own all resulting trademarks. IMMEDICA shall use the Product Trademarks registered by LICENSOR in connection
                                                                                with the Product in the Field within the Territory.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.85pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36.35pt">10.</TD><TD><B>INFRINGEMENT; MISAPPROPRIATION</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37.2pt">10.1.</TD><TD STYLE="text-align: justify"><B>Notification. </B>Each Party will promptly notify the other Party in writing of any actual or threatened
infringement, misappropriation or other violation by a Third Party of any Licensed Technology or any Product Trademark in the Territory
of which it becomes aware <B>(&ldquo;Third Party Infringement&rdquo;).</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37.3pt">10.2.</TD><TD><B>Infringement Action.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><B>10.2.1.</B></TD><TD><B>Right of First Enforcement.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify">LICENSOR shall have the first right (but not the obligation), at its own expense, to control enforcement
of the Licensed Technology and Product Trademarks against any Third Party Infringement (each an <B>&ldquo;Enforcement Action&rdquo;),
</B>after having conferred with IMMEDICA. LICENSOR shall keep IMMEDICA reasonably updated with regard to the progress of any such Enforcement
Action that it takes. LICENSOR shall give IMMEDICA timely notice of any proposed settlement of any such action instituted by LICENSOR
and shall not enter into any settlement that would: (i) admit the liability of IMMEDICA or its Affiliates, or (ii) materially affect the
scope of validity of any Licensed Patent or Trademark, or (iii) materially adversely effect the Commercialization of the Product in the
Territory, in each case with respect to the foregoing clauses (i)-(iii), without the prior written consent of IMMEDICA, which consent
shall not be unreasonably withheld, conditioned or delayed.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify">If LICENSOR does not initiate proceedings within [*] from the date of IMMEDICA&rsquo;s request that LICENSOR
initiate such proceedings, then IMMEDICA shall have the right but shall not be obliged, upon prior written notice to LICENSOR, to initiate
infringement proceedings or take other action it believes appropriate against such Third Party Infringement at its own expense.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><B>10.2.2.</B></TD><TD STYLE="text-align: justify"><B>Assistance. </B>At the request and sole cost and expense of the Party controlling an Enforcement
                                                                          Action, the other Party shall provide reasonable assistance in connection therewith. If one Party brings any suit, action or
                                                                          proceeding under this Section 10.2, the other Party agrees to be joined as party plaintiff if reasonably necessary to prosecute the
                                                                          suit, action or proceeding and to give the first Party authority to file, prosecute and control the suit, action or proceeding;
                                                                          provided however that such non- controlling Party shall have the right, at its own expense, to be represented in any such action in
                                                                          which it is a party by independent counsel of its own choice.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><B>10.2.3.</B></TD><TD STYLE="text-align: justify"><B>Recoveries. </B>Any recoveries resulting from an action relating to a claim of Third Party Infringement
shall first be applied against payment of each Party&rsquo;s costs and expenses incurred in connection therewith. Any remaining recoveries
shall be retained by IMMEDICA; provided that LICENSOR shall be entitled to a Royalty on such remaining recoveries at the applicable rate
set forth in Section&nbsp;6.1 as if the amount of such remaining recoveries were Net Sales of IMMEDICA in the Calendar Year in which the
recoveries were received by IMMEDICA. Notwithstanding the foregoing, any recoveries resulting from an action relating to a claim of Third
Party Infringement shall not be included in the calculation of any commercial milestones under Section&nbsp;1.2 of <U>Schedule B</U>.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><B>10.2.4.</B></TD><TD STYLE="text-align: justify"><B>Third Party Infringement Claims. </B>If the Development, Manufacture or Commercialization of any Product
in any country of the Territory pursuant to this Agreement results in a claim, suit or proceeding alleging patent or other intellectual
property infringement against the LICENSOR or IMMEDICA (or their respective Affiliates, or Sublicensees) (collectively, <B>&ldquo;Infringement
Actions&rdquo;), </B>such Party shall promptly notify the other Party hereto in writing. IMMEDICA shall be indemnified in respect of any
such Infringement Action in accordance with Section 13.1 and LICENSOR shall have the right to direct and control the defense thereof,
at its own expense with counsel of its choice in accordance with Section 13.3. LICENSOR shall keep IMMEDICA reasonably informed of all
material developments in connection with any such Infringement Action.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.65pt">11.</TD><TD><B>CONFIDENTIALITY</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36.35pt">11.1.</TD><TD STYLE="text-align: justify"><B>Definition. &ldquo;Confidential Information&rdquo; </B>means the terms and provisions of this Agreement
and other proprietary information and data of a financial, commercial or technical nature that the disclosing Party or any of its Affiliates
has supplied or otherwise made available to the other Party or its Affiliates, whether disclosed in writing, orally or otherwise. The
terms of this Agreement shall be considered the Confidential Information of both Parties.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36.1pt">11.2.</TD><TD STYLE="text-align: justify"><B>Obligations. </B>During the term of this Agreement, and for [*] thereafter (or, in the case of Confidential
Information constituting a trade secret, for such longer period of time that the Confidential Information remains a trade secret under
Applicable Law), the receiving Party will protect all Confidential Information against unauthorized access, use or disclosure to Third
Parties with the same degree of care as the receiving Party uses for its own similar information, but in no event less than a reasonable
degree of care. The receiving Party may disclose the Confidential Information to its Affiliates, and their respective directors, officers,
employees, subcontractors, consultants, attorneys, and accountants, banks (to the extent required by applicable borrowing documentation)
and investors who hold a majority of the voting equity of a Party (collectively, <B>&ldquo;Recipients&rdquo;) </B>who (a)&nbsp;have a
need-to-know such information for purposes related to this Agreement, (b)&nbsp;are informed of the confidential nature of the Confidential
Information and the receiving Party&rsquo; s obligations hereunder, and (c) are bound by written obligations of confidentiality with terms
and conditions at least as restrictive as those set forth in this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36.6pt">11.3.</TD><TD><B>Exceptions.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">11.3.1.</TD><TD STYLE="text-align: justify">The obligations under this Section 11 shall not apply to any information to the extent the receiving Party
can demonstrate by competent evidence that such information:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">is (at the time of disclosure) or becomes (after the time of disclosure) known to the public or part of
the public domain through no breach of this Agreement by the receiving Party or any Recipients to whom it disclosed such information;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">was known to, or was otherwise in the possession of, the receiving Party prior to the time of disclosure
by the disclosing Party;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">is disclosed to the receiving Party on a nonconfidential basis by a Third Party who is entitled to disclose
it without breaching any confidentiality obligation to the disclosing Party; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">is independently developed by or on behalf of the receiving Party or any of its Affiliates, as evidenced
by its written records, without use or access to the Confidential Information.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">11.3.2.</TD><TD STYLE="text-align: justify">Notwithstanding anything herein to the contrary, the receiving Party may disclose Confidential Information
to the extent such disclosure is required under Applicable Laws or a court order or other governmental order, provided that the receiving
Party: (a)&nbsp;provides the disclosing Party with prompt notice of such disclosure requirement if legally permitted, (b) affords the
disclosing Party an opportunity to oppose or limit, or secure confidential treatment for such required disclosure and (c)&nbsp;if the
disclosing Party is unsuccessful in its efforts pursuant to subsection&nbsp;(b), discloses only that portion of the Confidential Information
that the receiving Party is legally required to disclose as advised by the receiving Party&rsquo;s legal counsel. Confidential Information
disclosed pursuant to this Section&nbsp;11 shall remain subject to the restrictions set forth herein for all other purposes.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">11.3.3.</TD><TD STYLE="text-align: justify">In the event that LICENSOR wishes to assign, pledge or otherwise transfer its rights to receive some or
all of the Milestone Payments and Royalties payable hereunder, LICENSOR may disclose to a Third Party such Confidential Information of
IMMEDICA as LICENSOR deems reasonably necessary in connection with any such proposed assignment, provided that LICENSOR shall hold such
Third Parties to written obligations of confidentiality with terms and conditions at least as restrictive as those set forth in this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">11.3.4.</TD><TD STYLE="text-align: justify">IMMEDICA may disclose Confidential Information of the LICENSOR to the extent such disclosure is reasonably
necessary in the following instances:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">with LICENSOR&rsquo; s written consent (such consent not to be unreasonably withheld, conditioned or delayed),
filing for, prosecuting or enforcing Licensed Patents in accordance with this Agreement;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">in Regulatory Filings or otherwise in seeking, obtaining and maintaining Regulatory Approvals (including
complying with the requirements of Regulatory Authorities with respect to filing for, obtaining and maintaining such Regulatory Approvals);</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">the Development and/or Commercialization of the Product in the Territory, provided, that any Third Party
to whom IMMEDICA discloses Confidential Information pursuant to this clause&nbsp;(c) (i)&nbsp;are informed of the confidential nature
of the Confidential Information and IMMEDICA&rsquo;s obligations hereunder and (ii) are bound by written obligations of confidentiality
with terms and conditions at least as restrictive as those set forth in this Agreement; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">disclosing to actual or <I>bona fide </I>potential Sublicensees or subcontractors in connection with the
exercise of its rights under this Agreement or related activities, provided, that such Sublicensees and subcontractors (i)&nbsp;are informed
of the confidential nature of the Confidential Information and IMMEDICA&rsquo;s obligations hereunder and (ii)&nbsp;are bound by written
obligations of confidentiality with terms and conditions at least as restrictive as those set forth in this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">11.3.5.</TD><TD STYLE="text-align: justify">Each Party shall be responsible for any breaches of confidentiality by any of its Affiliates, subcontractors,
Sublicensees, Recipients, advisors and Third Parties to whom it discloses Confidential Information pursuant to Section 11.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">11.3.6.</TD><TD STYLE="text-align: justify"><B>Confidential Disclosure of Terms. </B>Each Party agrees not to disclose to any Third Party the existence
and/or terms of this Agreement without the prior written consent of the other Party hereto, except as permitted under this Section&nbsp;11,
and notwithstanding the foregoing, each Party may disclose the existence and/or terms of this Agreement to its advisors (including financial
advisors, attorneys and accountants), potential and existing investors, collaboration partners or acquirers, and others on a reasonable
need to know basis, in each case under circumstances that reasonably protect the confidentiality thereof.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt">11.4.</TD><TD STYLE="text-align: justify"><B>Right to Injunctive Relief. </B>The Parties agree that breaches of this Section 11 may cause irreparable
harm to the non-breaching Party and shall entitle the non-breaching Party, in addition to any other remedies available to it (subject
to the terms of this Agreement), the right to seek injunctive relief enjoining such action, and each Party hereby waives any requirement
to post a bond or other security or prove actual damages or that monetary damages will not afford an adequate remedy.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.95pt">11.5.</TD><TD STYLE="text-align: justify"><B>Ongoing Obligation for Confidentiality. </B>Upon expiration or termination of this Agreement, the receiving
Party shall, and shall cause its Recipients to, destroy or return (as requested by the disclosing Party) any Confidential Information
of the disclosing Party, except for one copy which may be retained in its confidential files for archive purposes.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36.5pt">11.6.</TD><TD STYLE="text-align: justify"><B>Data Protection Regulations. </B>Each Party will collect, use, and disclose information governed by
this Agreement in compliance with all applicable privacy and data protection laws, rules, and regulations and in accordance with the terms
of a data sharing agreement that will be agreed by the Parties acting reasonably and in good faith within [*] of the Effective Date. The
Parties shall enter into any additional agreements regarding the collection, use, processing or disclosure of such information as mandated
by such data protection laws, rules and regulations. The Parties shall notify each other promptly of any unauthorized uses or disclosures
of such information of which they become aware.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">12.</TD><TD><B>REPRESENTATIONS, WARRANTIES AND COVENANTS</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">12.1.</TD><TD STYLE="text-align: justify"><B>Representations and Warranties by Each Party. </B>Each Party represents and warrants to the other Party
as of the Effective Date that:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.1.1.</TD><TD STYLE="text-align: justify">it is a corporation duly organized, validly existing, and in good standing under the laws of its jurisdiction
of formation;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.1.2.</TD><TD STYLE="text-align: justify">it has full corporate power and authority to execute, deliver, and perform this Agreement, and has taken
all corporate action required by Applicable Law and its organizational documents to authorize the execution and delivery of this Agreement
and the consummation of the transactions contemplated by this Agreement;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.1.3.</TD><TD STYLE="text-align: justify">this Agreement constitutes a valid and binding agreement enforceable against it in accordance with its
terms;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.1.4.</TD><TD STYLE="text-align: justify">all consents, approvals and authorizations from all governmental authorities or other Third Parties required
to be obtained by such Party in connection with this Agreement have been obtained; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.1.5.</TD><TD STYLE="text-align: justify">the execution and delivery of this Agreement and all other instruments and documents required to be executed
pursuant to this Agreement, and the consummation of the transactions contemplated hereby do not and shall not: (i) conflict with or result
in a breach of any provision of its organizational documents, (ii) result in a breach of any agreement to which it is a party that would
impair the performance of its obligations hereunder; or (iii) violate any Applicable Law.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">12.2.</TD><TD><B>Representations and Warranties by LICENSOR. </B>LICENSOR represents and warrants to IMMEDICA as of the Effective Date that:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.2.1.</TD><TD STYLE="text-align: justify">there is no actual alleged or threatened claim that has been notified in writing to the Licensor or its
Affiliates or, to its Knowledge, any pending or possible claim that the Development, Manufacture or Commercialization of the Product within
the Territory infringes, misappropriates or otherwise violates the Intellectual Property Rights of a Third Party. As used in this Section
12.2, <B>&ldquo;Knowledge&rdquo; </B>means knowledge of the officers of LICENSOR, and is not meant to require or imply that any particular
inquiry or investigation has been undertaken including, without limitation, obtaining any type of search (independent of that performed
by the actual governmental authority during the normal course of patent prosecution, as applicable, in a jurisdiction) or opinion of counsel,
provided that it shall include the knowledge that would be obtained from reasonable inquiries that a person in that position would normally
be expected to have made;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.2.2.</TD><TD STYLE="text-align: justify">there is no actual, pending, alleged or threatened claim by LICENSOR or its Affiliate alleging that a
Third Party is or was infringing, misappropriating or otherwise violating the Licensed Technology within the Territory;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.2.3.</TD><TD STYLE="text-align: justify">to its Knowledge, the practice of the Licensed Patents or the Licensed Know-How and the Development, Manufacture
and/or Commercialization of any Product does not infringe, violate or misappropriate the Intellectual Property Rights of any Third Party;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.2.4.</TD><TD STYLE="text-align: justify"><U>Schedule A</U> sets forth a true and complete list of all Licensed Patents Controlled by the LICENSOR
or its Affiliates as of the Effective Date that Cover the Product, and the LICENSOR has the full right and authority to grant to IMMEDICA
the right to use, sell, offer to sell, import and sublicense the Patent Rights in the Territory described in <U>Schedule A</U>, and to
enforce such Patent Rights in accordance with Section 10 above;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.2.5.</TD><TD STYLE="text-align: justify">the LICENSOR has not previously granted and will not grant any right, license or interest in or to a Product,
Licensed Know-How and/or Licensed Patents, or any portion thereof, that is in conflict with, limits or derogates from the rights or licenses
granted to IMMEDICA under this Agreement;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.2.6.</TD><TD STYLE="text-align: justify">the Licensed Patents and the Licensed Know-How are free and clear of all liens, claims, security interests
or other encumbrances of any kind and during the term of this Agreement, the LICENSOR shall not permit the Licensed Patents or the Licensed
Know-How to become encumbered by any liens, claims, security interests or other encumbrances, in each case of the foregoing that could
diminish IMMEDICA&rsquo;s rights or licenses with respect to Licensed Patent Rights;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.2.7.</TD><TD STYLE="text-align: justify">the LICENSOR has not knowingly withheld any Licensed Know-How that is reasonably relevant for IMMEDICA&rsquo;s
conduct of activities under this Agreement and, to the LICENSOR&rsquo;S Knowledge, all Licensed Know-How provided to IMMEDICA is free
from any material inaccuracies;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.2.8.</TD><TD STYLE="text-align: justify">the LICENSOR has disclosed to IMMEDICA all material information relating to the safety and efficacy of
the Product known to it or its Affiliates;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.2.9.</TD><TD STYLE="text-align: justify">the LICENSOR has complied with all Applicable Laws, including any disclosure requirements, in connection
with the filing, prosecution and maintenance of the Licensed Patents and, to the LICENSOR&rsquo;s Knowledge, none of the issued Licensed
Patents are invalid or unenforceable;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.2.10.</TD><TD STYLE="text-align: justify">the LICENSOR has conducted, and its contractors and consultants have conducted, all its Development activities
relating to the Product, including the Phase III Clinical Trial, in accordance with Applicable Laws including, as applicable, GLP and
GCP;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.2.11.</TD><TD STYLE="text-align: justify">neither the LICENSOR nor any of its Affiliates are, or have been, debarred or disqualified by any Regulatory
Authority; and none of the LICENSOR or any of its Affiliates&rsquo; employees or contractors who were involved in the Development, Manufacture
or Commercialization of the Product are, or have been, debarred or disqualified by any Regulatory Authority;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.2.12.</TD><TD STYLE="text-align: justify">the materials and documents provided to IMMEDICA in the course of IMMEDICA&rsquo;s due diligence preceding
execution of this Agreement were free from any material inaccuracies;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.2.13.</TD><TD STYLE="text-align: justify">the LICENSOR has made available to IMMEDICA all material information in the LICENSOR&rsquo;s or its Affiliate&rsquo;s
control relating to the Development and Manufacture of the Products as conducted by or on behalf of the LICENSOR and its Affiliates prior
to the Effective Date, including complete and correct copies of the following: adverse event reports; clinical study reports and material
study data; and Regulatory Authority inspection reports, notices of adverse findings, warning letters, Regulatory Filings and other material
correspondence with Regulatory Authorities;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.2.14.</TD><TD STYLE="text-align: justify">neither the LICENSOR nor any of its employees have been &ldquo;debarred&rdquo; by the FDA or the EMA,
or subject to a similar sanction from another Regulatory Authority, nor have debarment proceedings against the LICENSOR or any of its
employees been commenced. The LICENSOR will promptly notify IMMEDICA in writing if any such proceedings have commenced or if the LICENSOR
or any of its employees are debarred by the FDA or the EMA or any other Regulatory Agency;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.2.15.</TD><TD STYLE="text-align: justify">it shall not hire or retain as an officer or employee any person who has been convicted of a felony under
the laws of the United States for conduct relating to the regulation of any drug product under the FDCA. If at any time this representation
and warranty is no longer accurate, the LICENSOR shall immediately notify IMMEDICA of such fact;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.2.16.</TD><TD STYLE="text-align: justify">all personal data and biological specimens collected from or disclosed by human subjects in Clinical Studies
of the Products have been collected, used, processed and disclosed in compliance with Applicable Laws;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.2.17.</TD><TD STYLE="text-align: justify">to the Knowledge of the LICENSOR, the Phase III Clinical Trial will, if it meets its primary endpoints,
produce sufficient clinical data to support an application for Regulatory Approval of the Product in AML with the EMA without the need
for additional Clinical Studies, provided that this representation and warranty shall not be taken as a representation and or warranty
that the Phase III Clinical Trial will meet its primary endpoints or that any application for Regulatory Approval for the Product will
be successful;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.2.18.</TD><TD STYLE="text-align: justify">the Existing Agreements are in full force and effect and the Licensor has complied in all material respects
with each of its obligations the Existing Agreements in a timely manner, and has paid all payments owed by the LICENSOR under the Existing
Agreements in full and on time;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.2.19.</TD><TD STYLE="text-align: justify">the LICENSOR is not in breach of any material term of the Manufacturing Agreements and, to its Knowledge,
no counterparty to the Manufacturing Agreements is in breach of any material term of the Manufacturing Agreements; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.2.20.</TD><TD STYLE="text-align: justify">to its Knowledge, the Facility meets all requirements under Applicable Law, including under GMP, for the
Manufacture of the Product for Commercialization in the European Union.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">12.3.</TD><TD STYLE="text-align: justify"><B>Representations and Warranties by IMMEDICA. </B>IMMEDICA represents and warrants to LICENSOR as of
the Effective Date that:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">12.3.1.</FONT></TD><TD STYLE="text-align: justify">to its Knowledge, the practice of the Licensed Patents or the Licensed Know-How and the Development, Manufacture
and/or Commercialization of any Product within the Territory does not infringe, violate or misappropriate the Intellectual Property Rights
of any Third Party. As used in this Section&nbsp;12.3, <B>&ldquo;Knowledge&rdquo; </B>means knowledge of the officers of IMMEDICA, and
is not meant to require or imply that any particular inquiry or investigation has been undertaken including, without limitation, obtaining
any type of search (independent of that performed by the actual governmental authority during the normal course of patent prosecution,
as applicable, in a jurisdiction) or opinion of counsel, provided that it shall include the knowledge that would be obtained from reasonable
inquiries that a person in that position would normally be expected to have made; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">12.3.2.</FONT></TD><TD STYLE="text-align: justify">to its Knowledge, the granted patents within the Licensed Patents are valid and enforceable.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">12.4.</TD><TD STYLE="text-align: justify"><B>No Other Warranties. </B>EXCEPT AS EXPRESSLY STATED IN THIS SECTION&nbsp;12, NEITHER PARTY MAKES ANY
REPRESENTATIONS OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO
WARRANTIES OF TITLE, NON- INFRINGEMENT, VALIDITY, ENFORCEABILITY, MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">12.5.</TD><TD><B>Maintenance of the Existing Agreements.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">12.5.1.</FONT></TD><TD STYLE="text-align: justify">On an Existing Agreement-by-Existing Agreement basis, the LICENSOR shall ensure that such Existing Agreement
is not terminated, revoked or allowed to expire during the term of this Agreement for any reason attributable to the LICENSOR. The LICENSOR
shall:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 78.85pt"></TD><TD STYLE="width: 36.45pt">(a)</TD><TD STYLE="text-align: justify">not terminate such Existing Agreement without first obtaining IMMEDICA&rsquo;s express written consent
to such termination;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 78.55pt"></TD><TD STYLE="width: 36.65pt">(b)</TD><TD STYLE="text-align: justify">ensure that it complies, at all times, with each of its obligations under such Existing Agreement in a
timely manner, and shall ensure that all payments owed by the LICENSOR under such Existing Agreement are paid in full and on time; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 78.8pt"></TD><TD STYLE="width: 36.75pt">(c)</TD><TD STYLE="text-align: justify">not agree or consent to any amendment, supplement, or other modification (including termination) to such
Existing Agreement which could adversely affect IMMEDICA&rsquo;s rights under this Agreement without IMMEDICA&rsquo;s prior written consent.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">12.6.</TD><TD><B>Maintenance of the Manufacturing Agreements.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.6.1.</TD><TD STYLE="text-align: justify">On a Manufacturing Agreement-by-Manufacturing Agreement basis, from and after the Effective Date, the
LICENSOR shall ensure that such Manufacturing Agreement is not terminated, revoked or allowed to expire during the term of this Agreement
for any reason attributable to the LICENSOR. The LICENSOR shall:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 77.35pt"></TD><TD STYLE="width: 35.7pt">(a)</TD><TD STYLE="text-align: justify">not terminate such Manufacturing Agreement without first obtaining IMMEDICA&rsquo;s express written consent
to such termination (such consent not to be unreasonably withheld, conditioned or delayed);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 76.95pt"></TD><TD STYLE="width: 35.75pt">(b)</TD><TD STYLE="text-align: justify">ensure that it complies, at all times, with each of its obligations under such Manufacturing Agreement
in a timely manner, and shall ensure that all payments owed by the LICENSOR under such Manufacturing Agreement are paid in full and on
time; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 77.25pt"></TD><TD STYLE="width: 35.55pt">(c)</TD><TD STYLE="text-align: justify">not agree or consent to any amendment, supplement, or other modification (including termination) to such
Manufacturing Agreement which could adversely affect IMMEDICA or the supply of Product under this Agreement without IMMEDICA&rsquo;s prior
written consent (such consent not to be unreasonably withheld, conditioned or delayed).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 82.5pt; text-align: justify; text-indent: 0.15pt">Notwithstanding
the foregoing, LICENSOR shall have the right without needing the consent of IMMEDICA to utilize other manufacturers provided that LICENSOR
shall be responsible for any studies necessary to demonstrate the equivalence of the Product manufactured at such other manufacturers
and the terms of any agreements with such manufacturers, to the extent such terms impact IMMEDICA&rsquo;s rights or the LICENSOR&rsquo;s
ability to supply Product under the terms of this Agreement, are no less favourable in any material respect than the terms of the Manufacturing
Agreements. LICENSOR shall continue to supply the Product to IMMEDICA without amendment until such time as any change or variation to
a Regulatory Approval that is required as a result of such use of alternative manufacturers is approved by the applicable Regulatory Authority.
If the LICENSOR proposes to enter into any new agreements with Third Parties relating to the Manufacture of the Product it shall notify
IMMEDICA in writing and such proposal shall be discussed at the JSC. LICENSOR shall keep IMMEDICA reasonably informed with regard to the
progress of any discussions with any such Third Party and will provide to IMMEDICA a copy of any agreement entered into with such a Third
Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 82.5pt; text-align: justify; text-indent: 0.15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 82.5pt; text-align: justify; text-indent: 0.15pt"></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 82.5pt; text-align: justify; text-indent: 0.15pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.6.2.</TD><TD STYLE="text-align: justify">The LICENSOR covenants that promptly and in any event within [*] of the Effective Date, subject to Section&nbsp;12.6.l(c),
LICENSOR shall put in place an amendment to each of the Manufacturing Agreements to cover clinical and commercial supply of the Product
to IMMEDICA in the Territory as contemplated by this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">13.</TD><TD><B>INDEMNIFICATION</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">13.1.</TD><TD STYLE="text-align: justify"><B>Indemnification by LICENSOR. </B>The LICENSOR agrees to indemnify, hold harmless and defend IMMEDICA,
its Affiliates and Sublicensees and their respective officers, directors, employees, contractors, agents and assigns (collectively the
<B>&ldquo;IMMEDICA Indemnitees&rdquo;), </B>from and against any Claims arising or resulting from (a)&nbsp;the Development of a Product,
including the performance of any Clinical Studies by the LICENSOR, its Affiliates, or respective subcontractors, (b) any breach by the
LICENSOR of any representation, warranty or covenant as set forth in this Agreement, (c) any Claim or allegation that the Development,
Manufacture and Commercialization of the Product in the Territory infringes the Intellectual Property Rights of a Third Party (including
any Infringement Action) or (d) the negligence, recklessness or wrongful intentional acts or omissions of any Licensor Indemnitees; except
to the extent in each case (a) to (c) such Claims result from the breach of this Agreement by IMMEDICA, or the negligence, recklessness
or wrongful intentional acts or omissions of any IMMEDICA Indemnitees.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt"><B>13.2.</B></FONT></TD><TD STYLE="text-align: justify"><B>Indemnification by IMMEDICA. </B>IMMEDICA agrees to indemnify, hold harmless and defend LICENSOR and
its Affiliates, and their respective officers, directors, employees, contractors, agents and assigns (collectively, <B>&ldquo;Licensor
Indemnitees&rdquo;), </B>from and against any Claims arising or resulting from: (a) the Development of a Product by IMMEDICA, its Affiliates,
its Sublicensees or their respective subcontractors, (b)&nbsp;the Commercialization of a Product by IMMEDICA, its Affiliates, its Sublicensees,
or their respective subcontractors, (c) the negligence, recklessness or wrongful intentional acts or omissions of IMMEDICA, its Affiliates,
its Sublicensees or their respective subcontractors, or (d) breach by IMMEDICA of any representation, warranty or covenant as set forth
in this Agreement; except to the extent in each case (a) to (d), such Claims result from the breach of this Agreement by the LICENSOR,
or the negligence, recklessness or wrongful intentional acts or omissions of any Licensor Indemnitees.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt"><B>13.3.</B></FONT></TD><TD STYLE="text-align: justify"><B>Indemnification Procedure. </B>In connection with any Claim for which a Party (the <B>&ldquo;Indemnitee&rdquo;)
</B>seeks indemnification from the other Party (the <B>&ldquo;Indemnitor&rdquo;) </B>pursuant to this Agreement, the Indemnitee shall:
(a) give the Indemnitor prompt written notice of the Claim; provided, however, that failure to provide such notice shall not relieve the
Indemnitor from its liability or obligation hereunder, except to the extent of any material prejudice as a direct result of such failure;
(b) cooperate with the Indemnitor, at the Indemnitor&rsquo;s expense, in connection with the defense and settlement of the Claim; and
(c) permit the Indemnitor to control the defense and settlement of the Claim; provided, however, that the Indemnitor may not settle the
Claim without the Indemnitee&rsquo;s prior written consent, which shall not be unreasonably withheld, conditioned or delayed, in the event
such settlement materially adversely impacts the Indemnitee&rsquo;s rights or obligations. Further, the Indemnitee shall have the right
to participate (but not control) and be represented in any suit or action by advisory counsel of its selection and at its own expense.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt"><B>13.4.</B></FONT></TD><TD STYLE="text-align: justify"><B>Third Party Intellectual Property. </B>If a Third Party notifies IMMEDICA, its Affiliates, distributors
or Sublicensees that Intellectual Property Rights owned or controlled by such Third Party cover the use or sale of the Product in the
Territory <B>(&ldquo;Third Party IP Rights&rdquo;), </B>then IMMEDICA shall, upon becoming aware of such notice, promptly notify LICENSOR
<B>(&ldquo;Third Party Notice&rdquo;) </B>and give LICENSOR the exclusive right to negotiate with such Third Party. If LICENSOR obtains
a license or other right from such Third Party for such Third Party IP Rights, LICENSOR shall ensure that LICENSOR has the right to sublicense
to IMMEDICA under this Agreement, and LICENSOR shall bear all costs and expenses of such license (including milestones and royalties).
In any event, from the date of LICENSOR&rsquo;s receipt of the Third Party Notice, LICENSOR shall indemnify, hold harmless and defend
the IMMEDICA Indemnitees from and against any Claims from such Third Party with respect to the infringement of the Third Party IP Rights
from the use or sale of the Product in the Territory.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">14.</TD><TD STYLE="text-align: justify"><B>LIMITATION OF LIABILITY</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt; text-transform: uppercase">14.1.</FONT></TD><TD STYLE="text-align: justify">Consequential Damages Waiver. <FONT STYLE="font-size: 10pt; text-transform: uppercase">EXCEPT FOR A BREACH
OF SECTION&nbsp;11, NEITHER PARTY SHALL BE LIABLE FOR ANY LOSS OF GOODWILL, REPUTATION, BUSINESS, REVENUES, INDIRECT PROFITS, ANTICIPATED
PROFITS, CONTRACTS, OR OPPORTUNITIES (REGARDLESS OF HOW THESE ARE CLASSIFIED AS DAMAGES) OR ANY INDIRECT, CONSEQUENTIAL, SPECIAL, EXEMPLARY
OR PUNITIVE DAMAGES, REGARDLESS OF WHETHER IT HAS BEEN INFORMED OF THE POSSIBILITY OR LIKELIHOOD OF SUCH DAMAGES OR THE TYPE OF CLAIM,
CONTRACT OR TORT (INCLUDING NEGLIGENCE).</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.05pt"><FONT STYLE="text-transform: uppercase">NOTHING
IN THIS AGREEMENT EXCLUDES OR LIMITS ANY LIABILITY FOR DEATH OR PERSONAL INJURY CAUSED BY NEGLIGENCE, FOR FRAUD OR FOR ANY OTHER LIABILITY
WHICH CANNOT LEGALLY BE EXCLUDED OR LIMITED.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.5pt; text-align: justify; text-indent: 0.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.05pt"><FONT STYLE="text-transform: uppercase">NOTWITHSTANDING
THE FOREGOING, THE LIMITATIONS SET FORTH IN THIS SECTION&nbsp;14.1 SHALL NOT LIMIT AN INDEMNITOR&rsquo; S LIABILITY FOR DAMAGES AWARDED
TO ANY THIRD PARTY IN CONNECTION WITH ANY CLAIM FOR WHICH A PARTY IS ENTITLED TO INDEMNIFICATION UNDER SECTION&nbsp;13.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.05pt"><FONT STYLE="text-transform: uppercase">NOTWITHSTANDING
ANY OTHER PROVISION IN THIS SECTION 14.1, THE LICENSOR SHALL NOT BE LIABLE FOR ANY LOSS OF PROFIT CLAIMED BY IMMEDICA TO THE EXTENT SUCH
LOSS OF PROFIT ARISES FROM AN ACT OR OMISSION OF A THIRD PARTY SUPPLIER TO LICENSOR AND THE TERMS OF THE CONTRACT BETWEEN LICENSOR AND
SUCH THIRD PARTY SUPPLIER EXCLUDES OR LIMITS THE RECOVERY OF SUCH LOSS OF PROFIT.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.4pt; text-align: justify; text-indent: 0.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.05pt"><FONT STYLE="text-transform: uppercase">A
PARTY&rsquo;S AGGREGATE LIABILITY FOR ANY AND ALL CLAIMS BY THE OTHER PARTY FOR ANY DIRECT LOSS OF PROFIT ARISING OUT OF OR IN CONNECTION
WITH THIS AGREEMENT SHALL NOT EXCEED</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.25pt; text-align: justify; text-indent: 0.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">[*]
OF THE TOTAL OF ANY SUMS WHICH HAVE BEEN PAID BY IMMEDICA TO LICENSOR UNDER THIS AGREEMENT EXCLUDING, EXCEPT IN THE CASE OF AN INTENTIONAL
BREACH BY LICENSOR WITHIN [*] OF THE EFFECTIVE DATE, THE UPFRONT PAYMENT REFERRED TO IN SECTION&nbsp;6.1.1,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.35pt; text-align: justify; text-indent: 35.15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">TOGETHER
WTTH</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 76.2pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">A
SUM EQUIVALENT TO [*] OF THE TOTAL VALUE OF NET PROFIT ON SALES OF THE PRODUCT ACHIEVED BY IMMEDICA IN THE [*] PRIOR TO THE DATE ON WHICH
THE MATTER GIVING RISE TO THE CLAIM FIRST AROSE.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.5pt; text-align: justify; text-indent: 34.9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">15.</TD><TD><B>TERM; TERMINATION</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">15.1.</TD><TD STYLE="text-align: justify"><B>Term. </B>The term of this Agreement shall commence as of the Effective Date and shall continue until
terminated in accordance with this Section 15.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">15.2.</TD><TD STYLE="text-align: justify"><B>Termination for Cause. </B>Each Party shall have the right, without prejudice to any other remedies
available to it at law or in equity, to terminate this Agreement in the event the other Party is in material breach of this Agreement
and fails to cure such breach within [*] of receiving notice thereof; <U>provided, however,</U> if such breach is capable of being cured,
but cannot be cured within such [*] period, and the breaching Party initiates actions to cure such breach within such period and thereafter
diligently pursues such actions, the breaching Party shall have such additional period as is reasonable to cure such breach, but in no
event will such additional period exceed [*]. Any termination by a Party under this Section 15.2 shall be without prejudice to any damages
or other legal or equitable remedies to which it may be entitled from the other Party.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">15.3.</TD><TD STYLE="text-align: justify"><B>Termination for a Bankruptcy Event. </B>Each Party shall have the right to terminate this Agreement
in the event of a Bankruptcy Event with respect to the other Party. <B>&ldquo;Bankruptcy Event&rdquo; </B>means the occurrence of any
of the following: (a) the institution of any bankruptcy, receivership, insolvency, reorganization or other similar proceedings by or against
a Party under any bankruptcy, insolvency, or other similar law now or hereinafter in effect, including any section or chapter of the United
States Bankruptcy Code, as amended or under any similar laws or statutes of the United States or any state thereof (the <B>&ldquo;Bankruptcy
Code&rdquo;), </B>where in the case of involuntary proceedings such proceedings have not been dismissed or discharged within [*] after
they are instituted, (b) the insolvency of a Party or making of an assignment for the benefit of creditors, (c) the institution of any
reorganization, arrangement or other readjustment of debt plan of a Party not involving the Bankruptcy Code, or (d) appointment of a receiver
for all or substantially all of a Party&rsquo;s assets (each an <B>&ldquo;Insolvency Event&rdquo;). </B>All rights and licenses now or
hereafter granted by the LICENSOR to IMMEDICA under or pursuant to this Agreement, including, for the avoidance of doubt, the license
granted to IMMEDICA pursuant to Section 2.1, are, for all purposes of Section&nbsp;365(n) of the Bankruptcy Code, licenses of rights to
&ldquo;intellectual property&rdquo; as defined in the Bankruptcy Code. Upon the occurrence of any Insolvency Event with respect to LICENSOR,
the LICENSOR agrees that IMMEDICA, as licensee of such rights under this Agreement, shall retain and may fully exercise all of its rights
and elections under the Bankruptcy Code. Without limiting the generality of the foregoing, the LICENSOR and IMMEDICA intend and agree
that any sale of the LICENSOR&rsquo;s assets under Section 363 of the Bankruptcy Code shall be subject to IMMEDICA&rsquo;s rights under
Section 365(n), that IMMEDICA cannot be compelled to accept a money satisfaction of its interests in the intellectual property licensed
pursuant to this Agreement, and that any such sale therefore may not be made to a purchaser &ldquo;free and clear&rdquo; of IMMEDICA&rsquo;s
rights under this Agreement and Section&nbsp;365(n) without the express, contemporaneous consent of IMMEDICA.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">15.4.</TD><TD STYLE="text-align: justify"><B>Termination for Challenge to Licensed Technology. </B>LICENSOR shall have the right to terminate this
Agreement at any time after the Effective Date on [*] written notice in its entirety or on a country-by-country basis in the event IMMEDICA
or any of its Affiliates or Sublicensees contests or challenges, or supports or assists any Third Party to contest or challenge, in any
patent office, court, regulatory agency or other forum, the validity, enforceability or scope of, any of the Licensed Patents (a <B>&ldquo;Patent
Challenge&rdquo;); </B>provided that if a Licensed Patent is asserted against IMMEDICA, or any of its Affiliates or Sublicensees in an
infringement action or other legal proceeding with respect to activities outside the licenses granted herein, or any sublicense granted
hereunder, then any claim or action taken in defense of such assertion shall not be deemed a Patent Challenge. Any termination for Patent
Challenge shall be subject to the notification and cure procedure set out in Section 15.2, including a right for IMMEDICA to withdraw
or rectify the Patent Challenge during the cure period in which case LICENSOR shall have no right to terminate this Agreement at the end
of the cure period if the Patent Challenge has been so withdrawn or rectified. Any attempt to cure a breach of this Section&nbsp;15.4
requires IMMEDICA to reimburse LICENSOR for any and all expenses and costs, including all legal fees, incurred as a result of the Patent
Challenge.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">15.5.</TD><TD STYLE="text-align: justify"><B>Termination by IMMEDICA. </B>IMMEDICA shall have the right to terminate this Agreement in its entirety,
or on a country-by-country basis, without cause, and for any or no reason on not less than [*] prior written notice to the LICENSOR.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">15.6.</TD><TD><B>Effect of Termination or Expiration.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">15.6.1.</TD><TD STYLE="text-align: justify">Upon termination or expiration of this Agreement, IMMEDICA shall pay to LICENSOR all amounts due to LICENSOR
as of the effective date of termination or expiration within [*] following the effective date of termination or expiration.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">15.6.2.</TD><TD STYLE="text-align: justify">Upon termination of this Agreement, IMMEDICA shall have the right to sell its remaining inventory of Product
following the termination of this Agreement so long as IMMEDICA has fully paid, and continues to fully pay when due, any and all Royalties
owed to LICENSOR, and IMMEDICA otherwise is not in material breach of this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">15.6.3.</TD><TD STYLE="text-align: justify">Upon termination of this Agreement but not expiration, all licenses granted by one Party to the other
Party shall terminate. For clarity, termination of the licenses granted by LICENSOR to IMMEDICA shall terminate all sublicenses granted
by IMMEDICA hereunder.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">15.6.4.</TD><TD STYLE="text-align: justify">With the exception of termination of this Agreement by IMMEDICA pursuant to Section 15.2 or 15.3, upon
termination of this Agreement:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify">To the extent permitted by applicable Regulatory Authorities, IMMEDICA shall, at IMMEDICA&rsquo;s cost:
(i) transfer, or cause to be transferred, to LICENSOR all Regulatory Filings and Regulatory Approvals held by IMMEDICA, its Affiliates
and its Sublicensees with respect to the Product, and (ii) to the extent subsection (i) is not permitted by the applicable Regulatory
Authority, permit LICENSOR, or cause its Affiliates and its Sublicensees to permit LICENSOR to cross-reference and rely upon any Regulatory
Approvals and Regulatory Filings owned by IMMEDICA, its Affiliates and its Sublicensees with respect to the Product.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">15.7.</TD><TD STYLE="text-align: justify"><B>Survival. </B>Expiration or termination of this Agreement shall not relieve the Parties of any obligation
accruing hereunder prior to such expiration or termination. Without limiting the foregoing, the provisions of Sections 1, 5.4, 7.10, 8.1,
8.2, 8.3, 9.1, 9.2, 9.3, 9.4, 11, 13, 15.6, 18 and 19 shall survive expiration or termination of this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">16.</TD><TD><B>PUBLICITY</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">16.1.</TD><TD><B>Publicity.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">16.1.1.</FONT></TD><TD STYLE="text-align: justify">Subject to IMMEDICA&rsquo;s rights pursuant to Section 2.1.2, neither Party (nor any of its Affiliates
or agents) shall use the trademarks of the other Party or its Affiliates in any press release, publication or other form of promotional
disclosure without the prior written consent of the other Party in each instance.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">16.1.2.</FONT></TD><TD STYLE="text-align: justify">The Parties have mutually approved a press release attached hereto as <U>Schedule&nbsp;D</U> with respect
to this Agreement. Each Party agrees not to issue any other press release or other public statement, whether written, electronic, oral
or otherwise, disclosing the existence of this Agreement, the terms hereof or any information relating to this Agreement without the prior
written consent of the other Party, <U>provided however,</U> that (i)&nbsp;neither Party will be prevented from complying with any duty
of disclosure it may have pursuant to Applicable Law or the rules of any recognized stock exchange so long as the disclosing Party provides
the other Party prior written notice to the extent practicable and only discloses information to the extent required, in the reasonable
opinion of such Party&rsquo;s legal counsel, by Applicable Law or the rules of any recognized stock exchange, (ii)&nbsp;once the press
release set out in <U>Schedule D</U> has been released, each Party may disclose the information contained in such press release without
further consent, and (iii)&nbsp;IMMEDICA shall have the right to publicly disclose without the LICENSOR&rsquo;s prior written consent:
(A)&nbsp;the achievement of any milestone under this Agreement ; or (B)&nbsp;any information (other than Confidential Information of Licensor)
relating to the Development or Commercialization of any Products in the Territory.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">17.</TD><TD><B>INSURANCE</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">17.1.</TD><TD STYLE="text-align: justify"><B>Insurance Requirements. </B>The Parties will each maintain during the term of this Agreement and for
[*] after termination or expiration of this Agreement, commercial general liability insurance from a minimum [*] rated insurance company,
including contractual liability and product liability or clinical trials, if applicable, with coverage limits of [*] per occurrence and
[*] in the aggregate. Each Party has the right to provide the total limits required by any combination of primary and umbrella/excess
coverage. The minimum level of insurance set forth herein shall not be construed to create a limit on a Party&rsquo;s liability hereunder.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">17.2.</TD><TD STYLE="text-align: justify"><B>Policy Notification. </B>On request, each Party shall provide the other Party with certified copies
of such policies or original certificates of insurance evidencing such insurance: (a) prior to execution by both Parties of this Agreement,
and (b) prior to expiration of any such coverage.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">18.</TD><TD><B>DISPUTE RESOLUTION</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">18.1.</TD><TD STYLE="text-align: justify"><B>General. </B>Except for disputes for which injunctive or other equitable relief is sought to prevent
the unauthorized use or disclosure of proprietary materials or information or prevent the infringement or misappropriation of a Party&rsquo;s
Intellectual Property Rights, the following procedures shall be used to resolve any dispute arising out of or in connection with this
Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">18.2.</TD><TD STYLE="text-align: justify"><B>Meeting. </B>Promptly after the written request of either Party, each of the Parties shall appoint
a designated representative to meet in person or by telephone to attempt in good faith to resolve any dispute arising out of or in connection
with this Agreement. If the designated representatives do not resolve the dispute within [*] of such request, then an executive officer
of each Party shall meet in person or by telephone to review and attempt to resolve the dispute in good faith. The executive officers
shall have [*] to attempt to resolve the dispute.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">18.3.</TD><TD><B>Arbitration.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">18.3.1.</TD><TD STYLE="text-align: justify"> Any disputes arising out of or in connection with this
Agreement, including any question regarding its existence, validity or termination that are not otherwise resolved by the Parties in
accordance with Section 18.2 shall be finally settled under the Rules of Arbitration of the International Chamber of Commerce by one
or more arbitrators appointed in accordance with the said Rules. The Parties agree, pursuant to Article 30(2)(b) of said Rules that the
Expedited Procedure Rules shall apply irrespective of the amount in dispute. The language of the arbitration shall be English. The number
of arbitrators shall be one; provided that if the Parties fail to nominate a mutually acceptable sole arbitrator within [*] from the
date when the Request for Arbitration has been received by the other Party, the number of arbitrators shall be three. The seat, or legal
place, of arbitration shall be London, England.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 80.1pt; text-align: justify; text-indent: -37.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">18.3.2.</TD><TD STYLE="text-align: justify">The arbitrator(s) shall not be an officer or employee of either Party. The cost of the arbitration, including
the fees and expenses of the arbitrator(s), will be shared equally by the Parties. The prevailing Party shall be entitled to recover from
the losing Party the prevailing Party&rsquo;s arbitration costs, including reasonable attorneys&rsquo; fees and costs and the fees and
expenses of the arbitrator(s). The arbitration award will be presented to the Parties in writing, and upon the request of either Party,
will include findings fact and conclusions of law. The award may be confirmed and enforced in any court of competent jurisdiction.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">18.3.3.</TD><TD STYLE="text-align: justify">If a Party asserted to be in breach under Section 15.2 above disputes the asserted breach, this Agreement
shall not be terminated and the licenses herein shall not be affected as a result of the disputed breach unless and until it has been
determined in accordance with this Section 18.3 that this Agreement was materially breached, and such breach is not cured within [*] after
such determination or such longer period as the arbitrator may establish.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">19.</TD><TD><B>GENERAL PROVISIONS</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">19.1.</TD><TD STYLE="text-align: justify"><B>Compliance. </B>The Parties shall conduct their business in accordance with all Applicable Laws. Without
limiting the generality of the foregoing, each Party further acknowledges and ensures that it and its Affiliates, Sublicensees and subcontractors
are familiar with the provisions of the United States Foreign Corrupt Practices Act, the UK Bribery Act and applicable local bribery and
corruption laws, and shall not take or permit any action that will either constitute a violation under, or cause the other Party to be
in violation of, the provisions of the United States Foreign Corrupt Practices Act, the UK Bribery Act or applicable local bribery and
corruption law or other Applicable Laws (collectively, <B>&ldquo;Improper Conduct&rdquo;). </B>In addition to any other rights either
Party may have under this Agreement, if a Party (the <B>&ldquo;Improper Party&rdquo;) </B>notifies the other Party of, or if such other
Party otherwise has a reasonable suspicion of, the occurrence of Improper Conduct, such other Party shall have the right to have an independent
auditor inspect the premises, books and records of the Improper Party relevant to such Improper Conduct for the purpose of ensuring compliance
under this Section 19.1.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">19.2.</TD><TD STYLE="text-align: justify"><B>Assignment and Subcontracting. </B>Neither Party may assign its rights and obligations under this Agreement
without the other Party&rsquo;s prior written consent, except that: (a) LICENSOR may assign to a Third Party its rights to receive some
or all of the Fees payable hereunder, (b) each Party may assign its rights and obligations under this Agreement or any part hereof to
one or more of its Affiliates without the consent of the other Party; (c) LICENSOR may assign this Agreement in its entirety without the
consent of IMMEDICA to a successor to all or substantially all of its business to which this Agreement relates; and (d) IMMEDICA may assign
this Agreement in its entirety without the consent of LICENSOR to a successor to all or substantially all of its business to which this
Agreement relates provided that such successor is not a Competitor. For purposes of this Section 19.2, <B>&ldquo;Competitor&rdquo; </B>means
a Third Party that is Developing or commercializing an antibody, or another biological therapeutic molecule, directed to the Target in
the Field. The assigning Party shall provide the other Party with prompt written notice of any such assignment. Any permitted assignee
pursuant to clauses (b), (c) and (d) above shall assume all obligations of its assignor under this Agreement, and no permitted assignment
shall relieve the assignor of liability for its obligations hereunder. The LICENSOR shall not assign or otherwise transfer to any Affiliate
or any Third Party any ownership interest in or to any Licensed Know-How or Licensed Patent, unless (i)&nbsp;the LICENSOR&rsquo;s entire
business associated with the Product, including all Manufacturing rights relating to the Product, are assigned to such Affiliate or Third
Party and (ii) this Agreement is concurrently assigned therewith. Any attempted assignment in contravention of the foregoing shall be
void. Each Party shall be entitled to appoint subcontractors to carry out its obligations under this Agreement provided that such subcontractors
are engaged under contracts that are consistent with the terms of this Agreement and such subcontracting shall not relieve a Party of
its obligations under this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">19.3.</TD><TD STYLE="text-align: justify"><B>Severability. </B>Should one or more of the provisions of this Agreement become void or unenforceable
as a matter of law, then such provision will be ineffective only to the extent of such prohibition or invalidity, without invalidating
the remainder of this Agreement, and the Parties agree to substitute a valid and forceable provision therefor which, as nearly possible,
achieves the desired economic effect and mutual understanding of the Parties under this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">19.4.</TD><TD STYLE="text-align: justify"><B>Governing Law. </B>This Agreement and any issues, disputes or claims arising out of or in connection
with it (whether contractual or non-contractual in nature such as claims in tort, from breach of statute or regulation or otherwise) shall
be governed by, and construed in accordance with, the laws of England and Wales, without giving effect to any conflicts of laws provision
thereof or of any other jurisdiction that would produce a contrary result, except that issues subject to the arbitration clause and any
arbitration hereunder shall be governed by the applicable commercial arbitration rules and regulations.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">19.5.</TD><TD STYLE="text-align: justify"><B>Force Majeure. </B>Except with respect to delays or nonperformance caused by the negligent or intentional
act or omission of a Party, any delay or nonperformance by such Party (other than payment obligations under this Agreement) will not be
considered a breach of this Agreement to the extent such delay or nonperformance is caused by acts of God, natural disasters, acts of
the government or civil or military authority, fire, floods, epidemics, pandemics, quarantine, energy crises, war or riots or other similar
cause outside of the reasonable control of such Party (each, a <B>&ldquo;Force Majeure Event&rdquo;), </B>provided that the Party affected
by such Force Majeure Event will promptly begin or resume performance as soon as reasonably practicable after the event has abated. In
the event that the Force Majeure Event is a recognized widespread epidemic or pandemic (including the current COVID-19 pandemic) that
delays or renders impracticable or unsafe the performance by either or both of the Parties under this Agreement, the Parties will negotiate
in good faith appropriate modifications to this Agreement to allow performance hereunder that is consistent with the health and safety
of the Parties, their representatives, the general public and/or any participants in any Clinical Studies.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">19.6.</TD><TD STYLE="text-align: justify"><B>Waivers and Amendments. </B>The failure of any Party to assert a right hereunder or to insist upon
compliance with any term or condition of this Agreement shall not constitute a waiver of that right or excuse a similar subsequent failure
to perform any such term or condition by the other Party. No waiver shall be effective unless it has been given in writing and signed
by the Party giving such waiver. No provision of this Agreement may be amended or modified other than by a written document signed by
authorized representatives of each Party.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">19.7.</TD><TD STYLE="text-align: justify"><B>Relationship of the Parties. </B>Nothing contained in this Agreement shall be deemed to constitute
a partnership, joint venture, or legal entity of any type between LICENSOR and IMMEDICA, or to constitute one Party as the agent of the
other. Moreover, each Party agrees not to construe this Agreement, or any of the transactions contemplated hereby, as a partnership for
any tax purposes. Each Party shall act solely as an independent contractor, and nothing in this Agreement shall be construed to give any
Party the power or authority to act for, bind, or commit the other Party.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">19.8.</TD><TD STYLE="text-align: justify"><B>Successors and Assigns. </B>This Agreement shall be binding upon and inure to the benefit of the Parties
hereto and their respective successors and permitted assigns.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">19.9.</TD><TD STYLE="text-align: justify"><B>Notices. </B>All notices, consents, waivers, and other communications under this Agreement must be
in writing and will be deemed to have been duly given when: (a) delivered by hand (with written confirmation of receipt), (b) sent by
email (with confirmation of receipt), provided that a copy is also sent by an internationally recognized overnight delivery service (receipt
requested), or (c) when received by the addressee, if sent by an internationally recognized overnight delivery service (receipt requested),
in each case to the appropriate addresses and email addresses set forth below (or to such other addresses and email addresses as a Party
may designate by written notice):</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in">If to LICENSOR:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2in">Actinium Pharmaceuticals, Inc.<BR>
275 Madison Avenue, Suite 702<BR>
New York, New York, 10016<BR>
Email: [*]<BR>
Attention: General Counsel<BR>
With a copy addressed to the CFO at<BR>
Email: [*]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 188.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in">If to IMMEDICA:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2in">Immedica Pharma AB<BR>
Norrtullsgatan 15<BR>
SE 113 29 Stockholm<BR>
Sweden<BR>
Email: [*]<BR>
Attention: General Counsel<BR>
With a copy addressed to the CEO at<BR>
Email: [*]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 188.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">19.10.</TD><TD STYLE="text-align: justify"><B>Further Assurances. </B>IMMEDICA and LICENSOR hereby covenant and agree without the necessity of any
further consideration, to execute, acknowledge and deliver any and all such other documents and take any such other action as may be reasonably
necessary or appropriate to carry out the intent and purposes of this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">19.11.</TD><TD STYLE="text-align: justify"><B>No Third Party Beneficiary Rights. </B>This Agreement is not intended to and shall not be construed
to give any Third Party any interest or rights (including, without limitation, any third party beneficiary rights) with respect to or
in connection with any agreement or provision contained herein or contemplated hereby.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">19.12.</TD><TD><B>Entire Agreement.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40.75pt"></TD><TD STYLE="width: 35.3pt">(a)</TD><TD STYLE="text-align: justify">This Agreement, together with its Schedules, sets forth the entire agreement and understanding of the
Parties as to the subject matter hereof and supersedes all proposals, oral or written, and all other prior communications between the
Parties with respect to such subject matter.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40.8pt"></TD><TD STYLE="width: 35.55pt">(b)</TD><TD STYLE="text-align: justify">In the event of any conflict between a material provision of this Agreement and any Schedule hereto, the
Agreement shall control.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">19.13.</TD><TD STYLE="text-align: justify"><B>Interpretation. </B>The headings of Sections of this Agreement are not a part of this Agreement, but
are included for convenience of reference and shall not affect its meaning or interpretation. In this Agreement: (a) the word &ldquo;
including&rdquo; shall be deemed to be followed by the phrase &ldquo;without limitation&rdquo; or like expression; (b) the singular shall
include the plural and vice versa; and (c) masculine, feminine and neuter pronouns and expressions shall be interchangeable. Each accounting
term used herein that is not specifically defined herein shall have the meaning given to it under generally accepted cost accounting principles,
but only to the extent consistent with its usage and the other definitions in this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">19.14.</TD><TD STYLE="text-align: justify"><B>Counterparts. </B>This Agreement may be executed in two or more counterparts, each of which shall be
deemed an original, but all of which together shall constitute one and the same instrument. Delivery of an executed counterpart of a signature
page to this Agreement bye- mail of a .pdf attachment shall be effective as delivery of a manually executed counterpart of this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">19.15.</TD><TD STYLE="text-align: justify"><B>Cumulative Remedies. </B>No remedy referred to in this Agreement is intended to be exclusive, but each
shall be cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under law.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">19.16.</TD><TD STYLE="text-align: justify"><B>Waiver of Rule of Construction. </B>Each Party has had the opportunity to consult with counsel in connection
with the review, drafting and negotiation of this Agreement. Accordingly, any rule of construction that any ambiguity in this Agreement
shall be construed against the drafting Party shall not apply.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>[Signature page(s) follow]</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the Parties
intending to be bound have caused this Agreement to be executed by their duly authorized representatives as of the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Actinium Pharmaceuticals, Inc.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Immedica Pharma AB</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 35%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Sandesh Seth</FONT></TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 35%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Anders Edvell</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandesh Seth</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anders Edvell</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SCHEDULE A: PATENT RIGHTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">[*]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE B: PAYMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.9pt"></TD><TD STYLE="width: 35.1pt"><FONT STYLE="font-size: 10pt">1.</FONT></TD><TD><B>PAYMENTS</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-weight: normal">1.1.</FONT></TD><TD STYLE="text-align: justify">Upfront Payment. In consideration of the licenses and rights granted to IMMEDICA hereunder, IMMEDICA shall
pay to LICENSOR a one-time upfront, non-refundable and non-creditable payment of US$35,000,000 (in words: thirty five million US dollars).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.1pt"></TD><TD STYLE="width: 35.9pt">1.2.</TD><TD><B>Milestone Payments.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36.05pt"></TD><TD STYLE="width: 35.95pt">1.2.1.</TD><TD STYLE="text-align: justify">In further consideration of the licenses and rights granted to IMMEDICA hereunder, upon first achievement
of each Milestone set forth below, the corresponding non-creditable and non-refundable Milestone Payments shall be payable by IMMEDICA
to LICENSOR:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border: black 1pt solid; width: 59%; padding-right: 7.5pt; padding-bottom: 12pt; padding-left: 8.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>REGULATORY MILESTONES</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; width: 41%; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 8.3pt; padding-bottom: 12pt; padding-left: 9.8pt; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>MILESTONE PAYMENT</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 7.5pt; padding-bottom: 12pt; padding-left: 8.25pt; font-size: 10pt; text-align: justify; text-indent: 0.05pt">[*]</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 8.3pt; padding-bottom: 12pt; padding-left: 9.8pt; font-size: 10pt; text-align: center">[*]</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.1pt">For the purposes of the milestones
in the table above &ldquo;Indication&rdquo; shall mean a separate and distinct indication requiring a separate Regulatory Approval. Assuming
that the first Indication is conditioning treatment for bone marrow transplantation in AML, the second and third Indications shall not
be conditioning treatment for bone marrow transplant in AML.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.1pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border: black 1pt solid; width: 59%; padding-bottom: 12pt; padding-left: 34.5pt; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>COMMERCIAL MILESTONES</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; width: 41%; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 6.8pt; padding-bottom: 12pt; padding-left: 6pt; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>MILESTONE PAYMENT</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 4.15pt; padding-bottom: 12pt; padding-left: 28.6pt; font-size: 10pt; text-align: justify; text-indent: -17.45pt">[*]</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 6.8pt; padding-bottom: 12pt; padding-left: 6pt; font-size: 10pt; text-align: center">[*]</TD></TR>
  </TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.2.2.</TD><TD STYLE="text-align: justify">For the avoidance of doubt: (i) each Milestone Payment shall be payable only once upon the first achievement
of the applicable Milestone; (ii) satisfaction of a Milestone by an Affiliate of IMMEDICA or Sublicensee of IMMEDICA shall be deemed to
have been satisfied by IMMEDICA for purposes of this Section&nbsp;1.2 of <U>Schedule&nbsp;B;</U> (iii)&nbsp;the total Regulatory Milestones
shall not, in any circumstances, exceed [*]; and (iii) the total Commercial Milestones shall not, in any circumstances, exceed [*].</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.85pt">1.3.</TD><TD><B>Royalties.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 35.55pt">1.3.1.</TD><TD STYLE="text-align: justify"><B>Royalty Rate. </B>In consideration of the licenses and rights granted to IMMEDICA hereunder, IMMEDICA
will pay to LICENSOR Royalties on Net Sales of Product in the Territory, where such Royalties shall be calculated each Calendar Quarter
by multiplying the Net Sales for such Calendar Quarter by the applicable rate set forth in the table below, subject to the provisions
of this Section 1.3 of <U>Schedule&nbsp;B</U>. For clarity, the Royalties are inclusive of the cost of supply of Product under this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border: black 1pt solid; width: 59%; padding-bottom: 12pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>TIME PERIOD OF NET SALES</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; width: 41%; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-bottom: 12pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>ROYALTY RATE</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-bottom: 12pt; font-size: 10pt">[*]</TD>
    <TD STYLE="text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-bottom: 12pt; font-size: 10pt">[*]</TD></TR>
  </TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36.05pt">1.3.2.</TD><TD STYLE="text-align: justify"><B>One Royalty: </B>No more than one royalty payment shall be due under this Agreement with respect to
each sale of a Product in the Field in the Territory.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE C: THE SPECIFICATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">[*]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-style: normal"><B>SCHEDULE
D: PRESS RELEASE</B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> [*]</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>f10q0622ex10-2_actinium.htm
<DESCRIPTION>SUBLEASE AGREEMENT, DATED APRIL 28, 2022, BETWEEN ABN AMRO HOLDINGS USA LLC AND ACTINIUM PHARMACEUTICALS, INC.
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.2</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><U>EXECUTION COPY</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AGREEMENT OF SUBLEASE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>between</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ABN AMRO HOLDING USA LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>as Sublandlord</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>and</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ACTINIUM PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>as Subtenant</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Premises: Entire 23<SUP>rd</SUP> Floor</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>100 Park Avenue </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>New York, New York 10017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>AGREEMENT OF SUBLEASE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">THIS AGREEMENT OF SUBLEASE (this &ldquo;Sublease&rdquo;),
made and entered into as of the __ day of April, 2022, by and between ABN AMRO HOLDING USA LLC, a Delaware limited liability company,
having offices at 100 Park Avenue, New York, New York 10017 (&ldquo;Sublandlord&rdquo;), and ACTINIUM PHARMACEUTICALS, INC., a Delaware
corporation, having offices at 275 Madison Avenue, New York, New York 10016 (&ldquo;Subtenant&rdquo;).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>W</U> <U>I</U> <U>T</U> <U>N</U> <U>E</U> <U>S</U> <U>S</U> <U>E</U> <U>T</U> <U>H</U>:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">WHEREAS, SLG 100 Park LLC, (&ldquo;Landlord&rdquo;)
leased to Sublandlord&rsquo;s predecessor-in interest certain premises (the &ldquo;Original Premises&rdquo;) at 100 Park Avenue, New York,
New York 10017 (the &ldquo;Building&rdquo;), pursuant to a certain Lease Agreement (the &ldquo;Original Lease&rdquo;) dated as of July
10, 2009, as amended by a certain First Lease Modification and Additional Space Agreement (the &ldquo;First Amendment&rdquo;) dated as
of March 1, 2011, a certain Second Lease Modification and Additional Space Agreement (the &ldquo;Second Amendment&rdquo;) dated as of
January 31, 2014 and a certain Third Lease Modification and Additional Space Agreement (the &ldquo;Third Amendment&rdquo;) dated as of
March 31, 2017, (the Original Lease, as amended by the First Amendment, the Second Amendment and the Third Amendment, is hereinafter referred
to as the &ldquo;Lease&rdquo; and the premises currently leased by Sublandlord pursuant to the Lease are hereinafter referred to as the
&ldquo;Premises&rdquo;); and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">WHEREAS, Subtenant desires to sublease the entire
23<SUP>rd</SUP> floor portion of the Premises (the &ldquo;Subleased Premises&rdquo;) consisting of approximately 10,889 rentable square
feet, as more particularly described in &ldquo;Exhibit A&rdquo; which is attached to this Sublease as an integral part hereof, from Sublandlord,
and Sublandlord is willing to sublease the Subleased Premises to Subtenant, upon the terms and conditions hereinafter set forth;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">NOW, THEREFORE, in consideration of the foregoing
premises and the mutual covenants and obligations herein contained, the parties hereby agree as follows:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1. <U>Subleased Premises</U>. Sublandlord
hereby subleases the Subleased Premises to Subtenant, and Subtenant hereby hires the Subleased Premises from Sublandlord, upon and subject
to the terms and conditions set forth herein.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2. <U>Term of Sublease</U>. The term of this
Sublease (the &ldquo;Term&rdquo;) shall commence on the later of (a) the date upon which a written consent to this Sublease is issued
by Landlord following the signing of this Sublease by Sublandlord and Subtenant and (b) June 1, 2022 (the &ldquo;Commencement Date&rdquo;),
and shall terminate on July 30, 2027 (the &ldquo;Expiration Date&rdquo;), unless sooner terminated as provided herein. Sublandlord shall
deliver vacant possession of the Subleased Premises to Subtenant in their &ldquo;as is&rdquo; condition and broom clean on the Commencement
Date, and Subtenant shall accept such possession.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3. <U>Fixed
Rent</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a) Subject
to the increases stipulated in Paragraph 4(b) below, during the term of this Sublease, Subtenant shall pay Sublandlord fixed rent (&ldquo;Fixed
Rent&rdquo;) for the Subleased Premises in the amount of Five Hundred Ninety Eight Thousand Eight Hundred Ninety Five and 00/100 Dollars
($598,895.00) per annum, payable in advance in equal monthly installments of Forty Nine Thousand Nine Hundred Seven and 92/100 Dollars
($49,907.92) on or before the first day of each month.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b) Notwithstanding
anything to the contrary in the foregoing, Subtenant shall pay the first monthly installment of Fixed Rent upon the signing of this Sublease
by Subtenant.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c) The
Fixed Rent for any portion of a calendar month falling within the Term shall be prorated.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d) Fixed
Rent and all other amounts payable by Subtenant to Sublandlord under this Sublease (such other amounts are herein called &ldquo;Additional
Rent&rdquo;) shall be paid promptly when due, without notice or demand therefor, without deduction, abatement, counterclaim, or setoff
of any kind for any reason whatsoever.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(e) Fixed
Rent and Additional Rent shall be paid in U.S. Dollars and by wire transfer or ACH to such account of Sublandlord as Sublandlord may from
time to time designate by notice to Subtenant.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(f) Notwithstanding
the foregoing, provided that Subtenant is not then in default under this Sublease, the Fixed Rent payable for the first five (5) months
after the Commencement Date shall be abated at no cost or expense to Subtenant. If Subtenant during such five (5) month abatement period
defaults (after a failure to cure following any applicable notice and cure period) under this Sublease, the rent abatement for the balance
of such period shall be forfeited, and Subtenant shall pay to Sublandlord, within five (5) days after demand, the Fixed Rent which would
have been payable for the prior portion of the abatement period but for the abatement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4. <U>Additional Rent</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a) Except
as otherwise provided herein, during the term of this Sublease, Subtenant shall pay Sublandlord as Additional Rent all amounts payable
by Sublandlord to Landlord as Additional Rent for the Subleased Premises pursuant to the Lease as and when such amounts are due under
the Lease.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b) In
lieu of payments on account of &ldquo;Expenses&rdquo; and &ldquo;Real Estate Taxes&rdquo; (as those terms are defined in the Lease), the
parties agree that the Fixed Rent payable by Subtenant pursuant to Paragraph 3(a) above shall be increased annually at a compound rate
of two percent (2%) per annum, with the increases to take place on the first anniversary of the Commencement Date and on each subsequent
anniversary thereof.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c) During
the term of this Sublease, Subtenant shall pay Sublandlord for electricity supplied to the Subleased Premises at the rate of 105% of Landlord&rsquo;s
Cost (as defined in the Lease) of the Subtenant&rsquo;s usage as shown on the submeter located in Subleased Premises as and when payments
on account of electricity are due under the Lease.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d) In
the case of any of Additional Rent payments which are not due on a regular basis on the first day of the month, Sublandlord shall give
Subtenant fifteen (15) days&rsquo; prior written notice thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">5. <U>Subordination to and Incorporation of Lease,
Etc</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a) <U>Obligations</U>.
Subtenant confirms that it has read the Lease and is familiar with all of the terms and provisions set forth therein. Subject to the modifications
and exclusions set forth in this Sublease, the terms, provisions , covenants, stipulations, conditions, rights, obligations, remedies,
agreements and definitions contained in the Lease are incorporated herein by reference and are made a part hereof and shall, as between
Sublandlord and Subtenant (as if they were the &ldquo;Landlord&rdquo; and the &ldquo;Tenant,&rdquo; respectively, under the Lease and
as if the Subleased Premises were the Premises referred to in the Lease), constitute the terms of this Sublease as if herein set forth
at length, mutatis mutandis, except to the extent that they do not relate to the Subleased Premises or are inapplicable, inconsistent
with, or modified by the terms of this Sublease, and except as otherwise set forth herein. Subtenant agrees to observe, carry out, perform
and discharge the terms and provisions of the Lease as they relate to the Subleased Premises to the extent required to be observed, carried
out, performed or discharged by Sublandlord thereunder, except where inapplicable or inconsistent with the terms of this Sublease.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b) <U>Subordination,
Etc</U>. Subtenant hereby agrees that (i) this Sublease is and shall remain in all respects subject and subordinate to the Lease and to
any matters to which the Lease is or shall be subordinate, (ii) except to the extent otherwise expressly permitted by this Sublease, Subtenant
will occupy the Subleased Premises in accordance with the terms of the Lease, will maintain the Subleased Premises in accordance with
the provisions of the Lease as though it were the &ldquo;Tenant&rdquo; thereunder and will not do or cause to be done, or suffer any act
or omit to do, any act which might result in a violation of or a default under any of the terms, conditions, covenants or agreements of
the Lease.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c) <U>Conflicting
Terms</U>. Except as otherwise specifically provided herein, in the event that any term and/or condition of this Sublease shall conflict
with, or be inconsistent with, any term and/or condition of the Lease, this Sublease will govern, unless such term and/or condition would
constitute a default under or breach of the Lease, in which case the Lease will govern. Subtenant shall not take or suffer any action
which would constitute a default under, or be a violation of, the Lease.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d) <U>Excluded
Articles</U>. The following provisions of the Lease shall be deemed to be excluded from this Sublease: (i) Original Lease &ndash; Section
1.01; Article 2; Article 3; Article 5; Article 12; Sections 13.01 through 13.03 and Section 3.05 (as they provide for Nondisturbance Agreements);
Section 13.11; Section 13.12; Article 17; Article 18; Article 22; Section 25.01 (second sentence); Article 27; Article 29; Article 31;
Article 40; Article 48; Article 50; Article 51; Article 52; Exhibit A; Exhibit B; Exhibits F-1 and F-2; Exhibit I; Exhibit J and Exhibit
K; (ii) First Amendment &ndash; Sections 3.2 through 3.6; Articles 4 through 6; Section 7.1 (last sentence); Articles 8 through 12; and
Exhibits B through D; (iii) Second Amendment &ndash; Articles 3 through 13; and Exhibits A through D; and (iv) Third Amendment &ndash;Articles
3 through 13; Exhibits A through Exhibit C.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(e) <U>Termination
of Lease</U>. In the event that the term of the Lease is terminated prior to the Expiration Date, this Sublease shall automatically cease
and terminate on the date of such termination. In the event of such termination, Sublandlord shall return to Subtenant that portion of
Fixed Rent and Additional Rent paid in advance by Subtenant, if any, pro-rated as of the date of such termination. Sublandlord agrees
that, without the prior written consent of Subtenant, it will not voluntarily agree with Landlord to terminate the Lease with respect
to the Subleased Premises prior to the Expiration Date.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(f) <U>Entry
and Inspection</U>. Sublandlord shall have the right to enter and inspect the Subleased Premises pursuant to the applicable provisions
of the Lease during business hours (except in an emergency) and upon notice (which may be given orally). Sublandlord agrees that Subtenant
and its agents may have access to the Subleased Premises prior to the Commencement Date, provided that it gives Sublandlord notice of
each proposed access at least twenty-four (24) hours in advance. Such access shall be only for taking measurements and other planning
purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(g) <U>Services</U>.
Subtenant shall be entitled to the services, utilities and repairs which Landlord is obligated to furnish or make to Sublandlord with
respect to the Subleased Premises pursuant to the terms of the Lease, but Sublandlord shall have no obligation to make any repairs or
provide such utilities or services. Sublandlord shall in no event be liable to Subtenant nor shall the obligations of Subtenant thereunder
be impaired, or the performance thereof be excused, because of any failure or delay on the part of Landlord in furnishing such services
or in making such repairs unless such failure or delay results from a default by Sublandlord under the Lease. If Landlord shall default
in any of its obligations to perform services with respect to the Subleased Premises, Sublandlord, at the reasonable cost of Subtenant,
will reasonably assist Subtenant&rsquo;s efforts to obtain such services from Landlord.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(h) <U>Consents
and Notices</U>. In all provisions of this Sublease (including provisions of the Lease incorporated hereby) requiring the approval or
consent of Sublandlord, Subtenant shall be required to obtain the approval or consent of Sublandlord as well as the approval or consent
of Landlord. At the request of Subtenant, Sublandlord shall promptly apply to Landlord for any such approval or consent. In all provisions
of this Sublease (including provisions of the Lease incorporated hereby) requiring that notice be given, Subtenant shall be required to
give notice to both Sublandlord and Landlord. Notwithstanding anything to the contrary set forth in this Sublease, any covenants, representations
or other undertakings of Landlord under the Lease shall not be deemed to be made by, or otherwise constitute obligations of, Sublandlord
under this Sublease.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(i) <U>Landlord&rsquo;s
Consent to Sublease</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(A) Sublandlord
shall, promptly after execution of this Sublease by both parties, submit a copy of same to Landlord and shall use all reasonable efforts
to obtain Landlord&rsquo;s consent to this Sublease; provided, however, that Sublandlord shall not be required to make any payment or commence
any action or proceeding in order to obtain Landlord&rsquo;s consent to this Sublease and shall not in any event be liable to Subtenant for
any failure to obtain same (as long as Sublandlord shall have used all reasonable efforts as aforesaid to obtain Landlord&rsquo;s consent to
this Sublease). Subtenant shall fully cooperate with Sublandlord in order to obtain Landlord&rsquo;s consent to this Sublease, including, but
not limited to, promptly supplying such financial, business or other information or documentation as Landlord may reasonably request of
Sublandlord in connection with this Sublease. In the event that Landlord&rsquo;s consent to this Sublease is not obtained within thirty five
(35) days after the date of this Sublease, either party may terminate this Sublease at any time prior to the issuance of such consent
by giving written notice of termination to the other party. If this Sublease is terminated pursuant to the immediately preceding sentence
of this Paragraph 5(i)(A), Sublandlord shall promptly return to Subtenant the first monthly installment of Fixed Rent which was paid by
Subtenant pursuant to Paragraph 3(b) above and the Security Deposit which was submitted by Subtenant pursuant to Paragraph 19(a) below
and, except as aforesaid, neither party shall have any further obligation to the other party under this Sublease.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(B) Landlord&rsquo;s consent
to this Sublease shall not be deemed or construed to modify, amend or affect the terms and provisions of the Lease, or Sublandlord&rsquo;s obligations
thereunder, which shall continue to apply to the Premises, including the Subleased Premises, and the occupants thereof, as if the Sublease
had not been made.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">6. <U>Use
of Subleased Premises: Quiet Enjoyment</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a) Subtenant
covenants that it will use and occupy the Subleased Premises solely for the purposes expressly permitted by the Lease.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b) As
long as Subtenant pays, when due, all Fixed Rent and Additional Rent due hereunder and performs and observes all of the terms, covenants
and conditions of this Sublease and the Lease, Subtenant shall have, hold and enjoy the Subleased Premises peaceably and quietly during
the Term hereof without hindrance or molestation by Sublandlord, or any party claiming through or under Sublandlord, subject to the terms
and conditions of this Sublease and the Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">7. <U>Improvements</U>.
Subtenant shall be entitled to make alterations, improvements and other changes (collectively hereinafter referred to as &ldquo;Sublease
Improvements&rdquo;) to the Subleased Premises in accordance with the applicable provisions of the Lease and this Sublease, including
the installation of supplemental air conditioning units and/or handling equipment (it being understood that Sublandlord makes no representation
as to the availability of condenser water for any such supplemental units for purchase from Landlord). All such Sublease Improvements
shall be subject to the prior written consent of Sublandlord and Landlord. All Sublease Improvements shall be performed by Subtenant at
its sole cost and expense. Subtenant&rsquo;s rights and obligations with respect to Sublease Improvements shall be governed and limited by the
relevant provisions of the Lease and this Sublease. Subtenant shall reimburse Sublandlord, within ten (10) days after written demand,
for all reasonable actual out-of-pocket costs incurred by Sublandlord for reviewing Subtenant&rsquo;s plans for any proposed Sublease
Improvement and for assisting Subtenant to obtain Landlord&rsquo;s consent thereto.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">8. <U>Default
by Subtenant</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a) The
following shall constitute events of default (each an &ldquo;Event of Default&rdquo;):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> (i) if (A) Subtenant shall fail to pay any
Fixed Rent or Additional Rent on the due date thereof and such default shall continue for a period of seven (7) days after notice by Sublandlord
to Subtenant of such default (provided, however, that Sublandlord shall not be required to deliver such notice more than two (2) times
in any twelve (12) month period, it being understood that any further failure to pay any Fixed Rent or Additional Rent on the due date
thereof within such twelve (12) month period shall constitute an immediate Event of Default), or (B) Subtenant shall fail to comply with
any term, provision or covenant of this Sublease or any applicable term, provision or covenant of the Lease, or Subtenant shall violate
any rules and regulations now or hereafter established for the operation of the Building and Subtenant shall fail to remedy such failure
within fifteen (15) days after written notice from Sublandlord, or if such failure complained of shall be of a nature that the same cannot
be completely cured and remedied within said fifteen (15) day period, and Subtenant shall not (1) promptly upon the giving by Sublandlord
of such notice, advise Sublandlord of Subtenant&rsquo;s intention to institute all steps necessary to remedy such situation, (2) promptly institute
and thereafter diligently pursue all steps necessary to remedy the same and (3) effect such remedy within a reasonable time (not to exceed
sixty (60) days) after the date of the giving of said notice by Sublandlord and in any event prior to such time as would either (y) subject
Landlord, Sublandlord, Sublandlord&rsquo;s agents or any mortgagee or ground lessee to civil or criminal liability or prosecution for a crime,
or (z) cause a default under any applicable mortgage or ground lease; or</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> (ii) if (A) any petition is filed by Subtenant
under any provision of Federal or state bankruptcy laws or other statute whether domestic or foreign involving creditors&rsquo; rights or the
insolvency of debtors or any such petition is filed against Subtenant and Subtenant fails to secure a dismissal or stay thereof within
thirty (30) days, or (B) Subtenant shall become insolvent or make an assignment for the benefit of creditors, or (C) a receiver is appointed
for all or substantially all of the assets of Subtenant and Subtenant fails to secure a dismissal or stay thereof within sixty (60) days,
or (D) all or a material portion of the Subleased Premises shall be abandoned, deserted or vacated.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b) Upon
the occurrence of an Event of Default, Sublandlord shall have the right, at its option, to do and perform any one or more of the following,
in addition to, and not in limitation of any other remedy or right permitted it by law, by this Sublease or by the Lease:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(i) terminate
this Sublease, in which event Subtenant shall immediately surrender the Subleased Premises to Sublandlord, but if Subtenant shall fail
to do so, Sublandlord may, without prejudice to any other right or remedy Sublandlord may have, either by law or under this Sublease or
otherwise, obtain possession or rent in arrears or damages for breach of contract, enter upon the Subleased Premises and expel or remove
Subtenant and Subtenant&rsquo;s personal property, with or without force and without being liable to Subtenant, and Subtenant agrees to indemnify
and hold Sublandlord harmless for all losses or damage which Sublandlord may suffer by reason of such termination, whether through inability
to relet the Subleased Premises or through decrease in rent or by damage to the Subleased Premises, or otherwise, or</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(ii) enter
the Subleased Premises and remove Subtenant and its personal property therefrom without terminating this Sublease or being liable to Subtenant
in any manner whatsoever for such acts, and, at Sublandlord&rsquo;s option, relet the Subleased Premises as the agent of Subtenant and receive
rent therefor, and in such event Subtenant shall be liable on a monthly basis when rent is otherwise due and payable to Sublandlord for
any deficiency which may arise by reason of such reletting during the remainder of the Term of this Sublease, but shall not be entitled
to any surplus so arising. In the event of a conflict between the provisions of this Paragraph 8 and the provisions of the Lease, the
provisions of this Paragraph 8 shall prevail.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">9. <U>Subletting
and Assignment</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a) Subtenant
shall not assign, mortgage, pledge, encumber or in any manner transfer this Sublease or any part thereof nor sublet or suffer the Subleased
Premises or any part thereof to be used by others, except as expressly permitted by this Sublease and the Lease. It is understood that
a change in control of Subtenant shall be deemed to constitute an assignment of this Sublease. The provisions of the Lease relating to
assignment and subletting shall be deemed to be incorporated into this Sublease.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b) If
this Sublease is assigned in violation of the provisions of this Sublease, Sublandlord may and is hereby empowered to collect rent from
the assignee. In such event, Sublandlord may apply the net amount received by it to the Fixed Rent, Additional Rent or any other payments
herein reserved or provided for, and no such collection shall be deemed a waiver of the covenant herein against assignment, mortgage,
pledge or encumbrance, or an acceptance of the assignee as a tenant or subtenant under this Sublease or a release of Subtenant from the
further performance of its covenants herein. If the Subleased Premises or any part thereof is sublet or occupied by others in violation
of the provisions of this Sublease, Sublandlord is hereby empowered to collect rent from the subtenant or other occupant, and to apply
the same to the curing of any default hereunder in any order of priority Sublandlord may elect, any unexpended balance to be applied by
Sublandlord against any rental or other obligations subsequently becoming due. The making of any assignment, mortgage, pledge, encumbrance
or subletting in whole or in part, and whether or not in violation of the provisions of this Sublease, shall not operate to relieve Subtenant
from its obligations under this Sublease and, notwithstanding any such assignment, mortgage, pledge, encumbrance or subletting, Subtenant
shall remain liable for the payment of all Fixed Rent, Additional Rent and other charges and for the due performance of all the covenants,
agreements, terms and provisions of this Sublease until the end of the Term. Each and every assignee, whether as assignee or as successor
in interest of Subtenant or as assignee or successor in interest of any assignee, shall immediately be and become and remain liable jointly
and severally with Subtenant and with each other for the payment of the Fixed Rent, Additional Rent and other charges payable under this
Sublease and for the due performance of all the covenants, agreements terms and provisions of this Sublease on the part of Subtenant to
be paid and performed until the end of the Term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c) Any
proposal by Subtenant to assign this Sublease or to further sublet the Subleased Premises or any portion thereof shall be subject to the
prior written consent of Landlord and Sublandlord. Sublandlord&rsquo;s consent to a proposed assignment or subletting of the Subleased
Premises shall be deemed to have been granted provided that Landlord has given its consent therefor. Subtenant shall reimburse Sublandlord
for all reasonable out-of-pocket expenses incurred in connection with a proposed assignment or subletting.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">10. <U>Liability
Insurance</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a) Neither
Sublandlord nor its successors, assigns, employees or agents shall be liable for any loss of or damage to property of Subtenant or Subtenant&rsquo;s
subtenants, assigns, employees, agents or visitors, except for loss or damage resulting from Sublandlord&rsquo;s gross negligence or willful
misconduct. With respect to the Subleased Premises, Sublandlord, its successors, assigns, employees and agents shall not be liable for
any injury or damage to persons or property except for loss or damage resulting from the gross negligence or willful misconduct of Sublandlord,
its successors, assigns, employees and agents.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b) Subtenant
shall maintain with respect to the Subleased Premises comprehensive general public liability insurance, property insurance and other insurance
in the manner and with the minimum limits set forth in the Lease, with insurance companies qualified to do business in the State of New
York and otherwise meeting the standards set forth in the Lease, insuring Subtenant, Sublandlord, Landlord and any other parties required
in accordance with the Lease as named insureds, against, inter alia, claims and liabilities for bodily injury or death to persons, and
damage to property. Each party shall look exclusively to any insurance carried by it pursuant to this Sublease and the Lease for loss
or damage to property resulting from the negligence of the other party or its agents, servants, employees, contractors, invitees or licensees,
and, to the extent permitted by law, Sublandlord and Subtenant each hereby releases and waives all right of recovery against the other
or anyone claiming through or under each of them by way of subrogation or otherwise, provided that such waivers of liability are permitted
and are available under both Sublandlord&rsquo;s and Subtenant&rsquo;s policies of insurance or such waivers are approved by their insurance carriers.
Each party agrees to pay the added cost, if any, of obtaining such approval from its insurance carrier. Subtenant shall deliver certificates
of insurance to Sublandlord with respect to all insurance required under this Sublease and the Lease on or before the signing of this
Sublease by Subtenant. Each of Subtenant&rsquo;s policies of insurance shall provide that such policy may not be materially changed, amended,
canceled or allowed to lapse except upon thirty (30) days&rsquo; prior notice to Sublandlord, Landlord and any other parties required in accordance
with the Lease. Such insurance shall be subject to Sublandlord&rsquo;s approval as to form, content, coverage and expiration dates, which approval
shall be deemed granted if not refused within fifteen (15) days after delivery of the certificates of insurance to Sublandlord.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">11. <U>Indemnification</U>.
Except as provided in Paragraph 10 hereof, Subtenant shall indemnify and hold harmless Sublandlord from and against all claims, losses,
costs, damages, expenses and liabilities (including, but not limited to, the costs of legal proceedings and reasonable attorneys&rsquo; fees
and disbursements) which Sublandlord may incur, pay or have asserted against it by reason of any injuries to persons occurring in, on
or about the Subleased Premises caused by the acts or omissions of Subtenant, its agents, employees, guests or invitees or by reason of
any breach, failure or default hereunder on Subtenant&rsquo;s part, including any breach or default which results in a breach of or possible
termination or forfeiture of the Lease. In the event of a conflict between the provisions of this Paragraph 11 and any provision of the
Lease, the provisions of this Paragraph 11 shall prevail. The provisions of this Paragraph 11 shall survive the expiration or earlier
termination of this Sublease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">12. <U>Subtenant&rsquo;s
Rights</U>. Notwithstanding anything to the contrary herein set forth, Subtenant shall in no case have any rights in respect of the Subleased
Premises greater than the rights of Sublandlord under the Lease.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">13. <U>Possession,
Care and Condition of Subleased Premises</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a) <U>Possession
and Condition</U>. Subtenant acknowledges that it has examined the Subleased Premises and that it is leasing the Subleased Premises in
their &ldquo;as is&rdquo; condition. Sublandlord shall have no obligation to perform any work or supply any materials to prepare the Subleased
Premises for Subtenant&rsquo;s occupancy. Subject to Paragraph 7 above, Subtenant shall, at its sole cost and expense, make any alterations
and improvements that it requires to prepare the Subleased Premises for its occupancy thereof. Sublandlord has made no representation
or warranty concerning the condition of the Subleased Premises except as expressly set forth in this Sublease. Notwithstanding the forgoing,
Sublandlord shall grant to Subtenant a work allowance in the amount of One Hundred Thousand and 00/100 Dollars ($100,000.00) (the &ldquo;Allowance&rdquo;)
to be utilized by Subtenant for the hard and soft costs of the work to be done by Subtenant to prepare the Subleased Premises for its
occupancy (&ldquo;Subtenant&rsquo;s Work&rdquo;). Subtenant&rsquo;s Work shall be deemed to be Subtenant Improvements for purposes of
this Sublease, and the terms and provisions of Paragraph 7 above shall be applicable thereto. Upon completion of Subtenant&rsquo;s Work,
Subtenant&rsquo;s shall submit to Sublandlord: (a) copies of bills and receipts indicating that all contractors, sub-contractors and soft
cost providers performing or supporting the performance of Subtenant&rsquo;s Work have been paid in full, (b) the documents identified
in Section 8.1 (a)(iii), items (iii), (iv) and (v) of the First Amendment and (c) the document identified in Section 8.1 (d), item (x)
of the First Amendment. Within twenty (20) days after submission of the foregoing items and a requisition showing the total amount expended
on Subtenant&rsquo;s Work, and provided that Subtenant is not then in default under this Sublease, Sublandlord shall pay to Subtenant
the lesser of the amount indicated in Subtenant&rsquo;s requisition and the amount of the Allowance.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b) <U>Included
Property</U>. Sublandlord shall leave the furniture, fixtures and equipment which are presently situated in the Subleased Premises, and
which are identified in Exhibit &ldquo;B&rdquo; which is attached hereto as an integral part hereof (the &ldquo;Included Property&rdquo;)
in the Subleased Premises. Subtenant shall take possession of the Included Property in its &ldquo;as is&rdquo;, &ldquo;where is&rdquo;
condition. Sublandlord makes no representations or warranties with respect to the Included Property. The Included Property shall remain
the property of Sublandlord, and Subtenant shall exercise the care of a prudent custodian in its use and care of the Included Property
during the Term. Notwithstanding the foregoing, if this Sublease has not then been terminated in accordance with the terms hereof, then,
on July 1, 2027 title to the Included Property shall, without any action on the part of the Sublandlord or Subtenant, be transferred to
Subtenant and Subtenant shall thereupon be the owner of the Included Property for all purposes. Thereafter, upon the expiration of the
Term, Subtenant at its sole cost and expense, shall remove the Included Property from the Subleased Premises. If Subtenant shall fail
to remove any of the Included Property, Sublandlord may arrange for such removal and the costs of such removal plus an incremental amount
of fifteen percent (15%) shall be paid to Sublandlord by Subtenant within fifteen (15) days after demand therefor. In addition to the
Included Property, Sublandlord shall leave the existing supplemental air conditioning unit (the &ldquo;A/C Unit&rdquo;) which services
the IDF closet in the Subleased Premises for Subtenant&rsquo;s use. Sublandlord makes no representation as to the condition of the Unit.
It shall be the responsibility of Subtenant to maintain the Unit, to carry a maintenance contract covering the Unit and to replace the
Unit, if necessary.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c) <U>Restoration
of Subleased Premises</U>. On the date upon which the term hereof shall expire and come to an end, whether by expiration, by lapse of
time or otherwise, Subtenant, at its sole cost and expense, shall quit and surrender the Subleased Premises to Sublandlord in good order
and condition and broom clean. Prior to such date, Subtenant, at its sole cost, shall remove all of the Sublease Improvements it (or such
portion thereof as shall be required by Landlord) and otherwise restore the Subleased Premises to its condition on the Commencement Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d) <U>Freight
Elevator</U>. Sublandlord shall pay for or reimburse Subtenant for up to ten (10) hours of overtime freight elevator usage for Subtenant&rsquo;s
move-in to the Subleased Premises.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(e) <U>Holdover</U>.
Notwithstanding anything to the contrary provided elsewhere in this Sublease, if Subtenant holds over in the Subleased Premises after
the Expiration Date, Subtenant shall pay to Sublandlord within five (5) days after demand in each case one hundred twenty five percent
(125%) of all amounts that Sublandlord is required to pay Landlord on account of such holdover. In addition, Subtenant shall be liable
to Sublandlord for all damages (including consequential damages), costs and expenses (including attorneys&rsquo; fees and expenses) incurred
by Sublandlord as a consequence of the holdover.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(f) <U>Obligation
to Repair</U>. Subtenant shall take good care of the Subleased Premises and the fixtures and appurtenances therein. All damage or injury
to the Subleased Premises and to its fixtures, appurtenances and equipment or to the Building caused by Subtenant&rsquo;s moving of Subtenant&rsquo;s
property in or out of the Building or by Subtenant&rsquo;s installation or removal of furniture, fixtures or other property, or resulting from
Subtenant&rsquo;s negligent acts, omissions or misconduct shall be promptly repaired by Subtenant, at its sole cost and expense, to the reasonable
satisfaction of Sublandlord and Landlord. If a request is made by Landlord for Sublandlord to make reasonable repairs the Subleased Premises
in accordance with the Lease, Subtenant shall undertake such repair at its cost in accordance with the Lease. All of said repairs required
to be made by Subtenant shall be in quality and class equal to the original work or installation and shall be done in a good and workmanlike
manner. If Subtenant fails to make such repairs, the same may be made by Sublandlord or Landlord at the expense of Subtenant and all sums
so spent and expenses incurred by Sublandlord plus an incremental amount of fifteen percent (15%) of such sums shall be collectible as
Additional Rent and shall be paid by Subtenant to Sublandlord within five (5) days after rendition of a bill or statement therefor.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">14. <U>Notices</U>.
Notices, demands and any other communications hereunder shall be in writing and shall be given or made by personal delivery, by overnight
delivery by a recognized national courier service or by certified mail, return receipt requested, addressed to the parties at the addresses
hereinabove set forth (and, in the case of Sublandlord, addressed to the attention of its Chief Operating Officer with a copy addressed
to the attention of its General Counsel), or such other address which either party may hereafter designate for such purpose by a written
notice. Notices, demands and other communications shall be deemed given (a) if delivered by personal delivery or by overnight courier
service, on the date of delivery or rejection of delivery, or (b) if sent by certified mail, upon receipt or rejection of such delivery.
Sublandlord shall, within five (5) days after receipt thereof, give to Subtenant a copy of each notice or demand received from Landlord
relating to the Subleased Premises, and Subtenant shall, within five (5) days after receipt thereof, give to Sublandlord a copy of each
notice or demand received from Landlord relating to the Subleased Premises.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">15. <U>Miscellaneous</U>.
This Sublease contains the entire agreement of the parties with respect to the transactions contemplated hereby, supersedes all prior
agreements or understandings between the parties (except as otherwise provided herein) and may not be changed or modified in any way unless
such change or modification is in writing and signed by the parties hereto. Neither Sublandlord nor Subtenant has made any representations
or warranties with respect to this Sublease except as set forth herein. If any provision of this Sublease shall be held to be invalid
or unenforceable in any respect, the validity or enforceability of the remaining portions of this Sublease shall be unaffected thereby.
This Sublease shall be binding upon, inure to the benefit of and be enforceable by the parties hereto and their respective successors
and assigns. The headings in this Sublease are for convenience only and shall not be used in construing the intentions of the parties.
This Sublease shall be governed by and construed in accordance with the laws of the State of New York. Sublandlord and Subtenant each
represents that it has full right and authority to enter into this Sublease and that the officer signing this Sublease on its behalf is
authorized to do so. This Sublease may be signed in counterparts, each of which shall constitute an original but all of which, when taken
together, shall constitute one instrument. Faxed signatures, emailed copies of signatures and signatures exchanged via PDF or other electronic
means shall be binding to the same extent as original signatures. Sublandlord and Subtenant each waives, to the extent permitted by law,
the right to a jury trial in any action or legal proceeding between the parties arising out of this Sublease or Subtenant&rsquo;s occupancy
of the Subleased Premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">16. <U>Attorneys&rsquo;
Fees</U>. If either party hereto is made or becomes a party to any litigation commenced by or against the other party involving the enforcement
of any of the rights and remedies of such party, or arising on account of the default of the other party in the performance of such party&rsquo;s
obligations hereunder, then the prevailing party in such litigation, or the party becoming involved in such litigation because of a claim
against such other party, as the case may be, shall be reimbursed by the other party for all costs and reasonable attorneys&rsquo; fees incurred
by such party in such litigation.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">17. <U>Interest;
Late Charges</U>. Subtenant shall, on demand, pay interest on any Fixed Rent, Additional Rent and other amounts payable by Subtenant to
Sublandlord pursuant hereto if any such amount is received after its due date. Interest for each calendar month or portion thereof shall
be at the rate of one and one-half percent (1&frac12;%) of the overdue amount (but in no event in excess of the maximum rate permitted
by law). In addition, if any Fixed Rent, Additional Rent or other amount payable by Subtenant to Sublandlord pursuant hereto is not paid
within ten (10) days after its due date, Subtenant shall pay to Sublandlord a late charge of five cents ($.05) for each Dollar of the
overdue amount to defray Sublandlord&rsquo;s administrative costs for handling the late payment. The right of Sublandlord to collect interest
and late charges shall be without derogation of any other right of Sublandlord hereunder, the amounts payable under this Paragraph 17
shall be deemed to be Additional Rent for purposes of this Sublease.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">18. <U>Brokerage</U>.
Sublandlord and Subtenant each represents and warrants to the other that it has had no dealings or communications with any broker or agent
in connection with this Sublease other than Jones Lang LaSalle Brokerage, Inc. and Lee &amp; Associates (the &ldquo;Brokers&rdquo;). In
the event any broker or agent other than the Brokers claims that it is entitled to a commission due to the acts of Sublandlord or Subtenant,
such party covenants and agrees to pay, hold harmless and indemnify the other party from and against any and all costs, expenses or liability
incurred by the other party in connection with or relating to any claims for compensation, commissions and fees asserted by such broker
or agent with respect to this Sublease or the negotiation hereof (including, without limitation, the cost of legal fees and related expenses
incurred in connection with defending against such claims). Sublandlord agrees to pay the commissions owing to the Brokers pursuant to
a separate agreement or agreements.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">19. <U>Security</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a) As
security for the full and punctual performance by Subtenant of all of the terms and conditions of this Sublease, Subtenant shall submit
to Sublandlord on or before the date that it signs this Sublease and shall maintain throughout the term of this Sublease a security deposit
in the amount of Two Hundred Ninety Nine Thousand Four Hundred Forty Seven and 50/100 Dollars ($299,447.50) (the &ldquo;Security Deposit&rdquo;).
The Security Deposit shall take the form of an irrevocable standby letter of credit in form and substance satisfactory to Sublandlord
(the &ldquo;Letter of Credit&rdquo;) issued by a commercial bank which is a member of the New York Clearing House Association or another
commercial bank which is acceptable to Sublandlord and shall have an initial term which is not less than one (1) year from its date of
issuance. The Letter of Credit shall provide that Sublandlord may draw thereunder by the submission of only a sight draft and, unless
otherwise agreed by Sublandlord, shall permit Sublandlord to make presentment thereunder at an office of the bank located in the City
of New York. In each case, the Letter of Credit shall further provide that Sublandlord may draw the full amount thereof if it is not extended
for an additional one (1) year period at least forty five (45) days prior to its stated expiration date. The final Letter of Credit issued
hereunder shall have an expiration date which is no early than ninety (90) days after the Expiration Date. Each Letter of Credit shall
be in form and substance fully satisfactory to Sublandlord.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b) Whenever
Subtenant is in default under this Sublease and such default has continued after any applicable written notice has been delivered to Subtenant
and beyond any applicable cure period or whenever Sublandlord has obtained a judgment against Subtenant based on a claim arising out of
this Sublease, Sublandlord may draw the amount of such default or judgment, as the case may be, from the Security Deposit, to the extent
required for the payment of any Fixed Rent or Additional Rent or for any sum which Sublandlord may expend or be required to expend by
reason of Subtenant&rsquo;s default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c) In
the case of every use, application or retention of the Security Deposit, Subtenant shall, within three (3) days after demand, replenish
the Security Deposit to the amount which Subtenant is required to maintain hereunder and the failure to do so shall constitute an Event
of Default hereunder without any notice or cure period.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d) In
lieu of the Letter of Credit, Subtenant shall have the option of submitting the Security Deposit in cash on or before the date that it
signs this Sublease; provided, however, that, in such case, Subtenant shall substitute a Letter of Credit which meets the requirements
of Paragraph 19(a) above for the cash Security Deposit within sixty (60) days after the date of this Sublease and the failure of Subtenant
to do so shall constitute an Event of Default hereunder without any notice or cure period. Sublandlord shall return the cash Security
Deposit to Subtenant immediately after its receipt of the Letter of Credit.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">20. <U>Consent
to Jurisdiction</U>. Each of the parties hereto hereby irrevocably consents and agrees that any legal action or proceeding with respect
to this Sublease may be brought in any of the Federal or state courts having subject matter jurisdiction located in the Borough of Manhattan,
The City of New York, and, by its execution and delivery of this Sublease, each such party hereby (a) accepts the non-exclusive jurisdiction
of the aforesaid courts, (b) irrevocably agrees to be bound by any final judgment (after any appeal) of any such court with respect to
this Sublease, and (c) irrevocably waives, to the fullest extent permitted by law, any objection which it may now or hereafter have to
the laying of venue of any suit, action or proceeding with respect to this Sublease brought in any such court, and further irrevocably
waives, to the fullest extent permitted by law, any claim that any such suit, action or proceeding brought in any such court has been
brought in an inconvenient forum.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">21. <U>Representations
and Warranties</U>. Sublandlord hereby represents and warrants to Subtenant that, as of this date, Sublandlord has not received from Landlord
or given to Landlord any notice of a default under the Lease and, to the best of its knowledge, no default under the Lease currently exists.
Further, Sublandlord represents and warrants to Subtenant that, as of this date, the Lease is in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF, this Sublease has been executed
by the duly authorized representatives of the parties as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SUBLANDLORD:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ABN AMRO HOLDING USA LLC</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8239;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SUBTENANT:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ACTINIUM PHARMACEUTICALS, INC.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SUBTENANT ACKNOWLEDGEMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">STATE OF NEW YORK</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="width: 70%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ss.:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COUNTY OF-NEW YORK </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On the __ day of _____________, 2022, before me,
the undersigned, a Notary Public in and for said state, personally appeared ___________________________ who proved to me on the basis
of satisfactory evidence to be the individual whose name is subscribed to the within instrument and acknowledged to me that he (she) executed
the same in his (her) capacity , and that by his (her) signature on the instrument, the individual, or the person upon behalf of which
the individual acted, executed the instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notary Public</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>f10q0622ex31-1_actinium.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>18 U.S.C. SECTION 1350,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO SECTION 302 OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Sandesh Seth, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">I have reviewed this Form 10-Q of Actinium Pharmaceuticals,
Inc.;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the registrant as of, and for, the periods presented in this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify">I am responsible for establishing and maintaining disclosure
controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as
defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">a)</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which
this report is being prepared;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">b)</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting, or
caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">c)</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the registrant&rsquo;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">d)</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the registrant&rsquo;s
internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant&rsquo;s internal control over financial reporting; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: justify">I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board
of directors (or persons performing the equivalent functions):</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">a)</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
ability to record, process, summarize and report financial information; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">b)</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management
or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: August 12, 2022</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Sandesh Seth</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandesh Seth</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman and Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Duly Authorized Officer, <BR>
Principal Executive Officer)</FONT>&#8239;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-indent: 0.5in"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>f10q0622ex31-2_actinium.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL FINANCIAL AND ACCOUNTING
OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>18 U.S.C. SECTION 1350,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO SECTION 302 OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Steve O&rsquo;Loughlin, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">I have reviewed this Form 10-Q of Actinium Pharmaceuticals,
Inc.;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the registrant as of, and for, the periods presented in this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify">I am responsible for establishing and maintaining disclosure
controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as
defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">a)</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which
this report is being prepared;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">b)</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting, or
caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">c)</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the registrant&rsquo;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">d)</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the registrant&rsquo;s
internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant&rsquo;s internal control over financial reporting; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: justify">I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board
of directors (or persons performing the equivalent functions):</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">a)</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
ability to record, process, summarize and report financial information; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">b)</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management
or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: August 12, 2022</FONT></TD>
    <TD STYLE="width: 4%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Steve O&rsquo;Loughlin</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steve O&rsquo;Loughlin</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Duly Authorized Officer,<BR>
Principal Financial and Accounting Officer)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>f10q0622ex32-1_actinium.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>18 U.S.C. SECTION 1350,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Quarterly Report of Actinium
Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;) on Form 10-Q for the period ended June 30, 2022 as filed with the Securities and Exchange
Commission on the date hereof (the &ldquo;Report&rdquo;), I, Sandesh Seth, Chairman &amp; CEO of the Company, certify, pursuant to 18
U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">The Report fully complies with the requirements of Section
13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">The information contained in the Quarterly Report fairly
presents, in all material respects, the financial condition and result of operations of the Company.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: August 12, 2022</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Sandesh Seth</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandesh Seth</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman and Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Duly Authorized Officer, <BR>
Principal Executive Officer)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>f10q0622ex32-2_actinium.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL FINANCIAL AND ACCOUNTING
OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>18 U.S.C. SECTION 1350,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Quarterly Report of Actinium
Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;) on Form 10-Q for the period ended June 30, 2022 as filed with the Securities and Exchange
Commission on the date hereof (the &ldquo;Report&rdquo;), I, Steve O&rsquo;Loughlin, Chief Financial Officer of the Company, certify,
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">The Report fully complies with the requirements of Section
13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">The information contained in the Quarterly Report fairly
presents, in all material respects, the financial condition and result of operations of the Company.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: August 12, 2022</FONT></TD>
    <TD STYLE="text-align: justify; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify; width: 36%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Steve O&rsquo;Loughlin</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steve O&rsquo;Loughlin</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Duly Authorized Officer, <BR>
Principal Financial and Accounting Officer)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>atnm-20220630.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Aug 12 02:15:31 UTC 2022 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2022" targetNamespace="http://actiniumpharmaceuticals.com/20220630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:atnm="http://actiniumpharmaceuticals.com/20220630" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="atnm-20220630_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="atnm-20220630_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="atnm-20220630_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="atnm-20220630_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet" id="atnm_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals" id="atnm_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement" id="atnm_r_ConsolidatedIncomeStatement">
        <link:definition>003 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement_Parentheticals" id="atnm_r_ConsolidatedIncomeStatement_Parentheticals">
        <link:definition>004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3" id="atnm_r_ShareholdersEquityType2or3">
        <link:definition>005 - Statement - Condensed Consolidated Statement of Changes in Stockholders&#8217; Equity (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow" id="atnm_r_ConsolidatedCashFlow">
        <link:definition>006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies" id="atnm_r_DescriptionofBusinessandSummaryofSignificantAccountingPolicies">
        <link:definition>007 - Disclosure - Description of Business and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsandContingencies" id="atnm_r_CommitmentsandContingencies">
        <link:definition>008 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/Leases" id="atnm_r_Leases">
        <link:definition>009 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/OtherRevenue" id="atnm_r_OtherRevenue">
        <link:definition>010 - Disclosure - Other Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/Equity" id="atnm_r_Equity">
        <link:definition>011 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/SubsequentEvent" id="atnm_r_SubsequentEvent">
        <link:definition>012 - Disclosure - Subsequent Event</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy" id="atnm_r_AccountingPoliciesByPolicy">
        <link:definition>013 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" id="atnm_r_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables">
        <link:definition>014 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/LeasesTables" id="atnm_r_LeasesTables">
        <link:definition>015 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/EquityTables" id="atnm_r_EquityTables">
        <link:definition>016 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable" id="atnm_r_ScheduleofcashcashequivalentsandrestrictedcashTable">
        <link:definition>017 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details) - Schedule of cash, cash equivalents and restricted cash</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable" id="atnm_r_ScheduleofdilutednetlosspershareantidilutiveTable">
        <link:definition>018 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details) - Schedule of diluted net loss per share anti-dilutive</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesDetails" id="atnm_r_CommitmentsandContingenciesDetails">
        <link:definition>019 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/LeasesDetails" id="atnm_r_LeasesDetails">
        <link:definition>020 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofcomponentsofleaseexpenseTable" id="atnm_r_ScheduleofcomponentsofleaseexpenseTable">
        <link:definition>021 - Disclosure - Leases (Details) - Schedule of components of lease expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable" id="atnm_r_ScheduleofsupplementalcashflowinformationrelatedtoleasesTable">
        <link:definition>022 - Disclosure - Leases (Details) - Schedule of supplemental cash flow information related to leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofweightedaverageremainingleasetermsTable" id="atnm_r_ScheduleofweightedaverageremainingleasetermsTable">
        <link:definition>023 - Disclosure - Leases (Details) - Schedule of weighted average remaining lease terms</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb5nsTZF1hxsII3StF2nMaFie2WjubTneMhItBwoNuKpVkBjepuDGZJv0uAY/2011DiRxFwSK8IV5mRgvGfHwlBphcd0S/9cahV/vLA5QTpMuHsLSaekfOQE+nOwFp1gLwGaIR82N4BdA/qqO+LqocFMcsLb+CKpnMLguXk/dClIuZ4s7bLRTp12jwSERaIqdwlwSSuibmDa6K7/Tv0jHUyViFTmPawTyNOHqErC3RO3A==] CSR-->
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofweightedaveragediscountratesTable" id="atnm_r_ScheduleofweightedaveragediscountratesTable">
        <link:definition>024 - Disclosure - Leases (Details) - Schedule of weighted average discount rates</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable" id="atnm_r_ScheduleofmaturitiesofleaseliabilitiesTable">
        <link:definition>025 - Disclosure - Leases (Details) - Schedule of maturities of lease liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/OtherRevenueDetails" id="atnm_r_OtherRevenueDetails">
        <link:definition>026 - Disclosure - Other Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/EquityDetails" id="atnm_r_EquityDetails">
        <link:definition>027 - Disclosure - Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofstockoptionactivityTable" id="atnm_r_ScheduleofstockoptionactivityTable">
        <link:definition>028 - Disclosure - Equity  (Details) - Schedule of stock option activity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable" id="atnm_r_ScheduleofwarrantactivitiesTable">
        <link:definition>029 - Disclosure - Equity  (Details) - Schedule of warrant activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/SubsequentEventDetails" id="atnm_r_SubsequentEventDetails">
        <link:definition>030 - Disclosure - Subsequent Event (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd"/>
  <xs:element name="ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract"/>
  <xs:element name="ScheduleOfDilutedNetLossPerShareAntiDilutiveAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfDilutedNetLossPerShareAntiDilutiveAbstract"/>
  <xs:element name="ScheduleOfComponentsOfLeaseExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfComponentsOfLeaseExpenseAbstract"/>
  <xs:element name="ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract"/>
  <xs:element name="ScheduleOfWeightedAverageRemainingLeaseTermsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAbstract"/>
  <xs:element name="ScheduleOfWeightedAverageDiscountRatesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfWeightedAverageDiscountRatesAbstract"/>
  <xs:element name="ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract"/>
  <xs:element name="OtherRevenueAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_OtherRevenueAbstract"/>
  <xs:element name="ScheduleOfStockOptionActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfStockOptionActivityAbstract"/>
  <xs:element name="ScheduleOfWarrantActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfWarrantActivitiesAbstract"/>
  <xs:element name="UnlabeledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract"/>
  <xs:element name="UnlabeledAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract0"/>
  <xs:element name="UnlabeledAbstract00" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract00"/>
  <xs:element name="UnlabeledAbstract000" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract000"/>
  <xs:element name="UnlabeledAbstract0000" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract0000"/>
  <xs:element name="UnlabeledAbstract00000" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract00000"/>
  <xs:element name="UnlabeledAbstract000000" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract000000"/>
  <xs:element name="UnlabeledAbstract0000000" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract0000000"/>
  <xs:element name="UnlabeledAbstract00000000" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract00000000"/>
  <xs:element name="UnlabeledAbstract000000000" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract000000000"/>
  <xs:element name="UnlabeledAbstract0000000000" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract0000000000"/>
  <xs:element name="UnlabeledAbstract00000000000" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract00000000000"/>
  <xs:element name="UnlabeledAbstract000000000000" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract000000000000"/>
  <xs:element name="UnlabeledAbstract0000000000000" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract0000000000000"/>
  <xs:element name="UnlabeledAbstract00000000000000" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract00000000000000"/>
  <xs:element name="UnlabeledAbstract000000000000000" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract000000000000000"/>
  <xs:element name="UnlabeledAbstract0000000000000000" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract0000000000000000"/>
  <xs:element name="UnlabeledAbstract00000000000000000" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract00000000000000000"/>
  <xs:element name="UnlabeledAbstract000000000000000000" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract000000000000000000"/>
  <xs:element name="UnlabeledAbstract0000000000000000000" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract0000000000000000000"/>
  <xs:element name="FinanceLeaseCostAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_FinanceLeaseCostAbstract"/>
  <xs:element name="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract"/>
  <xs:element name="UnlabeledAbstract00000000000000000000" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract00000000000000000000"/>
  <xs:element name="NonCashActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_NonCashActivityAbstract"/>
  <xs:element name="WeightedAverageRemainingLeaseTermAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_WeightedAverageRemainingLeaseTermAbstract"/>
  <xs:element name="WeightedAverageDiscountRatesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_WeightedAverageDiscountRatesAbstract"/>
  <xs:element name="UnlabeledAbstract000000000000000000000" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract000000000000000000000"/>
  <xs:element name="UnlabeledAbstract0000000000000000000000" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract0000000000000000000000"/>
  <xs:element name="LongtermFinanceLeaseObligationsNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="atnm_LongtermFinanceLeaseObligationsNoncurrent"/>
  <xs:element name="StockIssuedDuringPeriodSharesIssuanceOfCommonStockFromExerciseOfPrefundedWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_StockIssuedDuringPeriodSharesIssuanceOfCommonStockFromExerciseOfPrefundedWarrants"/>
  <xs:element name="IncreaseDecreaseInOperatingLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnm_IncreaseDecreaseInOperatingLeaseLiabilities"/>
  <xs:element name="SalesOfSharesOfCommonStockNetOfCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnm_SalesOfSharesOfCommonStockNetOfCosts"/>
  <xs:element name="LeasesTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_LeasesTextBlock"/>
  <xs:element name="OtherRevenueTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_OtherRevenueTextBlock"/>
  <xs:element name="NatureOfBusinessPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_NatureOfBusinessPolicyTextBlock"/>
  <xs:element name="PandemicOnFinancialStatements" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_PandemicOnFinancialStatements"/>
  <xs:element name="GrantRevenuePolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_GrantRevenuePolicyTextBlock"/>
  <xs:element name="LicenseRevenueTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_LicenseRevenueTextBlock"/>
  <xs:element name="Accountingstandardsrecentlyissuedpolicytextblock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_Accountingstandardsrecentlyissuedpolicytextblock"/>
  <xs:element name="ScheduleOrDescriptionOfWeightedAverageTerm" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOrDescriptionOfWeightedAverageTerm"/>
  <xs:element name="ScheduleOfWeightedAverageDiscountRate" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfWeightedAverageDiscountRate"/>
  <xs:element name="OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock"/>
  <xs:element name="EquityTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="atnm_EquityTablesTable"/>
  <xs:element name="EquityTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_EquityTablesLineItems"/>
  <xs:element name="LeaseDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_LeaseDomain"/>
  <xs:element name="LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable"/>
  <xs:element name="LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems"/>
  <xs:element name="PaymentWithImputedInterestPremium" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnm_PaymentWithImputedInterestPremium"/>
  <xs:element name="MaturitiesOfLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="atnm_MaturitiesOfLeaseLiabilities"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1"/>
  <xs:element name="NumberOfWarrantsOutstandings" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="atnm_NumberOfWarrantsOutstandings"/>
  <xs:element name="NumberOfSharesExercised1" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_NumberOfSharesExercised1"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
  <xs:element name="MilestonePayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnm_MilestonePayment"/>
  <xs:element name="DescriptionOfRoyaltyPaymentToRelatedParty" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_DescriptionOfRoyaltyPaymentToRelatedParty"/>
  <xs:element name="NumberOfOperatingLease" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_NumberOfOperatingLease"/>
  <xs:element name="NumberOfFinanceLease" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_NumberOfFinanceLease"/>
  <xs:element name="AdditionSpaceForOperatingLease" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_AdditionSpaceForOperatingLease"/>
  <xs:element name="RecognitionOfDeferredRevenue1" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="atnm_RecognitionOfDeferredRevenue1"/>
  <xs:element name="RevenueRecognized" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnm_RevenueRecognized"/>
  <xs:element name="UpfrontPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="atnm_UpfrontPayment"/>
  <xs:element name="LongtermLicenseRevenueDeferred" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="atnm_LongtermLicenseRevenueDeferred"/>
  <xs:element name="AgreementDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_AgreementDomain"/>
  <xs:element name="EquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="atnm_EquityDetailsTable"/>
  <xs:element name="EquityDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_EquityDetailsLineItems"/>
  <xs:element name="PurchaseOfCommonStockDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_PurchaseOfCommonStockDescription"/>
  <xs:element name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="atnm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight"/>
  <xs:element name="StockOptionTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_StockOptionTerm"/>
  <xs:element name="VestingPeriodOfStockOption" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_VestingPeriodOfStockOption"/>
  <xs:element name="AggregateFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="atnm_AggregateFairValue"/>
  <xs:element name="StockOptionDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_StockOptionDescription"/>
  <xs:element name="UnrecognizedCompensationExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnrecognizedCompensationExpense"/>
  <xs:element name="WeightedAverageTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_WeightedAverageTerm"/>
  <xs:element name="CompensationExpenseRelatedToStockOptions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnm_CompensationExpenseRelatedToStockOptions"/>
  <xs:element name="SubsequentEventDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="atnm_SubsequentEventDetailsTable"/>
  <xs:element name="SubsequentEventDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_SubsequentEventDetailsLineItems"/>
  <xs:element name="SharesOfCommonStockValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnm_SharesOfCommonStockValue"/>
  <xs:element name="NetProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnm_NetProceeds"/>
  <xs:element name="NumberOfShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_NumberOfShares"/>
  <xs:element name="AgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="atnm_AgreementAxis"/>
  <xs:element name="LeaseAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="atnm_LeaseAxis"/>
  <xs:element name="CapitalOnDemandSalesAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_CapitalOnDemandSalesAgreementMember"/>
  <xs:element name="FinanceLeaseLiabilitiesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_FinanceLeaseLiabilitiesMember"/>
  <xs:element name="OperatingLeaseLiabilitiesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_OperatingLeaseLiabilitiesMember"/>
  <xs:element name="StocksOptionMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_StocksOptionMember"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>atnm-20220630_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Aug 12 02:15:31 UTC 2022 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_ConsolidatedBalanceSheet" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_ConsolidatedIncomeStatement" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_ConsolidatedCashFlow" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"/>
  <calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_SecurityDeposit" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_NotesPayableCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRevenue" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="atnm_LongtermFinanceLeaseObligationsNoncurrent" xlink:href="atnm-20220630.xsd#atnm_LongtermFinanceLeaseObligationsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="atnm_LongtermFinanceLeaseObligationsNoncurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" weight="1"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb5nsTZF1hxsII3StF2nMaFie2WjubTneMhItBwoNuKpVkBjepuDGZJv0uAY/2011DiRxFwSK8IV5mRgvGfHwlBphcd0S/9cahV/vLA5QTpMuHsLSaekfOQE+nOwFp1gLwGaIR82N4BdA/qqO+LqocFMcsLb+CKpnMLguXk/dClIuZ4s7bLRTp12jwSERaIqdwlwSSuibmDa95VD8NVIMrT4G44cbop5fKFdSRZfryjEg==] CSR-->
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_SubleaseIncome" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestIncomeExpenseNet" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="atnm_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:href="atnm-20220630.xsd#atnm_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="atnm_IncreaseDecreaseInOperatingLeaseLiabilities" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="9" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="atnm_SalesOfSharesOfCommonStockNetOfCosts" xlink:href="atnm-20220630.xsd#atnm_SalesOfSharesOfCommonStockNetOfCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="atnm_SalesOfSharesOfCommonStockNetOfCosts" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>atnm-20220630_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Aug 12 02:15:31 UTC 2022 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_ConsolidatedBalanceSheet" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_ConsolidatedIncomeStatement" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_ConsolidatedIncomeStatement_Parentheticals" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_ShareholdersEquityType2or3" roleURI="http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_ConsolidatedCashFlow" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_DescriptionofBusinessandSummaryofSignificantAccountingPolicies" roleURI="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_CommitmentsandContingencies" roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_Leases" roleURI="http://actiniumpharmaceuticals.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_OtherRevenue" roleURI="http://actiniumpharmaceuticals.com/role/OtherRevenue"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_Equity" roleURI="http://actiniumpharmaceuticals.com/role/Equity"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_SubsequentEvent" roleURI="http://actiniumpharmaceuticals.com/role/SubsequentEvent"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_AccountingPoliciesByPolicy" roleURI="http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" roleURI="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_LeasesTables" roleURI="http://actiniumpharmaceuticals.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_EquityTables" roleURI="http://actiniumpharmaceuticals.com/role/EquityTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_ScheduleofcashcashequivalentsandrestrictedcashTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_ScheduleofdilutednetlosspershareantidilutiveTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_ScheduleofcomponentsofleaseexpenseTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofcomponentsofleaseexpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_ScheduleofsupplementalcashflowinformationrelatedtoleasesTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_ScheduleofweightedaverageremainingleasetermsTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofweightedaverageremainingleasetermsTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_ScheduleofweightedaveragediscountratesTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofweightedaveragediscountratesTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_ScheduleofmaturitiesofleaseliabilitiesTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_ScheduleofstockoptionactivityTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofstockoptionactivityTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_ScheduleofwarrantactivitiesTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_CommitmentsandContingenciesDetails" roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_LeasesDetails" roleURI="http://actiniumpharmaceuticals.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_OtherRevenueDetails" roleURI="http://actiniumpharmaceuticals.com/role/OtherRevenueDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_EquityDetails" roleURI="http://actiniumpharmaceuticals.com/role/EquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_SubsequentEventDetails" roleURI="http://actiniumpharmaceuticals.com/role/SubsequentEventDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#DocumentAndEntityInformation" roleURI="http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_SecurityDeposit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_AssetsCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_Assets" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_LiabilitiesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_DeferredRevenue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_LongtermFinanceLeaseObligationsNoncurrent" xlink:href="atnm-20220630.xsd#atnm_LongtermFinanceLeaseObligationsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="atnm_LongtermFinanceLeaseObligationsNoncurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_Liabilities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_CommitmentsAndContingencies" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_StockholdersEquity" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenuesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_SubleaseIncome" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_Revenues" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeExpenseNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_StockIssuedDuringPeriodSharesIssuanceOfCommonStockFromExerciseOfPrefundedWarrants" xlink:href="atnm-20220630.xsd#atnm_StockIssuedDuringPeriodSharesIssuanceOfCommonStockFromExerciseOfPrefundedWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atnm_StockIssuedDuringPeriodSharesIssuanceOfCommonStockFromExerciseOfPrefundedWarrants" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:href="atnm-20220630.xsd#atnm_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="atnm_IncreaseDecreaseInOperatingLeaseLiabilities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_SalesOfSharesOfCommonStockNetOfCosts" xlink:href="atnm-20220630.xsd#atnm_SalesOfSharesOfCommonStockNetOfCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="atnm_SalesOfSharesOfCommonStockNetOfCosts" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/Leases">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="atnm_LeasesTextBlock" xlink:href="atnm-20220630.xsd#atnm_LeasesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="atnm_LeasesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/OtherRevenue">
    <loc xlink:type="locator" xlink:label="atnm_OtherRevenueAbstract" xlink:href="atnm-20220630.xsd#atnm_OtherRevenueAbstract"/>
    <loc xlink:type="locator" xlink:label="atnm_OtherRevenueTextBlock" xlink:href="atnm-20220630.xsd#atnm_OtherRevenueTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_OtherRevenueAbstract" xlink:to="atnm_OtherRevenueTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/Equity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/SubsequentEvent">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventsTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="atnm_NatureOfBusinessPolicyTextBlock" xlink:href="atnm-20220630.xsd#atnm_NatureOfBusinessPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="atnm_NatureOfBusinessPolicyTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_PandemicOnFinancialStatements" xlink:href="atnm-20220630.xsd#atnm_PandemicOnFinancialStatements"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="atnm_PandemicOnFinancialStatements" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_GrantRevenuePolicyTextBlock" xlink:href="atnm-20220630.xsd#atnm_GrantRevenuePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="atnm_GrantRevenuePolicyTextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_LicenseRevenueTextBlock" xlink:href="atnm-20220630.xsd#atnm_LicenseRevenueTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="atnm_LicenseRevenueTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_Accountingstandardsrecentlyissuedpolicytextblock" xlink:href="atnm-20220630.xsd#atnm_Accountingstandardsrecentlyissuedpolicytextblock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="atnm_Accountingstandardsrecentlyissuedpolicytextblock" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="15" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/LeasesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOrDescriptionOfWeightedAverageTerm" xlink:href="atnm-20220630.xsd#atnm_ScheduleOrDescriptionOfWeightedAverageTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="atnm_ScheduleOrDescriptionOfWeightedAverageTerm" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfWeightedAverageDiscountRate" xlink:href="atnm-20220630.xsd#atnm_ScheduleOfWeightedAverageDiscountRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="atnm_ScheduleOfWeightedAverageDiscountRate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="atnm-20220630.xsd#atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityTables">
    <loc xlink:type="locator" xlink:label="atnm_EquityTablesLineItems" xlink:href="atnm-20220630.xsd#atnm_EquityTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="atnm_EquityTablesTable" xlink:href="atnm-20220630.xsd#atnm_EquityTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="atnm_EquityTablesLineItems" xlink:to="atnm_EquityTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_EquityTablesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_StocksOptionMember" xlink:href="atnm-20220630.xsd#atnm_StocksOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="atnm_StocksOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityTablesLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityTablesLineItems" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb5nsTZF1hxsII3StF2nMaFie2WjubTneMhItBwoNuKpVkBjepuDGZJv0uAY/2011DiRxFwSK8IV5mRgvGfHwlBphcd0S/9cahV/vLA5QTpMuHsLSaekfOQE+nOwFp1gLwGaIR82N4BdA/qqO+LqocFMcsLb+CKpnMLguXk/dClIuZ4s7bLRTp12jwSERaIqdwlwSSuibmDa6K7/Tv0jHUyMYrAyQ20OwI50WLPUCrpJg==] CSR-->
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable">
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:href="atnm-20220630.xsd#atnm_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherRestrictedAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherRestrictedAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:to="us-gaap_OtherRestrictedAssetsCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable">
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofcomponentsofleaseexpenseTable">
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfComponentsOfLeaseExpenseAbstract" xlink:href="atnm-20220630.xsd#atnm_ScheduleOfComponentsOfLeaseExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfComponentsOfLeaseExpenseAbstract" xlink:to="us-gaap_OperatingLeaseExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfComponentsOfLeaseExpenseAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfComponentsOfLeaseExpenseAbstract" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_OperatingLeaseCost" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable">
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:href="atnm-20220630.xsd#atnm_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_NonCashActivityAbstract" xlink:href="atnm-20220630.xsd#atnm_NonCashActivityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="atnm_NonCashActivityAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_NonCashActivityAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_NonCashActivityAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofweightedaverageremainingleasetermsTable">
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAbstract" xlink:href="atnm-20220630.xsd#atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAbstract"/>
    <loc xlink:type="locator" xlink:label="atnm_WeightedAverageRemainingLeaseTermAbstract" xlink:href="atnm-20220630.xsd#atnm_WeightedAverageRemainingLeaseTermAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAbstract" xlink:to="atnm_WeightedAverageRemainingLeaseTermAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_WeightedAverageRemainingLeaseTermAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_WeightedAverageRemainingLeaseTermAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofweightedaveragediscountratesTable">
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfWeightedAverageDiscountRatesAbstract" xlink:href="atnm-20220630.xsd#atnm_ScheduleOfWeightedAverageDiscountRatesAbstract"/>
    <loc xlink:type="locator" xlink:label="atnm_WeightedAverageDiscountRatesAbstract" xlink:href="atnm-20220630.xsd#atnm_WeightedAverageDiscountRatesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfWeightedAverageDiscountRatesAbstract" xlink:to="atnm_WeightedAverageDiscountRatesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_WeightedAverageDiscountRatesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_WeightedAverageDiscountRatesAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable">
    <loc xlink:type="locator" xlink:label="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:href="atnm-20220630.xsd#atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems"/>
    <loc xlink:type="locator" xlink:label="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable" xlink:href="atnm-20220630.xsd#atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:to="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_LeaseAxis" xlink:href="atnm-20220630.xsd#atnm_LeaseAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable" xlink:to="atnm_LeaseAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_LeaseDomain" xlink:href="atnm-20220630.xsd#atnm_LeaseDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="atnm_LeaseAxis" xlink:to="atnm_LeaseDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_LeaseDomain_0" xlink:href="atnm-20220630.xsd#atnm_LeaseDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="atnm_LeaseAxis" xlink:to="atnm_LeaseDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_OperatingLeaseLiabilitiesMember" xlink:href="atnm-20220630.xsd#atnm_OperatingLeaseLiabilitiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_LeaseDomain" xlink:to="atnm_OperatingLeaseLiabilitiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_FinanceLeaseLiabilitiesMember" xlink:href="atnm-20220630.xsd#atnm_FinanceLeaseLiabilitiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_LeaseDomain" xlink:to="atnm_FinanceLeaseLiabilitiesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_PaymentWithImputedInterestPremium" xlink:href="atnm-20220630.xsd#atnm_PaymentWithImputedInterestPremium"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:to="atnm_PaymentWithImputedInterestPremium" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_MaturitiesOfLeaseLiabilities" xlink:href="atnm-20220630.xsd#atnm_MaturitiesOfLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_PaymentWithImputedInterestPremium" xlink:to="atnm_MaturitiesOfLeaseLiabilities" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofstockoptionactivityTable">
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfStockOptionActivityAbstract" xlink:href="atnm-20220630.xsd#atnm_ScheduleOfStockOptionActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="atnm-20220630.xsd#atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfStockOptionActivityAbstract" xlink:to="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="14" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_NumberOfWarrantsOutstandings" xlink:href="atnm-20220630.xsd#atnm_NumberOfWarrantsOutstandings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="atnm_NumberOfWarrantsOutstandings" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="atnm-20220630.xsd#atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_NumberOfSharesExercised1" xlink:href="atnm-20220630.xsd#atnm_NumberOfSharesExercised1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="atnm_NumberOfSharesExercised1" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="15" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="atnm_MilestonePayment" xlink:href="atnm-20220630.xsd#atnm_MilestonePayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="atnm_MilestonePayment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_DescriptionOfRoyaltyPaymentToRelatedParty" xlink:href="atnm-20220630.xsd#atnm_DescriptionOfRoyaltyPaymentToRelatedParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="atnm_DescriptionOfRoyaltyPaymentToRelatedParty" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/LeasesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="atnm_NumberOfOperatingLease" xlink:href="atnm-20220630.xsd#atnm_NumberOfOperatingLease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="atnm_NumberOfOperatingLease" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_NumberOfFinanceLease" xlink:href="atnm-20220630.xsd#atnm_NumberOfFinanceLease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="atnm_NumberOfFinanceLease" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_AdditionSpaceForOperatingLease" xlink:href="atnm-20220630.xsd#atnm_AdditionSpaceForOperatingLease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="atnm_AdditionSpaceForOperatingLease" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/OtherRevenueDetails">
    <loc xlink:type="locator" xlink:label="atnm_OtherRevenueAbstract" xlink:href="atnm-20220630.xsd#atnm_OtherRevenueAbstract"/>
    <loc xlink:type="locator" xlink:label="atnm_RecognitionOfDeferredRevenue1" xlink:href="atnm-20220630.xsd#atnm_RecognitionOfDeferredRevenue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_OtherRevenueAbstract" xlink:to="atnm_RecognitionOfDeferredRevenue1" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_RevenueRecognized" xlink:href="atnm-20220630.xsd#atnm_RevenueRecognized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_OtherRevenueAbstract" xlink:to="atnm_RevenueRecognized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_UpfrontPayment" xlink:href="atnm-20220630.xsd#atnm_UpfrontPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_OtherRevenueAbstract" xlink:to="atnm_UpfrontPayment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_OtherRevenueAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_LongtermLicenseRevenueDeferred" xlink:href="atnm-20220630.xsd#atnm_LongtermLicenseRevenueDeferred"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_OtherRevenueAbstract" xlink:to="atnm_LongtermLicenseRevenueDeferred" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityDetails">
    <loc xlink:type="locator" xlink:label="atnm_EquityDetailsLineItems" xlink:href="atnm-20220630.xsd#atnm_EquityDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="atnm_EquityDetailsTable" xlink:href="atnm-20220630.xsd#atnm_EquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="atnm_EquityDetailsLineItems" xlink:to="atnm_EquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_AgreementAxis" xlink:href="atnm-20220630.xsd#atnm_AgreementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_EquityDetailsTable" xlink:to="atnm_AgreementAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_AgreementDomain" xlink:href="atnm-20220630.xsd#atnm_AgreementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="atnm_AgreementAxis" xlink:to="atnm_AgreementDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_AgreementDomain_0" xlink:href="atnm-20220630.xsd#atnm_AgreementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="atnm_AgreementAxis" xlink:to="atnm_AgreementDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_EquityDetailsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_EquityDetailsTable" xlink:to="srt_RangeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_CapitalOnDemandSalesAgreementMember" xlink:href="atnm-20220630.xsd#atnm_CapitalOnDemandSalesAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_AgreementDomain" xlink:to="atnm_CapitalOnDemandSalesAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_PurchaseOfCommonStockDescription" xlink:href="atnm-20220630.xsd#atnm_PurchaseOfCommonStockDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="atnm_PurchaseOfCommonStockDescription" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight" xlink:href="atnm-20220630.xsd#atnm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="atnm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_StockOptionTerm" xlink:href="atnm-20220630.xsd#atnm_StockOptionTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="atnm_StockOptionTerm" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_VestingPeriodOfStockOption" xlink:href="atnm-20220630.xsd#atnm_VestingPeriodOfStockOption"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="atnm_VestingPeriodOfStockOption" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_AggregateFairValue" xlink:href="atnm-20220630.xsd#atnm_AggregateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="atnm_AggregateFairValue" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_StockOptionDescription" xlink:href="atnm-20220630.xsd#atnm_StockOptionDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="atnm_StockOptionDescription" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_UnrecognizedCompensationExpense" xlink:href="atnm-20220630.xsd#atnm_UnrecognizedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="atnm_UnrecognizedCompensationExpense" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_WeightedAverageTerm" xlink:href="atnm-20220630.xsd#atnm_WeightedAverageTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="atnm_WeightedAverageTerm" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_CompensationExpenseRelatedToStockOptions" xlink:href="atnm-20220630.xsd#atnm_CompensationExpenseRelatedToStockOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="atnm_CompensationExpenseRelatedToStockOptions" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/SubsequentEventDetails">
    <loc xlink:type="locator" xlink:label="atnm_SubsequentEventDetailsLineItems" xlink:href="atnm-20220630.xsd#atnm_SubsequentEventDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="atnm_SubsequentEventDetailsTable" xlink:href="atnm-20220630.xsd#atnm_SubsequentEventDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="atnm_SubsequentEventDetailsLineItems" xlink:to="atnm_SubsequentEventDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_SubsequentEventDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_SharesOfCommonStockValue" xlink:href="atnm-20220630.xsd#atnm_SharesOfCommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_SubsequentEventDetailsLineItems" xlink:to="atnm_SharesOfCommonStockValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_NetProceeds" xlink:href="atnm-20220630.xsd#atnm_NetProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_SubsequentEventDetailsLineItems" xlink:to="atnm_NetProceeds" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_SubsequentEventDetailsLineItems" xlink:to="us-gaap_PaymentsForRepurchaseOfWarrants" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_SubsequentEventDetailsLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_SubsequentEventDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_SubsequentEventDetailsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_SubsequentEventDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_NumberOfShares" xlink:href="atnm-20220630.xsd#atnm_NumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_SubsequentEventDetailsLineItems" xlink:to="atnm_NumberOfShares" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentQuarterlyReport" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="29" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>atnm-20220630_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Aug 12 02:15:31 UTC 2022 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Total revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided By/Used In Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Used In Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided By Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net change in cash, cash equivalents, and restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents, and restricted cash at beginning of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Cash, cash equivalents, and restricted cash at end of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:href="atnm-20220630.xsd#atnm_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract_lbl" xml:lang="en-US">Schedule of cash, cash equivalents and restricted cash [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:to="atnm_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfDilutedNetLossPerShareAntiDilutiveAbstract" xlink:href="atnm-20220630.xsd#atnm_ScheduleOfDilutedNetLossPerShareAntiDilutiveAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfDilutedNetLossPerShareAntiDilutiveAbstract_lbl" xml:lang="en-US">Schedule of diluted net loss per share anti-dilutive [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfDilutedNetLossPerShareAntiDilutiveAbstract" xlink:to="atnm_ScheduleOfDilutedNetLossPerShareAntiDilutiveAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfComponentsOfLeaseExpenseAbstract" xlink:href="atnm-20220630.xsd#atnm_ScheduleOfComponentsOfLeaseExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfComponentsOfLeaseExpenseAbstract_lbl" xml:lang="en-US">Schedule of components of lease expense [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfComponentsOfLeaseExpenseAbstract" xlink:to="atnm_ScheduleOfComponentsOfLeaseExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:href="atnm-20220630.xsd#atnm_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract_lbl" xml:lang="en-US">Schedule of supplemental cash flow information related to leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="atnm_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAbstract" xlink:href="atnm-20220630.xsd#atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAbstract_lbl" xml:lang="en-US">Schedule of weighted average remaining lease terms [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAbstract" xlink:to="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfWeightedAverageDiscountRatesAbstract" xlink:href="atnm-20220630.xsd#atnm_ScheduleOfWeightedAverageDiscountRatesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfWeightedAverageDiscountRatesAbstract_lbl" xml:lang="en-US">Schedule of weighted average discount rates [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfWeightedAverageDiscountRatesAbstract" xlink:to="atnm_ScheduleOfWeightedAverageDiscountRatesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:href="atnm-20220630.xsd#atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule of maturities of lease liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:to="atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_LeaseAxis" xlink:href="atnm-20220630.xsd#atnm_LeaseAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_LeaseAxis_lbl" xml:lang="en-US">Lease [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeaseAxis" xlink:to="atnm_LeaseAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_OtherRevenueAbstract" xlink:href="atnm-20220630.xsd#atnm_OtherRevenueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_OtherRevenueAbstract_lbl" xml:lang="en-US">Other revenue [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OtherRevenueAbstract" xlink:to="atnm_OtherRevenueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders&apos; Equity Note [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfStockOptionActivityAbstract" xlink:href="atnm-20220630.xsd#atnm_ScheduleOfStockOptionActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfStockOptionActivityAbstract_lbl" xml:lang="en-US">Schedule of stock option activity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfStockOptionActivityAbstract" xlink:to="atnm_ScheduleOfStockOptionActivityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Shares, Outstanding Beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Number of Shares, Outstanding Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfWarrantActivitiesAbstract" xlink:href="atnm-20220630.xsd#atnm_ScheduleOfWarrantActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfWarrantActivitiesAbstract_lbl" xml:lang="en-US">Schedule of warrant activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfWarrantActivitiesAbstract" xlink:to="atnm_ScheduleOfWarrantActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_NumberOfWarrantsOutstandings" xlink:href="atnm-20220630.xsd#atnm_NumberOfWarrantsOutstandings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="atnm_NumberOfWarrantsOutstandings_lbl" xml:lang="en-US">Number of Shares, Outstanding Beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NumberOfWarrantsOutstandings" xlink:to="atnm_NumberOfWarrantsOutstandings_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="atnm_NumberOfWarrantsOutstandings_lbl0" xml:lang="en-US">Number of Shares, Outstanding Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NumberOfWarrantsOutstandings" xlink:to="atnm_NumberOfWarrantsOutstandings_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding Beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Weighted Average Exercise Price,Outstanding Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding Beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl0" xml:lang="en-US">Aggregate Intrinsic Value,Outstanding Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US">Restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract" xlink:href="atnm-20220630.xsd#atnm_UnlabeledAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract" xlink:to="atnm_UnlabeledAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net of accumulated depreciation of $395 and $335</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Property and equipment, net of accumulated depreciation (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xml:lang="en-US">Security deposit &#8211; long term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating leases right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xml:lang="en-US">Finance leases right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract0" xlink:href="atnm-20220630.xsd#atnm_UnlabeledAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract0_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract0" xlink:to="atnm_UnlabeledAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other revenue deferred&#8211; current liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating leases current liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US">Finance leases current liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract00" xlink:href="atnm-20220630.xsd#atnm_UnlabeledAbstract00"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract00_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract00" xlink:to="atnm_UnlabeledAbstract00_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US">Long-term license revenue deferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Long-term operating leases obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_LongtermFinanceLeaseObligationsNoncurrent" xlink:href="atnm-20220630.xsd#atnm_LongtermFinanceLeaseObligationsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_LongtermFinanceLeaseObligationsNoncurrent_lbl" xml:lang="en-US">Long-term finance leases obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LongtermFinanceLeaseObligationsNoncurrent" xlink:to="atnm_LongtermFinanceLeaseObligationsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract000" xlink:href="atnm-20220630.xsd#atnm_UnlabeledAbstract000"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract000_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract000" xlink:to="atnm_UnlabeledAbstract000_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract0000" xlink:href="atnm-20220630.xsd#atnm_UnlabeledAbstract0000"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract0000_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract0000" xlink:to="atnm_UnlabeledAbstract0000_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.001 par value; 50,000,000 shares authorized, 0 shares issued and outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.001 par value; 1,000,000,000 shares authorized; 24,870,623 and 22,143,974 shares issued and outstanding, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract00000" xlink:href="atnm-20220630.xsd#atnm_UnlabeledAbstract00000"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract00000_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract00000" xlink:to="atnm_UnlabeledAbstract00000_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US">Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubleaseIncome_lbl" xml:lang="en-US">Other revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract000000" xlink:href="atnm-20220630.xsd#atnm_UnlabeledAbstract000000"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract000000_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract000000" xlink:to="atnm_UnlabeledAbstract000000_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development, net of reimbursements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract0000000" xlink:href="atnm-20220630.xsd#atnm_UnlabeledAbstract0000000"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract0000000_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract0000000" xlink:to="atnm_UnlabeledAbstract0000000_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract00000000" xlink:href="atnm-20220630.xsd#atnm_UnlabeledAbstract00000000"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract00000000_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract00000000" xlink:to="atnm_UnlabeledAbstract00000000_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Interest income - net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract000000000" xlink:href="atnm-20220630.xsd#atnm_UnlabeledAbstract000000000"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract000000000_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract000000000" xlink:to="atnm_UnlabeledAbstract000000000_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract0000000000" xlink:href="atnm-20220630.xsd#atnm_UnlabeledAbstract0000000000"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract0000000000_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract0000000000" xlink:to="atnm_UnlabeledAbstract0000000000_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per common share &#8211; basic and diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per common share &#8211; basic and diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average common shares outstanding &#8211; basic and diluted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average common shares outstanding &#8211; basic and diluted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract00000000000" xlink:href="atnm-20220630.xsd#atnm_UnlabeledAbstract00000000000"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract00000000000_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract00000000000" xlink:to="atnm_UnlabeledAbstract00000000000_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract000000000000" xlink:href="atnm-20220630.xsd#atnm_UnlabeledAbstract000000000000"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract000000000000_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract000000000000" xlink:to="atnm_UnlabeledAbstract000000000000_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Sale of common stock, net of issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Sale of common stock, net of issuance costs (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract0000000000000" xlink:href="atnm-20220630.xsd#atnm_UnlabeledAbstract0000000000000"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract0000000000000_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract0000000000000" xlink:to="atnm_UnlabeledAbstract0000000000000_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Sale of common stock, net of costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Sale of common stock, net of costs (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract00000000000000" xlink:href="atnm-20220630.xsd#atnm_UnlabeledAbstract00000000000000"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract00000000000000_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract00000000000000" xlink:to="atnm_UnlabeledAbstract00000000000000_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_StockIssuedDuringPeriodSharesIssuanceOfCommonStockFromExerciseOfPrefundedWarrants" xlink:href="atnm-20220630.xsd#atnm_StockIssuedDuringPeriodSharesIssuanceOfCommonStockFromExerciseOfPrefundedWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_StockIssuedDuringPeriodSharesIssuanceOfCommonStockFromExerciseOfPrefundedWarrants_lbl" xml:lang="en-US">Stock-based compensation (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_StockIssuedDuringPeriodSharesIssuanceOfCommonStockFromExerciseOfPrefundedWarrants" xlink:to="atnm_StockIssuedDuringPeriodSharesIssuanceOfCommonStockFromExerciseOfPrefundedWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Operating Activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits_lbl" xml:lang="en-US">Payment of security deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US">Other revenue deferred&#8211; current liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Long-term license revenue deferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:href="atnm-20220630.xsd#atnm_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="atnm_IncreaseDecreaseInOperatingLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract000000000000000" xlink:href="atnm-20220630.xsd#atnm_UnlabeledAbstract000000000000000"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract000000000000000_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract000000000000000" xlink:to="atnm_UnlabeledAbstract000000000000000_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows Used In Investing Activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract0000000000000000" xlink:href="atnm-20220630.xsd#atnm_UnlabeledAbstract0000000000000000"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract0000000000000000_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract0000000000000000" xlink:to="atnm_UnlabeledAbstract0000000000000000_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Financing Activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_SalesOfSharesOfCommonStockNetOfCosts" xlink:href="atnm-20220630.xsd#atnm_SalesOfSharesOfCommonStockNetOfCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_SalesOfSharesOfCommonStockNetOfCosts_lbl" xml:lang="en-US">Sales of shares of common stock, net of costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SalesOfSharesOfCommonStockNetOfCosts" xlink:to="atnm_SalesOfSharesOfCommonStockNetOfCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract00000000000000000" xlink:href="atnm-20220630.xsd#atnm_UnlabeledAbstract00000000000000000"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract00000000000000000_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract00000000000000000" xlink:to="atnm_UnlabeledAbstract00000000000000000_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract000000000000000000" xlink:href="atnm-20220630.xsd#atnm_UnlabeledAbstract000000000000000000"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract000000000000000000_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract000000000000000000" xlink:to="atnm_UnlabeledAbstract000000000000000000_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Cash paid for income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US">Payments on finance leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl0" xml:lang="en-US">Financing cash flow use from finance leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-In Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Description of Business and Summary of Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xml:lang="en-US">Schedule of cash, cash equivalents and restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherRestrictedAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherRestrictedAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherRestrictedAssetsCurrent_lbl" xml:lang="en-US">Restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherRestrictedAssetsCurrent" xlink:to="us-gaap_OtherRestrictedAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of diluted net loss per share anti-dilutive</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_LeasesTextBlock" xlink:href="atnm-20220630.xsd#atnm_LeasesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_LeasesTextBlock_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeasesTextBlock" xlink:to="atnm_LeasesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of components of lease expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating lease expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract0000000000000000000" xlink:href="atnm-20220630.xsd#atnm_UnlabeledAbstract0000000000000000000"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract0000000000000000000_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract0000000000000000000" xlink:to="atnm_UnlabeledAbstract0000000000000000000_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_FinanceLeaseCostAbstract" xlink:href="atnm-20220630.xsd#atnm_FinanceLeaseCostAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_FinanceLeaseCostAbstract_lbl" xml:lang="en-US">Finance lease cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_FinanceLeaseCostAbstract" xlink:to="atnm_FinanceLeaseCostAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US">Amortization of right-to-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xml:lang="en-US">Interest on lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Total finance lease cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xml:lang="en-US">Schedule of supplemental cash flow information related to leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:href="atnm-20220630.xsd#atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating cash flow use from operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" xml:lang="en-US">Operating cash flow use from finance leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract00000000000000000000" xlink:href="atnm-20220630.xsd#atnm_UnlabeledAbstract00000000000000000000"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract00000000000000000000_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract00000000000000000000" xlink:to="atnm_UnlabeledAbstract00000000000000000000_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_NonCashActivityAbstract" xlink:href="atnm-20220630.xsd#atnm_NonCashActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_NonCashActivityAbstract_lbl" xml:lang="en-US">Non-cash activity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NonCashActivityAbstract" xlink:to="atnm_NonCashActivityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xml:lang="en-US">Finance Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOrDescriptionOfWeightedAverageTerm" xlink:href="atnm-20220630.xsd#atnm_ScheduleOrDescriptionOfWeightedAverageTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_ScheduleOrDescriptionOfWeightedAverageTerm_lbl" xml:lang="en-US">Schedule of weighted average remaining lease terms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOrDescriptionOfWeightedAverageTerm" xlink:to="atnm_ScheduleOrDescriptionOfWeightedAverageTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_WeightedAverageRemainingLeaseTermAbstract" xlink:href="atnm-20220630.xsd#atnm_WeightedAverageRemainingLeaseTermAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_WeightedAverageRemainingLeaseTermAbstract_lbl" xml:lang="en-US">Weighted average remaining lease term:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WeightedAverageRemainingLeaseTermAbstract" xlink:to="atnm_WeightedAverageRemainingLeaseTermAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Finance Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfWeightedAverageDiscountRate" xlink:href="atnm-20220630.xsd#atnm_ScheduleOfWeightedAverageDiscountRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_ScheduleOfWeightedAverageDiscountRate_lbl" xml:lang="en-US">Schedule of weighted average discount rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfWeightedAverageDiscountRate" xlink:to="atnm_ScheduleOfWeightedAverageDiscountRate_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_WeightedAverageDiscountRatesAbstract" xlink:href="atnm-20220630.xsd#atnm_WeightedAverageDiscountRatesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_WeightedAverageDiscountRatesAbstract_lbl" xml:lang="en-US">Weighted average discount rates:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WeightedAverageDiscountRatesAbstract" xlink:to="atnm_WeightedAverageDiscountRatesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Finance Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="atnm-20220630.xsd#atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of maturities of lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_lbl" xml:lang="en-US">2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_lbl" xml:lang="en-US">2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_lbl" xml:lang="en-US">2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_lbl" xml:lang="en-US">2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_PaymentWithImputedInterestPremium" xlink:href="atnm-20220630.xsd#atnm_PaymentWithImputedInterestPremium"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_PaymentWithImputedInterestPremium_lbl" xml:lang="en-US">Less imputed interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_PaymentWithImputedInterestPremium" xlink:to="atnm_PaymentWithImputedInterestPremium_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_MaturitiesOfLeaseLiabilities" xlink:href="atnm-20220630.xsd#atnm_MaturitiesOfLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_MaturitiesOfLeaseLiabilities_lbl" xml:lang="en-US">Present value of lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_MaturitiesOfLeaseLiabilities" xlink:to="atnm_MaturitiesOfLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_OtherRevenueTextBlock" xlink:href="atnm-20220630.xsd#atnm_OtherRevenueTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_OtherRevenueTextBlock_lbl" xml:lang="en-US">Other revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OtherRevenueTextBlock" xlink:to="atnm_OtherRevenueTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of stock option activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding Beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted Average Exercise Price, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years),Outstanding Beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding Beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of Shares, Granted | shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Number of Shares, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted Average Exercise Price, Cancelled/Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="atnm-20220630.xsd#atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term, Outstanding Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract000000000000000000000" xlink:href="atnm-20220630.xsd#atnm_UnlabeledAbstract000000000000000000000"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract000000000000000000000_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract000000000000000000000" xlink:to="atnm_UnlabeledAbstract000000000000000000000_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of Shares Exercisable Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0" xml:lang="en-US">Number of Shares, Exercisable Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercisable Ending | $ / shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted Average Exercise Price, Exercisable Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years), Exercisable Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of warrant activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual term (in years),Outstanding beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_NumberOfSharesExercised1" xlink:href="atnm-20220630.xsd#atnm_NumberOfSharesExercised1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_NumberOfSharesExercised1_lbl" xml:lang="en-US">Number of Shares, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NumberOfSharesExercised1" xlink:to="atnm_NumberOfSharesExercised1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of Shares, Cancelled/Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0" xml:lang="en-US">Number of Shares, Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="atnm-20220630.xsd#atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years),Outstanding Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract0000000000000000000000" xlink:href="atnm-20220630.xsd#atnm_UnlabeledAbstract0000000000000000000000"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract0000000000000000000000_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract0000000000000000000000" xlink:to="atnm_UnlabeledAbstract0000000000000000000000_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Event</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantMember_lbl0" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_OperatingLeaseLiabilitiesMember" xlink:href="atnm-20220630.xsd#atnm_OperatingLeaseLiabilitiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_OperatingLeaseLiabilitiesMember_lbl" xml:lang="en-US">Operating Leases [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OperatingLeaseLiabilitiesMember" xlink:to="atnm_OperatingLeaseLiabilitiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_FinanceLeaseLiabilitiesMember" xlink:href="atnm-20220630.xsd#atnm_FinanceLeaseLiabilitiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_FinanceLeaseLiabilitiesMember_lbl" xml:lang="en-US">Finance Leases [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_FinanceLeaseLiabilitiesMember" xlink:to="atnm_FinanceLeaseLiabilitiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_StocksOptionMember" xlink:href="atnm-20220630.xsd#atnm_StocksOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_StocksOptionMember_lbl" xml:lang="en-US">Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_StocksOptionMember" xlink:to="atnm_StocksOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_AgreementAxis" xlink:href="atnm-20220630.xsd#atnm_AgreementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_AgreementAxis_lbl" xml:lang="en-US">Agreement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AgreementAxis" xlink:to="atnm_AgreementAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_MilestonePayment" xlink:href="atnm-20220630.xsd#atnm_MilestonePayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_MilestonePayment_lbl" xml:lang="en-US">Milestone payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_MilestonePayment" xlink:to="atnm_MilestonePayment_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_DescriptionOfRoyaltyPaymentToRelatedParty" xlink:href="atnm-20220630.xsd#atnm_DescriptionOfRoyaltyPaymentToRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_DescriptionOfRoyaltyPaymentToRelatedParty_lbl" xml:lang="en-US">Description of royalty payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_DescriptionOfRoyaltyPaymentToRelatedParty" xlink:to="atnm_DescriptionOfRoyaltyPaymentToRelatedParty_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_NumberOfOperatingLease" xlink:href="atnm-20220630.xsd#atnm_NumberOfOperatingLease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_NumberOfOperatingLease_lbl" xml:lang="en-US">Number of operating lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NumberOfOperatingLease" xlink:to="atnm_NumberOfOperatingLease_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_NumberOfFinanceLease" xlink:href="atnm-20220630.xsd#atnm_NumberOfFinanceLease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_NumberOfFinanceLease_lbl" xml:lang="en-US">Number of finance lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NumberOfFinanceLease" xlink:to="atnm_NumberOfFinanceLease_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_AdditionSpaceForOperatingLease" xlink:href="atnm-20220630.xsd#atnm_AdditionSpaceForOperatingLease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_AdditionSpaceForOperatingLease_lbl" xml:lang="en-US">Operating lease of auxiliary corporate office space</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AdditionSpaceForOperatingLease" xlink:to="atnm_AdditionSpaceForOperatingLease_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_RecognitionOfDeferredRevenue1" xlink:href="atnm-20220630.xsd#atnm_RecognitionOfDeferredRevenue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_RecognitionOfDeferredRevenue1_lbl" xml:lang="en-US">Recognition of deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RecognitionOfDeferredRevenue1" xlink:to="atnm_RecognitionOfDeferredRevenue1_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_RevenueRecognized" xlink:href="atnm-20220630.xsd#atnm_RevenueRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_RevenueRecognized_lbl" xml:lang="en-US">Revenue recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RevenueRecognized" xlink:to="atnm_RevenueRecognized_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UpfrontPayment" xlink:href="atnm-20220630.xsd#atnm_UpfrontPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UpfrontPayment_lbl" xml:lang="en-US">Upfront payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UpfrontPayment" xlink:to="atnm_UpfrontPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Other revenue - current liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb5nsTZF1hxsII3StF2nMaFie2WjubTneMhItBwoNuKpVkBjepuDGZJv0uAY/2011DiRxFwSK8IV5mRgvGfHwlBphcd0S/9cahV/vLA5QTpMuHsLSaekfOQE+nOwFp1gLwGaIR82N4BdA/qqO+LqocFMcsLb+CKpnMLguXk/dClIuZ4s7bLRTp12jwSERaIqdwlwSSuibmDa+VQ74Q/9zDojSGNW3mEaz4=] CSR-->
    <loc xlink:type="locator" xlink:label="atnm_LongtermLicenseRevenueDeferred" xlink:href="atnm-20220630.xsd#atnm_LongtermLicenseRevenueDeferred"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_LongtermLicenseRevenueDeferred_lbl" xml:lang="en-US">Long-term license revenue deferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LongtermLicenseRevenueDeferred" xlink:to="atnm_LongtermLicenseRevenueDeferred_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Aggregate value of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of common stock, shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Gross proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Net proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_PurchaseOfCommonStockDescription" xlink:href="atnm-20220630.xsd#atnm_PurchaseOfCommonStockDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_PurchaseOfCommonStockDescription_lbl" xml:lang="en-US">Purchase of common stock, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_PurchaseOfCommonStockDescription" xlink:to="atnm_PurchaseOfCommonStockDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight" xlink:href="atnm-20220630.xsd#atnm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight_lbl" xml:lang="en-US">Exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight" xlink:to="atnm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_StockOptionTerm" xlink:href="atnm-20220630.xsd#atnm_StockOptionTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_StockOptionTerm_lbl" xml:lang="en-US">Stock option term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_StockOptionTerm" xlink:to="atnm_StockOptionTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_VestingPeriodOfStockOption" xlink:href="atnm-20220630.xsd#atnm_VestingPeriodOfStockOption"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_VestingPeriodOfStockOption_lbl" xml:lang="en-US">Vesting period of stock option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_VestingPeriodOfStockOption" xlink:to="atnm_VestingPeriodOfStockOption_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_AggregateFairValue" xlink:href="atnm-20220630.xsd#atnm_AggregateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_AggregateFairValue_lbl" xml:lang="en-US">Aggregate fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AggregateFairValue" xlink:to="atnm_AggregateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_StockOptionDescription" xlink:href="atnm-20220630.xsd#atnm_StockOptionDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_StockOptionDescription_lbl" xml:lang="en-US">Stock option, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_StockOptionDescription" xlink:to="atnm_StockOptionDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnrecognizedCompensationExpense" xlink:href="atnm-20220630.xsd#atnm_UnrecognizedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnrecognizedCompensationExpense_lbl" xml:lang="en-US">Unrecognized compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnrecognizedCompensationExpense" xlink:to="atnm_UnrecognizedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_WeightedAverageTerm" xlink:href="atnm-20220630.xsd#atnm_WeightedAverageTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_WeightedAverageTerm_lbl" xml:lang="en-US">Weighted average term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WeightedAverageTerm" xlink:to="atnm_WeightedAverageTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_CompensationExpenseRelatedToStockOptions" xlink:href="atnm-20220630.xsd#atnm_CompensationExpenseRelatedToStockOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_CompensationExpenseRelatedToStockOptions_lbl" xml:lang="en-US">Compensation expense related to stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CompensationExpenseRelatedToStockOptions" xlink:to="atnm_CompensationExpenseRelatedToStockOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_SharesOfCommonStockValue" xlink:href="atnm-20220630.xsd#atnm_SharesOfCommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_SharesOfCommonStockValue_lbl" xml:lang="en-US">Shares of common stock value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SharesOfCommonStockValue" xlink:to="atnm_SharesOfCommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_NetProceeds" xlink:href="atnm-20220630.xsd#atnm_NetProceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_NetProceeds_lbl" xml:lang="en-US">Net proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NetProceeds" xlink:to="atnm_NetProceeds_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForRepurchaseOfWarrants_lbl" xml:lang="en-US">Aggregate purchase of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfWarrants" xlink:to="us-gaap_PaymentsForRepurchaseOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US">Underwritten offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Price pe share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Warrants exercisable term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_NumberOfShares" xlink:href="atnm-20220630.xsd#atnm_NumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_NumberOfShares_lbl" xml:lang="en-US">Warrants outstanding (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NumberOfShares" xlink:to="atnm_NumberOfShares_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_NatureOfBusinessPolicyTextBlock" xlink:href="atnm-20220630.xsd#atnm_NatureOfBusinessPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_NatureOfBusinessPolicyTextBlock_lbl" xml:lang="en-US">Nature of Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NatureOfBusinessPolicyTextBlock" xlink:to="atnm_NatureOfBusinessPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_PandemicOnFinancialStatements" xlink:href="atnm-20220630.xsd#atnm_PandemicOnFinancialStatements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_PandemicOnFinancialStatements_lbl" xml:lang="en-US">Impact of COVID&#8211;19 Pandemic on Financial Statements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_PandemicOnFinancialStatements" xlink:to="atnm_PandemicOnFinancialStatements_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy_lbl" xml:lang="en-US">Collaborative Arrangements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_GrantRevenuePolicyTextBlock" xlink:href="atnm-20220630.xsd#atnm_GrantRevenuePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_GrantRevenuePolicyTextBlock_lbl" xml:lang="en-US">Grant Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_GrantRevenuePolicyTextBlock" xlink:to="atnm_GrantRevenuePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_LicenseRevenueTextBlock" xlink:href="atnm-20220630.xsd#atnm_LicenseRevenueTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_LicenseRevenueTextBlock_lbl" xml:lang="en-US">License Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LicenseRevenueTextBlock" xlink:to="atnm_LicenseRevenueTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Share-Based Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss Per Common Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_Accountingstandardsrecentlyissuedpolicytextblock" xlink:href="atnm-20220630.xsd#atnm_Accountingstandardsrecentlyissuedpolicytextblock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_Accountingstandardsrecentlyissuedpolicytextblock_lbl" xml:lang="en-US">Recently Adopted Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_Accountingstandardsrecentlyissuedpolicytextblock" xlink:to="atnm_Accountingstandardsrecentlyissuedpolicytextblock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_CapitalOnDemandSalesAgreementMember" xlink:href="atnm-20220630.xsd#atnm_CapitalOnDemandSalesAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_CapitalOnDemandSalesAgreementMember_lbl" xml:lang="en-US">Capital on Demand Sales Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CapitalOnDemandSalesAgreementMember" xlink:to="atnm_CapitalOnDemandSalesAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Stock option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockOptionMember_lbl0" xml:lang="en-US">Equity Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_EquityTablesTable" xlink:href="atnm-20220630.xsd#atnm_EquityTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_EquityTablesTable_lbl" xml:lang="en-US">Equity (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_EquityTablesTable" xlink:to="atnm_EquityTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_EquityTablesLineItems" xlink:href="atnm-20220630.xsd#atnm_EquityTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_EquityTablesLineItems_lbl" xml:lang="en-US">Equity (Tables) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_EquityTablesLineItems" xlink:to="atnm_EquityTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_LeaseDomain" xlink:href="atnm-20220630.xsd#atnm_LeaseDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LeaseDomain_lbl" xml:lang="en-US">Lease [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeaseDomain" xlink:to="atnm_LeaseDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable" xlink:href="atnm-20220630.xsd#atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable_lbl" xml:lang="en-US">Leases (Details) - Schedule of maturities of lease liabilities [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable" xlink:to="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:href="atnm-20220630.xsd#atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems_lbl" xml:lang="en-US">Leases (Details) - Schedule of maturities of lease liabilities [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:to="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_AgreementDomain" xlink:href="atnm-20220630.xsd#atnm_AgreementDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_AgreementDomain_lbl" xml:lang="en-US">Agreement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AgreementDomain" xlink:to="atnm_AgreementDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xml:lang="en-US">Derivative Contract [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_EquityDetailsTable" xlink:href="atnm-20220630.xsd#atnm_EquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_EquityDetailsTable_lbl" xml:lang="en-US">Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_EquityDetailsTable" xlink:to="atnm_EquityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_EquityDetailsLineItems" xlink:href="atnm-20220630.xsd#atnm_EquityDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_EquityDetailsLineItems_lbl" xml:lang="en-US">Equity (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_EquityDetailsLineItems" xlink:to="atnm_EquityDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_SubsequentEventDetailsTable" xlink:href="atnm-20220630.xsd#atnm_SubsequentEventDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_SubsequentEventDetailsTable_lbl" xml:lang="en-US">Subsequent Event (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SubsequentEventDetailsTable" xlink:to="atnm_SubsequentEventDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_SubsequentEventDetailsLineItems" xlink:href="atnm-20220630.xsd#atnm_SubsequentEventDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_SubsequentEventDetailsLineItems_lbl" xml:lang="en-US">Subsequent Event (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SubsequentEventDetailsLineItems" xlink:to="atnm_SubsequentEventDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_Accountingstandardsrecentlyissuedpolicytextblock_lbl0" xml:lang="en-US">Accounting Standards Recently Issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_Accountingstandardsrecentlyissuedpolicytextblock" xlink:to="atnm_Accountingstandardsrecentlyissuedpolicytextblock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_AdditionSpaceForOperatingLease_lbl0" xml:lang="en-US">Addition of auxiliary corporate office sapce for operating lease.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AdditionSpaceForOperatingLease" xlink:to="atnm_AdditionSpaceForOperatingLease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight_lbl0" xml:lang="en-US">Exercise price per share or per unit of warrants or rights outstanding.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight" xlink:to="atnm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_DescriptionOfRoyaltyPaymentToRelatedParty_lbl0" xml:lang="en-US">Description of royalty payment to related party.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_DescriptionOfRoyaltyPaymentToRelatedParty" xlink:to="atnm_DescriptionOfRoyaltyPaymentToRelatedParty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_LongtermFinanceLeaseObligationsNoncurrent_lbl0" xml:lang="en-US">Long-term finance lease obligations.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LongtermFinanceLeaseObligationsNoncurrent" xlink:to="atnm_LongtermFinanceLeaseObligationsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_LongtermLicenseRevenueDeferred_lbl0" xml:lang="en-US">The amount of long-term license revenue deferred.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LongtermLicenseRevenueDeferred" xlink:to="atnm_LongtermLicenseRevenueDeferred_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_MilestonePayment_lbl0" xml:lang="en-US">The amount of milestone payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_MilestonePayment" xlink:to="atnm_MilestonePayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_NatureOfBusinessPolicyTextBlock_lbl0" xml:lang="en-US">Nature of Business policy text block.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NatureOfBusinessPolicyTextBlock" xlink:to="atnm_NatureOfBusinessPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_NetProceeds_lbl0" xml:lang="en-US">Net proceeds.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NetProceeds" xlink:to="atnm_NetProceeds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_NumberOfFinanceLease_lbl0" xml:lang="en-US">The number of finance lease for office equipment and furniture.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NumberOfFinanceLease" xlink:to="atnm_NumberOfFinanceLease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_NumberOfOperatingLease_lbl0" xml:lang="en-US">The number of operating lease for corporate office.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NumberOfOperatingLease" xlink:to="atnm_NumberOfOperatingLease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_NumberOfShares_lbl0" xml:lang="en-US">Number of shares sold.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NumberOfShares" xlink:to="atnm_NumberOfShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_NumberOfSharesExercised1_lbl0" xml:lang="en-US">Number of share options (or share units) exercised during the current period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NumberOfSharesExercised1" xlink:to="atnm_NumberOfSharesExercised1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of maturities of lease liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_PandemicOnFinancialStatements_lbl0" xml:lang="en-US">Impact of COVID&#8211;19 Pandemic on Financial Statements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_PandemicOnFinancialStatements" xlink:to="atnm_PandemicOnFinancialStatements_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_PurchaseOfCommonStockDescription_lbl0" xml:lang="en-US">Description of purchase of common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_PurchaseOfCommonStockDescription" xlink:to="atnm_PurchaseOfCommonStockDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_RecognitionOfDeferredRevenue1_lbl0" xml:lang="en-US">Recognition of deferred revenue.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RecognitionOfDeferredRevenue1" xlink:to="atnm_RecognitionOfDeferredRevenue1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_RevenueRecognized_lbl0" xml:lang="en-US">The amount of revenue recognized.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RevenueRecognized" xlink:to="atnm_RevenueRecognized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Weighted average remaining contractual term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl0" xml:lang="en-US">Weighted average remaining contractual term for option awards outstanding, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_SharesOfCommonStockValue_lbl0" xml:lang="en-US">Shares of common stock value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SharesOfCommonStockValue" xlink:to="atnm_SharesOfCommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_StockIssuedDuringPeriodSharesIssuanceOfCommonStockFromExerciseOfPrefundedWarrants_lbl0" xml:lang="en-US">Number of Issuance of common stock from exercise of pre-funded warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_StockIssuedDuringPeriodSharesIssuanceOfCommonStockFromExerciseOfPrefundedWarrants" xlink:to="atnm_StockIssuedDuringPeriodSharesIssuanceOfCommonStockFromExerciseOfPrefundedWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_StockOptionDescription_lbl0" xml:lang="en-US">Stock option, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_StockOptionDescription" xlink:to="atnm_StockOptionDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_StockOptionTerm_lbl0" xml:lang="en-US">Stock option term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_StockOptionTerm" xlink:to="atnm_StockOptionTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_UnrecognizedCompensationExpense_lbl0" xml:lang="en-US">Unrecognized compensation expense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnrecognizedCompensationExpense" xlink:to="atnm_UnrecognizedCompensationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_UpfrontPayment_lbl0" xml:lang="en-US">Upfront payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UpfrontPayment" xlink:to="atnm_UpfrontPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_VestingPeriodOfStockOption_lbl0" xml:lang="en-US">Vesting period of stock option.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_VestingPeriodOfStockOption" xlink:to="atnm_VestingPeriodOfStockOption_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_WeightedAverageTerm_lbl0" xml:lang="en-US">Weighted average term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WeightedAverageTerm" xlink:to="atnm_WeightedAverageTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_AgreementAxis_lbl0" xml:lang="en-US">Agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AgreementAxis" xlink:to="atnm_AgreementAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_IncreaseDecreaseInOperatingLeaseLiabilities_lbl0" xml:lang="en-US">IncreaseDecreaseInOperatingLeaseLiabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="atnm_IncreaseDecreaseInOperatingLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_RecognitionOfDeferredRevenue1_lbl1" xml:lang="en-US">RecognitionOfDeferredRevenue1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RecognitionOfDeferredRevenue1" xlink:to="atnm_RecognitionOfDeferredRevenue1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract0000_lbl0" xml:lang="en-US">UnlabeledAbstract0000</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract0000" xlink:to="atnm_UnlabeledAbstract0000_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock_lbl1" xml:lang="en-US">OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_AggregateFairValue_lbl0" xml:lang="en-US">AggregateFairValue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AggregateFairValue" xlink:to="atnm_AggregateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract000000000_lbl0" xml:lang="en-US">UnlabeledAbstract000000000</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract000000000" xlink:to="atnm_UnlabeledAbstract000000000_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl1" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_CompensationExpenseRelatedToStockOptions_lbl0" xml:lang="en-US">CompensationExpenseRelatedToStockOptions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CompensationExpenseRelatedToStockOptions" xlink:to="atnm_CompensationExpenseRelatedToStockOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_StocksOptionMember_lbl0" xml:lang="en-US">StocksOptionMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_StocksOptionMember" xlink:to="atnm_StocksOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract0000000000000000000_lbl0" xml:lang="en-US">UnlabeledAbstract0000000000000000000</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract0000000000000000000" xlink:to="atnm_UnlabeledAbstract0000000000000000000_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_PandemicOnFinancialStatements_lbl1" xml:lang="en-US">PandemicOnFinancialStatements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_PandemicOnFinancialStatements" xlink:to="atnm_PandemicOnFinancialStatements_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_PaymentWithImputedInterestPremium_lbl0" xml:lang="en-US">PaymentWithImputedInterestPremium</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_PaymentWithImputedInterestPremium" xlink:to="atnm_PaymentWithImputedInterestPremium_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract0000000000000000000000_lbl0" xml:lang="en-US">UnlabeledAbstract0000000000000000000000</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract0000000000000000000000" xlink:to="atnm_UnlabeledAbstract0000000000000000000000_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_WeightedAverageTerm_lbl1" xml:lang="en-US">WeightedAverageTerm</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WeightedAverageTerm" xlink:to="atnm_WeightedAverageTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_NatureOfBusinessPolicyTextBlock_lbl1" xml:lang="en-US">NatureOfBusinessPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NatureOfBusinessPolicyTextBlock" xlink:to="atnm_NatureOfBusinessPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_FinanceLeaseCostAbstract_lbl0" xml:lang="en-US">FinanceLeaseCostAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_FinanceLeaseCostAbstract" xlink:to="atnm_FinanceLeaseCostAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_AdditionSpaceForOperatingLease_lbl1" xml:lang="en-US">AdditionSpaceForOperatingLease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AdditionSpaceForOperatingLease" xlink:to="atnm_AdditionSpaceForOperatingLease_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_VestingPeriodOfStockOption_lbl1" xml:lang="en-US">VestingPeriodOfStockOption</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_VestingPeriodOfStockOption" xlink:to="atnm_VestingPeriodOfStockOption_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_NumberOfOperatingLease_lbl1" xml:lang="en-US">NumberOfOperatingLease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NumberOfOperatingLease" xlink:to="atnm_NumberOfOperatingLease_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight_lbl1" xml:lang="en-US">ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight" xlink:to="atnm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LicenseRevenueTextBlock_lbl0" xml:lang="en-US">LicenseRevenueTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LicenseRevenueTextBlock" xlink:to="atnm_LicenseRevenueTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_CapitalOnDemandSalesAgreementMember_lbl0" xml:lang="en-US">CapitalOnDemandSalesAgreementMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CapitalOnDemandSalesAgreementMember" xlink:to="atnm_CapitalOnDemandSalesAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_NetProceeds_lbl1" xml:lang="en-US">NetProceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NetProceeds" xlink:to="atnm_NetProceeds_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_GrantRevenuePolicyTextBlock_lbl0" xml:lang="en-US">GrantRevenuePolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_GrantRevenuePolicyTextBlock" xlink:to="atnm_GrantRevenuePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract00_lbl0" xml:lang="en-US">UnlabeledAbstract00</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract00" xlink:to="atnm_UnlabeledAbstract00_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_SalesOfSharesOfCommonStockNetOfCosts_lbl0" xml:lang="en-US">SalesOfSharesOfCommonStockNetOfCosts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SalesOfSharesOfCommonStockNetOfCosts" xlink:to="atnm_SalesOfSharesOfCommonStockNetOfCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract_lbl0" xml:lang="en-US">UnlabeledAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract" xlink:to="atnm_UnlabeledAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfWeightedAverageDiscountRate_lbl0" xml:lang="en-US">ScheduleOfWeightedAverageDiscountRate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfWeightedAverageDiscountRate" xlink:to="atnm_ScheduleOfWeightedAverageDiscountRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_OperatingLeaseLiabilitiesMember_lbl0" xml:lang="en-US">OperatingLeaseLiabilitiesMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OperatingLeaseLiabilitiesMember" xlink:to="atnm_OperatingLeaseLiabilitiesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LongtermFinanceLeaseObligationsNoncurrent_lbl1" xml:lang="en-US">LongtermFinanceLeaseObligationsNoncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LongtermFinanceLeaseObligationsNoncurrent" xlink:to="atnm_LongtermFinanceLeaseObligationsNoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract000000000000_lbl0" xml:lang="en-US">UnlabeledAbstract000000000000</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract000000000000" xlink:to="atnm_UnlabeledAbstract000000000000_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract000000000000000000_lbl0" xml:lang="en-US">UnlabeledAbstract000000000000000000</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract000000000000000000" xlink:to="atnm_UnlabeledAbstract000000000000000000_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_FinanceLeaseLiabilitiesMember_lbl0" xml:lang="en-US">FinanceLeaseLiabilitiesMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_FinanceLeaseLiabilitiesMember" xlink:to="atnm_FinanceLeaseLiabilitiesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnrecognizedCompensationExpense_lbl1" xml:lang="en-US">UnrecognizedCompensationExpense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnrecognizedCompensationExpense" xlink:to="atnm_UnrecognizedCompensationExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LeasesTextBlock_lbl0" xml:lang="en-US">LeasesTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeasesTextBlock" xlink:to="atnm_LeasesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_NonCashActivityAbstract_lbl0" xml:lang="en-US">NonCashActivityAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NonCashActivityAbstract" xlink:to="atnm_NonCashActivityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LeaseAxis_lbl0" xml:lang="en-US">LeaseAxis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeaseAxis" xlink:to="atnm_LeaseAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_SharesOfCommonStockValue_lbl1" xml:lang="en-US">SharesOfCommonStockValue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SharesOfCommonStockValue" xlink:to="atnm_SharesOfCommonStockValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract0000000000_lbl0" xml:lang="en-US">UnlabeledAbstract0000000000</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract0000000000" xlink:to="atnm_UnlabeledAbstract0000000000_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_Accountingstandardsrecentlyissuedpolicytextblock_lbl1" xml:lang="en-US">Accountingstandardsrecentlyissuedpolicytextblock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_Accountingstandardsrecentlyissuedpolicytextblock" xlink:to="atnm_Accountingstandardsrecentlyissuedpolicytextblock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_NumberOfWarrantsOutstandings_lbl1" xml:lang="en-US">NumberOfWarrantsOutstandings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NumberOfWarrantsOutstandings" xlink:to="atnm_NumberOfWarrantsOutstandings_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract000_lbl0" xml:lang="en-US">UnlabeledAbstract000</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract000" xlink:to="atnm_UnlabeledAbstract000_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_NumberOfSharesExercised1_lbl1" xml:lang="en-US">NumberOfSharesExercised1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NumberOfSharesExercised1" xlink:to="atnm_NumberOfSharesExercised1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_WeightedAverageDiscountRatesAbstract_lbl0" xml:lang="en-US">WeightedAverageDiscountRatesAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WeightedAverageDiscountRatesAbstract" xlink:to="atnm_WeightedAverageDiscountRatesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_lbl1" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_AgreementAxis_lbl1" xml:lang="en-US">AgreementAxis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AgreementAxis" xlink:to="atnm_AgreementAxis_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract000000000000000_lbl0" xml:lang="en-US">UnlabeledAbstract000000000000000</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract000000000000000" xlink:to="atnm_UnlabeledAbstract000000000000000_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_StockIssuedDuringPeriodSharesIssuanceOfCommonStockFromExerciseOfPrefundedWarrants_lbl1" xml:lang="en-US">StockIssuedDuringPeriodSharesIssuanceOfCommonStockFromExerciseOfPrefundedWarrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_StockIssuedDuringPeriodSharesIssuanceOfCommonStockFromExerciseOfPrefundedWarrants" xlink:to="atnm_StockIssuedDuringPeriodSharesIssuanceOfCommonStockFromExerciseOfPrefundedWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LongtermLicenseRevenueDeferred_lbl1" xml:lang="en-US">LongtermLicenseRevenueDeferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LongtermLicenseRevenueDeferred" xlink:to="atnm_LongtermLicenseRevenueDeferred_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_OtherRevenueTextBlock_lbl0" xml:lang="en-US">OtherRevenueTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OtherRevenueTextBlock" xlink:to="atnm_OtherRevenueTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_PurchaseOfCommonStockDescription_lbl1" xml:lang="en-US">PurchaseOfCommonStockDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_PurchaseOfCommonStockDescription" xlink:to="atnm_PurchaseOfCommonStockDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract00000000000000000_lbl0" xml:lang="en-US">UnlabeledAbstract00000000000000000</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract00000000000000000" xlink:to="atnm_UnlabeledAbstract00000000000000000_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOrDescriptionOfWeightedAverageTerm_lbl0" xml:lang="en-US">ScheduleOrDescriptionOfWeightedAverageTerm</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOrDescriptionOfWeightedAverageTerm" xlink:to="atnm_ScheduleOrDescriptionOfWeightedAverageTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract000000000000000000000_lbl0" xml:lang="en-US">UnlabeledAbstract000000000000000000000</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract000000000000000000000" xlink:to="atnm_UnlabeledAbstract000000000000000000000_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl0" xml:lang="en-US">CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract0_lbl0" xml:lang="en-US">UnlabeledAbstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract0" xlink:to="atnm_UnlabeledAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract00000000_lbl0" xml:lang="en-US">UnlabeledAbstract00000000</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract00000000" xlink:to="atnm_UnlabeledAbstract00000000_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_MaturitiesOfLeaseLiabilities_lbl0" xml:lang="en-US">MaturitiesOfLeaseLiabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_MaturitiesOfLeaseLiabilities" xlink:to="atnm_MaturitiesOfLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_StockOptionTerm_lbl1" xml:lang="en-US">StockOptionTerm</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_StockOptionTerm" xlink:to="atnm_StockOptionTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract00000000000_lbl0" xml:lang="en-US">UnlabeledAbstract00000000000</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract00000000000" xlink:to="atnm_UnlabeledAbstract00000000000_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_NumberOfFinanceLease_lbl1" xml:lang="en-US">NumberOfFinanceLease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NumberOfFinanceLease" xlink:to="atnm_NumberOfFinanceLease_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_DescriptionOfRoyaltyPaymentToRelatedParty_lbl1" xml:lang="en-US">DescriptionOfRoyaltyPaymentToRelatedParty</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_DescriptionOfRoyaltyPaymentToRelatedParty" xlink:to="atnm_DescriptionOfRoyaltyPaymentToRelatedParty_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract000000_lbl0" xml:lang="en-US">UnlabeledAbstract000000</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract000000" xlink:to="atnm_UnlabeledAbstract000000_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_RevenueRecognized_lbl1" xml:lang="en-US">RevenueRecognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RevenueRecognized" xlink:to="atnm_RevenueRecognized_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_WeightedAverageRemainingLeaseTermAbstract_lbl0" xml:lang="en-US">WeightedAverageRemainingLeaseTermAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WeightedAverageRemainingLeaseTermAbstract" xlink:to="atnm_WeightedAverageRemainingLeaseTermAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UpfrontPayment_lbl1" xml:lang="en-US">UpfrontPayment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UpfrontPayment" xlink:to="atnm_UpfrontPayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract0000000_lbl0" xml:lang="en-US">UnlabeledAbstract0000000</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract0000000" xlink:to="atnm_UnlabeledAbstract0000000_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_StockOptionDescription_lbl1" xml:lang="en-US">StockOptionDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_StockOptionDescription" xlink:to="atnm_StockOptionDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_NumberOfShares_lbl1" xml:lang="en-US">NumberOfShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NumberOfShares" xlink:to="atnm_NumberOfShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract00000_lbl0" xml:lang="en-US">UnlabeledAbstract00000</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract00000" xlink:to="atnm_UnlabeledAbstract00000_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract0000000000000_lbl0" xml:lang="en-US">UnlabeledAbstract0000000000000</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract0000000000000" xlink:to="atnm_UnlabeledAbstract0000000000000_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract00000000000000_lbl0" xml:lang="en-US">UnlabeledAbstract00000000000000</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract00000000000000" xlink:to="atnm_UnlabeledAbstract00000000000000_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_MilestonePayment_lbl1" xml:lang="en-US">MilestonePayment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_MilestonePayment" xlink:to="atnm_MilestonePayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract00000000000000000000_lbl0" xml:lang="en-US">UnlabeledAbstract00000000000000000000</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract00000000000000000000" xlink:to="atnm_UnlabeledAbstract00000000000000000000_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract0000000000000000_lbl0" xml:lang="en-US">UnlabeledAbstract0000000000000000</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract0000000000000000" xlink:to="atnm_UnlabeledAbstract0000000000000000_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl1" xml:lang="en-US">Finance Lease, Principal Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl0" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl0" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl0" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl0" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl0" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Finance Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Four</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl0" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDeposit_lbl0" xml:lang="en-US">Security Deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl0" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl0" xml:lang="en-US">Revenues [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Stockholders&apos; Equity Note Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl0" xml:lang="en-US">Entity Address, State or Province</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfWarrants_lbl0" xml:lang="en-US">Payments for Repurchase of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfWarrants" xlink:to="us-gaap_PaymentsForRepurchaseOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl0" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl0" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl0" xml:lang="en-US">Deferred Revenue, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashCurrent_lbl0" xml:lang="en-US">Restricted Cash, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl0" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl0" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl0" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Rolling Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl0" xml:lang="en-US">Warrants and Rights Outstanding, Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl0" xml:lang="en-US">Notes Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl0" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl0" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl0" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl0" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl0" xml:lang="en-US">Schedule of Stockholders&apos; Equity Note, Warrants or Rights [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherRestrictedAssetsCurrent_lbl0" xml:lang="en-US">Other Restricted Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherRestrictedAssetsCurrent" xlink:to="us-gaap_OtherRestrictedAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl0" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl0" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl0" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl0" xml:lang="en-US">Interest Income (Expense), Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Finance Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits_lbl0" xml:lang="en-US">Increase (Decrease) in Security Deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl0" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl0" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl0" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl0" xml:lang="en-US">Sale of Stock, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl1" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl0" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl0" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl0" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl0" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Next Rolling 12 Months</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy_lbl0" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl0" xml:lang="en-US">Operating Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0" xml:lang="en-US">Revenue [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl0" xml:lang="en-US">Other Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl0" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl0" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl1" xml:lang="en-US">Stockholders&apos; Equity, Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl0" xml:lang="en-US">Entity Tax Identification Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl0" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl0" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl0" xml:lang="en-US">Deposits Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl0" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl0" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl0" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl0" xml:lang="en-US">Income Taxes Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_lbl0" xml:lang="en-US">Deferred Offering Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl0" xml:lang="en-US">Document Quarterly Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl0" xml:lang="en-US">Finance Lease, Interest Payment on Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostAbstract_lbl0" xml:lang="en-US">Lease, Cost [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl0" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl1" xml:lang="en-US">Equity Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenue_lbl0" xml:lang="en-US">Deferred Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubleaseIncome_lbl0" xml:lang="en-US">Sublease Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl0" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl0" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl0" xml:lang="en-US">Operating Lease, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl0" xml:lang="en-US">Finance Lease, Interest Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl0" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl0" xml:lang="en-US">Operating Lease, Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>atnm-20220630_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Aug 12 02:15:31 UTC 2022 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_ConsolidatedBalanceSheet" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_ConsolidatedIncomeStatement" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_ConsolidatedIncomeStatement_Parentheticals" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_ShareholdersEquityType2or3" roleURI="http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_ConsolidatedCashFlow" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_DescriptionofBusinessandSummaryofSignificantAccountingPolicies" roleURI="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_CommitmentsandContingencies" roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_Leases" roleURI="http://actiniumpharmaceuticals.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_OtherRevenue" roleURI="http://actiniumpharmaceuticals.com/role/OtherRevenue"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_Equity" roleURI="http://actiniumpharmaceuticals.com/role/Equity"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_SubsequentEvent" roleURI="http://actiniumpharmaceuticals.com/role/SubsequentEvent"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_AccountingPoliciesByPolicy" roleURI="http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" roleURI="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_LeasesTables" roleURI="http://actiniumpharmaceuticals.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_EquityTables" roleURI="http://actiniumpharmaceuticals.com/role/EquityTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_ScheduleofcashcashequivalentsandrestrictedcashTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_ScheduleofdilutednetlosspershareantidilutiveTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_ScheduleofcomponentsofleaseexpenseTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofcomponentsofleaseexpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_ScheduleofsupplementalcashflowinformationrelatedtoleasesTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_ScheduleofweightedaverageremainingleasetermsTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofweightedaverageremainingleasetermsTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_ScheduleofweightedaveragediscountratesTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofweightedaveragediscountratesTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_ScheduleofmaturitiesofleaseliabilitiesTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_ScheduleofstockoptionactivityTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofstockoptionactivityTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_ScheduleofwarrantactivitiesTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_CommitmentsandContingenciesDetails" roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_LeasesDetails" roleURI="http://actiniumpharmaceuticals.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_OtherRevenueDetails" roleURI="http://actiniumpharmaceuticals.com/role/OtherRevenueDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_EquityDetails" roleURI="http://actiniumpharmaceuticals.com/role/EquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#atnm_r_SubsequentEventDetails" roleURI="http://actiniumpharmaceuticals.com/role/SubsequentEventDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20220630.xsd#DocumentAndEntityInformation" roleURI="http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_SecurityDeposit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_AssetsCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_Assets" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_LiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_DeferredRevenue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LongtermFinanceLeaseObligationsNoncurrent" xlink:href="atnm-20220630.xsd#atnm_LongtermFinanceLeaseObligationsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="LongtermFinanceLeaseObligationsNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_Liabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_CommitmentsAndContingencies" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenuesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_SubleaseIncome" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_Revenues" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeExpenseNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="3.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesIssuanceOfCommonStockFromExerciseOfPrefundedWarrants" xlink:href="atnm-20220630.xsd#atnm_StockIssuedDuringPeriodSharesIssuanceOfCommonStockFromExerciseOfPrefundedWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesIssuanceOfCommonStockFromExerciseOfPrefundedWarrants" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreaseInOperatingLeaseLiabilities" xlink:href="atnm-20220630.xsd#atnm_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="IncreaseDecreaseInOperatingLeaseLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="SalesOfSharesOfCommonStockNetOfCosts" xlink:href="atnm-20220630.xsd#atnm_SalesOfSharesOfCommonStockNetOfCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="SalesOfSharesOfCommonStockNetOfCosts" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/Leases">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="LeasesTextBlock" xlink:href="atnm-20220630.xsd#atnm_LeasesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="LeasesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/OtherRevenue">
    <loc xlink:type="locator" xlink:label="OtherRevenueAbstract" xlink:href="atnm-20220630.xsd#atnm_OtherRevenueAbstract"/>
    <loc xlink:type="locator" xlink:label="OtherRevenueTextBlock" xlink:href="atnm-20220630.xsd#atnm_OtherRevenueTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherRevenueAbstract" xlink:to="OtherRevenueTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/Equity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/SubsequentEvent">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="NatureOfBusinessPolicyTextBlock" xlink:href="atnm-20220630.xsd#atnm_NatureOfBusinessPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="NatureOfBusinessPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PandemicOnFinancialStatements" xlink:href="atnm-20220630.xsd#atnm_PandemicOnFinancialStatements"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="PandemicOnFinancialStatements" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrantRevenuePolicyTextBlock" xlink:href="atnm-20220630.xsd#atnm_GrantRevenuePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="GrantRevenuePolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LicenseRevenueTextBlock" xlink:href="atnm-20220630.xsd#atnm_LicenseRevenueTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="LicenseRevenueTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Accountingstandardsrecentlyissuedpolicytextblock" xlink:href="atnm-20220630.xsd#atnm_Accountingstandardsrecentlyissuedpolicytextblock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="Accountingstandardsrecentlyissuedpolicytextblock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/LeasesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOrDescriptionOfWeightedAverageTerm" xlink:href="atnm-20220630.xsd#atnm_ScheduleOrDescriptionOfWeightedAverageTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="ScheduleOrDescriptionOfWeightedAverageTerm" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfWeightedAverageDiscountRate" xlink:href="atnm-20220630.xsd#atnm_ScheduleOfWeightedAverageDiscountRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="ScheduleOfWeightedAverageDiscountRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="atnm-20220630.xsd#atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityTables">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityTablesTable" xlink:href="atnm-20220630.xsd#atnm_EquityTablesTable"/>
    <loc xlink:type="locator" xlink:label="EquityTablesLineItems" xlink:href="atnm-20220630.xsd#atnm_EquityTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="EquityTablesTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityTablesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="StocksOptionMember" xlink:href="atnm-20220630.xsd#atnm_StocksOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="StocksOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityTablesTable" xlink:to="EquityTablesLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityTablesLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityTablesLineItems" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb5nsTZF1hxsII3StF2nMaFie2WjubTneMhItBwoNuKpVkBjepuDGZJv0uAY/2011DiRxFwSK8IV5mRgvGfHwlBphcd0S/9cahV/vLA5QTpMuHsLSaekfOQE+nOwFp1gLwGaIR82N4BdA/qqO+LqocFMcsLb+CKpnMLguXk/dClIuZ4s7bLRTp12jwSERaIqdwlwSSuibmDa+qJP+hgChjN8SW5DhdUGuob0YkU89Bv8Q==] CSR-->
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:href="atnm-20220630.xsd#atnm_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherRestrictedAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherRestrictedAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:to="us-gaap_OtherRestrictedAssetsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfDilutedNetLossPerShareAntiDilutiveAbstract" xlink:href="atnm-20220630.xsd#atnm_ScheduleOfDilutedNetLossPerShareAntiDilutiveAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDilutedNetLossPerShareAntiDilutiveAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_WarrantMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofcomponentsofleaseexpenseTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfComponentsOfLeaseExpenseAbstract" xlink:href="atnm-20220630.xsd#atnm_ScheduleOfComponentsOfLeaseExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfLeaseExpenseAbstract" xlink:to="us-gaap_OperatingLeaseExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfLeaseExpenseAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfLeaseExpenseAbstract" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_OperatingLeaseCost" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:href="atnm-20220630.xsd#atnm_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NonCashActivityAbstract" xlink:href="atnm-20220630.xsd#atnm_NonCashActivityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="NonCashActivityAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonCashActivityAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonCashActivityAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofweightedaverageremainingleasetermsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfWeightedAverageRemainingLeaseTermsAbstract" xlink:href="atnm-20220630.xsd#atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAbstract"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageRemainingLeaseTermAbstract" xlink:href="atnm-20220630.xsd#atnm_WeightedAverageRemainingLeaseTermAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageRemainingLeaseTermsAbstract" xlink:to="WeightedAverageRemainingLeaseTermAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageRemainingLeaseTermAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageRemainingLeaseTermAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofweightedaveragediscountratesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfWeightedAverageDiscountRatesAbstract" xlink:href="atnm-20220630.xsd#atnm_ScheduleOfWeightedAverageDiscountRatesAbstract"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageDiscountRatesAbstract" xlink:href="atnm-20220630.xsd#atnm_WeightedAverageDiscountRatesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageDiscountRatesAbstract" xlink:to="WeightedAverageDiscountRatesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageDiscountRatesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageDiscountRatesAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:href="atnm-20220630.xsd#atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable" xlink:href="atnm-20220630.xsd#atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:href="atnm-20220630.xsd#atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:to="LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="LeaseAxis" xlink:href="atnm-20220630.xsd#atnm_LeaseAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable" xlink:to="LeaseAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLeaseLiabilitiesMember" xlink:href="atnm-20220630.xsd#atnm_OperatingLeaseLiabilitiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeaseAxis" xlink:to="OperatingLeaseLiabilitiesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceLeaseLiabilitiesMember" xlink:href="atnm-20220630.xsd#atnm_FinanceLeaseLiabilitiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeaseAxis" xlink:to="FinanceLeaseLiabilitiesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable" xlink:to="LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentWithImputedInterestPremium" xlink:href="atnm-20220630.xsd#atnm_PaymentWithImputedInterestPremium"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:to="PaymentWithImputedInterestPremium" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MaturitiesOfLeaseLiabilities" xlink:href="atnm-20220630.xsd#atnm_MaturitiesOfLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PaymentWithImputedInterestPremium" xlink:to="MaturitiesOfLeaseLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofstockoptionactivityTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfStockOptionActivityAbstract" xlink:href="atnm-20220630.xsd#atnm_ScheduleOfStockOptionActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="atnm-20220630.xsd#atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfWarrantActivitiesAbstract" xlink:href="atnm-20220630.xsd#atnm_ScheduleOfWarrantActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantActivitiesAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_WarrantMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="NumberOfWarrantsOutstandings" xlink:href="atnm-20220630.xsd#atnm_NumberOfWarrantsOutstandings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="NumberOfWarrantsOutstandings" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfWarrantsOutstandings_0" xlink:href="atnm-20220630.xsd#atnm_NumberOfWarrantsOutstandings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="NumberOfWarrantsOutstandings_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="atnm-20220630.xsd#atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfSharesExercised1" xlink:href="atnm-20220630.xsd#atnm_NumberOfSharesExercised1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="NumberOfSharesExercised1" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="MilestonePayment" xlink:href="atnm-20220630.xsd#atnm_MilestonePayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="MilestonePayment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfRoyaltyPaymentToRelatedParty" xlink:href="atnm-20220630.xsd#atnm_DescriptionOfRoyaltyPaymentToRelatedParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="DescriptionOfRoyaltyPaymentToRelatedParty" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/LeasesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="NumberOfOperatingLease" xlink:href="atnm-20220630.xsd#atnm_NumberOfOperatingLease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="NumberOfOperatingLease" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfFinanceLease" xlink:href="atnm-20220630.xsd#atnm_NumberOfFinanceLease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="NumberOfFinanceLease" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionSpaceForOperatingLease" xlink:href="atnm-20220630.xsd#atnm_AdditionSpaceForOperatingLease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="AdditionSpaceForOperatingLease" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/OtherRevenueDetails">
    <loc xlink:type="locator" xlink:label="OtherRevenueAbstract" xlink:href="atnm-20220630.xsd#atnm_OtherRevenueAbstract"/>
    <loc xlink:type="locator" xlink:label="RecognitionOfDeferredRevenue1" xlink:href="atnm-20220630.xsd#atnm_RecognitionOfDeferredRevenue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherRevenueAbstract" xlink:to="RecognitionOfDeferredRevenue1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RevenueRecognized" xlink:href="atnm-20220630.xsd#atnm_RevenueRecognized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherRevenueAbstract" xlink:to="RevenueRecognized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UpfrontPayment" xlink:href="atnm-20220630.xsd#atnm_UpfrontPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherRevenueAbstract" xlink:to="UpfrontPayment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherRevenueAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LongtermLicenseRevenueDeferred" xlink:href="atnm-20220630.xsd#atnm_LongtermLicenseRevenueDeferred"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherRevenueAbstract" xlink:to="LongtermLicenseRevenueDeferred" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityDetailsTable" xlink:href="atnm-20220630.xsd#atnm_EquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="EquityDetailsLineItems" xlink:href="atnm-20220630.xsd#atnm_EquityDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="EquityDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="AgreementAxis" xlink:href="atnm-20220630.xsd#atnm_AgreementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="AgreementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AgreementDomain" xlink:href="atnm-20220630.xsd#atnm_AgreementDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AgreementAxis" xlink:to="AgreementDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CapitalOnDemandSalesAgreementMember" xlink:href="atnm-20220630.xsd#atnm_CapitalOnDemandSalesAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AgreementAxis" xlink:to="CapitalOnDemandSalesAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_StockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="srt_RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="EquityDetailsLineItems" order="4.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseOfCommonStockDescription" xlink:href="atnm-20220630.xsd#atnm_PurchaseOfCommonStockDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="PurchaseOfCommonStockDescription" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight" xlink:href="atnm-20220630.xsd#atnm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockOptionTerm" xlink:href="atnm-20220630.xsd#atnm_StockOptionTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="StockOptionTerm" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="VestingPeriodOfStockOption" xlink:href="atnm-20220630.xsd#atnm_VestingPeriodOfStockOption"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="VestingPeriodOfStockOption" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateFairValue" xlink:href="atnm-20220630.xsd#atnm_AggregateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="AggregateFairValue" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockOptionDescription" xlink:href="atnm-20220630.xsd#atnm_StockOptionDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="StockOptionDescription" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnrecognizedCompensationExpense" xlink:href="atnm-20220630.xsd#atnm_UnrecognizedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="UnrecognizedCompensationExpense" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageTerm" xlink:href="atnm-20220630.xsd#atnm_WeightedAverageTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="WeightedAverageTerm" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CompensationExpenseRelatedToStockOptions" xlink:href="atnm-20220630.xsd#atnm_CompensationExpenseRelatedToStockOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="CompensationExpenseRelatedToStockOptions" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/SubsequentEventDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventDetailsTable" xlink:href="atnm-20220630.xsd#atnm_SubsequentEventDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventDetailsLineItems" xlink:href="atnm-20220630.xsd#atnm_SubsequentEventDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SubsequentEventDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventDetailsTable" xlink:to="SubsequentEventDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="SharesOfCommonStockValue" xlink:href="atnm-20220630.xsd#atnm_SharesOfCommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventDetailsLineItems" xlink:to="SharesOfCommonStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetProceeds" xlink:href="atnm-20220630.xsd#atnm_NetProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventDetailsLineItems" xlink:to="NetProceeds" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventDetailsLineItems" xlink:to="us-gaap_PaymentsForRepurchaseOfWarrants" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventDetailsLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventDetailsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfShares" xlink:href="atnm-20220630.xsd#atnm_NumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventDetailsLineItems" xlink:to="NumberOfShares" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="atnm-20220630.xsd#atnm_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentQuarterlyReport" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140021011438352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Aug. 12, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ACTINIUM
PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ATNM<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,184,654<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001388320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">74-2963609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">275 Madison Ave, 7th Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(646)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">677-3870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140021011531696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 116,330<span></span>
</td>
<td class="nump">$ 77,829<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">392<span></span>
</td>
<td class="nump">392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,525<span></span>
</td>
<td class="nump">1,478<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">118,297<span></span>
</td>
<td class="nump">79,749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation of $395 and $335</a></td>
<td class="nump">557<span></span>
</td>
<td class="nump">340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Security deposit &#8211; long term</a></td>
<td class="nump">299<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating leases right-of-use assets</a></td>
<td class="nump">2,629<span></span>
</td>
<td class="nump">241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance leases right-of-use assets</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">121,800<span></span>
</td>
<td class="nump">80,388<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">5,767<span></span>
</td>
<td class="nump">5,535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other revenue deferred&#8211; current liability</a></td>
<td class="nump">204<span></span>
</td>
<td class="nump">998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating leases current liability</a></td>
<td class="nump">292<span></span>
</td>
<td class="nump">245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance leases current liability</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">6,282<span></span>
</td>
<td class="nump">6,840<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Long-term license revenue deferred</a></td>
<td class="nump">35,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term operating leases obligations</a></td>
<td class="nump">2,335<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_LongtermFinanceLeaseObligationsNoncurrent', window );">Long-term finance leases obligations</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">43,619<span></span>
</td>
<td class="nump">6,843<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 50,000,000 shares authorized, 0 shares issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 1,000,000,000 shares authorized; 24,870,623 and 22,143,974 shares issued and outstanding, respectively</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">346,800<span></span>
</td>
<td class="nump">329,271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(268,644)<span></span>
</td>
<td class="num">(255,748)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Equity</a></td>
<td class="nump">78,181<span></span>
</td>
<td class="nump">73,545<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders&#8217; Equity</a></td>
<td class="nump">$ 121,800<span></span>
</td>
<td class="nump">$ 80,388<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_LongtermFinanceLeaseObligationsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term finance lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_LongtermFinanceLeaseObligationsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140021011401424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parentheticals) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Property and equipment, net of accumulated depreciation (in Dollars)</a></td>
<td class="nump">$ 395<span></span>
</td>
<td class="nump">$ 335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">24,870,623<span></span>
</td>
<td class="nump">22,143,974<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">24,870,623<span></span>
</td>
<td class="nump">22,143,974<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140021011663792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Other revenue</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">266<span></span>
</td>
<td class="nump">985<span></span>
</td>
<td class="nump">888<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">266<span></span>
</td>
<td class="nump">985<span></span>
</td>
<td class="nump">888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development, net of reimbursements</a></td>
<td class="nump">4,662<span></span>
</td>
<td class="nump">3,631<span></span>
</td>
<td class="nump">9,031<span></span>
</td>
<td class="nump">7,907<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">3,233<span></span>
</td>
<td class="nump">1,710<span></span>
</td>
<td class="nump">4,968<span></span>
</td>
<td class="nump">3,428<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">7,895<span></span>
</td>
<td class="nump">5,341<span></span>
</td>
<td class="nump">13,999<span></span>
</td>
<td class="nump">11,335<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(7,850)<span></span>
</td>
<td class="num">(5,075)<span></span>
</td>
<td class="num">(13,014)<span></span>
</td>
<td class="num">(10,447)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income - net</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="nump">118<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="nump">118<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (7,767)<span></span>
</td>
<td class="num">$ (5,021)<span></span>
</td>
<td class="num">$ (12,896)<span></span>
</td>
<td class="num">$ (10,341)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share &#8211; basic and diluted (in Dollars per share)</a></td>
<td class="num">$ (0.33)<span></span>
</td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (0.56)<span></span>
</td>
<td class="num">$ (0.54)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding &#8211; basic and diluted (in Shares)</a></td>
<td class="nump">23,731,886<span></span>
</td>
<td class="nump">20,231,278<span></span>
</td>
<td class="nump">22,942,317<span></span>
</td>
<td class="nump">19,308,487<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140021011371808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share &#8211; basic and diluted (in Dollars per share)</a></td>
<td class="num">$ (0.33)<span></span>
</td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (0.56)<span></span>
</td>
<td class="num">$ (0.54)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding &#8211; basic and diluted (in Shares)</a></td>
<td class="nump">23,731,886<span></span>
</td>
<td class="nump">20,231,278<span></span>
</td>
<td class="nump">22,942,317<span></span>
</td>
<td class="nump">19,308,487<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140020935736096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Changes in Stockholders&#8217; Equity (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 292,275<span></span>
</td>
<td class="num">$ (230,974)<span></span>
</td>
<td class="nump">$ 61,319<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2020</a></td>
<td class="nump">17,532,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">376<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">376<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock, net of costs</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">14,360<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">14,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock, net of costs (in Shares)</a></td>
<td class="nump">1,712,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,320)<span></span>
</td>
<td class="num">(5,320)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2021</a></td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">307,011<span></span>
</td>
<td class="num">(236,294)<span></span>
</td>
<td class="nump">70,736<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2021</a></td>
<td class="nump">19,245,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">292,275<span></span>
</td>
<td class="num">(230,974)<span></span>
</td>
<td class="nump">61,319<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2020</a></td>
<td class="nump">17,532,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,341)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 30, 2021</a></td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">321,793<span></span>
</td>
<td class="num">(241,315)<span></span>
</td>
<td class="nump">80,499<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2021</a></td>
<td class="nump">21,090,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2021</a></td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">307,011<span></span>
</td>
<td class="num">(236,294)<span></span>
</td>
<td class="nump">70,736<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2021</a></td>
<td class="nump">19,245,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">459<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_StockIssuedDuringPeriodSharesIssuanceOfCommonStockFromExerciseOfPrefundedWarrants', window );">Stock-based compensation (in Shares)</a></td>
<td class="nump">8,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Sale of common stock, net of issuance costs</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">14,317<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">14,319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Sale of common stock, net of issuance costs (in Shares)</a></td>
<td class="nump">1,835,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in Shares)</a></td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,021)<span></span>
</td>
<td class="num">(5,021)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 30, 2021</a></td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">321,793<span></span>
</td>
<td class="num">(241,315)<span></span>
</td>
<td class="nump">80,499<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2021</a></td>
<td class="nump">21,090,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">329,271<span></span>
</td>
<td class="num">(255,748)<span></span>
</td>
<td class="nump">73,545<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2021</a></td>
<td class="nump">22,143,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">421<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,129)<span></span>
</td>
<td class="num">(5,129)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2022</a></td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">329,692<span></span>
</td>
<td class="num">(260,877)<span></span>
</td>
<td class="nump">68,837<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2022</a></td>
<td class="nump">22,143,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">329,271<span></span>
</td>
<td class="num">(255,748)<span></span>
</td>
<td class="nump">73,545<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2021</a></td>
<td class="nump">22,143,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,896)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 30, 2022</a></td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">346,800<span></span>
</td>
<td class="num">(268,644)<span></span>
</td>
<td class="nump">78,181<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2022</a></td>
<td class="nump">24,870,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2022</a></td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">329,692<span></span>
</td>
<td class="num">(260,877)<span></span>
</td>
<td class="nump">68,837<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2022</a></td>
<td class="nump">22,143,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">425<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Sale of common stock, net of issuance costs</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">16,683<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">16,686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Sale of common stock, net of issuance costs (in Shares)</a></td>
<td class="nump">2,726,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7,767)<span></span>
</td>
<td class="num">(7,767)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 30, 2022</a></td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">$ 346,800<span></span>
</td>
<td class="num">$ (268,644)<span></span>
</td>
<td class="nump">$ 78,181<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2022</a></td>
<td class="nump">24,870,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_StockIssuedDuringPeriodSharesIssuanceOfCommonStockFromExerciseOfPrefundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Issuance of common stock from exercise of pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_StockIssuedDuringPeriodSharesIssuanceOfCommonStockFromExerciseOfPrefundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140021011559840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (12,896)<span></span>
</td>
<td class="num">$ (10,341)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">846<span></span>
</td>
<td class="nump">835<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation</a></td>
<td class="nump">317<span></span>
</td>
<td class="nump">254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(47)<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInSecurityDeposits', window );">Payment of security deposit</a></td>
<td class="num">(299)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">232<span></span>
</td>
<td class="num">(913)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Other revenue deferred&#8211; current liability</a></td>
<td class="num">(794)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Long-term license revenue deferred</a></td>
<td class="nump">35,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(222)<span></span>
</td>
<td class="num">(167)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Provided By/Used In Operating Activities</a></td>
<td class="nump">22,137<span></span>
</td>
<td class="num">(10,226)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(277)<span></span>
</td>
<td class="num">(65)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Used In Investing Activities</a></td>
<td class="num">(277)<span></span>
</td>
<td class="num">(65)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments on finance leases</a></td>
<td class="num">(45)<span></span>
</td>
<td class="num">(42)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_SalesOfSharesOfCommonStockNetOfCosts', window );">Sales of shares of common stock, net of costs</a></td>
<td class="nump">16,686<span></span>
</td>
<td class="nump">28,680<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Provided By Financing Activities</a></td>
<td class="nump">16,641<span></span>
</td>
<td class="nump">28,644<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents, and restricted cash</a></td>
<td class="nump">38,501<span></span>
</td>
<td class="nump">18,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of period</a></td>
<td class="nump">78,221<span></span>
</td>
<td class="nump">63,999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of period</a></td>
<td class="nump">116,722<span></span>
</td>
<td class="nump">82,352<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_SalesOfSharesOfCommonStockNetOfCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_SalesOfSharesOfCommonStockNetOfCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInSecurityDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in security deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInSecurityDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140021014194832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Description of Business and Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1 - Description of Business and Summary of Significant Accounting Policies</b>&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Nature of Business -</b> Actinium
Pharmaceuticals, Inc. (the &#8220;Company&#8221; or &#8220;Actinium&#8221;) is a clinical-stage, biopharmaceutical company focused on
developing and potentially commercializing targeted radiotherapies for patients with unmet needs. The Company applies its proprietary
technology platform consisting of over 195 patents and patent applications, know-how and clinical experience in approximately 600 patients
to develop novel therapies for blood cancer and solid tumor indications. Its clinical and preclinical development programs utilize multiple
isotopes including Actinium-225, Iodine-131 and Lutetium-177 directed at multiple validated cancer targets including CD45, CD33, CD38,
CD47, HER2 and HER3 for targeted conditioning prior to cell and gene therapies including bone marrow transplant and cancer therapeutics
as single agents or in combination with other therapeutic modalities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
of Presentation - </b>The accompanying unaudited condensed consolidated financial statements and related notes have been prepared in
accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for condensed financial
information, and pursuant to the rules and regulations of the United States Securities and Exchange Commission (the &#8220;SEC&#8221;)
with respect to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required
by U.S. GAAP for complete financial statements. The unaudited condensed consolidated financial statements reflect all adjustments (consisting
of normal recurring adjustments) which are, in the opinion of management, necessary for a fair statement of the results for the condensed
periods presented. Condensed results are not necessarily indicative of the results for the full year. These unaudited condensed consolidated
financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in
the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principles
of Consolidation -</b> The basis of consolidation is unchanged from the disclosure in the Company&#8217;s Notes to the Consolidated Financial
Statements section in its Report on Form 10-K for the year ended December 31, 2021. The unaudited condensed consolidated financial statements
include the Company&#8217;s accounts and those of the Company&#8217;s wholly owned subsidiaries.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use
of Estimates </b>- The preparation of these unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated
financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Impact
of COVID&#8211;19 Pandemic on Financial Statements - </b>The global health crisis caused by the novel coronavirus (&#8220;COVID-19&#8221;)
pandemic and its resurgences has and may continue to negatively impact global economic activity, which, despite progress in vaccination
efforts, remains uncertain and cannot be predicted with confidence. In addition, the Omicron variants of COVID-19, including subvariants
BA.4 and BA.5, which appear to be the most transmissible variants to date, have spread globally. The full impact of the Omicron variants,
or any subsequent variants, cannot be predicted at this time, and could depend on numerous factors, including vaccination rates among
the population, the effectiveness of COVID-19 vaccines against the Omicron variants and subsequent variants and the response by governmental
bodies and regulators.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
countries around the world have continued to impose quarantines and restrictions on travel and mass gatherings to slow the spread of
the virus. Accordingly, the Company&#8217;s ability to continue to operate its business may also be limited. Such events may result in
a period of business, supply and drug product manufacturing disruption, and in reduced operations, any of which could materially affect
the Company&#8217;s business, financial condition and results of operations. In response to COVID-19, the Company implemented hybrid
working for its office-based staff, while its research staff has been actively working in its laboratory throughout the pandemic and
thus far, has not experienced a significant disruption or delay in its operations as it relates to the clinical development, preclinical
research or drug production of its drug candidates.&#160;A continuation or worsening of the levels of market disruption and volatility
seen in the recent past could have an adverse effect on the Company&#8217;s ability to access capital, which could in the future negatively
affect the Company&#8217;s liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially
affect the Company&#8217;s business and the value of the Company&#8217;s common stock.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
COVID-19 may result in delays in receiving approvals from local and foreign regulatory authorities, delays in necessary interactions
with IRB&#8217;s or Institutional Review Boards, local and foreign regulators, ethics committees and other important agencies and contractors
due to limitations in employee resources or forced furlough of government employees.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, COVID-19 has not had a financial impact on the Company. The Company continues to monitor the impacts of COVID-19 on the global
economy and on its business operations. However, at this time, it is difficult to predict how long the potential operational impacts
of COVID-19 will last or to what degree further disruption might impact the Company&#8217;s operations and financial results.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash,
Cash Equivalents and Restricted Cash -</b> The Company considers all highly liquid accounts with original maturities of three months
or less to be cash equivalents. Balances held by the Company are typically in excess of Federal Deposit Insurance Corporation insured
limits.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of cash, cash equivalents and restricted cash at June 30, 2022 and December 31, 2021:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">116,330</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">77,829</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Restricted cash</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">392</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">392</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Cash, cash equivalents and restricted cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">116,772</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">78,221</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
cash relates to a certificate of deposit held as collateral for a letter of credit issued in connection with the Company&#8217;s lease
for corporate office space.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Leases
</b>&#8211; The Company has operating and finance leases for corporate office space, office equipment and furniture located at the corporate
office space. Leases with an initial term of 12 months or less are not recorded on the balance sheet; lease expense for these leases
is recognized on a straight-line basis over the lease term. The Company entered into a lease for corporate office space effective June
1, 2022 and paid a security deposit to the landlord. A certificate of deposit will be provided as collateral for a letter of credit to
be issued with this new office space during 2022 and at that time, the security deposit will be returned to the Company.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Revenue
Recognition </b>- The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) Topic 606, <i>Revenue From
Contracts With Customers</i> (&#8220;ASC 606&#8221;). Under ASC 606, an entity recognizes revenue when its customer obtains control of
promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods
or services. To determine revenue recognition for arrangements within the scope of ASC 606, the entity performs the following five steps:
(i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction
price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract;
and (v) recognize revenue as the entity satisfies a performance obligation. The Company only applies the five-step model to contracts
when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers
to the customer.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses whether the promised goods
or services promised within each contract are distinct and, therefore, represent a separate performance obligation.&#160;Goods and services
that are determined not to be distinct are combined with other promised goods and services until a distinct bundle is identified. In
determining whether goods or services are distinct, the Company evaluates certain criteria, including whether (i)&#160;the customer can
benefit from the good or service either on its own or together with other resources that are readily available to the customer (capable
of being distinct) and (ii)&#160;the good or service is separately identifiable from other goods or services in the contract (distinct
in the context of the contract).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; ">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company then determines the transaction price, which is the amount of consideration it expects to be entitled from a customer in exchange
for the promised goods or services for each performance obligation and recognizes the associated revenue as each performance obligation
is satisfied. The Company&#8217;s estimate of the transaction price for each contract includes all variable consideration to which it
expects to be entitled. Variable consideration includes payments in the form of collaboration milestone payments. If an arrangement includes
collaboration milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates
the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue
reversal would not occur, the associated milestone value is included in the transaction price.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
606 requires the Company to allocate the arrangement consideration on a relative standalone selling price basis for each performance
obligation after determining the transaction price of the contract and identifying the performance obligations to which that amount should
be allocated. The relative standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised
good or service separately to a customer. The Company then recognizes as revenue the amount of the transaction price that is allocated
to the respective performance obligation as each performance obligation is satisfied, either at a point in time or over time, and if
over time, recognition is based on the use of an output or input method.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Collaborative
Arrangements - </b>The Company follows the accounting guidance for collaboration agreements with third parties, which requires that certain
transactions between the Company and collaborators be recorded in its consolidated statements of operations and comprehensive loss on
either a gross basis or net basis, depending on the characteristics of the collaborative relationship, and requires enhanced disclosure
of collaborative relationships. The Company evaluates its collaboration agreements for proper classification in its consolidated statements
of operations and comprehensive loss based on the nature of the underlying activity. When the Company has concluded that it has a customer
relationship with one of its collaborators, the Company follows the guidance of ASC 606<i>.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Grant Revenue <i>&#8211; </i></b>The
Company has a grant from a government-sponsored entity for research and development related activities that provides for payments for
reimbursed costs, which includes overhead and general and administrative costs as well as an administrative fee. The Company recognizes
revenue from grants as it performs services and all conditions are met under this arrangement. Associated expenses are recognized when
incurred as research and development expense. Revenue and related expenses are presented gross in the consolidated statements of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>License Revenue <i>&#8211;
</i></b>The Company entered into a product licensing agreement whereby the Company allowed a third party to commercialize a certain product
in specified territories using the Company&#8217;s trademarks. The terms of this arrangement includes payment to the Company for a combination
of one or more of the following: upfront license fees; development, regulatory and sales-based milestone payments; and royalties on net
sales of licensed products. The Company uses its judgment to determine whether milestones or other variable consideration should be included
in the transaction price.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Upfront
license fees</i>: If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance
obligations identified in the arrangement, the Company will recognize revenue from upfront license fees allocated to the license when
the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled
with other promises, the Company determines whether the combined performance obligation is satisfied over time or at a point in time.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Development,
regulatory or commercial milestone payments</i>: At the inception of each arrangement that includes payments based on the achievement
of certain development, regulatory and sales-based or commercial events, the Company evaluates whether the milestones are considered
probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it
is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price.
Milestone payments that are not within the Company&#8217;s or the licensee&#8217;s control, such as regulatory approvals, are not considered
probable of being achieved until regulatory approval is received. At the end of each subsequent reporting period, the Company will re-evaluate
the probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust the Company&#8217;s
estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis and recorded as part of license
revenue during the period of adjustment.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Sales-based
milestone payments and royalties</i>: For arrangements that include sales-based royalties, including milestone payments based on the
volume of sales, the Company will determine whether the license is deemed to be the predominant item to which the royalties or sales-based
milestones relate and if such is the case, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii)
when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upfront
payments and fees may require deferral of revenue recognition to a future period until the Company performs its obligations under these
arrangements or when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur or when
the uncertainty associated with any variable consideration is subsequently resolved. Amounts payable to the Company are recorded as accounts
receivable when the Company&#8217;s right to consideration is unconditional.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and Development Costs -</b> Research and development costs are expensed as incurred. These costs include the costs of manufacturing drug
product, the costs of clinical trials, costs of employees and associated overhead, and depreciation and amortization costs related to
facilities and equipment. Research and development reimbursements are recorded by the Company as a reduction of research and development
costs.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share-Based
Payments -</b> The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing
model. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee
is required to provide service in exchange for the award. The Company accounts for forfeitures of stock options as they occur.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Net
Loss Per Common Share</b> - Basic loss per common share is computed by dividing the net loss available to common stockholders by the
weighted average number of shares of common stock outstanding during the reporting period. For periods of net loss, diluted loss per
share is calculated similarly to basic loss per share because the impact of all potential dilutive common shares is anti-dilutive. For
the three months ended June 30, 2022 and 2021, the Company&#8217;s potentially dilutive shares, which include outstanding common stock
options and warrants, have not been included in the computation of diluted net loss per share as the result would have been anti-dilutive.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,431</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">859</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,053</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,114</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,484</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,973</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recently
Adopted Accounting Pronouncements &#8211; </b>In May 2021, FASB issued ASU 2021-04, <i>Earnings Per Share (topic 260), Debt &#8212; Modifications
and Extinguishments (Subtopic 470-50), Compensation &#8211; Stock Compensation (Topic 718) and Derivatives and Hedging &#8211; Contracts
in an Entity&#8217;s Own Equity (Subtopic 815-40) &#8211; Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding
Equity-Classified Written Call Options</i>, which provides guidance of a modification or an exchange of a freestanding equity-classified
written call option that remains equity classified after modification or exchange as (1) an adjustment to equity and, if so, the related
earnings per share (EPS) effects, if any, or (2) an expense and, if so, the manner and pattern of recognition. The amendments in this
ASU are effective January 1, 2022, including interim periods. The Company adopted this standard effective January 1, 2022 and the standard
did not have a material effect on the Company&#8217;s financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2021, the FASB issued ASU 2021-10, <i>Government Assistance (Topic 832), Disclosures by Business Entities about Government Assistance</i>,
which provides guidance on disclosure requirements to entities other than not-for-profit entities about transaction with a government
that are accounted for by applying a grant or contribution accounting model by analogy. ASU 2021-10 requires an entity to make annual
disclosures related to (1) the nature of the transactions and the related accounting policy used to account for the government transactions,
(2) quantification and disclosure of amounts related to the government transactions included in balance sheet and income statement financial
statement line items, and (3) significant terms and conditions of the government transactions, including commitments and contingencies.
The amendments of ASU 2021-10 are effective January 1, 2022, including interim periods. The Company adopted this standard effective January
1, 2022, and the standard did not have a material impact on the Company&#8217;s financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recently
Issued Accounting Pronouncements &#8211; </b>In October 2021, FASB issued ASU 2021-08, <i>Business Combinations (Topic 805), Account
for Contract Assets and Contract Liabilities from Contracts with Customers</i>, which provides guidance on accounting for contract assets
and contract liabilities acquired in a business combination in accordance with ASC 606. To achieve this, an acquirer may assess how the
acquiree applied ASC 606 to determine what to record for the acquired revenue contracts. Generally, this should result in an acquirer
recognizing and measuring the acquired contract assets and contract liabilities consistent with how they were recognized and measured
in the acquiree&#8217;s financial statements. The amendments of ASU 2021-08 are effective January 1, 2023, including interim periods.
Early adoption is permitted, including adoption in an interim period. The Company will evaluate the impact of ASU 2021-08 on any future
business combinations the Company may enter in the future.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140021014156256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 - Commitments and Contingencies</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 15, 2012, the Company entered into a license and sponsored research agreement with Fred Hutchinson Cancer Research Center (&#8220;FHCRC&#8221;)
to build upon previous and ongoing clinical trials with apamistamab (licensed antibody). FHCRC has completed both a Phase 1 and Phase
2 clinical trial with apamistamab. The Company has been granted exclusive rights to the antibody and related master cell bank developed
by FHCRC. A milestone payment of $1 million will be due to FHCRC upon U.S. Food and Drug Administration (&#8220;FDA&#8221;) approval
of the first drug utilizing the licensed antibody. Upon commercial sale of the drug, royalty payments of 2% of net sales will be due
to FHCRC.&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140021013167680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_LeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
3 - Leases </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company entered into a
lease for corporate office space, effective June 1, 2022. As of June 30, 2022, the Company has two operating leases for corporate office
space and two finance leases for office equipment and furniture located in one of the corporate office spaces. In addition, the Company
has auxiliary corporate office space that it rents on a month-to-month basis; this rental is accounted for as an operating lease with
the same term as the Company&#8217;s main office.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of lease expense are as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June&#160;30,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June&#160;30,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June&#160;30,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June&#160;30,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Operating lease expense</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">141</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">93</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">234</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">186</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Finance lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Amortization of right-to-use assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">21</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">41</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">41</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Interest on lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total finance lease cost</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">21</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">23</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">43</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">46</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental
cash flow information related to leases are as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash
flow information:</b></span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June&#160;30,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June&#160;30,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cash paid for amounts included in the measurement of lease liabilities:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Operating cash flow use from operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">239</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">188</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Operating cash flow use from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Financing cash flow use from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">45</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">42</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Non-cash activity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Right-of-use assets obtained in exchange for lease obligations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,605</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Finance Leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
average remaining lease terms are as follows at June 30, 2022:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; ">
    <td>Weighted average remaining lease term:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">5.0 years</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Finance Leases</td><td>&#160;</td>
    <td style="text-align: center">0.5 year</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the interest rate implicit in the leases was not readily determinable at the time that the leases were evaluated, the Company used its
incremental borrowing rate based on the information available in determining the present value of lease payments. The Company&#8217;s
incremental borrowing rate was based on the term of the lease, the economic environment of the lease and reflect the rate the Company
would have had to pay to borrow on a secured basis. Below is information on the weighted average discount rates used at the time that
the leases were evaluated:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>Weighted average discount rates:</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right">4.8%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Finance Leases</td><td>&#160;</td>
    <td style="text-align: right">8.0%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maturities
of lease liabilities are as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;&#160;&#160;</b></span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)<br/> Year ending December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Operating <br/> Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Finance <br/> Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 76%">2022 (excluding six months ended June 30, 2022)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">113</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">17</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">606</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">618</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">630</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">643</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">2027</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">380</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,990</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">22</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(363</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Present value of lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,627</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">21</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_LeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_LeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140021014257664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Revenue<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_OtherRevenueAbstract', window );"><strong>Other revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_OtherRevenueTextBlock', window );">Other revenue</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4 &#8211; Other revenue </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determined that certain collaborations with a third party are within the scope of ASC 606. The collaboration agreement is made
up of multiple modules related to various research activities. The Company identified a single performance obligation to provide research
services within each module for which the Company receives monetary consideration. The third party can choose to proceed with each module
or can terminate the agreement at any time. The Company recognizes revenue for each module on a straight-line basis over the expected
module period. Revenue for succeeding modules is not recognized until all contingencies are resolved, inclusive of the third party&#8217;s
ability to terminate the module. Other revenue recognized during the three months and six months ended June 30, 2022 was $0.0 million
and $0.9 million, respectively, and for the three months and six months ended June 30, 2021 was $0.3 million and $0.9 million, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has a grant from a government-sponsored entity for research and development related activities that provide for payments for
reimbursed costs, which includes overhead and general and administrative costs as well as an administrative fee. The Company recognizes
revenue from grants as it performs services under this arrangement. Associated expenses are recognized when incurred as research and
development expense. Other revenue recognized during the three months and six months ended June 30, 2022 was $0.0 million and $0.1 million,
respectively. There was no other revenue recognized from a grant from a government-sponsored entity during the six months ended June
30, 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 7, 2022, the Company
entered into a license and supply agreement (the &#8220;License Agreement&#8221;) with Immedica Pharma AB (&#8220;Immedica&#8221;), pursuant
to which Immedica licensed the exclusive product rights for commercialization of Iomab-B (I-131 apamistamab) in the European Economic
Area, Middle East and North Africa (EUMENA) including Algeria, Andorra, Bahrain, Cyprus, Egypt, Iran, Iraq, Israel, Jordan, Kuwait, Lebanon,
Libya, Monaco, Morocco, Oman, Palestine, Qatar, San Marino, Saudi Arabia, Switzerland, Syria, Tunisia, Turkey, the United Arab Emirates,
the United Kingdom, the Vatican City and Yemen. Upon signing, the Company was entitled to an upfront payment of $35 million from Immedica,
which was received in May 2022. Under the terms of the License Agreement, the Company is eligible to receive regulatory and commercial
milestone payments and is entitled to receive royalties in the mid-20 percent range on net sales of the product in certain countries that
may result from the License Agreement. The Company will continue to be responsible for certain clinical development activities and the
manufacturing of Iomab-B and will retain commercialization rights in the U.S. and rest of the world.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s contract liabilities
are recorded within Other revenue deferred &#8211; current liability or Long-term license revenue deferred in its condensed consolidated
balance sheets depending on the short-term or long-term nature of the payments to be recognized. The Company&#8217;s contract liabilities
primarily consist of advanced payments from licensees. Other revenue deferred &#8211; current liability was $0.2 million at June 30, 2022
and $0.9 million at December 31, 2021. Long-term license revenue deferred was $35.0 million at June 30, 2022; there was no long-term license
revenue deferred at December 31, 2021. This deferred revenue will be recognized upon EU regulatory approval of Iomab B.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_OtherRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_OtherRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_OtherRevenueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_OtherRevenueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140021013934320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5 - Equity&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020 the Company entered into the Capital on Demand&#8482; Sales Agreement with JonesTrading Institutional Services LLC, or JonesTrading,
pursuant to which the Company may sell, from time to time, through or to JonesTrading, up to an aggregate of $200 million of its common
stock. Shares of common stock are offered pursuant to a shelf registration statement on Form S-3 filed with the SEC on August 7, 2020.
As of December 31, 2021, the Company had sold 6.7 million shares of common stock, resulting in gross proceeds of $59.1 million and net
proceeds of $57.0 million. For the six months ended June 30, 2022, the Company sold 2.7 million shares of common stock, resulting in
gross proceeds of $17.2 million and net proceeds of $16.7 million. For the six months ended June 30, 2021, the Company sold 3.5 million
shares of common stock, resulting in gross proceeds of $29.6 million and net proceeds of $28.7 million.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 28, 2022, the Company entered into an Amendment and Restated Capital on Demand&#8482; Sales Agreement (the &#8220;A&amp;R Sales
Agreement&#8221;) with JonesTrading and B. Riley Securities, Inc. (&#8220;B. Riley Securities&#8221;). The A&amp;R Sales Agreement modifies
the original Capital on Demand&#8482; Sales Agreement to include B. Riley Securities as an additional sales agent thereunder.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock
Options</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of stock option activity for the six months ended June 30, 2022:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number&#160;of<br/> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Exercise <br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Term <br/> (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 53%">Outstanding, January 1, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,362</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">12.45</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">8.69</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">120</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.23</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(51</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">8.89</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Outstanding, June 30, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,431</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">11.97</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: center">8.36</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Exercisable, June 30, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">473</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">22.19</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: center">7.07</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the six months ended June 30, 2022, the Company granted new employees options to purchase 120 thousand shares of common stock with an
exercise price ranging from $5.20 to $5.93 per share, a term of 10 years, and a vesting period of 4 years.&#160;The options have an aggregated
fair value of $442 thousand that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing
model include: (1) discount rate range from 1.52% to 3.03% (2) expected life of 6 years, (3) expected volatility range from 78.8% to
79.9%, and (4) zero expected dividends.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair values of all options issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation
expense at June 30, 2022 was $4.4 million related to unvested options, which is expected to be expensed over a weighted average of 3.0
years. During the six months ended June 30, 2022 and 2021, the Company recorded compensation expense related to stock options of $0.8
million and $0.7 million, respectively. &#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
is a summary of warrant activity for the six months ended June 30, 2022:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Exercise <br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Term <br/> (in&#160;years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 53%">Outstanding, January 1, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,112</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">20.52</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">1.76</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;276</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Cancelled/Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(59</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">3.62</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Outstanding, June 30, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,053</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">21.01</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: center">1.32</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Exercisable, June 30, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,049</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">20.57</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: center">1.31</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140021022548320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Event</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6 &#8211; Subsequent Event</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
June 30, 2022, the Company has sold 0.3 million shares of common stock under its A&amp;R Sales Agreement, resulting in net proceeds of
$1.4 million.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 2, 2022, warrants to purchase an aggregate of 0.6 million shares of common stock expired. These warrants were issued on August
2, 2017, when the Company completed an underwritten offering of 0.7 million shares of its common stock and warrants to purchase an aggregate
of 0.6 million shares of its common stock at a price of $22.50 per share and related warrant. The warrants were exercisable for a period
of 5 years at an exercise price of $31.50 per share. As of August 12, 2022, the Company has 1.4 million warrants outstanding.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140021009712768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_NatureOfBusinessPolicyTextBlock', window );">Nature of Business</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Nature of Business -</b> Actinium
Pharmaceuticals, Inc. (the &#8220;Company&#8221; or &#8220;Actinium&#8221;) is a clinical-stage, biopharmaceutical company focused on
developing and potentially commercializing targeted radiotherapies for patients with unmet needs. The Company applies its proprietary
technology platform consisting of over 195 patents and patent applications, know-how and clinical experience in approximately 600 patients
to develop novel therapies for blood cancer and solid tumor indications. Its clinical and preclinical development programs utilize multiple
isotopes including Actinium-225, Iodine-131 and Lutetium-177 directed at multiple validated cancer targets including CD45, CD33, CD38,
CD47, HER2 and HER3 for targeted conditioning prior to cell and gene therapies including bone marrow transplant and cancer therapeutics
as single agents or in combination with other therapeutic modalities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
of Presentation - </b>The accompanying unaudited condensed consolidated financial statements and related notes have been prepared in
accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for condensed financial
information, and pursuant to the rules and regulations of the United States Securities and Exchange Commission (the &#8220;SEC&#8221;)
with respect to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required
by U.S. GAAP for complete financial statements. The unaudited condensed consolidated financial statements reflect all adjustments (consisting
of normal recurring adjustments) which are, in the opinion of management, necessary for a fair statement of the results for the condensed
periods presented. Condensed results are not necessarily indicative of the results for the full year. These unaudited condensed consolidated
financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in
the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principles
of Consolidation -</b> The basis of consolidation is unchanged from the disclosure in the Company&#8217;s Notes to the Consolidated Financial
Statements section in its Report on Form 10-K for the year ended December 31, 2021. The unaudited condensed consolidated financial statements
include the Company&#8217;s accounts and those of the Company&#8217;s wholly owned subsidiaries.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use
of Estimates </b>- The preparation of these unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated
financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_PandemicOnFinancialStatements', window );">Impact of COVID&#8211;19 Pandemic on Financial Statements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Impact
of COVID&#8211;19 Pandemic on Financial Statements - </b>The global health crisis caused by the novel coronavirus (&#8220;COVID-19&#8221;)
pandemic and its resurgences has and may continue to negatively impact global economic activity, which, despite progress in vaccination
efforts, remains uncertain and cannot be predicted with confidence. In addition, the Omicron variants of COVID-19, including subvariants
BA.4 and BA.5, which appear to be the most transmissible variants to date, have spread globally. The full impact of the Omicron variants,
or any subsequent variants, cannot be predicted at this time, and could depend on numerous factors, including vaccination rates among
the population, the effectiveness of COVID-19 vaccines against the Omicron variants and subsequent variants and the response by governmental
bodies and regulators.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
countries around the world have continued to impose quarantines and restrictions on travel and mass gatherings to slow the spread of
the virus. Accordingly, the Company&#8217;s ability to continue to operate its business may also be limited. Such events may result in
a period of business, supply and drug product manufacturing disruption, and in reduced operations, any of which could materially affect
the Company&#8217;s business, financial condition and results of operations. In response to COVID-19, the Company implemented hybrid
working for its office-based staff, while its research staff has been actively working in its laboratory throughout the pandemic and
thus far, has not experienced a significant disruption or delay in its operations as it relates to the clinical development, preclinical
research or drug production of its drug candidates.&#160;A continuation or worsening of the levels of market disruption and volatility
seen in the recent past could have an adverse effect on the Company&#8217;s ability to access capital, which could in the future negatively
affect the Company&#8217;s liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially
affect the Company&#8217;s business and the value of the Company&#8217;s common stock.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
COVID-19 may result in delays in receiving approvals from local and foreign regulatory authorities, delays in necessary interactions
with IRB&#8217;s or Institutional Review Boards, local and foreign regulators, ethics committees and other important agencies and contractors
due to limitations in employee resources or forced furlough of government employees.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, COVID-19 has not had a financial impact on the Company. The Company continues to monitor the impacts of COVID-19 on the global
economy and on its business operations. However, at this time, it is difficult to predict how long the potential operational impacts
of COVID-19 will last or to what degree further disruption might impact the Company&#8217;s operations and financial results.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;&#160;</b></span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash,
Cash Equivalents and Restricted Cash -</b> The Company considers all highly liquid accounts with original maturities of three months
or less to be cash equivalents. Balances held by the Company are typically in excess of Federal Deposit Insurance Corporation insured
limits.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of cash, cash equivalents and restricted cash at June 30, 2022 and December 31, 2021:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">116,330</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">77,829</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Restricted cash</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">392</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">392</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Cash, cash equivalents and restricted cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">116,772</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">78,221</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
cash relates to a certificate of deposit held as collateral for a letter of credit issued in connection with the Company&#8217;s lease
for corporate office space.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Leases
</b>&#8211; The Company has operating and finance leases for corporate office space, office equipment and furniture located at the corporate
office space. Leases with an initial term of 12 months or less are not recorded on the balance sheet; lease expense for these leases
is recognized on a straight-line basis over the lease term. The Company entered into a lease for corporate office space effective June
1, 2022 and paid a security deposit to the landlord. A certificate of deposit will be provided as collateral for a letter of credit to
be issued with this new office space during 2022 and at that time, the security deposit will be returned to the Company.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Revenue
Recognition </b>- The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) Topic 606, <i>Revenue From
Contracts With Customers</i> (&#8220;ASC 606&#8221;). Under ASC 606, an entity recognizes revenue when its customer obtains control of
promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods
or services. To determine revenue recognition for arrangements within the scope of ASC 606, the entity performs the following five steps:
(i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction
price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract;
and (v) recognize revenue as the entity satisfies a performance obligation. The Company only applies the five-step model to contracts
when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers
to the customer.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses whether the promised goods
or services promised within each contract are distinct and, therefore, represent a separate performance obligation.&#160;Goods and services
that are determined not to be distinct are combined with other promised goods and services until a distinct bundle is identified. In
determining whether goods or services are distinct, the Company evaluates certain criteria, including whether (i)&#160;the customer can
benefit from the good or service either on its own or together with other resources that are readily available to the customer (capable
of being distinct) and (ii)&#160;the good or service is separately identifiable from other goods or services in the contract (distinct
in the context of the contract).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; ">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company then determines the transaction price, which is the amount of consideration it expects to be entitled from a customer in exchange
for the promised goods or services for each performance obligation and recognizes the associated revenue as each performance obligation
is satisfied. The Company&#8217;s estimate of the transaction price for each contract includes all variable consideration to which it
expects to be entitled. Variable consideration includes payments in the form of collaboration milestone payments. If an arrangement includes
collaboration milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates
the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue
reversal would not occur, the associated milestone value is included in the transaction price.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
606 requires the Company to allocate the arrangement consideration on a relative standalone selling price basis for each performance
obligation after determining the transaction price of the contract and identifying the performance obligations to which that amount should
be allocated. The relative standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised
good or service separately to a customer. The Company then recognizes as revenue the amount of the transaction price that is allocated
to the respective performance obligation as each performance obligation is satisfied, either at a point in time or over time, and if
over time, recognition is based on the use of an output or input method.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaborative Arrangements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Collaborative
Arrangements - </b>The Company follows the accounting guidance for collaboration agreements with third parties, which requires that certain
transactions between the Company and collaborators be recorded in its consolidated statements of operations and comprehensive loss on
either a gross basis or net basis, depending on the characteristics of the collaborative relationship, and requires enhanced disclosure
of collaborative relationships. The Company evaluates its collaboration agreements for proper classification in its consolidated statements
of operations and comprehensive loss based on the nature of the underlying activity. When the Company has concluded that it has a customer
relationship with one of its collaborators, the Company follows the guidance of ASC 606<i>.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_GrantRevenuePolicyTextBlock', window );">Grant Revenue</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Grant Revenue <i>&#8211; </i></b>The
Company has a grant from a government-sponsored entity for research and development related activities that provides for payments for
reimbursed costs, which includes overhead and general and administrative costs as well as an administrative fee. The Company recognizes
revenue from grants as it performs services and all conditions are met under this arrangement. Associated expenses are recognized when
incurred as research and development expense. Revenue and related expenses are presented gross in the consolidated statements of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_LicenseRevenueTextBlock', window );">License Revenue</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>License Revenue <i>&#8211;
</i></b>The Company entered into a product licensing agreement whereby the Company allowed a third party to commercialize a certain product
in specified territories using the Company&#8217;s trademarks. The terms of this arrangement includes payment to the Company for a combination
of one or more of the following: upfront license fees; development, regulatory and sales-based milestone payments; and royalties on net
sales of licensed products. The Company uses its judgment to determine whether milestones or other variable consideration should be included
in the transaction price.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Upfront
license fees</i>: If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance
obligations identified in the arrangement, the Company will recognize revenue from upfront license fees allocated to the license when
the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled
with other promises, the Company determines whether the combined performance obligation is satisfied over time or at a point in time.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Development,
regulatory or commercial milestone payments</i>: At the inception of each arrangement that includes payments based on the achievement
of certain development, regulatory and sales-based or commercial events, the Company evaluates whether the milestones are considered
probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it
is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price.
Milestone payments that are not within the Company&#8217;s or the licensee&#8217;s control, such as regulatory approvals, are not considered
probable of being achieved until regulatory approval is received. At the end of each subsequent reporting period, the Company will re-evaluate
the probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust the Company&#8217;s
estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis and recorded as part of license
revenue during the period of adjustment.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Sales-based
milestone payments and royalties</i>: For arrangements that include sales-based royalties, including milestone payments based on the
volume of sales, the Company will determine whether the license is deemed to be the predominant item to which the royalties or sales-based
milestones relate and if such is the case, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii)
when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upfront
payments and fees may require deferral of revenue recognition to a future period until the Company performs its obligations under these
arrangements or when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur or when
the uncertainty associated with any variable consideration is subsequently resolved. Amounts payable to the Company are recorded as accounts
receivable when the Company&#8217;s right to consideration is unconditional.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and Development Costs -</b> Research and development costs are expensed as incurred. These costs include the costs of manufacturing drug
product, the costs of clinical trials, costs of employees and associated overhead, and depreciation and amortization costs related to
facilities and equipment. Research and development reimbursements are recorded by the Company as a reduction of research and development
costs.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Share-Based Payments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share-Based
Payments -</b> The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing
model. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee
is required to provide service in exchange for the award. The Company accounts for forfeitures of stock options as they occur.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><b>Net
Loss Per Common Share</b> - Basic loss per common share is computed by dividing the net loss available to common stockholders by the
weighted average number of shares of common stock outstanding during the reporting period. For periods of net loss, diluted loss per
share is calculated similarly to basic loss per share because the impact of all potential dilutive common shares is anti-dilutive. For
the three months ended June 30, 2022 and 2021, the Company&#8217;s potentially dilutive shares, which include outstanding common stock
options and warrants, have not been included in the computation of diluted net loss per share as the result would have been anti-dilutive.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_Accountingstandardsrecentlyissuedpolicytextblock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recently
Adopted Accounting Pronouncements &#8211; </b>In May 2021, FASB issued ASU 2021-04, <i>Earnings Per Share (topic 260), Debt &#8212; Modifications
and Extinguishments (Subtopic 470-50), Compensation &#8211; Stock Compensation (Topic 718) and Derivatives and Hedging &#8211; Contracts
in an Entity&#8217;s Own Equity (Subtopic 815-40) &#8211; Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding
Equity-Classified Written Call Options</i>, which provides guidance of a modification or an exchange of a freestanding equity-classified
written call option that remains equity classified after modification or exchange as (1) an adjustment to equity and, if so, the related
earnings per share (EPS) effects, if any, or (2) an expense and, if so, the manner and pattern of recognition. The amendments in this
ASU are effective January 1, 2022, including interim periods. The Company adopted this standard effective January 1, 2022 and the standard
did not have a material effect on the Company&#8217;s financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2021, the FASB issued ASU 2021-10, <i>Government Assistance (Topic 832), Disclosures by Business Entities about Government Assistance</i>,
which provides guidance on disclosure requirements to entities other than not-for-profit entities about transaction with a government
that are accounted for by applying a grant or contribution accounting model by analogy. ASU 2021-10 requires an entity to make annual
disclosures related to (1) the nature of the transactions and the related accounting policy used to account for the government transactions,
(2) quantification and disclosure of amounts related to the government transactions included in balance sheet and income statement financial
statement line items, and (3) significant terms and conditions of the government transactions, including commitments and contingencies.
The amendments of ASU 2021-10 are effective January 1, 2022, including interim periods. The Company adopted this standard effective January
1, 2022, and the standard did not have a material impact on the Company&#8217;s financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recently
Issued Accounting Pronouncements &#8211; </b>In October 2021, FASB issued ASU 2021-08, <i>Business Combinations (Topic 805), Account
for Contract Assets and Contract Liabilities from Contracts with Customers</i>, which provides guidance on accounting for contract assets
and contract liabilities acquired in a business combination in accordance with ASC 606. To achieve this, an acquirer may assess how the
acquiree applied ASC 606 to determine what to record for the acquired revenue contracts. Generally, this should result in an acquirer
recognizing and measuring the acquired contract assets and contract liabilities consistent with how they were recognized and measured
in the acquiree&#8217;s financial statements. The amendments of ASU 2021-08 are effective January 1, 2023, including interim periods.
Early adoption is permitted, including adoption in an interim period. The Company will evaluate the impact of ASU 2021-08 on any future
business combinations the Company may enter in the future.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_Accountingstandardsrecentlyissuedpolicytextblock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounting Standards Recently Issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_Accountingstandardsrecentlyissuedpolicytextblock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_GrantRevenuePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_GrantRevenuePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_LicenseRevenueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_LicenseRevenueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_NatureOfBusinessPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nature of Business policy text block.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_NatureOfBusinessPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_PandemicOnFinancialStatements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Impact of COVID&#8211;19 Pandemic on Financial Statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_PandemicOnFinancialStatements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140021014333216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of cash, cash equivalents and restricted cash</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">116,330</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">77,829</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Restricted cash</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">392</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">392</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Cash, cash equivalents and restricted cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">116,772</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">78,221</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of diluted net loss per share anti-dilutive</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,431</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">859</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,053</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,114</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,484</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,973</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140021011907520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of components of lease expense</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June&#160;30,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June&#160;30,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June&#160;30,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June&#160;30,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Operating lease expense</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">141</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">93</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">234</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">186</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Finance lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Amortization of right-to-use assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">21</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">41</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">41</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Interest on lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total finance lease cost</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">21</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">23</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">43</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">46</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of supplemental cash flow information related to leases</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June&#160;30,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June&#160;30,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cash paid for amounts included in the measurement of lease liabilities:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Operating cash flow use from operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">239</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">188</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Operating cash flow use from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Financing cash flow use from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">45</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">42</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Non-cash activity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Right-of-use assets obtained in exchange for lease obligations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,605</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Finance Leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_ScheduleOrDescriptionOfWeightedAverageTerm', window );">Schedule of weighted average remaining lease terms</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; ">
    <td>Weighted average remaining lease term:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">5.0 years</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Finance Leases</td><td>&#160;</td>
    <td style="text-align: center">0.5 year</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_ScheduleOfWeightedAverageDiscountRate', window );">Schedule of weighted average discount rates</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>Weighted average discount rates:</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right">4.8%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Finance Leases</td><td>&#160;</td>
    <td style="text-align: right">8.0%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock', window );">Schedule of maturities of lease liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)<br/> Year ending December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Operating <br/> Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Finance <br/> Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 76%">2022 (excluding six months ended June 30, 2022)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">113</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">17</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">606</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">618</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">630</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">643</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">2027</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">380</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,990</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">22</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(363</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Present value of lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,627</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">21</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ScheduleOfWeightedAverageDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ScheduleOfWeightedAverageDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ScheduleOrDescriptionOfWeightedAverageTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ScheduleOrDescriptionOfWeightedAverageTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140021011353968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=atnm_StocksOptionMember', window );">Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EquityTablesLineItems', window );"><strong>Equity (Tables) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock option activity</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number&#160;of<br/> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Exercise <br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Term <br/> (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 53%">Outstanding, January 1, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,362</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">12.45</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">8.69</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">120</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.23</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(51</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">8.89</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Outstanding, June 30, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,431</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">11.97</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: center">8.36</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Exercisable, June 30, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">473</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">22.19</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: center">7.07</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;</span></p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EquityTablesLineItems', window );"><strong>Equity (Tables) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of warrant activities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Exercise <br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Term <br/> (in&#160;years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 53%">Outstanding, January 1, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,112</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">20.52</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">1.76</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;276</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Cancelled/Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(59</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">3.62</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Outstanding, June 30, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,053</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">21.01</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: center">1.32</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Exercisable, June 30, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,049</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">20.57</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: center">1.31</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_EquityTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_EquityTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=atnm_StocksOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=atnm_StocksOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140021011679376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Details) - Schedule of cash, cash equivalents and restricted cash - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract', window );"><strong>Schedule of cash, cash equivalents and restricted cash [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 116,330<span></span>
</td>
<td class="nump">$ 77,829<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherRestrictedAssetsCurrent', window );">Restricted cash</a></td>
<td class="nump">392<span></span>
</td>
<td class="nump">392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 116,772<span></span>
</td>
<td class="nump">$ 78,221<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; attributable to disposal group, including, but not limited to, discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherRestrictedAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets that are pledged or subject to withdrawal restrictions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=127002003&amp;loc=SL6242269-115581<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherRestrictedAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140021009696784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Details) - Schedule of diluted net loss per share anti-dilutive - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">3,484<span></span>
</td>
<td class="nump">2,973<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">1,431<span></span>
</td>
<td class="nump">859<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">2,053<span></span>
</td>
<td class="nump">2,114<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140021013967472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 15, 2012 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_MilestonePayment', window );">Milestone payment</a></td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DescriptionOfRoyaltyPaymentToRelatedParty', window );">Description of royalty payment</a></td>
<td class="text">Upon commercial sale of the drug, royalty payments of 2% of net sales will be due
to FHCRC.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_DescriptionOfRoyaltyPaymentToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of royalty payment to related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_DescriptionOfRoyaltyPaymentToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140021011314432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_NumberOfOperatingLease', window );">Number of operating lease</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_NumberOfFinanceLease', window );">Number of finance lease</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_AdditionSpaceForOperatingLease', window );">Operating lease of auxiliary corporate office space</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_AdditionSpaceForOperatingLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Addition of auxiliary corporate office sapce for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_AdditionSpaceForOperatingLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_NumberOfFinanceLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of finance lease for office equipment and furniture.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_NumberOfFinanceLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_NumberOfOperatingLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of operating lease for corporate office.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_NumberOfOperatingLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140021011327456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - Schedule of components of lease expense - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_ScheduleOfComponentsOfLeaseExpenseAbstract', window );"><strong>Schedule of components of lease expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="nump">$ 141<span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
<td class="nump">$ 234<span></span>
</td>
<td class="nump">$ 186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of right-to-use assets</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Total finance lease cost</a></td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ScheduleOfComponentsOfLeaseExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ScheduleOfComponentsOfLeaseExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140020935615344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - Schedule of supplemental cash flow information related to leases - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract', window );"><strong>Schedule of supplemental cash flow information related to leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flow use from operating leases</a></td>
<td class="nump">$ 239<span></span>
</td>
<td class="nump">$ 188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash flow use from finance leases</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash flow use from finance leases</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_NonCashActivityAbstract', window );"><strong>Non-cash activity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating leases</a></td>
<td class="nump">2,605<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Finance Leases</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_NonCashActivityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_NonCashActivityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140021014150656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details) - Schedule of weighted average remaining lease terms<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_WeightedAverageRemainingLeaseTermAbstract', window );"><strong>Weighted average remaining lease term:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance Leases</a></td>
<td class="text">6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_WeightedAverageRemainingLeaseTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_WeightedAverageRemainingLeaseTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140021013959936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details) - Schedule of weighted average discount rates<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_WeightedAverageDiscountRatesAbstract', window );"><strong>Weighted average discount rates:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases</a></td>
<td class="nump">4.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance Leases</a></td>
<td class="nump">8.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_WeightedAverageDiscountRatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_WeightedAverageDiscountRatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140020935683152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details) - Schedule of maturities of lease liabilities<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_LeaseAxis=atnm_OperatingLeaseLiabilitiesMember', window );">Operating Leases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems', window );"><strong>Leases (Details) - Schedule of maturities of lease liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths', window );">2022</a></td>
<td class="nump">$ 113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo', window );">2023</a></td>
<td class="nump">606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree', window );">2024</a></td>
<td class="nump">618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour', window );">2025</a></td>
<td class="nump">630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive', window );">2026</a></td>
<td class="nump">643<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive', window );">2027</a></td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">2,990<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_PaymentWithImputedInterestPremium', window );">Less imputed interest</a></td>
<td class="num">(363)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_MaturitiesOfLeaseLiabilities', window );">Present value of lease liabilities</a></td>
<td class="nump">2,627<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_LeaseAxis=atnm_FinanceLeaseLiabilitiesMember', window );">Finance Leases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems', window );"><strong>Leases (Details) - Schedule of maturities of lease liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths', window );">2022</a></td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo', window );">2023</a></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree', window );">2024</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour', window );">2025</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive', window );">2026</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive', window );">2027</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_PaymentWithImputedInterestPremium', window );">Less imputed interest</a></td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_MaturitiesOfLeaseLiabilities', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 21<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_MaturitiesOfLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_MaturitiesOfLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_PaymentWithImputedInterestPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_PaymentWithImputedInterestPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_LeaseAxis=atnm_OperatingLeaseLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_LeaseAxis=atnm_OperatingLeaseLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_LeaseAxis=atnm_FinanceLeaseLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_LeaseAxis=atnm_FinanceLeaseLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140021011512608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Revenue (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 07, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_OtherRevenueAbstract', window );"><strong>Other revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_RecognitionOfDeferredRevenue1', window );">Recognition of deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_RevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_UpfrontPayment', window );">Upfront payment</a></td>
<td class="nump">$ 35.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Other revenue - current liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_LongtermLicenseRevenueDeferred', window );">Long-term license revenue deferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_LongtermLicenseRevenueDeferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of long-term license revenue deferred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_LongtermLicenseRevenueDeferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_OtherRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_OtherRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_RecognitionOfDeferredRevenue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recognition of deferred revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_RecognitionOfDeferredRevenue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_RevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_RevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140020935543808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_PurchaseOfCommonStockDescription', window );">Purchase of common stock, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">During
the six months ended June 30, 2022, the Company granted new employees options to purchase 120 thousand shares of common stock with an
exercise price ranging from $5.20 to $5.93 per share, a term of 10 years, and a vesting period of 4 years.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_StockOptionTerm', window );">Stock option term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_VestingPeriodOfStockOption', window );">Vesting period of stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_AggregateFairValue', window );">Aggregate fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 442.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_StockOptionDescription', window );">Stock option, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Variables used in the Black-Scholes option-pricing
model include: (1) discount rate range from 1.52% to 3.03% (2) expected life of 6 years, (3) expected volatility range from 78.8% to
79.9%, and (4) zero expected dividends.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_UnrecognizedCompensationExpense', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_WeightedAverageTerm', window );">Weighted average term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_CompensationExpenseRelatedToStockOptions', window );">Compensation expense related to stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_AgreementAxis=atnm_CapitalOnDemandSalesAgreementMember', window );">Capital on Demand Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate value of common stock</a></td>
<td class="nump">$ 200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of common stock, shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.7<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
<td class="nump">6.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.2<span></span>
</td>
<td class="nump">$ 29.6<span></span>
</td>
<td class="nump">$ 59.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.7<span></span>
</td>
<td class="nump">$ 28.7<span></span>
</td>
<td class="nump">$ 57.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_AggregateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_AggregateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_CompensationExpenseRelatedToStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_CompensationExpenseRelatedToStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_EquityDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_EquityDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_PurchaseOfCommonStockDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of purchase of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_PurchaseOfCommonStockDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_StockOptionDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock option, Description</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_StockOptionDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_StockOptionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock option term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_StockOptionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_UnrecognizedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_UnrecognizedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_VestingPeriodOfStockOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Vesting period of stock option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_VestingPeriodOfStockOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_WeightedAverageTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_WeightedAverageTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_AgreementAxis=atnm_CapitalOnDemandSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_AgreementAxis=atnm_CapitalOnDemandSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140021009680400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity  (Details) - Schedule of stock option activity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_ScheduleOfStockOptionActivityAbstract', window );"><strong>Schedule of stock option activity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares, Outstanding Beginning | shares</a></td>
<td class="nump">1,362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding Beginning | $ / shares</a></td>
<td class="nump">$ 12.45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years),Outstanding Beginning</a></td>
<td class="text">8 years 8 months 8 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding Beginning | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Shares, Granted | shares | shares</a></td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted | $ / shares</a></td>
<td class="nump">$ 5.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Shares, Cancelled | shares</a></td>
<td class="num">(51)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Cancelled | $ / shares</a></td>
<td class="nump">$ 8.89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares, Outstanding Ending | shares</a></td>
<td class="nump">1,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding Ending | $ / shares</a></td>
<td class="nump">$ 11.97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Outstanding Ending</a></td>
<td class="text">8 years 4 months 9 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding Ending | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Shares Exercisable Ending | shares</a></td>
<td class="nump">473<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable Ending | $ / shares | $ / shares</a></td>
<td class="nump">$ 22.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (in years), Exercisable Ending</a></td>
<td class="text">7 years 25 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable Ending | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ScheduleOfStockOptionActivityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ScheduleOfStockOptionActivityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140020935296336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity  (Details) - Schedule of warrant activities - Warrant [Member]<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_NumberOfWarrantsOutstandings', window );">Number of Shares, Outstanding Beginning | shares</a></td>
<td class="nump">2,112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Outstanding Beginning | $ / shares</a></td>
<td class="nump">$ 20.52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term (in years),Outstanding beginning</a></td>
<td class="text">1 year 9 months 3 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value, Outstanding Beginning | $</a></td>
<td class="nump">$ 276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_NumberOfWarrantsOutstandings', window );">Number of Shares, Outstanding Ending | shares</a></td>
<td class="nump">2,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price,Outstanding Ending | $ / shares</a></td>
<td class="nump">$ 21.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Term (in years),Outstanding Ending</a></td>
<td class="text">1 year 3 months 25 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value,Outstanding Ending | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Shares, Exercisable Ending | shares</a></td>
<td class="nump">2,049<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable Ending | $ / shares</a></td>
<td class="nump">$ 20.57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (in years), Exercisable Ending</a></td>
<td class="text">1 year 3 months 21 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Exercisable Ending | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Shares, Granted | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_NumberOfSharesExercised1', window );">Number of Shares, Exercised | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Shares, Cancelled/Expired | shares</a></td>
<td class="num">(59)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Cancelled/Expired | $ / shares</a></td>
<td class="nump">$ 3.62<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_NumberOfSharesExercised1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_NumberOfSharesExercised1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_NumberOfWarrantsOutstandings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_NumberOfWarrantsOutstandings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140020935328976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Event (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Aug. 12, 2022</div></th>
<th class="th"><div>Aug. 02, 2017</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_SubsequentEventDetailsLineItems', window );"><strong>Subsequent Event (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_SharesOfCommonStockValue', window );">Shares of common stock value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_NetProceeds', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfWarrants', window );">Aggregate purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Underwritten offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price pe share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants exercisable term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_NumberOfShares', window );">Warrants outstanding (in Shares)</a></td>
<td class="nump">1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_SubsequentEventDetailsLineItems', window );"><strong>Subsequent Event (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfWarrants', window );">Aggregate purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_NetProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_NetProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_NumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_NumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_SharesOfCommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares of common stock value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_SharesOfCommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_SubsequentEventDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_SubsequentEventDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040515&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>f10q0622_actiniumpharma_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:atnm="http://actiniumpharmaceuticals.com/20220630"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:pf0="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="atnm-20220630.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2022-08-12</instant>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2012-05-16</startDate>
            <endDate>2012-06-15</endDate>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="atnm:LeaseAxis">atnm:OperatingLeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="atnm:LeaseAxis">atnm:FinanceLeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-07</endDate>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-03</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">atnm:StocksOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-02</startDate>
            <endDate>2017-08-02</endDate>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2017-08-02</instant>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2017-08-02</startDate>
            <endDate>2017-08-02</endDate>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-12</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <dei:DocumentType contextRef="c0">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c0">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c0">2022-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c0">001-36374</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c0">ACTINIUM PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c0">74-2963609</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c0">275 Madison Ave, 7th Floor</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c0">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c0">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c0">10016</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c0">(646)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c0">677-3870</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c0">Common stock, par value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c0">ATNM</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c0">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c0">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c0">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c0">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c0">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c1" decimals="INF" unitRef="shares">25184654</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="-3" unitRef="usd">116330000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="-3" unitRef="usd">77829000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent contextRef="c2" decimals="-3" unitRef="usd">392000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c3" decimals="-3" unitRef="usd">392000</us-gaap:RestrictedCashCurrent>
    <us-gaap:SecurityDeposit contextRef="c2" decimals="-3" unitRef="usd">50000</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit contextRef="c3" decimals="-3" unitRef="usd">50000</us-gaap:SecurityDeposit>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c2" decimals="-3" unitRef="usd">1525000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c3" decimals="-3" unitRef="usd">1478000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c2" decimals="-3" unitRef="usd">118297000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c3" decimals="-3" unitRef="usd">79749000</us-gaap:AssetsCurrent>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c2" decimals="-3" unitRef="usd">395000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c3" decimals="-3" unitRef="usd">335000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="-3" unitRef="usd">557000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="-3" unitRef="usd">340000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepositsAssetsNoncurrent contextRef="c2" decimals="-3" unitRef="usd">299000</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c2" decimals="-3" unitRef="usd">2629000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c3" decimals="-3" unitRef="usd">241000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c2" decimals="-3" unitRef="usd">18000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c3" decimals="-3" unitRef="usd">58000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:Assets contextRef="c2" decimals="-3" unitRef="usd">121800000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c3" decimals="-3" unitRef="usd">80388000</us-gaap:Assets>
    <us-gaap:NotesPayableCurrent contextRef="c2" decimals="-3" unitRef="usd">5767000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="c3" decimals="-3" unitRef="usd">5535000</us-gaap:NotesPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c2" decimals="-3" unitRef="usd">204000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c3" decimals="-3" unitRef="usd">998000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c2" decimals="-3" unitRef="usd">292000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c3" decimals="-3" unitRef="usd">245000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c2" decimals="-3" unitRef="usd">19000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c3" decimals="-3" unitRef="usd">62000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c2" decimals="-3" unitRef="usd">6282000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c3" decimals="-3" unitRef="usd">6840000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRevenue contextRef="c2" decimals="-3" unitRef="usd">35000000</us-gaap:DeferredRevenue>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c2" decimals="-3" unitRef="usd">2335000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <atnm:LongtermFinanceLeaseObligationsNoncurrent contextRef="c2" decimals="-3" unitRef="usd">2000</atnm:LongtermFinanceLeaseObligationsNoncurrent>
    <atnm:LongtermFinanceLeaseObligationsNoncurrent contextRef="c3" decimals="-3" unitRef="usd">3000</atnm:LongtermFinanceLeaseObligationsNoncurrent>
    <us-gaap:Liabilities contextRef="c2" decimals="-3" unitRef="usd">43619000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c3" decimals="-3" unitRef="usd">6843000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c2" decimals="3" unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c3" decimals="3" unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c2" decimals="0" unitRef="shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c3" decimals="0" unitRef="shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c2" decimals="0" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="c3" decimals="0" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c2" decimals="0" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c3" decimals="0" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c2" decimals="3" unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c3" decimals="3" unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c2" decimals="0" unitRef="shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c3" decimals="0" unitRef="shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c2" decimals="0" unitRef="shares">24870623</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c2" decimals="0" unitRef="shares">24870623</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c3" decimals="0" unitRef="shares">22143974</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c3" decimals="0" unitRef="shares">22143974</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c2" decimals="-3" unitRef="usd">25000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c3" decimals="-3" unitRef="usd">22000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c2" decimals="-3" unitRef="usd">346800000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c3" decimals="-3" unitRef="usd">329271000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c2" decimals="-3" unitRef="usd">-268644000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c3" decimals="-3" unitRef="usd">-255748000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="-3" unitRef="usd">78181000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="-3" unitRef="usd">73545000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c2" decimals="-3" unitRef="usd">121800000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c3" decimals="-3" unitRef="usd">80388000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:SubleaseIncome contextRef="c4" decimals="-3" unitRef="usd">45000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome contextRef="c5" decimals="-3" unitRef="usd">266000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome contextRef="c0" decimals="-3" unitRef="usd">985000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome contextRef="c6" decimals="-3" unitRef="usd">888000</us-gaap:SubleaseIncome>
    <us-gaap:Revenues contextRef="c4" decimals="-3" unitRef="usd">45000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c5" decimals="-3" unitRef="usd">266000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c0" decimals="-3" unitRef="usd">985000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c6" decimals="-3" unitRef="usd">888000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c4" decimals="-3" unitRef="usd">4662000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c5" decimals="-3" unitRef="usd">3631000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="-3" unitRef="usd">9031000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c6" decimals="-3" unitRef="usd">7907000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c4" decimals="-3" unitRef="usd">3233000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c5" decimals="-3" unitRef="usd">1710000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="-3" unitRef="usd">4968000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c6" decimals="-3" unitRef="usd">3428000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c4" decimals="-3" unitRef="usd">7895000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c5" decimals="-3" unitRef="usd">5341000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="-3" unitRef="usd">13999000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c6" decimals="-3" unitRef="usd">11335000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c4" decimals="-3" unitRef="usd">-7850000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c5" decimals="-3" unitRef="usd">-5075000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="-3" unitRef="usd">-13014000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c6" decimals="-3" unitRef="usd">-10447000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet contextRef="c4" decimals="-3" unitRef="usd">83000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="c5" decimals="-3" unitRef="usd">54000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="c0" decimals="-3" unitRef="usd">118000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="c6" decimals="-3" unitRef="usd">106000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:NonoperatingIncomeExpense contextRef="c4" decimals="-3" unitRef="usd">83000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c5" decimals="-3" unitRef="usd">54000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c0" decimals="-3" unitRef="usd">118000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c6" decimals="-3" unitRef="usd">106000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss contextRef="c4" decimals="-3" unitRef="usd">-7767000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="-3" unitRef="usd">-5021000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" unitRef="usd">-12896000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c6" decimals="-3" unitRef="usd">-10341000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic contextRef="c4" decimals="2" unitRef="usdPershares">-0.33</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="c5" decimals="2" unitRef="usdPershares">-0.25</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="c0" decimals="2" unitRef="usdPershares">-0.56</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="c6" decimals="2" unitRef="usdPershares">-0.54</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c4" decimals="0" unitRef="shares">23731886</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c5" decimals="0" unitRef="shares">20231278</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c0" decimals="0" unitRef="shares">22942317</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c6" decimals="0" unitRef="shares">19308487</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding contextRef="c7" decimals="0" unitRef="shares">22143974</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c7" decimals="-3" unitRef="usd">22000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c8" decimals="-3" unitRef="usd">329271000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c9" decimals="-3" unitRef="usd">-255748000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c3" decimals="-3" unitRef="usd">73545000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c11" decimals="-3" unitRef="usd">421000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c13" decimals="-3" unitRef="usd">421000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:NetIncomeLoss contextRef="c12" decimals="-3" unitRef="usd">-5129000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c13" decimals="-3" unitRef="usd">-5129000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding contextRef="c14" decimals="0" unitRef="shares">22143974</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c14" decimals="-3" unitRef="usd">22000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c15" decimals="-3" unitRef="usd">329692000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c16" decimals="-3" unitRef="usd">-260877000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c17" decimals="-3" unitRef="usd">68837000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c19" decimals="-3" unitRef="usd">425000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c4" decimals="-3" unitRef="usd">425000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="c18" decimals="0" unitRef="shares">2726649</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c18" decimals="-3" unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c19" decimals="-3" unitRef="usd">16683000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c4" decimals="-3" unitRef="usd">16686000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:NetIncomeLoss contextRef="c20" decimals="-3" unitRef="usd">-7767000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c4" decimals="-3" unitRef="usd">-7767000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding contextRef="c21" decimals="0" unitRef="shares">24870623</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c21" decimals="-3" unitRef="usd">25000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c22" decimals="-3" unitRef="usd">346800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c23" decimals="-3" unitRef="usd">-268644000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c2" decimals="-3" unitRef="usd">78181000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding contextRef="c24" decimals="0" unitRef="shares">17532893</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c24" decimals="-3" unitRef="usd">18000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c25" decimals="-3" unitRef="usd">292275000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c26" decimals="-3" unitRef="usd">-230974000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c27" decimals="-3" unitRef="usd">61319000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c29" decimals="-3" unitRef="usd">376000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c31" decimals="-3" unitRef="usd">376000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c28" decimals="0" unitRef="shares">1712745</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c28" decimals="-3" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c29" decimals="-3" unitRef="usd">14360000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c31" decimals="-3" unitRef="usd">14361000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss contextRef="c30" decimals="-3" unitRef="usd">-5320000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c31" decimals="-3" unitRef="usd">-5320000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding contextRef="c32" decimals="0" unitRef="shares">19245638</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c32" decimals="-3" unitRef="usd">19000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c33" decimals="-3" unitRef="usd">307011000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c34" decimals="-3" unitRef="usd">-236294000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c35" decimals="-3" unitRef="usd">70736000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <atnm:StockIssuedDuringPeriodSharesIssuanceOfCommonStockFromExerciseOfPrefundedWarrants contextRef="c36" decimals="0" unitRef="shares">8705</atnm:StockIssuedDuringPeriodSharesIssuanceOfCommonStockFromExerciseOfPrefundedWarrants>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c37" decimals="-3" unitRef="usd">459000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c5" decimals="-3" unitRef="usd">459000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="c36" decimals="0" unitRef="shares">1835688</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c36" decimals="-3" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c37" decimals="-3" unitRef="usd">14317000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c5" decimals="-3" unitRef="usd">14319000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c36" decimals="0" unitRef="shares">900</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c37" decimals="-3" unitRef="usd">6000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c5" decimals="-3" unitRef="usd">6000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss contextRef="c38" decimals="-3" unitRef="usd">-5021000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="-3" unitRef="usd">-5021000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding contextRef="c39" decimals="0" unitRef="shares">21090931</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c39" decimals="-3" unitRef="usd">21000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c40" decimals="-3" unitRef="usd">321793000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c41" decimals="-3" unitRef="usd">-241315000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c42" decimals="-3" unitRef="usd">80499000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" unitRef="usd">-12896000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c6" decimals="-3" unitRef="usd">-10341000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="-3" unitRef="usd">846000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c6" decimals="-3" unitRef="usd">835000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationAndAmortization contextRef="c0" decimals="-3" unitRef="usd">317000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c6" decimals="-3" unitRef="usd">254000</us-gaap:DepreciationAndAmortization>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c0" decimals="-3" unitRef="usd">47000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c6" decimals="-3" unitRef="usd">-106000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInSecurityDeposits contextRef="c0" decimals="-3" unitRef="usd">-299000</us-gaap:IncreaseDecreaseInSecurityDeposits>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c0" decimals="-3" unitRef="usd">232000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c6" decimals="-3" unitRef="usd">-913000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c0" decimals="-3" unitRef="usd">-794000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c0" decimals="-3" unitRef="usd">35000000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <atnm:IncreaseDecreaseInOperatingLeaseLiabilities contextRef="c0" decimals="-3" unitRef="usd">-222000</atnm:IncreaseDecreaseInOperatingLeaseLiabilities>
    <atnm:IncreaseDecreaseInOperatingLeaseLiabilities contextRef="c6" decimals="-3" unitRef="usd">-167000</atnm:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="-3" unitRef="usd">22137000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c6" decimals="-3" unitRef="usd">-10226000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c0" decimals="-3" unitRef="usd">277000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c6" decimals="-3" unitRef="usd">65000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c0" decimals="-3" unitRef="usd">-277000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c6" decimals="-3" unitRef="usd">-65000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c0" decimals="-3" unitRef="usd">45000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c6" decimals="-3" unitRef="usd">42000</us-gaap:FinanceLeasePrincipalPayments>
    <atnm:SalesOfSharesOfCommonStockNetOfCosts contextRef="c0" decimals="-3" unitRef="usd">16686000</atnm:SalesOfSharesOfCommonStockNetOfCosts>
    <atnm:SalesOfSharesOfCommonStockNetOfCosts contextRef="c6" decimals="-3" unitRef="usd">28680000</atnm:SalesOfSharesOfCommonStockNetOfCosts>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c6" decimals="-3" unitRef="usd">6000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="-3" unitRef="usd">16641000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c6" decimals="-3" unitRef="usd">28644000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c0" decimals="-3" unitRef="usd">38501000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c6" decimals="-3" unitRef="usd">18353000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="-3" unitRef="usd">78221000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c27" decimals="-3" unitRef="usd">63999000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="-3" unitRef="usd">116722000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c42" decimals="-3" unitRef="usd">82352000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
1 - Description of Business and Summary of Significant Accounting Policies&lt;/b&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Nature of Business -&lt;/b&gt; Actinium
Pharmaceuticals, Inc. (the &#x201c;Company&#x201d; or &#x201c;Actinium&#x201d;) is a clinical-stage, biopharmaceutical company focused on
developing and potentially commercializing targeted radiotherapies for patients with unmet needs. The Company applies its proprietary
technology platform consisting of over 195 patents and patent applications, know-how and clinical experience in approximately 600 patients
to develop novel therapies for blood cancer and solid tumor indications. Its clinical and preclinical development programs utilize multiple
isotopes including Actinium-225, Iodine-131 and Lutetium-177 directed at multiple validated cancer targets including CD45, CD33, CD38,
CD47, HER2 and HER3 for targeted conditioning prior to cell and gene therapies including bone marrow transplant and cancer therapeutics
as single agents or in combination with other therapeutic modalities.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basis
of Presentation - &lt;/b&gt;The accompanying unaudited condensed consolidated financial statements and related notes have been prepared in
accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) for condensed financial
information, and pursuant to the rules and regulations of the United States Securities and Exchange Commission (the &#x201c;SEC&#x201d;)
with respect to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required
by U.S. GAAP for complete financial statements. The unaudited condensed consolidated financial statements reflect all adjustments (consisting
of normal recurring adjustments) which are, in the opinion of management, necessary for a fair statement of the results for the condensed
periods presented. Condensed results are not necessarily indicative of the results for the full year. These unaudited condensed consolidated
financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in
the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Principles
of Consolidation -&lt;/b&gt; The basis of consolidation is unchanged from the disclosure in the Company&#x2019;s Notes to the Consolidated Financial
Statements section in its Report on Form 10-K for the year ended December 31, 2021. The unaudited condensed consolidated financial statements
include the Company&#x2019;s accounts and those of the Company&#x2019;s wholly owned subsidiaries.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Use
of Estimates &lt;/b&gt;- The preparation of these unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated
financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Impact
of COVID&#x2013;19 Pandemic on Financial Statements - &lt;/b&gt;The global health crisis caused by the novel coronavirus (&#x201c;COVID-19&#x201d;)
pandemic and its resurgences has and may continue to negatively impact global economic activity, which, despite progress in vaccination
efforts, remains uncertain and cannot be predicted with confidence. In addition, the Omicron variants of COVID-19, including subvariants
BA.4 and BA.5, which appear to be the most transmissible variants to date, have spread globally. The full impact of the Omicron variants,
or any subsequent variants, cannot be predicted at this time, and could depend on numerous factors, including vaccination rates among
the population, the effectiveness of COVID-19 vaccines against the Omicron variants and subsequent variants and the response by governmental
bodies and regulators.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Many
countries around the world have continued to impose quarantines and restrictions on travel and mass gatherings to slow the spread of
the virus. Accordingly, the Company&#x2019;s ability to continue to operate its business may also be limited. Such events may result in
a period of business, supply and drug product manufacturing disruption, and in reduced operations, any of which could materially affect
the Company&#x2019;s business, financial condition and results of operations. In response to COVID-19, the Company implemented hybrid
working for its office-based staff, while its research staff has been actively working in its laboratory throughout the pandemic and
thus far, has not experienced a significant disruption or delay in its operations as it relates to the clinical development, preclinical
research or drug production of its drug candidates.&#160;A continuation or worsening of the levels of market disruption and volatility
seen in the recent past could have an adverse effect on the Company&#x2019;s ability to access capital, which could in the future negatively
affect the Company&#x2019;s liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially
affect the Company&#x2019;s business and the value of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Additionally,
COVID-19 may result in delays in receiving approvals from local and foreign regulatory authorities, delays in necessary interactions
with IRB&#x2019;s or Institutional Review Boards, local and foreign regulators, ethics committees and other important agencies and contractors
due to limitations in employee resources or forced furlough of government employees.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;To
date, COVID-19 has not had a financial impact on the Company. The Company continues to monitor the impacts of COVID-19 on the global
economy and on its business operations. However, at this time, it is difficult to predict how long the potential operational impacts
of COVID-19 will last or to what degree further disruption might impact the Company&#x2019;s operations and financial results.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Cash,
Cash Equivalents and Restricted Cash -&lt;/b&gt; The Company considers all highly liquid accounts with original maturities of three months
or less to be cash equivalents. Balances held by the Company are typically in excess of Federal Deposit Insurance Corporation insured
limits.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of cash, cash equivalents and restricted cash at June 30, 2022 and December 31, 2021:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;116,330&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;77,829&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;392&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;392&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Cash, cash equivalents and restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;116,772&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;78,221&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Restricted
cash relates to a certificate of deposit held as collateral for a letter of credit issued in connection with the Company&#x2019;s lease
for corporate office space.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Leases
&lt;/b&gt;&#x2013; The Company has operating and finance leases for corporate office space, office equipment and furniture located at the corporate
office space. Leases with an initial term of 12 months or less are not recorded on the balance sheet; lease expense for these leases
is recognized on a straight-line basis over the lease term. The Company entered into a lease for corporate office space effective June
1, 2022 and paid a security deposit to the landlord. A certificate of deposit will be provided as collateral for a letter of credit to
be issued with this new office space during 2022 and at that time, the security deposit will be returned to the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Revenue
Recognition &lt;/b&gt;- The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) Topic 606, &lt;i&gt;Revenue From
Contracts With Customers&lt;/i&gt; (&#x201c;ASC 606&#x201d;). Under ASC 606, an entity recognizes revenue when its customer obtains control of
promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods
or services. To determine revenue recognition for arrangements within the scope of ASC 606, the entity performs the following five steps:
(i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction
price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract;
and (v) recognize revenue as the entity satisfies a performance obligation. The Company only applies the five-step model to contracts
when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers
to the customer.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses whether the promised goods
or services promised within each contract are distinct and, therefore, represent a separate performance obligation.&#160;Goods and services
that are determined not to be distinct are combined with other promised goods and services until a distinct bundle is identified. In
determining whether goods or services are distinct, the Company evaluates certain criteria, including whether (i)&#160;the customer can
benefit from the good or service either on its own or together with other resources that are readily available to the customer (capable
of being distinct) and (ii)&#160;the good or service is separately identifiable from other goods or services in the contract (distinct
in the context of the contract).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; "&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company then determines the transaction price, which is the amount of consideration it expects to be entitled from a customer in exchange
for the promised goods or services for each performance obligation and recognizes the associated revenue as each performance obligation
is satisfied. The Company&#x2019;s estimate of the transaction price for each contract includes all variable consideration to which it
expects to be entitled. Variable consideration includes payments in the form of collaboration milestone payments. If an arrangement includes
collaboration milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates
the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue
reversal would not occur, the associated milestone value is included in the transaction price.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
606 requires the Company to allocate the arrangement consideration on a relative standalone selling price basis for each performance
obligation after determining the transaction price of the contract and identifying the performance obligations to which that amount should
be allocated. The relative standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised
good or service separately to a customer. The Company then recognizes as revenue the amount of the transaction price that is allocated
to the respective performance obligation as each performance obligation is satisfied, either at a point in time or over time, and if
over time, recognition is based on the use of an output or input method.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Collaborative
Arrangements - &lt;/b&gt;The Company follows the accounting guidance for collaboration agreements with third parties, which requires that certain
transactions between the Company and collaborators be recorded in its consolidated statements of operations and comprehensive loss on
either a gross basis or net basis, depending on the characteristics of the collaborative relationship, and requires enhanced disclosure
of collaborative relationships. The Company evaluates its collaboration agreements for proper classification in its consolidated statements
of operations and comprehensive loss based on the nature of the underlying activity. When the Company has concluded that it has a customer
relationship with one of its collaborators, the Company follows the guidance of ASC 606&lt;i&gt;.&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Grant Revenue &lt;i&gt;&#x2013; &lt;/i&gt;&lt;/b&gt;The
Company has a grant from a government-sponsored entity for research and development related activities that provides for payments for
reimbursed costs, which includes overhead and general and administrative costs as well as an administrative fee. The Company recognizes
revenue from grants as it performs services and all conditions are met under this arrangement. Associated expenses are recognized when
incurred as research and development expense. Revenue and related expenses are presented gross in the consolidated statements of operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;License Revenue &lt;i&gt;&#x2013;
&lt;/i&gt;&lt;/b&gt;The Company entered into a product licensing agreement whereby the Company allowed a third party to commercialize a certain product
in specified territories using the Company&#x2019;s trademarks. The terms of this arrangement includes payment to the Company for a combination
of one or more of the following: upfront license fees; development, regulatory and sales-based milestone payments; and royalties on net
sales of licensed products. The Company uses its judgment to determine whether milestones or other variable consideration should be included
in the transaction price.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Upfront
license fees&lt;/i&gt;: If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance
obligations identified in the arrangement, the Company will recognize revenue from upfront license fees allocated to the license when
the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled
with other promises, the Company determines whether the combined performance obligation is satisfied over time or at a point in time.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Development,
regulatory or commercial milestone payments&lt;/i&gt;: At the inception of each arrangement that includes payments based on the achievement
of certain development, regulatory and sales-based or commercial events, the Company evaluates whether the milestones are considered
probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it
is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price.
Milestone payments that are not within the Company&#x2019;s or the licensee&#x2019;s control, such as regulatory approvals, are not considered
probable of being achieved until regulatory approval is received. At the end of each subsequent reporting period, the Company will re-evaluate
the probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust the Company&#x2019;s
estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis and recorded as part of license
revenue during the period of adjustment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Sales-based
milestone payments and royalties&lt;/i&gt;: For arrangements that include sales-based royalties, including milestone payments based on the
volume of sales, the Company will determine whether the license is deemed to be the predominant item to which the royalties or sales-based
milestones relate and if such is the case, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii)
when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upfront
payments and fees may require deferral of revenue recognition to a future period until the Company performs its obligations under these
arrangements or when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur or when
the uncertainty associated with any variable consideration is subsequently resolved. Amounts payable to the Company are recorded as accounts
receivable when the Company&#x2019;s right to consideration is unconditional.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Research
and Development Costs -&lt;/b&gt; Research and development costs are expensed as incurred. These costs include the costs of manufacturing drug
product, the costs of clinical trials, costs of employees and associated overhead, and depreciation and amortization costs related to
facilities and equipment. Research and development reimbursements are recorded by the Company as a reduction of research and development
costs.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Share-Based
Payments -&lt;/b&gt; The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing
model. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee
is required to provide service in exchange for the award. The Company accounts for forfeitures of stock options as they occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;b&gt;Net
Loss Per Common Share&lt;/b&gt; - Basic loss per common share is computed by dividing the net loss available to common stockholders by the
weighted average number of shares of common stock outstanding during the reporting period. For periods of net loss, diluted loss per
share is calculated similarly to basic loss per share because the impact of all potential dilutive common shares is anti-dilutive. For
the three months ended June 30, 2022 and 2021, the Company&#x2019;s potentially dilutive shares, which include outstanding common stock
options and warrants, have not been included in the computation of diluted net loss per share as the result would have been anti-dilutive.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Options&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,431&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;859&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,053&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,114&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,484&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,973&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Recently
Adopted Accounting Pronouncements &#x2013; &lt;/b&gt;In May 2021, FASB issued ASU 2021-04, &lt;i&gt;Earnings Per Share (topic 260), Debt &#x2014; Modifications
and Extinguishments (Subtopic 470-50), Compensation &#x2013; Stock Compensation (Topic 718) and Derivatives and Hedging &#x2013; Contracts
in an Entity&#x2019;s Own Equity (Subtopic 815-40) &#x2013; Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding
Equity-Classified Written Call Options&lt;/i&gt;, which provides guidance of a modification or an exchange of a freestanding equity-classified
written call option that remains equity classified after modification or exchange as (1) an adjustment to equity and, if so, the related
earnings per share (EPS) effects, if any, or (2) an expense and, if so, the manner and pattern of recognition. The amendments in this
ASU are effective January 1, 2022, including interim periods. The Company adopted this standard effective January 1, 2022 and the standard
did not have a material effect on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2021, the FASB issued ASU 2021-10, &lt;i&gt;Government Assistance (Topic 832), Disclosures by Business Entities about Government Assistance&lt;/i&gt;,
which provides guidance on disclosure requirements to entities other than not-for-profit entities about transaction with a government
that are accounted for by applying a grant or contribution accounting model by analogy. ASU 2021-10 requires an entity to make annual
disclosures related to (1) the nature of the transactions and the related accounting policy used to account for the government transactions,
(2) quantification and disclosure of amounts related to the government transactions included in balance sheet and income statement financial
statement line items, and (3) significant terms and conditions of the government transactions, including commitments and contingencies.
The amendments of ASU 2021-10 are effective January 1, 2022, including interim periods. The Company adopted this standard effective January
1, 2022, and the standard did not have a material impact on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Recently
Issued Accounting Pronouncements &#x2013; &lt;/b&gt;In October 2021, FASB issued ASU 2021-08, &lt;i&gt;Business Combinations (Topic 805), Account
for Contract Assets and Contract Liabilities from Contracts with Customers&lt;/i&gt;, which provides guidance on accounting for contract assets
and contract liabilities acquired in a business combination in accordance with ASC 606. To achieve this, an acquirer may assess how the
acquiree applied ASC 606 to determine what to record for the acquired revenue contracts. Generally, this should result in an acquirer
recognizing and measuring the acquired contract assets and contract liabilities consistent with how they were recognized and measured
in the acquiree&#x2019;s financial statements. The amendments of ASU 2021-08 are effective January 1, 2023, including interim periods.
Early adoption is permitted, including adoption in an interim period. The Company will evaluate the impact of ASU 2021-08 on any future
business combinations the Company may enter in the future.&lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <atnm:NatureOfBusinessPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Nature of Business -&lt;/b&gt; Actinium
Pharmaceuticals, Inc. (the &#x201c;Company&#x201d; or &#x201c;Actinium&#x201d;) is a clinical-stage, biopharmaceutical company focused on
developing and potentially commercializing targeted radiotherapies for patients with unmet needs. The Company applies its proprietary
technology platform consisting of over 195 patents and patent applications, know-how and clinical experience in approximately 600 patients
to develop novel therapies for blood cancer and solid tumor indications. Its clinical and preclinical development programs utilize multiple
isotopes including Actinium-225, Iodine-131 and Lutetium-177 directed at multiple validated cancer targets including CD45, CD33, CD38,
CD47, HER2 and HER3 for targeted conditioning prior to cell and gene therapies including bone marrow transplant and cancer therapeutics
as single agents or in combination with other therapeutic modalities.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;</atnm:NatureOfBusinessPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basis
of Presentation - &lt;/b&gt;The accompanying unaudited condensed consolidated financial statements and related notes have been prepared in
accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) for condensed financial
information, and pursuant to the rules and regulations of the United States Securities and Exchange Commission (the &#x201c;SEC&#x201d;)
with respect to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required
by U.S. GAAP for complete financial statements. The unaudited condensed consolidated financial statements reflect all adjustments (consisting
of normal recurring adjustments) which are, in the opinion of management, necessary for a fair statement of the results for the condensed
periods presented. Condensed results are not necessarily indicative of the results for the full year. These unaudited condensed consolidated
financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in
the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Principles
of Consolidation -&lt;/b&gt; The basis of consolidation is unchanged from the disclosure in the Company&#x2019;s Notes to the Consolidated Financial
Statements section in its Report on Form 10-K for the year ended December 31, 2021. The unaudited condensed consolidated financial statements
include the Company&#x2019;s accounts and those of the Company&#x2019;s wholly owned subsidiaries.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Use
of Estimates &lt;/b&gt;- The preparation of these unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated
financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <atnm:PandemicOnFinancialStatements contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Impact
of COVID&#x2013;19 Pandemic on Financial Statements - &lt;/b&gt;The global health crisis caused by the novel coronavirus (&#x201c;COVID-19&#x201d;)
pandemic and its resurgences has and may continue to negatively impact global economic activity, which, despite progress in vaccination
efforts, remains uncertain and cannot be predicted with confidence. In addition, the Omicron variants of COVID-19, including subvariants
BA.4 and BA.5, which appear to be the most transmissible variants to date, have spread globally. The full impact of the Omicron variants,
or any subsequent variants, cannot be predicted at this time, and could depend on numerous factors, including vaccination rates among
the population, the effectiveness of COVID-19 vaccines against the Omicron variants and subsequent variants and the response by governmental
bodies and regulators.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Many
countries around the world have continued to impose quarantines and restrictions on travel and mass gatherings to slow the spread of
the virus. Accordingly, the Company&#x2019;s ability to continue to operate its business may also be limited. Such events may result in
a period of business, supply and drug product manufacturing disruption, and in reduced operations, any of which could materially affect
the Company&#x2019;s business, financial condition and results of operations. In response to COVID-19, the Company implemented hybrid
working for its office-based staff, while its research staff has been actively working in its laboratory throughout the pandemic and
thus far, has not experienced a significant disruption or delay in its operations as it relates to the clinical development, preclinical
research or drug production of its drug candidates.&#160;A continuation or worsening of the levels of market disruption and volatility
seen in the recent past could have an adverse effect on the Company&#x2019;s ability to access capital, which could in the future negatively
affect the Company&#x2019;s liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially
affect the Company&#x2019;s business and the value of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Additionally,
COVID-19 may result in delays in receiving approvals from local and foreign regulatory authorities, delays in necessary interactions
with IRB&#x2019;s or Institutional Review Boards, local and foreign regulators, ethics committees and other important agencies and contractors
due to limitations in employee resources or forced furlough of government employees.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;To
date, COVID-19 has not had a financial impact on the Company. The Company continues to monitor the impacts of COVID-19 on the global
economy and on its business operations. However, at this time, it is difficult to predict how long the potential operational impacts
of COVID-19 will last or to what degree further disruption might impact the Company&#x2019;s operations and financial results.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;</atnm:PandemicOnFinancialStatements>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Cash,
Cash Equivalents and Restricted Cash -&lt;/b&gt; The Company considers all highly liquid accounts with original maturities of three months
or less to be cash equivalents. Balances held by the Company are typically in excess of Federal Deposit Insurance Corporation insured
limits.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of cash, cash equivalents and restricted cash at June 30, 2022 and December 31, 2021:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;116,330&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;77,829&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;392&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;392&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Cash, cash equivalents and restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;116,772&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;78,221&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Restricted
cash relates to a certificate of deposit held as collateral for a letter of credit issued in connection with the Company&#x2019;s lease
for corporate office space.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;116,330&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;77,829&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;392&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;392&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Cash, cash equivalents and restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;116,772&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;78,221&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c2" decimals="-3" unitRef="usd">116330000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c3" decimals="-3" unitRef="usd">77829000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:OtherRestrictedAssetsCurrent contextRef="c2" decimals="-3" unitRef="usd">392000</us-gaap:OtherRestrictedAssetsCurrent>
    <us-gaap:OtherRestrictedAssetsCurrent contextRef="c3" decimals="-3" unitRef="usd">392000</us-gaap:OtherRestrictedAssetsCurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations contextRef="c2" decimals="-3" unitRef="usd">116772000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations contextRef="c3" decimals="-3" unitRef="usd">78221000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Leases
&lt;/b&gt;&#x2013; The Company has operating and finance leases for corporate office space, office equipment and furniture located at the corporate
office space. Leases with an initial term of 12 months or less are not recorded on the balance sheet; lease expense for these leases
is recognized on a straight-line basis over the lease term. The Company entered into a lease for corporate office space effective June
1, 2022 and paid a security deposit to the landlord. A certificate of deposit will be provided as collateral for a letter of credit to
be issued with this new office space during 2022 and at that time, the security deposit will be returned to the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Revenue
Recognition &lt;/b&gt;- The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) Topic 606, &lt;i&gt;Revenue From
Contracts With Customers&lt;/i&gt; (&#x201c;ASC 606&#x201d;). Under ASC 606, an entity recognizes revenue when its customer obtains control of
promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods
or services. To determine revenue recognition for arrangements within the scope of ASC 606, the entity performs the following five steps:
(i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction
price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract;
and (v) recognize revenue as the entity satisfies a performance obligation. The Company only applies the five-step model to contracts
when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers
to the customer.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses whether the promised goods
or services promised within each contract are distinct and, therefore, represent a separate performance obligation.&#160;Goods and services
that are determined not to be distinct are combined with other promised goods and services until a distinct bundle is identified. In
determining whether goods or services are distinct, the Company evaluates certain criteria, including whether (i)&#160;the customer can
benefit from the good or service either on its own or together with other resources that are readily available to the customer (capable
of being distinct) and (ii)&#160;the good or service is separately identifiable from other goods or services in the contract (distinct
in the context of the contract).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; "&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company then determines the transaction price, which is the amount of consideration it expects to be entitled from a customer in exchange
for the promised goods or services for each performance obligation and recognizes the associated revenue as each performance obligation
is satisfied. The Company&#x2019;s estimate of the transaction price for each contract includes all variable consideration to which it
expects to be entitled. Variable consideration includes payments in the form of collaboration milestone payments. If an arrangement includes
collaboration milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates
the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue
reversal would not occur, the associated milestone value is included in the transaction price.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
606 requires the Company to allocate the arrangement consideration on a relative standalone selling price basis for each performance
obligation after determining the transaction price of the contract and identifying the performance obligations to which that amount should
be allocated. The relative standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised
good or service separately to a customer. The Company then recognizes as revenue the amount of the transaction price that is allocated
to the respective performance obligation as each performance obligation is satisfied, either at a point in time or over time, and if
over time, recognition is based on the use of an output or input method.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:CollaborativeArrangementAccountingPolicy contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Collaborative
Arrangements - &lt;/b&gt;The Company follows the accounting guidance for collaboration agreements with third parties, which requires that certain
transactions between the Company and collaborators be recorded in its consolidated statements of operations and comprehensive loss on
either a gross basis or net basis, depending on the characteristics of the collaborative relationship, and requires enhanced disclosure
of collaborative relationships. The Company evaluates its collaboration agreements for proper classification in its consolidated statements
of operations and comprehensive loss based on the nature of the underlying activity. When the Company has concluded that it has a customer
relationship with one of its collaborators, the Company follows the guidance of ASC 606&lt;i&gt;.&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <atnm:GrantRevenuePolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Grant Revenue &lt;i&gt;&#x2013; &lt;/i&gt;&lt;/b&gt;The
Company has a grant from a government-sponsored entity for research and development related activities that provides for payments for
reimbursed costs, which includes overhead and general and administrative costs as well as an administrative fee. The Company recognizes
revenue from grants as it performs services and all conditions are met under this arrangement. Associated expenses are recognized when
incurred as research and development expense. Revenue and related expenses are presented gross in the consolidated statements of operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</atnm:GrantRevenuePolicyTextBlock>
    <atnm:LicenseRevenueTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;License Revenue &lt;i&gt;&#x2013;
&lt;/i&gt;&lt;/b&gt;The Company entered into a product licensing agreement whereby the Company allowed a third party to commercialize a certain product
in specified territories using the Company&#x2019;s trademarks. The terms of this arrangement includes payment to the Company for a combination
of one or more of the following: upfront license fees; development, regulatory and sales-based milestone payments; and royalties on net
sales of licensed products. The Company uses its judgment to determine whether milestones or other variable consideration should be included
in the transaction price.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Upfront
license fees&lt;/i&gt;: If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance
obligations identified in the arrangement, the Company will recognize revenue from upfront license fees allocated to the license when
the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled
with other promises, the Company determines whether the combined performance obligation is satisfied over time or at a point in time.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Development,
regulatory or commercial milestone payments&lt;/i&gt;: At the inception of each arrangement that includes payments based on the achievement
of certain development, regulatory and sales-based or commercial events, the Company evaluates whether the milestones are considered
probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it
is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price.
Milestone payments that are not within the Company&#x2019;s or the licensee&#x2019;s control, such as regulatory approvals, are not considered
probable of being achieved until regulatory approval is received. At the end of each subsequent reporting period, the Company will re-evaluate
the probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust the Company&#x2019;s
estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis and recorded as part of license
revenue during the period of adjustment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Sales-based
milestone payments and royalties&lt;/i&gt;: For arrangements that include sales-based royalties, including milestone payments based on the
volume of sales, the Company will determine whether the license is deemed to be the predominant item to which the royalties or sales-based
milestones relate and if such is the case, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii)
when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upfront
payments and fees may require deferral of revenue recognition to a future period until the Company performs its obligations under these
arrangements or when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur or when
the uncertainty associated with any variable consideration is subsequently resolved. Amounts payable to the Company are recorded as accounts
receivable when the Company&#x2019;s right to consideration is unconditional.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</atnm:LicenseRevenueTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Research
and Development Costs -&lt;/b&gt; Research and development costs are expensed as incurred. These costs include the costs of manufacturing drug
product, the costs of clinical trials, costs of employees and associated overhead, and depreciation and amortization costs related to
facilities and equipment. Research and development reimbursements are recorded by the Company as a reduction of research and development
costs.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Share-Based
Payments -&lt;/b&gt; The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing
model. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee
is required to provide service in exchange for the award. The Company accounts for forfeitures of stock options as they occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0">&lt;b&gt;Net
Loss Per Common Share&lt;/b&gt; - Basic loss per common share is computed by dividing the net loss available to common stockholders by the
weighted average number of shares of common stock outstanding during the reporting period. For periods of net loss, diluted loss per
share is calculated similarly to basic loss per share because the impact of all potential dilutive common shares is anti-dilutive. For
the three months ended June 30, 2022 and 2021, the Company&#x2019;s potentially dilutive shares, which include outstanding common stock
options and warrants, have not been included in the computation of diluted net loss per share as the result would have been anti-dilutive.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Options&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,431&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;859&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,053&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,114&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,484&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,973&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c43" decimals="0" unitRef="shares">1431</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c44" decimals="0" unitRef="shares">859</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c45" decimals="0" unitRef="shares">2053</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c46" decimals="0" unitRef="shares">2114</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c0" decimals="0" unitRef="shares">3484</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c6" decimals="0" unitRef="shares">2973</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <atnm:Accountingstandardsrecentlyissuedpolicytextblock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Recently
Adopted Accounting Pronouncements &#x2013; &lt;/b&gt;In May 2021, FASB issued ASU 2021-04, &lt;i&gt;Earnings Per Share (topic 260), Debt &#x2014; Modifications
and Extinguishments (Subtopic 470-50), Compensation &#x2013; Stock Compensation (Topic 718) and Derivatives and Hedging &#x2013; Contracts
in an Entity&#x2019;s Own Equity (Subtopic 815-40) &#x2013; Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding
Equity-Classified Written Call Options&lt;/i&gt;, which provides guidance of a modification or an exchange of a freestanding equity-classified
written call option that remains equity classified after modification or exchange as (1) an adjustment to equity and, if so, the related
earnings per share (EPS) effects, if any, or (2) an expense and, if so, the manner and pattern of recognition. The amendments in this
ASU are effective January 1, 2022, including interim periods. The Company adopted this standard effective January 1, 2022 and the standard
did not have a material effect on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2021, the FASB issued ASU 2021-10, &lt;i&gt;Government Assistance (Topic 832), Disclosures by Business Entities about Government Assistance&lt;/i&gt;,
which provides guidance on disclosure requirements to entities other than not-for-profit entities about transaction with a government
that are accounted for by applying a grant or contribution accounting model by analogy. ASU 2021-10 requires an entity to make annual
disclosures related to (1) the nature of the transactions and the related accounting policy used to account for the government transactions,
(2) quantification and disclosure of amounts related to the government transactions included in balance sheet and income statement financial
statement line items, and (3) significant terms and conditions of the government transactions, including commitments and contingencies.
The amendments of ASU 2021-10 are effective January 1, 2022, including interim periods. The Company adopted this standard effective January
1, 2022, and the standard did not have a material impact on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</atnm:Accountingstandardsrecentlyissuedpolicytextblock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Recently
Issued Accounting Pronouncements &#x2013; &lt;/b&gt;In October 2021, FASB issued ASU 2021-08, &lt;i&gt;Business Combinations (Topic 805), Account
for Contract Assets and Contract Liabilities from Contracts with Customers&lt;/i&gt;, which provides guidance on accounting for contract assets
and contract liabilities acquired in a business combination in accordance with ASC 606. To achieve this, an acquirer may assess how the
acquiree applied ASC 606 to determine what to record for the acquired revenue contracts. Generally, this should result in an acquirer
recognizing and measuring the acquired contract assets and contract liabilities consistent with how they were recognized and measured
in the acquiree&#x2019;s financial statements. The amendments of ASU 2021-08 are effective January 1, 2023, including interim periods.
Early adoption is permitted, including adoption in an interim period. The Company will evaluate the impact of ASU 2021-08 on any future
business combinations the Company may enter in the future.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
2 - Commitments and Contingencies&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 15, 2012, the Company entered into a license and sponsored research agreement with Fred Hutchinson Cancer Research Center (&#x201c;FHCRC&#x201d;)
to build upon previous and ongoing clinical trials with apamistamab (licensed antibody). FHCRC has completed both a Phase 1 and Phase
2 clinical trial with apamistamab. The Company has been granted exclusive rights to the antibody and related master cell bank developed
by FHCRC. A milestone payment of $1 million will be due to FHCRC upon U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) approval
of the first drug utilizing the licensed antibody. Upon commercial sale of the drug, royalty payments of 2% of net sales will be due
to FHCRC.&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <atnm:MilestonePayment contextRef="c47" decimals="-6" unitRef="usd">1000000</atnm:MilestonePayment>
    <atnm:DescriptionOfRoyaltyPaymentToRelatedParty contextRef="c47">Upon commercial sale of the drug, royalty payments of 2% of net sales will be due
to FHCRC.</atnm:DescriptionOfRoyaltyPaymentToRelatedParty>
    <atnm:LeasesTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
3 - Leases &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company entered into a
lease for corporate office space, effective June 1, 2022. As of June 30, 2022, the Company has two operating leases for corporate office
space and two finance leases for office equipment and furniture located in one of the corporate office spaces. In addition, the Company
has auxiliary corporate office space that it rents on a month-to-month basis; this rental is accounted for as an operating lease with
the same term as the Company&#x2019;s main office.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
components of lease expense are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three months ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Six months ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June&#160;30,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June&#160;30,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June&#160;30,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June&#160;30,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Operating lease expense&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;141&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;93&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;234&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;186&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Finance lease cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Amortization of right-to-use assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;21&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;41&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;41&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in"&gt;Interest on lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Total finance lease cost&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;21&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;23&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;43&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;46&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Supplemental
cash flow information related to leases are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Cash
flow information:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Six months ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June&#160;30,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June&#160;30,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Operating cash flow use from operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;239&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;188&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Operating cash flow use from finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Financing cash flow use from finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;45&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;42&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Non-cash activity:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,605&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-48"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Finance Leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-49"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-50"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted
average remaining lease terms are as follows at June 30, 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Weighted average remaining lease term:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center"&gt;5.0 years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Finance Leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;0.5 year&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
the interest rate implicit in the leases was not readily determinable at the time that the leases were evaluated, the Company used its
incremental borrowing rate based on the information available in determining the present value of lease payments. The Company&#x2019;s
incremental borrowing rate was based on the term of the lease, the economic environment of the lease and reflect the rate the Company
would have had to pay to borrow on a secured basis. Below is information on the weighted average discount rates used at the time that
the leases were evaluated:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Weighted average discount rates:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;4.8%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Finance Leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;8.0%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Maturities
of lease liabilities are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&#160;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;br/&gt; Year ending December 31,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Operating &lt;br/&gt; Leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Finance &lt;br/&gt; Leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; width: 76%"&gt;2022 (excluding six months ended June 30, 2022)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;113&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;17&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;606&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;618&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-51"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;630&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-52"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;643&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-53"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2027&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;380&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-54"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,990&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;22&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(363&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,627&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;21&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</atnm:LeasesTextBlock>
    <atnm:NumberOfOperatingLease contextRef="c0" decimals="0" unitRef="pure">2</atnm:NumberOfOperatingLease>
    <atnm:NumberOfFinanceLease contextRef="c0" decimals="0" unitRef="pure">2</atnm:NumberOfFinanceLease>
    <atnm:AdditionSpaceForOperatingLease contextRef="c0" decimals="0" unitRef="pure">1</atnm:AdditionSpaceForOperatingLease>
    <us-gaap:LeaseCostTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three months ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Six months ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June&#160;30,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June&#160;30,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June&#160;30,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June&#160;30,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Operating lease expense&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;141&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;93&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;234&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;186&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Finance lease cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Amortization of right-to-use assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;21&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;41&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;41&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in"&gt;Interest on lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Total finance lease cost&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;21&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;23&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;43&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;46&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseExpense contextRef="c4" decimals="-3" unitRef="usd">141000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c5" decimals="-3" unitRef="usd">93000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c0" decimals="-3" unitRef="usd">234000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c6" decimals="-3" unitRef="usd">186000</us-gaap:OperatingLeaseExpense>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c4" decimals="-3" unitRef="usd">20000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c5" decimals="-3" unitRef="usd">21000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c0" decimals="-3" unitRef="usd">41000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c6" decimals="-3" unitRef="usd">41000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c4" decimals="-3" unitRef="usd">1000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c5" decimals="-3" unitRef="usd">2000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c0" decimals="-3" unitRef="usd">2000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c6" decimals="-3" unitRef="usd">5000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:OperatingLeaseCost contextRef="c4" decimals="-3" unitRef="usd">21000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c5" decimals="-3" unitRef="usd">23000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c0" decimals="-3" unitRef="usd">43000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c6" decimals="-3" unitRef="usd">46000</us-gaap:OperatingLeaseCost>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Six months ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June&#160;30,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June&#160;30,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Operating cash flow use from operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;239&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;188&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Operating cash flow use from finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Financing cash flow use from finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;45&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;42&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Non-cash activity:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,605&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-48"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Finance Leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-49"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-50"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:OperatingLeasePayments contextRef="c0" decimals="-3" unitRef="usd">239000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c6" decimals="-3" unitRef="usd">188000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="c0" decimals="-3" unitRef="usd">2000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="c6" decimals="-3" unitRef="usd">5000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c0" decimals="-3" unitRef="usd">45000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c6" decimals="-3" unitRef="usd">42000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c0" decimals="-3" unitRef="usd">2605000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <atnm:ScheduleOrDescriptionOfWeightedAverageTerm contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Weighted average remaining lease term:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center"&gt;5.0 years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Finance Leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;0.5 year&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</atnm:ScheduleOrDescriptionOfWeightedAverageTerm>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c2">P5Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c2">P0Y6M</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <atnm:ScheduleOfWeightedAverageDiscountRate contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Weighted average discount rates:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;4.8%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Finance Leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;8.0%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</atnm:ScheduleOfWeightedAverageDiscountRate>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c2" decimals="3" unitRef="pure">0.048</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent contextRef="c2" decimals="3" unitRef="pure">0.08</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <atnm:OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;br/&gt; Year ending December 31,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Operating &lt;br/&gt; Leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Finance &lt;br/&gt; Leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; width: 76%"&gt;2022 (excluding six months ended June 30, 2022)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;113&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;17&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;606&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;618&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-51"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;630&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-52"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;643&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-53"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2027&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;380&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-54"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,990&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;22&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(363&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,627&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;21&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</atnm:OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths contextRef="c48" decimals="-3" unitRef="usd">113000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths contextRef="c49" decimals="-3" unitRef="usd">17000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo contextRef="c48" decimals="-3" unitRef="usd">606000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo contextRef="c49" decimals="-3" unitRef="usd">5000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree contextRef="c48" decimals="-3" unitRef="usd">618000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour contextRef="c48" decimals="-3" unitRef="usd">630000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive contextRef="c48" decimals="-3" unitRef="usd">643000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive contextRef="c48" decimals="-3" unitRef="usd">380000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c48" decimals="-3" unitRef="usd">2990000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c49" decimals="-3" unitRef="usd">22000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <atnm:PaymentWithImputedInterestPremium contextRef="c48" decimals="-3" unitRef="usd">-363000</atnm:PaymentWithImputedInterestPremium>
    <atnm:PaymentWithImputedInterestPremium contextRef="c49" decimals="-3" unitRef="usd">-1000</atnm:PaymentWithImputedInterestPremium>
    <atnm:MaturitiesOfLeaseLiabilities contextRef="c48" decimals="-3" unitRef="usd">2627000</atnm:MaturitiesOfLeaseLiabilities>
    <atnm:MaturitiesOfLeaseLiabilities contextRef="c49" decimals="-3" unitRef="usd">21000</atnm:MaturitiesOfLeaseLiabilities>
    <atnm:OtherRevenueTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
4 &#x2013; Other revenue &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determined that certain collaborations with a third party are within the scope of ASC 606. The collaboration agreement is made
up of multiple modules related to various research activities. The Company identified a single performance obligation to provide research
services within each module for which the Company receives monetary consideration. The third party can choose to proceed with each module
or can terminate the agreement at any time. The Company recognizes revenue for each module on a straight-line basis over the expected
module period. Revenue for succeeding modules is not recognized until all contingencies are resolved, inclusive of the third party&#x2019;s
ability to terminate the module. Other revenue recognized during the three months and six months ended June 30, 2022 was $0.0 million
and $0.9 million, respectively, and for the three months and six months ended June 30, 2021 was $0.3 million and $0.9 million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has a grant from a government-sponsored entity for research and development related activities that provide for payments for
reimbursed costs, which includes overhead and general and administrative costs as well as an administrative fee. The Company recognizes
revenue from grants as it performs services under this arrangement. Associated expenses are recognized when incurred as research and
development expense. Other revenue recognized during the three months and six months ended June 30, 2022 was $0.0 million and $0.1 million,
respectively. There was no other revenue recognized from a grant from a government-sponsored entity during the six months ended June
30, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On April 7, 2022, the Company
entered into a license and supply agreement (the &#x201c;License Agreement&#x201d;) with Immedica Pharma AB (&#x201c;Immedica&#x201d;), pursuant
to which Immedica licensed the exclusive product rights for commercialization of Iomab-B (I-131 apamistamab) in the European Economic
Area, Middle East and North Africa (EUMENA) including Algeria, Andorra, Bahrain, Cyprus, Egypt, Iran, Iraq, Israel, Jordan, Kuwait, Lebanon,
Libya, Monaco, Morocco, Oman, Palestine, Qatar, San Marino, Saudi Arabia, Switzerland, Syria, Tunisia, Turkey, the United Arab Emirates,
the United Kingdom, the Vatican City and Yemen. Upon signing, the Company was entitled to an upfront payment of $35 million from Immedica,
which was received in May 2022. Under the terms of the License Agreement, the Company is eligible to receive regulatory and commercial
milestone payments and is entitled to receive royalties in the mid-20 percent range on net sales of the product in certain countries that
may result from the License Agreement. The Company will continue to be responsible for certain clinical development activities and the
manufacturing of Iomab-B and will retain commercialization rights in the U.S. and rest of the world.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Company&#x2019;s contract liabilities
are recorded within Other revenue deferred &#x2013; current liability or Long-term license revenue deferred in its condensed consolidated
balance sheets depending on the short-term or long-term nature of the payments to be recognized. The Company&#x2019;s contract liabilities
primarily consist of advanced payments from licensees. Other revenue deferred &#x2013; current liability was $0.2 million at June 30, 2022
and $0.9 million at December 31, 2021. Long-term license revenue deferred was $35.0 million at June 30, 2022; there was no long-term license
revenue deferred at December 31, 2021. This deferred revenue will be recognized upon EU regulatory approval of Iomab B.&lt;/p&gt;</atnm:OtherRevenueTextBlock>
    <atnm:RecognitionOfDeferredRevenue1 contextRef="c4" decimals="-5" unitRef="usd">0</atnm:RecognitionOfDeferredRevenue1>
    <atnm:RecognitionOfDeferredRevenue1 contextRef="c0" decimals="-5" unitRef="usd">900000</atnm:RecognitionOfDeferredRevenue1>
    <atnm:RecognitionOfDeferredRevenue1 contextRef="c5" decimals="-5" unitRef="usd">300000</atnm:RecognitionOfDeferredRevenue1>
    <atnm:RecognitionOfDeferredRevenue1 contextRef="c6" decimals="-5" unitRef="usd">900000</atnm:RecognitionOfDeferredRevenue1>
    <atnm:RevenueRecognized contextRef="c4" decimals="-5" unitRef="usd">0</atnm:RevenueRecognized>
    <atnm:RevenueRecognized contextRef="c0" decimals="-5" unitRef="usd">100000</atnm:RevenueRecognized>
    <atnm:UpfrontPayment contextRef="c50" decimals="-6" unitRef="usd">35000000</atnm:UpfrontPayment>
    <us-gaap:DeferredRevenueCurrent contextRef="c2" decimals="-5" unitRef="usd">200000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent contextRef="c3" decimals="-5" unitRef="usd">900000</us-gaap:DeferredRevenueCurrent>
    <atnm:LongtermLicenseRevenueDeferred contextRef="c2" decimals="-5" unitRef="usd">35000000</atnm:LongtermLicenseRevenueDeferred>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
5 - Equity&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
August 2020 the Company entered into the Capital on Demand&#x2122; Sales Agreement with JonesTrading Institutional Services LLC, or JonesTrading,
pursuant to which the Company may sell, from time to time, through or to JonesTrading, up to an aggregate of $200 million of its common
stock. Shares of common stock are offered pursuant to a shelf registration statement on Form S-3 filed with the SEC on August 7, 2020.
As of December 31, 2021, the Company had sold 6.7 million shares of common stock, resulting in gross proceeds of $59.1 million and net
proceeds of $57.0 million. For the six months ended June 30, 2022, the Company sold 2.7 million shares of common stock, resulting in
gross proceeds of $17.2 million and net proceeds of $16.7 million. For the six months ended June 30, 2021, the Company sold 3.5 million
shares of common stock, resulting in gross proceeds of $29.6 million and net proceeds of $28.7 million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 28, 2022, the Company entered into an Amendment and Restated Capital on Demand&#x2122; Sales Agreement (the &#x201c;A&amp;amp;R Sales
Agreement&#x201d;) with JonesTrading and B. Riley Securities, Inc. (&#x201c;B. Riley Securities&#x201d;). The A&amp;amp;R Sales Agreement modifies
the original Capital on Demand&#x2122; Sales Agreement to include B. Riley Securities as an additional sales agent thereunder.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Stock
Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of stock option activity for the six months ended June 30, 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands, except for per-share amounts)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number&#160;of&lt;br/&gt; Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Exercise &lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Remaining &lt;br/&gt; Contractual &lt;br/&gt; Term &lt;br/&gt; (in years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate &lt;br/&gt; Intrinsic &lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 53%"&gt;Outstanding, January 1, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,362&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;12.45&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: center"&gt;8.69&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-55"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;120&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.23&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(51&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;8.89&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding, June 30, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,431&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;11.97&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: center"&gt;8.36&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-56"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Exercisable, June 30, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;473&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;22.19&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: center"&gt;7.07&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-57"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the six months ended June 30, 2022, the Company granted new employees options to purchase 120 thousand shares of common stock with an
exercise price ranging from $5.20 to $5.93 per share, a term of 10 years, and a vesting period of 4 years.&#160;The options have an aggregated
fair value of $442 thousand that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing
model include: (1) discount rate range from 1.52% to 3.03% (2) expected life of 6 years, (3) expected volatility range from 78.8% to
79.9%, and (4) zero expected dividends.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair values of all options issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation
expense at June 30, 2022 was $4.4 million related to unvested options, which is expected to be expensed over a weighted average of 3.0
years. During the six months ended June 30, 2022 and 2021, the Company recorded compensation expense related to stock options of $0.8
million and $0.7 million, respectively. &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Following
is a summary of warrant activity for the six months ended June 30, 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands, except for per-share amounts)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Exercise &lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Remaining &lt;br/&gt; Contractual &lt;br/&gt; Term &lt;br/&gt; (in&#160;years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate &lt;br/&gt; Intrinsic &lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 53%"&gt;Outstanding, January 1, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,112&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;20.52&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: center"&gt;1.76&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;276&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-58"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-59"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 9pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-60"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-61"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;Cancelled/Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(59&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;3.62&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding, June 30, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,053&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;21.01&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: center"&gt;1.32&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-62"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Exercisable, June 30, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,049&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;20.57&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: center"&gt;1.31&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-63"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c51" decimals="-6" unitRef="usd">200000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c52" decimals="-5" unitRef="shares">6700000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c52" decimals="-5" unitRef="usd">59100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="c52" decimals="-5" unitRef="usd">57000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c53" decimals="-5" unitRef="shares">2700000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c53" decimals="-5" unitRef="usd">17200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="c53" decimals="-5" unitRef="usd">16700000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c54" decimals="-5" unitRef="shares">3500000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c54" decimals="-5" unitRef="usd">29600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="c54" decimals="-5" unitRef="usd">28700000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c59">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands, except for per-share amounts)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number&#160;of&lt;br/&gt; Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Exercise &lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Remaining &lt;br/&gt; Contractual &lt;br/&gt; Term &lt;br/&gt; (in years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate &lt;br/&gt; Intrinsic &lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 53%"&gt;Outstanding, January 1, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,362&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;12.45&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: center"&gt;8.69&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-55"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;120&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.23&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(51&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;8.89&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding, June 30, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,431&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;11.97&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: center"&gt;8.36&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-56"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Exercisable, June 30, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;473&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;22.19&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: center"&gt;7.07&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-57"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c3" decimals="INF" unitRef="shares">1362</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="c0" decimals="2" unitRef="usdPershares">12.45</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c0">P8Y8M8D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c0" decimals="INF" unitRef="shares">120</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c0" decimals="2" unitRef="usdPershares">5.23</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c0" decimals="INF" unitRef="shares">51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="c0" decimals="2" unitRef="usdPershares">8.89</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c2" decimals="INF" unitRef="shares">1431</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c2" decimals="2" unitRef="usdPershares">11.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c0">P8Y4M9D</atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c2" decimals="INF" unitRef="shares">473</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="c2" decimals="2" unitRef="usdPershares">22.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c0">P7Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <atnm:PurchaseOfCommonStockDescription contextRef="c0">During
the six months ended June 30, 2022, the Company granted new employees options to purchase 120 thousand shares of common stock with an
exercise price ranging from $5.20 to $5.93 per share, a term of 10 years, and a vesting period of 4 years.</atnm:PurchaseOfCommonStockDescription>
    <atnm:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight contextRef="c55" decimals="2" unitRef="usdPershares">5.2</atnm:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight>
    <atnm:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight contextRef="c56" decimals="2" unitRef="usdPershares">5.93</atnm:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight>
    <atnm:StockOptionTerm contextRef="c57">P10Y</atnm:StockOptionTerm>
    <atnm:VestingPeriodOfStockOption contextRef="c57">P4Y</atnm:VestingPeriodOfStockOption>
    <atnm:AggregateFairValue contextRef="c57" decimals="-6" unitRef="usd">442000000</atnm:AggregateFairValue>
    <atnm:StockOptionDescription contextRef="c57">Variables used in the Black-Scholes option-pricing
model include: (1) discount rate range from 1.52% to 3.03% (2) expected life of 6 years, (3) expected volatility range from 78.8% to
79.9%, and (4) zero expected dividends.</atnm:StockOptionDescription>
    <atnm:UnrecognizedCompensationExpense contextRef="c57" decimals="-5" unitRef="usd">4400000</atnm:UnrecognizedCompensationExpense>
    <atnm:WeightedAverageTerm contextRef="c57">P3Y</atnm:WeightedAverageTerm>
    <atnm:CompensationExpenseRelatedToStockOptions contextRef="c57" decimals="-5" unitRef="usd">800000</atnm:CompensationExpenseRelatedToStockOptions>
    <atnm:CompensationExpenseRelatedToStockOptions contextRef="c58" decimals="-5" unitRef="usd">700000</atnm:CompensationExpenseRelatedToStockOptions>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="c60">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands, except for per-share amounts)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Exercise &lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Remaining &lt;br/&gt; Contractual &lt;br/&gt; Term &lt;br/&gt; (in&#160;years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate &lt;br/&gt; Intrinsic &lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 53%"&gt;Outstanding, January 1, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,112&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;20.52&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: center"&gt;1.76&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;276&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-58"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-59"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 9pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-60"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-61"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;Cancelled/Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(59&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;3.62&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding, June 30, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,053&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;21.01&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: center"&gt;1.32&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-62"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Exercisable, June 30, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,049&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;20.57&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: center"&gt;1.31&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-63"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <atnm:NumberOfWarrantsOutstandings contextRef="c61" decimals="0" unitRef="shares">2112</atnm:NumberOfWarrantsOutstandings>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="c61" decimals="2" unitRef="usdPershares">20.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c60">P1Y9M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="c61" decimals="-3" unitRef="usd">276000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c60" decimals="0" unitRef="shares">-59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="c60" decimals="2" unitRef="usdPershares">3.62</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <atnm:NumberOfWarrantsOutstandings contextRef="c62" decimals="0" unitRef="shares">2053</atnm:NumberOfWarrantsOutstandings>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="c62" decimals="2" unitRef="usdPershares">21.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="c60">P1Y3M25D</atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c62" decimals="0" unitRef="shares">2049</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="c62" decimals="2" unitRef="usdPershares">20.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c60">P1Y3M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SubsequentEventsTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
6 &#x2013; Subsequent Event&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Since
June 30, 2022, the Company has sold 0.3 million shares of common stock under its A&amp;amp;R Sales Agreement, resulting in net proceeds of
$1.4 million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 2, 2022, warrants to purchase an aggregate of 0.6 million shares of common stock expired. These warrants were issued on August
2, 2017, when the Company completed an underwritten offering of 0.7 million shares of its common stock and warrants to purchase an aggregate
of 0.6 million shares of its common stock at a price of $22.50 per share and related warrant. The warrants were exercisable for a period
of 5 years at an exercise price of $31.50 per share. As of August 12, 2022, the Company has 1.4 million warrants outstanding.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <atnm:SharesOfCommonStockValue contextRef="c2" decimals="-5" unitRef="usd">300000</atnm:SharesOfCommonStockValue>
    <atnm:NetProceeds contextRef="c2" decimals="-5" unitRef="usd">1400000</atnm:NetProceeds>
    <us-gaap:PaymentsForRepurchaseOfWarrants contextRef="c63" decimals="-5" unitRef="usd">600000</us-gaap:PaymentsForRepurchaseOfWarrants>
    <us-gaap:DeferredOfferingCosts contextRef="c64" decimals="-5" unitRef="usd">700000</us-gaap:DeferredOfferingCosts>
    <us-gaap:PaymentsForRepurchaseOfWarrants contextRef="c65" decimals="-5" unitRef="usd">600000</us-gaap:PaymentsForRepurchaseOfWarrants>
    <us-gaap:SaleOfStockPricePerShare contextRef="c64" decimals="2" unitRef="usdPershares">22.5</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c64">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c64" decimals="2" unitRef="usdPershares">31.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <atnm:NumberOfShares contextRef="c66" decimals="-5" unitRef="shares">1400000</atnm:NumberOfShares>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="c3"
      id="hidden-fact-0"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredRevenue
      contextRef="c3"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="c3"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c2"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c3"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c2"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c3"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="c4"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="c5"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="c0"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="c6"
      id="hidden-fact-10"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c5"
      decimals="2"
      id="hidden-fact-11"
      unitRef="usdPershares">-0.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c4"
      decimals="2"
      id="hidden-fact-12"
      unitRef="usdPershares">-0.33</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c6"
      decimals="2"
      id="hidden-fact-13"
      unitRef="usdPershares">-0.54</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="hidden-fact-14"
      unitRef="usdPershares">-0.56</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c6"
      decimals="0"
      id="hidden-fact-15"
      unitRef="shares">19308487</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c5"
      decimals="0"
      id="hidden-fact-16"
      unitRef="shares">20231278</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="0"
      id="hidden-fact-17"
      unitRef="shares">22942317</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c4"
      decimals="0"
      id="hidden-fact-18"
      unitRef="shares">23731886</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c10"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c12"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c10"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c11"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c18"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c20"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c20"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c18"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c19"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c28"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c30"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c30"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c28"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c29"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c36"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c38"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c38"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c36"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c38"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c36"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c37"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInSecurityDeposits
      contextRef="c6"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="c6"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="c6"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="c0"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="c0"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="c6"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="c0"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="c6"
      id="hidden-fact-47"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="c6"
      id="hidden-fact-48"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="c0"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="c6"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree
      contextRef="c49"
      id="hidden-fact-51"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour
      contextRef="c49"
      id="hidden-fact-52"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive
      contextRef="c49"
      id="hidden-fact-53"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive
      contextRef="c49"
      id="hidden-fact-54"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="c2"
      id="hidden-fact-55"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c2"
      id="hidden-fact-56"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="c2"
      id="hidden-fact-57"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c60"
      id="hidden-fact-58"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c60"
      id="hidden-fact-59"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <atnm:NumberOfSharesExercised1
      contextRef="c60"
      id="hidden-fact-60"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c60"
      id="hidden-fact-61"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="c62"
      id="hidden-fact-62"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="c62"
      id="hidden-fact-63"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:AmendmentFlag contextRef="c0">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="c0">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="c0">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c0">0001388320</dei:EntityCentralIndexKey>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>45
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MCID"R.^7E(K]C1J@[Q-/_P-02P,$%     @ &8@,56\6'T,: P  7@D  !@
M  !X;"]W;W)K<VAE971S+W-H965T-2YX;6RM5EUOVC 4_2M6-E6MM))/(*40
MJ06F=5(W5-3U8=J#20RQZL29[4#W[W?MA!18RJJM/!#;.>?<ZV/'U\,-%X\R
M)42AIXSE<F2E2A4#VY9Q2C(L.[P@.;Q9<I%A!5VQLF4A"$X,*6.VYS@].\,T
MMZ*A&9N):,A+Q6A.9@+),LNP^'5-&-^,+-?:#MS15:KT@!T-"[PB<Z+NBYF
MGMVH)#0CN:0\1X(L1]:5.YAV-=X OE&RD3MMI&>RX/Q1=VZ2D>7HA @CL=(*
M&!YK,B:,:2%(XV>M:34A-7&WO57_:.8.<UE@2<:</=!$I2,KM%!"EKADZHYO
M/I%Z/B;!F#-I_M&FQCH6BDNI>%:3(8.,YM43/]4^[!! IYW@U03OD!"\0/!K
M@O_:"$%-"%X;H5L3S-3M:N[&N E6.!H*OD%"HT%--XS[A@U^T5SOD[D2\)8"
M3T5CGB>PZB1!T)*<T00KZ,P5/& [*(GX$GTMB,!Z724ZO<]QF5# G*'3&18
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M#74)C- '9-S]J\D)C)IT]RTE1D]'C*)%IM"ZY N-009.1R:(,SW4!,U!5 U
MY5DS-%5:-%!:]Z*TT!O4V&$)>'M:E2#R7$F!,Q37]>4M/7T]IUR.ALOK64ZI
M$"A4+U ,'BM10+-XV'6I?)E!7Z6I(]XH6F0*K=L=0K+0RR^#Z5VG7.HW!!12
M0.AXGBNO38-F7;*$S*$77>T"UR,*7.V24T' !DP% 3LX%00,-:D@/7L1Y)>O
M=L$D %>[X%107X')0]2HM#"%=B1_<?;&7OU")L]L[I.LM%)VQ^'M-QYGJSB^
MXWA\J/)]\Q+?U[RJ\EWS=<OB#2MJ _[_NSRO?C[4[P6>WC1=_@]02P,$%
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M&@W("'4ZHIUJ/NN+]Z"- 68BW4D'BRP%QT(MG*+T=.RT'G24U+:W-MH5['U
MI/CH[)J*R)&82K]$X..ON$%&(Z*Y8-+N3ZG<PZ6\?DAFS^;6H+ SQ'M"YDU_
ME!,I_BO4(U)N0XK7H15Z7M7UO+SI+?*AG$'#R8C?CEYF^PQ-MO%8]P>;,_VM
M47B.V\>L_R%&H[/!9#+$T_GYX&+\(OOT2)+)BS']8R)_4_A(]?Q\3%0O!N/Q
MJ&>JC+?TZHX4N7*!BU=@4"H4FBN$SE(!X21EIJ'-#EZA&BQ1+)"GCBU*T41!
MYJDQ@RT0KU7"48:)G<BL4+HS(@74K:V+;*FH"^[AC\1[VN%A"C1'C<)G;E%>
MF6IZ)]X!U+)IP@$OOA*S*4]T*#OB*F0M1D"J7*5^R.(QUMEN$>FAH R&O]A9
MHD$CP5/%\3D"E!2]NI^*L^'9=K."EE+1?\@"Q9'/N03!-+4F"VL+) ]F=(PC
MFA"H6TH<E.0*ET21*&U('4 %?:D*YH4I&I Y@+_JV)Y31*M:LM&0.WQQ0%K9
MF=$+SJ0C\2MQYLAH6:-_D8G#1EN"LZCQAJTCVY0S7F<'1AS>5FJ+M* I ^B^
M(3)#]T[=&("X(%B9:^IV;ZNLY4VYV9HL$NQ;J6^';7LKJIL<MA2QDL(-18L*
M\("\;)JB3WE?'T1?IZB@EBB;J4K-$;%=:2?^/?9":3Z<P-8^5!'H%I%FSR2;
MPM+9EIH$3=WS2FKTE49U;5TKPC[:&UH@3)VIU*ZSI@=LU'V=A'XL%HS9NAT,
M6KLR#U;%/F',%,==D.VW_++>BOH>VF:DW7C )2QK+8^E:A,ZGK=B7^5C3X#X
M +>V9]-Q798TT3%* -XA<@1Z*DK4.U/6QN@C78*ANDR:R(VU*$6^YTM9+2)<
M_)A>6[K2%DZIW7F1H)*AY*^D S+8HMP0<KH$+ "\9XADY @\^1C4GW? FTHS
M<6O2'^RT$;2/48A>"GZ4UY5TT;/;=N-JR_8-V6X#'HD_=A_MR-=R'8?NMJ.&
MAM%#)@U"L6ICZ@^V4MU^I.^<NWKGR!O<+K5$LY\=?BJ)^ZC9G?()@Z+X\ L<
M/F.5NI1Q9#N:NN#/UM@^ZX5<M$J2KYL>?O0#=5*Q 2HM.AJCOU%R)2(EA+,%
M*Q[;J$Z0F.];(U\*GHP^G4>A?.#Q@!#6YGGC!H^C;6.E. L06/Y,WB.J0AFJ
M$-BA W IAKL<M10]EJLX<^OY:CL<*!=B!X IB@;EJI"&9/'*&#))-,^,;H9V
M9E76SZHY]0)]:-]M[$< $^\F(HZMVU.[<\YO0C^:/CK(+\G&0/1.[920/]>,
MJ_Z<BUPWR,;LCT<<]ST1;F@_F$;^2 %.MG5R,)&%+5M0RA[#=@^S8Z>5H&U[
M0&!T[2&3])T\VT"ZV[)L%.TW9LA2V:'K%L7W'D]"XK-@)_I@-VA+(P=_;35#
M  \:I#&-46GJ8,_.L]X;UVO@0#->W:1)I_$<&["L;4+=\&"A*WIH,W"ZP9>5
MRJXV84UWA^AVZ JPZPO3Q:-X#\O03=.C]]F7&E6F"IE)ZW,:.-_V;ENRWES,
M+6H)?_%(\B.RB7MTX3Y>164[EKGBV+4T-%F+EO76,O./TSSG- 6F<M1KPRAM
M%/3MQW&4;D+2+6'LP/I8D/SI8Q/3RR2T9A%QT8'+OB7I4HC"\.]A'6-<2IU>
MG6_*)J7>(\G_XG82N=(A8LN0<;NI4D,7UGV0Y&Z+U'FB(E)X-C,/PT$%PQ<B
MUJP(!JY8)JYW_3ZL:]Q=E,P1W"('9+PL]UF\/N$C;(U=XXOCF3;>^FX+ S7:
MBU!ICFCFXJNZ+,Z.78B!HN?8O5]"D,-KCIZ[-B@.Q4<5LO<6$_X=7#6-MT&\
M]<EILWW(?J^CFT>#D\E(7)R^R+ZRET%W/!B>3O!W-#K)/ML _TT&)Q<G>//B
M? )9<[9A=E78FFS?__T 46O)15' -L-NI*OX*IW$9/G$?K"USL7X;'A (_ L
MQ,WC5^*#+>*$R3=(9)";[T2\T7X9R>[?-[-X_.1\>'A*%,CR2-)HWY;M/=V+
M;2_M?^9SYZ.+@S2G.SB1XC#FV&^J6) B+8EN;*0F&,!SPY#>.?AW-/UTU8!@
MW AU,3H]/!D>=#1N:>1UW9F>N:A@3M-\LJ4VA?Q-ZF?YTN>=0_)3P<&Q+'(\
MG!HD (],XJNC^[!*3*DI;#V+,>HCD)7O%N@*(G86[Z[NK]LI_.K^"Z\<CA 9
MOVZNMZY E[@!XI/!+B9C\I/VN;&^H7YBMM[\-,16X1NW&5V)[Z;4Q<UM8O[3
ML.GH3WG.3*9I)1J>0J)$A'O^UE?$5"7,[-Z]U_$"F:3DX6%S(?"P=2&PZT?
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M:?S]>=0U<=AXTX2A3!\/C?BPK.A-1<L.9-\8NH']A@G&5WKY#U!+ P04
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M(SBE*2@/WN)7A7S^^H-$D]SEP*,LVAFD+=]MX$M>X)O 1Z-]X> 7G<ELFW^
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M^VZ!DR3F%+7484AH5>-_W8"9C8W1[6"6P3LD'Q/(CI=IA^I'U^DQ6ZX#K;?
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M'*8#,NVCNATX7?N'[)UV>!;[SUP*G-4L@/6EQI.G&_ &_7\VSO\$4$L#!!0
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MW6_O"*9?KCU[.PW%ZCCZQ%+C+>?(PS8K*%^#M8ZC+98E6ULWGM ^('R?A.;
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MRJQ2 R;P@$V*UV-R-QV3PX,C<D 8)[=+42C*$S5T-29FY-VX3N*\2L)_(HF
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M'X]#5N-1M= B+[__,Z%QFBAOESA1@C0 ?#X70C\N3(!F1HU^ U!+ P04
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M&^TMHTF(JN),,+F:2#_AWX#, 4>G5R!PDO(S=(YF\J2$10J(1K*X>9Z"K)K
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M:INP^_<=FP2E4H+Z AY[SIES& ]II\VSK0$<>9%"V8S6SC6K*+)%#9+9B6Y
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M)25L>2O=H^Z^P5#/E><KM+3A2[H^=SZCI&BMT_4 1@>U4/W(7X;_< 28)F<
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MDNM__%2-PPG [;\"\"J ]Q(P> 7@5P#_7(5^!>B?JS"H (-S%8(*$)P+&%:
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MTQO*?8;IP[EN"%J49\,5%?*D65YN 2? 5("\OZ94'!M*H/Y"$OX 4$L#!!0
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MI263ZO!5W&[4<1>Y[J#>KQB3QX9V4!V@I_\ 4$L#!!0    ( !F(#%6$,#!
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MV@45O_2.U_MAW+*;AV?=<OD=?YWQ4?_,' (DQP@DQS5(CAN0'&.0'+<@.>Y
M<MR#Y.!#E" H1.4H2.4H3.4H4.4H5.4H6.4H7.4H8.4H9!4H9!4H9!4H9!4H
M9!4H9!4H9!4H9!4H9!4H9!4H9!VAD'7TGV1]-V;YUS^:VC5K9*T/_JS[FS?[
M!%!+ 0(4 Q0    ( !F(#%4'04UB@0   +$    0              "  0
M  !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ &8@,5=5T9I'N    *P(
M !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%
M  @ &8@,59E<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE
M+W1H96UE,2YX;6Q02P$"% ,4    "  9B Q5DGP('^L%  #U'@  &
M        @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%
M  @ &8@,5:J+OA<&!@  LQD  !@              ("!+@X  'AL+W=O<FMS
M:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( !F(#%5:16C?1 ,  /D*   8
M              " @6H4  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"
M% ,4    "  9B Q5\_QM ?@$   S%@  &               @('D%P  >&PO
M=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ &8@,56\6'T,: P
M7@D  !@              ("!$AT  'AL+W=O<FMS:&5E=',O<VAE970U+GAM
M;%!+ 0(4 Q0    ( !F(#%5$2).#_ <  '4Z   8              " @6(@
M  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    "  9B Q5-<<.
M _H%  !4&   &               @(&4*   >&PO=V]R:W-H965T<R]S:&5E
M=#<N>&UL4$L! A0#%     @ &8@,5?0J6H>]#   0B   !@
M ("!Q"X  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( !F(
M#%4!5Q0!@ ,  +$'   8              " @;<[  !X;"]W;W)K<VAE971S
M+W-H965T.2YX;6Q02P$"% ,4    "  9B Q5@@;*UJD%   L#@  &0
M        @(%M/P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0
M   ( !F(#%5<KHL-IP<  *H2   9              " @4U%  !X;"]W;W)K
M<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ &8@,5>Y-(A'+!@  Y1
M !D              ("!*TT  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q0
M2P$"% ,4    "  9B Q5W*6[&RD#  !@!P  &0              @($M5
M>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( !F(#%4N<+,6
MM@T  . H   9              " @8U7  !X;"]W;W)K<VAE971S+W-H965T
M,30N>&UL4$L! A0#%     @ &8@,59L$L"G6 @  Q@8  !D
M ("!>F4  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    "  9
MB Q5F+'>XD0$   7#   &0              @(&':   >&PO=V]R:W-H965T
M<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( !F(#%4T'(4D1@,  '0)   9
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M970R,2YX;6Q02P$"% ,4    "  9B Q5R>,VHR@#  "O"@  &0
M    @('=>P  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    (
M !F(#%64(/!G^@(  !,*   9              " @3Q_  !X;"]W;W)K<VAE
M971S+W-H965T,C,N>&UL4$L! A0#%     @ &8@,59)/IRP* @  SP0  !D
M             ("!;8(  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"
M% ,4    "  9B Q5'>&J3 \"  ";!   &0              @(&NA   >&PO
M=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( !F(#%5>.5^B=@,
M -0.   9              " @?2&  !X;"]W;W)K<VAE971S+W-H965T,C8N
M>&UL4$L! A0#%     @ &8@,57!FZ&&$ P  +1$  !D              ("!
MH8H  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    "  9B Q5
MY18A#[,&   M*0  &0              @(%<C@  >&PO=V]R:W-H965T<R]S
M:&5E=#(X+GAM;%!+ 0(4 Q0    ( !F(#%6$L.BJY@,  $P/   9
M      " @4:5  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%
M  @ &8@,580P,$ M!   "1$  !D              ("!8YD  'AL+W=O<FMS
M:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    "  9B Q5)PR%O*\#   ?$@
M&0              @(''G0  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+
M 0(4 Q0    ( !F(#%65<][;00,  "84   -              "  :VA  !X
M;"]S='EL97,N>&UL4$L! A0#%     @ &8@,59>*NQS     $P(   L
M         ( !&:4  %]R96QS+RYR96QS4$L! A0#%     @ &8@,50B@_)'W
M @  'A4   \              ( ! J8  'AL+W=O<FMB;V]K+GAM;%!+ 0(4
M Q0    ( !F(#%6/>K1A70$  "03   :              "  2:I  !X;"]?
M<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( !F(#%7O6\H)A@$
M -43   3              "  ;NJ  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%
3!@     G "< B H  '*L      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>67</ContextCount>
  <ElementCount>216</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>14</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="f10q0622_actiniumpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="f10q0622_actiniumpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="f10q0622_actiniumpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="f10q0622_actiniumpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="f10q0622_actiniumpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement_Parentheticals</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="f10q0622_actiniumpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Condensed Consolidated Statement of Changes in Stockholders??? Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Condensed Consolidated Statement of Changes in Stockholders??? Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="f10q0622_actiniumpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="f10q0622_actiniumpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Description of Business and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="f10q0622_actiniumpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="f10q0622_actiniumpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="f10q0622_actiniumpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Other Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/OtherRevenue</Role>
      <ShortName>Other Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="f10q0622_actiniumpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="f10q0622_actiniumpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/SubsequentEvent</Role>
      <ShortName>Subsequent Event</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="f10q0622_actiniumpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>14</Position>
    </Report>
    <Report instance="f10q0622_actiniumpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="f10q0622_actiniumpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/Leases</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="f10q0622_actiniumpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/Equity</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="f10q0622_actiniumpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details) - Schedule of cash, cash equivalents and restricted cash</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Details) - Schedule of cash, cash equivalents and restricted cash</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="f10q0622_actiniumpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details) - Schedule of diluted net loss per share anti-dilutive</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Details) - Schedule of diluted net loss per share anti-dilutive</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="f10q0622_actiniumpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/CommitmentsandContingencies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="f10q0622_actiniumpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/LeasesTables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="f10q0622_actiniumpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Leases (Details) - Schedule of components of lease expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ScheduleofcomponentsofleaseexpenseTable</Role>
      <ShortName>Leases (Details) - Schedule of components of lease expense</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/LeasesTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="f10q0622_actiniumpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Leases (Details) - Schedule of supplemental cash flow information related to leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable</Role>
      <ShortName>Leases (Details) - Schedule of supplemental cash flow information related to leases</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/LeasesTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="f10q0622_actiniumpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Leases (Details) - Schedule of weighted average remaining lease terms</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ScheduleofweightedaverageremainingleasetermsTable</Role>
      <ShortName>Leases (Details) - Schedule of weighted average remaining lease terms</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/LeasesTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="f10q0622_actiniumpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Leases (Details) - Schedule of weighted average discount rates</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ScheduleofweightedaveragediscountratesTable</Role>
      <ShortName>Leases (Details) - Schedule of weighted average discount rates</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/LeasesTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="f10q0622_actiniumpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Leases (Details) - Schedule of maturities of lease liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable</Role>
      <ShortName>Leases (Details) - Schedule of maturities of lease liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/LeasesTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="f10q0622_actiniumpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Other Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/OtherRevenueDetails</Role>
      <ShortName>Other Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/OtherRevenue</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="f10q0622_actiniumpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/EquityDetails</Role>
      <ShortName>Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/EquityTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="f10q0622_actiniumpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Equity  (Details) - Schedule of stock option activity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ScheduleofstockoptionactivityTable</Role>
      <ShortName>Equity  (Details) - Schedule of stock option activity</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/EquityTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="f10q0622_actiniumpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Equity  (Details) - Schedule of warrant activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable</Role>
      <ShortName>Equity  (Details) - Schedule of warrant activities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/EquityTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="f10q0622_actiniumpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Subsequent Event (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/SubsequentEventDetails</Role>
      <ShortName>Subsequent Event (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/SubsequentEvent</ParentRole>
      <Position>31</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="f10q0622_actiniumpharma.htm">f10q0622_actiniumpharma.htm</File>
    <File>atnm-20220630.xsd</File>
    <File>atnm-20220630_cal.xml</File>
    <File>atnm-20220630_def.xml</File>
    <File>atnm-20220630_lab.xml</File>
    <File>atnm-20220630_pre.xml</File>
    <File>f10q0622ex10-1_actinium.htm</File>
    <File>f10q0622ex10-2_actinium.htm</File>
    <File>f10q0622ex31-1_actinium.htm</File>
    <File>f10q0622ex31-2_actinium.htm</File>
    <File>f10q0622ex32-1_actinium.htm</File>
    <File>f10q0622ex32-2_actinium.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="368">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>51
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "f10q0622_actiniumpharma.htm": {
   "axisCustom": 2,
   "axisStandard": 5,
   "contextCount": 67,
   "dts": {
    "calculationLink": {
     "local": [
      "atnm-20220630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "atnm-20220630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "f10q0622_actiniumpharma.htm"
     ]
    },
    "labelLink": {
     "local": [
      "atnm-20220630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "atnm-20220630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "atnm-20220630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd"
     ]
    }
   },
   "elementCount": 292,
   "entityCount": 1,
   "hidden": {
    "http://actiniumpharmaceuticals.com/20220630": 1,
    "http://fasb.org/us-gaap/2022": 63,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 68
   },
   "keyCustom": 41,
   "keyStandard": 175,
   "memberCustom": 4,
   "memberStandard": 8,
   "nsprefix": "atnm",
   "nsuri": "http://actiniumpharmaceuticals.com/20220630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "role": "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "atnm:LeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "009 - Disclosure - Leases",
     "role": "http://actiniumpharmaceuticals.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "atnm:LeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "atnm:OtherRevenueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "010 - Disclosure - Other Revenue",
     "role": "http://actiniumpharmaceuticals.com/role/OtherRevenue",
     "shortName": "Other Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "atnm:OtherRevenueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "011 - Disclosure - Equity",
     "role": "http://actiniumpharmaceuticals.com/role/Equity",
     "shortName": "Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "012 - Disclosure - Subsequent Event",
     "role": "http://actiniumpharmaceuticals.com/role/SubsequentEvent",
     "shortName": "Subsequent Event",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "atnm:NatureOfBusinessPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "013 - Disclosure - Accounting Policies, by Policy (Policies)",
     "role": "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "atnm:NatureOfBusinessPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "014 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)",
     "role": "http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables",
     "shortName": "Description of Business and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "015 - Disclosure - Leases (Tables)",
     "role": "http://actiniumpharmaceuticals.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c59",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "016 - Disclosure - Equity (Tables)",
     "role": "http://actiniumpharmaceuticals.com/role/EquityTables",
     "shortName": "Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c59",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "017 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details) - Schedule of cash, cash equivalents and restricted cash",
     "role": "http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable",
     "shortName": "Description of Business and Summary of Significant Accounting Policies (Details) - Schedule of cash, cash equivalents and restricted cash",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "018 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details) - Schedule of diluted net loss per share anti-dilutive",
     "role": "http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable",
     "shortName": "Description of Business and Summary of Significant Accounting Policies (Details) - Schedule of diluted net loss per share anti-dilutive",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "001 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c47",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "atnm:MilestonePayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "019 - Disclosure - Commitments and Contingencies (Details)",
     "role": "http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c47",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "atnm:MilestonePayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "atnm:NumberOfOperatingLease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "020 - Disclosure - Leases (Details)",
     "role": "http://actiniumpharmaceuticals.com/role/LeasesDetails",
     "shortName": "Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "atnm:NumberOfOperatingLease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "021 - Disclosure - Leases (Details) - Schedule of components of lease expense",
     "role": "http://actiniumpharmaceuticals.com/role/ScheduleofcomponentsofleaseexpenseTable",
     "shortName": "Leases (Details) - Schedule of components of lease expense",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "022 - Disclosure - Leases (Details) - Schedule of supplemental cash flow information related to leases",
     "role": "http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable",
     "shortName": "Leases (Details) - Schedule of supplemental cash flow information related to leases",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "atnm:ScheduleOrDescriptionOfWeightedAverageTerm",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c2",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "023 - Disclosure - Leases (Details) - Schedule of weighted average remaining lease terms",
     "role": "http://actiniumpharmaceuticals.com/role/ScheduleofweightedaverageremainingleasetermsTable",
     "shortName": "Leases (Details) - Schedule of weighted average remaining lease terms",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "atnm:ScheduleOrDescriptionOfWeightedAverageTerm",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c2",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "atnm:ScheduleOfWeightedAverageDiscountRate",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c2",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "024 - Disclosure - Leases (Details) - Schedule of weighted average discount rates",
     "role": "http://actiniumpharmaceuticals.com/role/ScheduleofweightedaveragediscountratesTable",
     "shortName": "Leases (Details) - Schedule of weighted average discount rates",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "atnm:ScheduleOfWeightedAverageDiscountRate",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c2",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "atnm:OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c48",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "025 - Disclosure - Leases (Details) - Schedule of maturities of lease liabilities",
     "role": "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable",
     "shortName": "Leases (Details) - Schedule of maturities of lease liabilities",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "atnm:OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c48",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "atnm:RecognitionOfDeferredRevenue1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "026 - Disclosure - Other Revenue (Details)",
     "role": "http://actiniumpharmaceuticals.com/role/OtherRevenueDetails",
     "shortName": "Other Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "atnm:RecognitionOfDeferredRevenue1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "atnm:PurchaseOfCommonStockDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "027 - Disclosure - Equity (Details)",
     "role": "http://actiniumpharmaceuticals.com/role/EquityDetails",
     "shortName": "Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "atnm:PurchaseOfCommonStockDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c3",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "028 - Disclosure - Equity  (Details) - Schedule of stock option activity",
     "role": "http://actiniumpharmaceuticals.com/role/ScheduleofstockoptionactivityTable",
     "shortName": "Equity  (Details) - Schedule of stock option activity",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c3",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "002 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)",
     "role": "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "shortName": "Condensed Consolidated Balance Sheets (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c61",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "atnm:NumberOfWarrantsOutstandings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "029 - Disclosure - Equity  (Details) - Schedule of warrant activities",
     "role": "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable",
     "shortName": "Equity  (Details) - Schedule of warrant activities",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c61",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "atnm:NumberOfWarrantsOutstandings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "atnm:SharesOfCommonStockValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "030 - Disclosure - Subsequent Event (Details)",
     "role": "http://actiniumpharmaceuticals.com/role/SubsequentEventDetails",
     "shortName": "Subsequent Event (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "atnm:SharesOfCommonStockValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SubleaseIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "003 - Statement - Condensed Consolidated Statements of Operations (Unaudited)",
     "role": "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement",
     "shortName": "Condensed Consolidated Statements of Operations (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SubleaseIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals)",
     "role": "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement_Parentheticals",
     "shortName": "Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c24",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "005 - Statement - Condensed Consolidated Statement of Changes in Stockholders\u2019 Equity (Unaudited)",
     "role": "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3",
     "shortName": "Condensed Consolidated Statement of Changes in Stockholders\u2019 Equity (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c29",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "007 - Disclosure - Description of Business and Summary of Significant Accounting Policies",
     "role": "http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies",
     "shortName": "Description of Business and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "008 - Disclosure - Commitments and Contingencies",
     "role": "http://actiniumpharmaceuticals.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0622_actiniumpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 14,
   "tag": {
    "atnm_Accountingstandardsrecentlyissuedpolicytextblock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Recently Issued.",
        "label": "Accountingstandardsrecentlyissuedpolicytextblock",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "Accountingstandardsrecentlyissuedpolicytextblock",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "atnm_AdditionSpaceForOperatingLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Addition of auxiliary corporate office sapce for operating lease.",
        "label": "AdditionSpaceForOperatingLease",
        "terseLabel": "Operating lease of auxiliary corporate office space"
       }
      }
     },
     "localname": "AdditionSpaceForOperatingLease",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/LeasesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "atnm_AggregateFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "AggregateFairValue",
        "terseLabel": "Aggregate fair value"
       }
      }
     },
     "localname": "AggregateFairValue",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_AgreementAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement.",
        "label": "AgreementAxis",
        "terseLabel": "Agreement [Axis]"
       }
      }
     },
     "localname": "AgreementAxis",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_AgreementDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Agreement [Domain]"
       }
      }
     },
     "localname": "AgreementDomain",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "atnm_CapitalOnDemandSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CapitalOnDemandSalesAgreementMember",
        "terseLabel": "Capital on Demand Sales Agreement [Member]"
       }
      }
     },
     "localname": "CapitalOnDemandSalesAgreementMember",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "atnm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight",
        "terseLabel": "Exercise price (in Dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "atnm_CompensationExpenseRelatedToStockOptions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "CompensationExpenseRelatedToStockOptions",
        "terseLabel": "Compensation expense related to stock options"
       }
      }
     },
     "localname": "CompensationExpenseRelatedToStockOptions",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_DescriptionOfRoyaltyPaymentToRelatedParty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of royalty payment to related party.",
        "label": "DescriptionOfRoyaltyPaymentToRelatedParty",
        "terseLabel": "Description of royalty payment"
       }
      }
     },
     "localname": "DescriptionOfRoyaltyPaymentToRelatedParty",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "xbrltype": "stringItemType"
    },
    "atnm_EquityDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity (Details) [Line Items]"
       }
      }
     },
     "localname": "EquityDetailsLineItems",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_EquityDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity (Details) [Table]"
       }
      }
     },
     "localname": "EquityDetailsTable",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_EquityTablesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity (Tables) [Line Items]"
       }
      }
     },
     "localname": "EquityTablesLineItems",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityTables"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_EquityTablesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity (Tables) [Table]"
       }
      }
     },
     "localname": "EquityTablesTable",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityTables"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_FinanceLeaseLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "FinanceLeaseLiabilitiesMember",
        "terseLabel": "Finance Leases [Member]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilitiesMember",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "atnm_GrantRevenuePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GrantRevenuePolicyTextBlock",
        "terseLabel": "Grant Revenue"
       }
      }
     },
     "localname": "GrantRevenuePolicyTextBlock",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "atnm_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "IncreaseDecreaseInOperatingLeaseLiabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_LeaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LeaseAxis",
        "terseLabel": "Lease [Axis]"
       }
      }
     },
     "localname": "LeaseAxis",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases (Details) - Schedule of maturities of lease liabilities [Line Items]"
       }
      }
     },
     "localname": "LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases (Details) - Schedule of maturities of lease liabilities [Table]"
       }
      }
     },
     "localname": "LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_LeasesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LeasesTextBlock",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LeasesTextBlock",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "atnm_LicenseRevenueTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LicenseRevenueTextBlock",
        "terseLabel": "License Revenue"
       }
      }
     },
     "localname": "LicenseRevenueTextBlock",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "atnm_LongtermFinanceLeaseObligationsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term finance lease obligations.",
        "label": "LongtermFinanceLeaseObligationsNoncurrent",
        "terseLabel": "Long-term finance leases obligations"
       }
      }
     },
     "localname": "LongtermFinanceLeaseObligationsNoncurrent",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_LongtermLicenseRevenueDeferred": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of long-term license revenue deferred.",
        "label": "LongtermLicenseRevenueDeferred",
        "terseLabel": "Long-term license revenue deferred"
       }
      }
     },
     "localname": "LongtermLicenseRevenueDeferred",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/OtherRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_MaturitiesOfLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "MaturitiesOfLeaseLiabilities",
        "terseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "MaturitiesOfLeaseLiabilities",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_MilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of milestone payment.",
        "label": "MilestonePayment",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "localname": "MilestonePayment",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_NatureOfBusinessPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature of Business policy text block.",
        "label": "NatureOfBusinessPolicyTextBlock",
        "terseLabel": "Nature of Business"
       }
      }
     },
     "localname": "NatureOfBusinessPolicyTextBlock",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "atnm_NetProceeds": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net proceeds.",
        "label": "NetProceeds",
        "terseLabel": "Net proceeds"
       }
      }
     },
     "localname": "NetProceeds",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_NonCashActivityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NonCashActivityAbstract",
        "terseLabel": "Non-cash activity:"
       }
      }
     },
     "localname": "NonCashActivityAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_NumberOfFinanceLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of finance lease for office equipment and furniture.",
        "label": "NumberOfFinanceLease",
        "terseLabel": "Number of finance lease"
       }
      }
     },
     "localname": "NumberOfFinanceLease",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/LeasesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "atnm_NumberOfOperatingLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of operating lease for corporate office.",
        "label": "NumberOfOperatingLease",
        "terseLabel": "Number of operating lease"
       }
      }
     },
     "localname": "NumberOfOperatingLease",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/LeasesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "atnm_NumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares sold.",
        "label": "NumberOfShares",
        "terseLabel": "Warrants outstanding (in Shares)"
       }
      }
     },
     "localname": "NumberOfShares",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "atnm_NumberOfSharesExercised1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "NumberOfSharesExercised1",
        "terseLabel": "Number of Shares, Exercised"
       }
      }
     },
     "localname": "NumberOfSharesExercised1",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "atnm_NumberOfWarrantsOutstandings": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NumberOfWarrantsOutstandings",
        "periodEndLabel": "Number of Shares, Outstanding Ending",
        "periodStartLabel": "Number of Shares, Outstanding Beginning"
       }
      }
     },
     "localname": "NumberOfWarrantsOutstandings",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of lease liabilities.",
        "label": "OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock",
        "terseLabel": "Schedule of maturities of lease liabilities"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "atnm_OperatingLeaseLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OperatingLeaseLiabilitiesMember",
        "terseLabel": "Operating Leases [Member]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesMember",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "atnm_OtherRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other revenue [Abstract]"
       }
      }
     },
     "localname": "OtherRevenueAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "xbrltype": "stringItemType"
    },
    "atnm_OtherRevenueTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OtherRevenueTextBlock",
        "terseLabel": "Other revenue"
       }
      }
     },
     "localname": "OtherRevenueTextBlock",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/OtherRevenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "atnm_PandemicOnFinancialStatements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impact of COVID\u201319 Pandemic on Financial Statements.",
        "label": "PandemicOnFinancialStatements",
        "terseLabel": "Impact of COVID\u201319 Pandemic on Financial Statements"
       }
      }
     },
     "localname": "PandemicOnFinancialStatements",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "atnm_PaymentWithImputedInterestPremium": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "PaymentWithImputedInterestPremium",
        "terseLabel": "Less imputed interest"
       }
      }
     },
     "localname": "PaymentWithImputedInterestPremium",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_PurchaseOfCommonStockDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of purchase of common stock.",
        "label": "PurchaseOfCommonStockDescription",
        "terseLabel": "Purchase of common stock, description"
       }
      }
     },
     "localname": "PurchaseOfCommonStockDescription",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_RecognitionOfDeferredRevenue1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recognition of deferred revenue.",
        "label": "RecognitionOfDeferredRevenue1",
        "terseLabel": "Recognition of deferred revenue"
       }
      }
     },
     "localname": "RecognitionOfDeferredRevenue1",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/OtherRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_RevenueRecognized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of revenue recognized.",
        "label": "RevenueRecognized",
        "terseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "RevenueRecognized",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/OtherRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_SalesOfSharesOfCommonStockNetOfCosts": {
     "auth_ref": [],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "SalesOfSharesOfCommonStockNetOfCosts",
        "terseLabel": "Sales of shares of common stock, net of costs"
       }
      }
     },
     "localname": "SalesOfSharesOfCommonStockNetOfCosts",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of cash, cash equivalents and restricted cash [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "xbrltype": "stringItemType"
    },
    "atnm_ScheduleOfComponentsOfLeaseExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of components of lease expense [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfLeaseExpenseAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "xbrltype": "stringItemType"
    },
    "atnm_ScheduleOfDilutedNetLossPerShareAntiDilutiveAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of diluted net loss per share anti-dilutive [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfDilutedNetLossPerShareAntiDilutiveAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "xbrltype": "stringItemType"
    },
    "atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of maturities of lease liabilities [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "xbrltype": "stringItemType"
    },
    "atnm_ScheduleOfStockOptionActivityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of stock option activity [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfStockOptionActivityAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "xbrltype": "stringItemType"
    },
    "atnm_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of supplemental cash flow information related to leases [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "xbrltype": "stringItemType"
    },
    "atnm_ScheduleOfWarrantActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of warrant activities [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfWarrantActivitiesAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "xbrltype": "stringItemType"
    },
    "atnm_ScheduleOfWeightedAverageDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ScheduleOfWeightedAverageDiscountRate",
        "terseLabel": "Schedule of weighted average discount rates"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageDiscountRate",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "atnm_ScheduleOfWeightedAverageDiscountRatesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of weighted average discount rates [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageDiscountRatesAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "xbrltype": "stringItemType"
    },
    "atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of weighted average remaining lease terms [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageRemainingLeaseTermsAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "xbrltype": "stringItemType"
    },
    "atnm_ScheduleOrDescriptionOfWeightedAverageTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ScheduleOrDescriptionOfWeightedAverageTerm",
        "terseLabel": "Schedule of weighted average remaining lease terms"
       }
      }
     },
     "localname": "ScheduleOrDescriptionOfWeightedAverageTerm",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term.",
        "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1",
        "terseLabel": "Weighted Average Remaining Contractual Term, Outstanding Ending"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofstockoptionactivityTable"
     ],
     "xbrltype": "durationItemType"
    },
    "atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms",
        "terseLabel": "Weighted Average Remaining Contractual Term (in years),Outstanding Ending"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "durationItemType"
    },
    "atnm_SharesOfCommonStockValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of common stock value.",
        "label": "SharesOfCommonStockValue",
        "terseLabel": "Shares of common stock value"
       }
      }
     },
     "localname": "SharesOfCommonStockValue",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_StockIssuedDuringPeriodSharesIssuanceOfCommonStockFromExerciseOfPrefundedWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Issuance of common stock from exercise of pre-funded warrants.",
        "label": "StockIssuedDuringPeriodSharesIssuanceOfCommonStockFromExerciseOfPrefundedWarrants",
        "terseLabel": "Stock-based compensation (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuanceOfCommonStockFromExerciseOfPrefundedWarrants",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "atnm_StockOptionDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock option, Description",
        "label": "StockOptionDescription",
        "terseLabel": "Stock option, description"
       }
      }
     },
     "localname": "StockOptionDescription",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_StockOptionTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock option term.",
        "label": "StockOptionTerm",
        "terseLabel": "Stock option term"
       }
      }
     },
     "localname": "StockOptionTerm",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "atnm_StocksOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "StocksOptionMember",
        "terseLabel": "Option [Member]"
       }
      }
     },
     "localname": "StocksOptionMember",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityTables"
     ],
     "xbrltype": "domainItemType"
    },
    "atnm_SubsequentEventDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event (Details) [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventDetailsLineItems",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_SubsequentEventDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event (Details) [Table]"
       }
      }
     },
     "localname": "SubsequentEventDetailsTable",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_UnrecognizedCompensationExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized compensation expense.",
        "label": "UnrecognizedCompensationExpense",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "UnrecognizedCompensationExpense",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_UpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payment.",
        "label": "UpfrontPayment",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "UpfrontPayment",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/OtherRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_VestingPeriodOfStockOption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting period of stock option.",
        "label": "VestingPeriodOfStockOption",
        "terseLabel": "Vesting period of stock option"
       }
      }
     },
     "localname": "VestingPeriodOfStockOption",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "atnm_WeightedAverageDiscountRatesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WeightedAverageDiscountRatesAbstract",
        "terseLabel": "Weighted average discount rates:"
       }
      }
     },
     "localname": "WeightedAverageDiscountRatesAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofweightedaveragediscountratesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_WeightedAverageRemainingLeaseTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WeightedAverageRemainingLeaseTermAbstract",
        "terseLabel": "Weighted average remaining lease term:"
       }
      }
     },
     "localname": "WeightedAverageRemainingLeaseTermAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofweightedaverageremainingleasetermsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_WeightedAverageTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average term",
        "label": "WeightedAverageTerm",
        "terseLabel": "Weighted average term"
       }
      }
     },
     "localname": "WeightedAverageTerm",
     "nsuri": "http://actiniumpharmaceuticals.com/20220630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r120",
      "r121",
      "r122",
      "r123",
      "r137",
      "r140",
      "r160",
      "r161",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r266",
      "r267",
      "r276",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r120",
      "r121",
      "r122",
      "r123",
      "r137",
      "r140",
      "r160",
      "r161",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r266",
      "r267",
      "r276",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r116",
      "r120",
      "r121",
      "r122",
      "r123",
      "r137",
      "r140",
      "r159",
      "r160",
      "r161",
      "r177",
      "r178",
      "r179",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r266",
      "r267",
      "r276",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r116",
      "r120",
      "r121",
      "r122",
      "r123",
      "r137",
      "r140",
      "r159",
      "r160",
      "r161",
      "r177",
      "r178",
      "r179",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r266",
      "r267",
      "r276",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r8",
      "r114"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Property and equipment, net of accumulated depreciation (in Dollars)"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r15",
      "r237"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r60",
      "r61",
      "r62",
      "r182",
      "r183",
      "r184",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r136",
      "r152",
      "r154"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r10",
      "r58",
      "r95",
      "r98",
      "r104",
      "r110",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r191",
      "r194",
      "r207",
      "r235",
      "r237",
      "r251",
      "r259"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r21",
      "r58",
      "r110",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r191",
      "r194",
      "r207",
      "r235",
      "r237"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total Current Assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current Assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r7",
      "r50"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r51",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r43",
      "r50",
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations": {
     "auth_ref": [
      "r43",
      "r50",
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; attributable to disposal group, including, but not limited to, discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations",
        "terseLabel": "Cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r43",
      "r208"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r7"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r155",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price per share (in Dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r155",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for collaborative arrangements.",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "terseLabel": "Collaborative Arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementAccountingPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r26",
      "r253",
      "r263"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r117",
      "r118",
      "r119",
      "r124",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r60",
      "r61",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock par value (in Dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r14",
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r14",
      "r237"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 1,000,000,000 shares authorized; 24,870,623 and 22,143,974 shares issued and outstanding, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Share-Based Payments"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r54",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredOfferingCosts": {
     "auth_ref": [
      "r112"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.",
        "label": "Deferred Offering Costs",
        "terseLabel": "Underwritten offering"
       }
      }
     },
     "localname": "DeferredOfferingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenue": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Deferred Revenue",
        "terseLabel": "Long-term license revenue deferred"
       }
      }
     },
     "localname": "DeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r11"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred Revenue, Current",
        "terseLabel": "Other revenue - current liability"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/OtherRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepositsAssetsNoncurrent": {
     "auth_ref": [
      "r9"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.",
        "label": "Deposits Assets, Noncurrent",
        "terseLabel": "Security deposit \u2013 long term"
       }
      }
     },
     "localname": "DepositsAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r48",
      "r113"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r28",
      "r198",
      "r199",
      "r200",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r36",
      "r65",
      "r66",
      "r67",
      "r68",
      "r69",
      "r73",
      "r75",
      "r77",
      "r78",
      "r79",
      "r82",
      "r83",
      "r204",
      "r205",
      "r255",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per common share \u2013 basic and diluted (in Dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r36",
      "r65",
      "r66",
      "r67",
      "r68",
      "r69",
      "r75",
      "r77",
      "r78",
      "r79",
      "r82",
      "r83",
      "r204",
      "r205",
      "r255",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per common share \u2013 basic and diluted (in Dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement_Parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r80",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Options [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r31",
      "r32",
      "r33",
      "r60",
      "r61",
      "r62",
      "r64",
      "r70",
      "r72",
      "r84",
      "r111",
      "r152",
      "r154",
      "r182",
      "r183",
      "r184",
      "r186",
      "r187",
      "r203",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r234",
      "r268",
      "r269",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r218",
      "r224",
      "r233"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest on lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofcomponentsofleaseexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "auth_ref": [
      "r221",
      "r227"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest paid on finance lease liability.",
        "label": "Finance Lease, Interest Payment on Liability",
        "terseLabel": "Operating cash flow use from finance leases"
       }
      }
     },
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r217"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Finance leases current liability"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r217"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Long-term operating leases obligations"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r220",
      "r227"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Payments on finance leases",
        "terseLabel": "Financing cash flow use from finance leases"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow",
      "http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r216"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Finance leases right-of-use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r218",
      "r224",
      "r233"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Amortization of right-to-use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofcomponentsofleaseexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r230",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Finance Leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofweightedaveragediscountratesTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r229",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Finance Leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofweightedaverageremainingleasetermsTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r45",
      "r52"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Other revenue deferred\u2013 current liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Long-term license revenue deferred"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInSecurityDeposits": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in security deposits.",
        "label": "Increase (Decrease) in Security Deposits",
        "terseLabel": "Payment of security deposit"
       }
      }
     },
     "localname": "IncreaseDecreaseInSecurityDeposits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r256"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest Income (Expense), Net",
        "terseLabel": "Interest income - net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r42",
      "r44",
      "r52"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of components of lease expense"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r232"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "terseLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive": {
     "auth_ref": [
      "r232"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Rolling Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive": {
     "auth_ref": [
      "r232"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour": {
     "auth_ref": [
      "r232"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree": {
     "auth_ref": [
      "r232"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo": {
     "auth_ref": [
      "r232"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths": {
     "auth_ref": [
      "r232"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Rolling 12 Months",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r23",
      "r58",
      "r99",
      "r110",
      "r125",
      "r126",
      "r127",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r192",
      "r194",
      "r195",
      "r207",
      "r235",
      "r236"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r19",
      "r58",
      "r110",
      "r207",
      "r237",
      "r252",
      "r261"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r25",
      "r58",
      "r110",
      "r125",
      "r126",
      "r127",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r192",
      "r194",
      "r195",
      "r207",
      "r235",
      "r236",
      "r237"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net Cash Provided By Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net Cash Used In Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r43",
      "r46",
      "r49"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net Cash Provided By/Used In Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows From Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r29",
      "r30",
      "r33",
      "r35",
      "r49",
      "r58",
      "r63",
      "r65",
      "r66",
      "r67",
      "r68",
      "r71",
      "r72",
      "r76",
      "r95",
      "r97",
      "r100",
      "r103",
      "r105",
      "r110",
      "r125",
      "r126",
      "r127",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r205",
      "r207",
      "r254",
      "r264"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow",
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement",
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r95",
      "r97",
      "r100",
      "r103",
      "r105"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r225",
      "r233"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Total finance lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofcomponentsofleaseexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r219"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofcomponentsofleaseexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r217"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating leases current liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r222",
      "r227"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flow use from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r216"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating leases right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r230",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofweightedaveragediscountratesTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r229",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofweightedaverageremainingleasetermsTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r3",
      "r59",
      "r92",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "Description of Business and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r24",
      "r237"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other revenue deferred\u2013 current liability"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherRestrictedAssetsCurrent": {
     "auth_ref": [
      "r20",
      "r273",
      "r274"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets that are pledged or subject to withdrawal restrictions, classified as other.",
        "label": "Other Restricted Assets, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "OtherRestrictedAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfWarrants": {
     "auth_ref": [
      "r41"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.",
        "label": "Payments for Repurchase of Warrants",
        "terseLabel": "Aggregate purchase of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r13",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock par value (in Dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r13",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r13",
      "r237"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 50,000,000 shares authorized, 0 shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r40"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Gross proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r40"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Net proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r40",
      "r181"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r115",
      "r237",
      "r258",
      "r262"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net of accumulated depreciation of $395 and $335"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r185",
      "r248",
      "r278"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development, net of reimbursements"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r7",
      "r53"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r16",
      "r154",
      "r237",
      "r260",
      "r271",
      "r272"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r60",
      "r61",
      "r62",
      "r64",
      "r70",
      "r72",
      "r111",
      "r182",
      "r183",
      "r184",
      "r186",
      "r187",
      "r203",
      "r268",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r93",
      "r94",
      "r96",
      "r101",
      "r102",
      "r106",
      "r107",
      "r108",
      "r157",
      "r158",
      "r249"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r55",
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r34",
      "r58",
      "r93",
      "r94",
      "r96",
      "r101",
      "r102",
      "r106",
      "r107",
      "r108",
      "r110",
      "r125",
      "r126",
      "r127",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r207",
      "r257"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "totalLabel": "Total revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r228",
      "r233"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Finance Leases"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r228",
      "r233"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Aggregate value of common stock"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of common stock, shares (in Shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Price pe share (in Dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of diluted net loss per share anti-dilutive"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Schedule of cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Schedule of supplemental cash flow information related to leases"
       }
      }
     },
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r164",
      "r173",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of stock option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r155",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of warrant activities"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r9"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security Deposit",
        "terseLabel": "Security deposit"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r171",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted Average Exercise Price,Outstanding Ending",
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding Beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of Shares Exercisable Ending",
        "verboseLabel": "Number of Shares, Exercisable Ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofstockoptionactivityTable",
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercisable Ending | $ / shares",
        "verboseLabel": "Weighted Average Exercise Price, Exercisable Ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofstockoptionactivityTable",
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of Shares, Cancelled",
        "terseLabel": "Number of Shares, Cancelled/Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofstockoptionactivityTable",
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of Shares, Granted | shares",
        "verboseLabel": "Number of Shares, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofstockoptionactivityTable",
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r180"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding Ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofstockoptionactivityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r165",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of Shares, Outstanding Ending",
        "periodStartLabel": "Number of Shares, Outstanding Beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofstockoptionactivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r165",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Outstanding Ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofstockoptionactivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r176"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable Ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r175"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding Beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofstockoptionactivityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Outstanding Beginning",
        "verboseLabel": "Weighted Average Exercise Price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofstockoptionactivityTable",
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Cancelled",
        "verboseLabel": "Weighted Average Exercise Price, Cancelled/Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofstockoptionactivityTable",
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofstockoptionactivityTable",
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "periodEndLabel": "Aggregate Intrinsic Value,Outstanding Ending",
        "periodStartLabel": "Aggregate Intrinsic Value, Outstanding Beginning"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r180"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable Ending"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofstockoptionactivityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term (in years), Exercisable Ending"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofstockoptionactivityTable",
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term (in years),Outstanding beginning"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term (in years),Outstanding Beginning"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofstockoptionactivityTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in Shares)",
        "periodStartLabel": "Balance (in Shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r27",
      "r31",
      "r32",
      "r33",
      "r60",
      "r61",
      "r62",
      "r64",
      "r70",
      "r72",
      "r84",
      "r111",
      "r152",
      "r154",
      "r182",
      "r183",
      "r184",
      "r186",
      "r187",
      "r203",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r234",
      "r268",
      "r269",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityTables",
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable",
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r60",
      "r61",
      "r62",
      "r84",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r152",
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Sale of common stock, net of costs (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Shares, Other",
        "terseLabel": "Sale of common stock, net of issuance costs (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r13",
      "r14",
      "r152",
      "r154",
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Exercise of stock options (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r152",
      "r154"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Sale of common stock, net of costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Value, Other",
        "terseLabel": "Sale of common stock, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r27",
      "r152",
      "r154"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Stock option [Member]",
        "verboseLabel": "Equity Option [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r14",
      "r17",
      "r18",
      "r58",
      "r109",
      "r110",
      "r207",
      "r237"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 Equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r32",
      "r58",
      "r60",
      "r61",
      "r62",
      "r64",
      "r70",
      "r110",
      "r111",
      "r154",
      "r182",
      "r183",
      "r184",
      "r186",
      "r187",
      "r189",
      "r190",
      "r196",
      "r203",
      "r207",
      "r209",
      "r210",
      "r214",
      "r234",
      "r269",
      "r270"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r57",
      "r139",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r154",
      "r156",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/Equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r226",
      "r233"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "terseLabel": "Other revenue"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/SubsequentEvent"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r215",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/SubsequentEvent"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r238",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/SubsequentEvent"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r85",
      "r86",
      "r87",
      "r88",
      "r89",
      "r90",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants [Member]",
        "verboseLabel": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityTables",
      "http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable",
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable",
      "http://actiniumpharmaceuticals.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Warrants exercisable term"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r74",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average common shares outstanding \u2013 basic and diluted (in Shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r73",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average common shares outstanding \u2013 basic and diluted (in Shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.A)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=127002003&loc=SL6242269-115581"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r279": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r280": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r281": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r282": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r283": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r284": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>52
<FILENAME>0001213900-22-047496-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-22-047496-xbrl.zip
M4$L#!!0    ( !F(#%6PMX<?* \  !29   1    871N;2TR,#(R,#8S,"YX
M<V3M7>ESVS86_]Z_ JN=V4FG570XCF-O[(YL68X:V7(E.6G2Z60@$I*0\#)
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MM4K'AL=&ST(NDR9U$*$\_\TDA$4)GB*93A5MG;?#65M+KSRR2@7  4,..'3
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M5BX+@3.1#8JDP&.M2;%6]_I:M:95:L?5@^.]JO;XT-!JE5IM^I5?3BQ,7KJ
M(4W83=AI:4'3N$NM]P[MZ[5*94^?-2Q-6QZ/Y8.E]J,]OW7UZ.A(]_\[;\IP
M6$,AMJI_OFD;<(!L4,:$<4"@5,#P,?,?MAT(N(_D1KLT90OY5WG6K"P?E:NU
M\E[U_9B9I2ENFG9"'0MU4$_S+3_F$Q>=EABV74L:Y#\;4-0[+0%.[+)$L/+K
M7D6*^+=\\HU^:SB$.18V)?;GP))=,08(\9(F13]V6O-. ,@QP9[M#@"U 40>
MQQ!8/I.Z;*LK1>EGZ=O:$L/31@87GVU$=C5W59I^E@&\#< &3<L9[6CK7(PT
MTK=2M(6>Y0^YMK!IR5HTYHB8R)S9*\6E0*D_ *5RH=YRX))*2PY_A\XT6J"+
MK-.2Q\I] -QO=<809PV/4I^V112E54R8Y4^$'F!=?S8$7]0EO#JR.)L]\0'W
MP0Z7K2<W4F)<)S[4EZ\>'@)+"&1UW@"43H13? *6AU(V/I[.&>G+M-?I<N\
MA3/KQ,<ESM<]3=!"9YYM^]+*6$R#V?=[U+$WL,>=K9%SJ(FHB#0E;81P?\#E
MQZF;V)JK#F*<8AC,C&P&5KB.N<&%9$*!2X!\;07YI#/%0-"CF$\ND.LPG#;N
MJ]+U,ZW8PW\-C@#NO76XDZ!]3Y$+L'DY=A%A2,RS.SY -$N7&D=CX5F)!5O
MU'XZ3$V%9Q+?BN!WPE .QW/5Q2<?^HZ+*)_<BRR$"PIE='%ELG:+TA_S$:J6
MNE L J(A2MGQ!QZ.3<VY=0C,Q/\HU00I>N%(4..B" 5)P+]SY?);I%-M)%:'
M'2GMKO<H7)M4FC(#T;J*2L,&A!3./@D734SDNN@',!&EJ1#K@C B(N$):#A(
M)^:V,>AB"W.,,DJ&0A3LX$%O'8[8/9B KH6RL3=,0[X35DW1XI@)14:93R1R
MH#(!S'R\J+3DGD/$HT$)DBJ5V#V4S;1-,B(D6EG>"YF8M&Q +-TEYZ+_SIB=
M2%5O9,Y$PZ5:8^X8[;(+<_FN-4.ZN(AUA&M*:]5Y@7I(2#8[:(A(ZEN^J](+
MY'_"ES8K8*09!T(G3F;+RDW:BCSL-R*E# #;\.(?8+4=TN>(VHLJ[[H6[OM=
M4*[Z%<=A\:45$?YM 5'O)R;;:.<.?!DXEA#*Y,8.GZ2]U[ZN8*?MNL!9^&*S
M."\+TY#OXD9-T<IF]#HRJ2YN&HYM.R0SX-?$YSI;XX&^#DG*VZ%UT\324F#=
M VRV2 .XF ,K[0, A9;<D^-X+"A!4D6L9.?!'&""S$M B5@DL3J$GBWQ0*9(
M8#!,_9 RAL*WX)?BX*:,:3LN8.K$S#R^;527\Q9J7#@4*Z"HI4_2((*Y[5=O
M$+/A$+GC@ A,?[D9I>D-<A()7%34\<L@__QT\W3PUY^?H>N-OY"#(_/[X;#_
M94(>+[S1U2$].KRN/3\^3)AU.(3?*]9'KG,#??Q^N/<RKL(VKWQM-FO&M3X<
MGS>^5(:F0;L'A#U\;58'8]9J[1F\62,WH(E1[=.SUWT@Z&;0XN<CY]:[=I]>
MSI^1ZUU<??TXK'CU+P*O:O4"=\;-D7']H?5T8'?ZPZO>[R/KW!U LV+H1Q ,
MGO1ANW[PQX-[X_W.V@9 +[V[/R[?D;M1TZWVVZ,KT.I\J-WNGYMU_?7U[EW[
MU8'-&\C:W7>-:Y?<M/O>YQ?=;%@M[^L^.^RV.P]NM?8\,BX[H/5JCJR187BX
M:U^ HX.GBP^W3ZT;^K!_M;\/NXY[T+MNFD;G:X].GB_[IZ=_:0VC,ZTK?5NC
M)JR5^L#P1%^I^3O[@86 J\622?U_L(V0MCN9B]TAFPMD- 6M<@)3@<\GS <-
MCW'1=2H0L#Q9'"V/L<2/^0#&V?1B*PMRS<-7V5Q.+1+ F?).GN%U+;E:GX[>
MM-?.R\+S3?>BF%A%01F/=CK*"0JMTI[9Z_(3F]I!# E,9:GJA8#+<OPZF4!N
MZE,Y2E>^8T5)V4HE:118JHF:A)?IQ1)+:*J;M@A)C$OSAB@;9C9IR]6AQJ)F
M(U[JA+/@/=LE9BQD3.6=@L;<TJF_;#LL,Y^VH*$@+F&]SR'\1*T["]^'D(&X
M/E_*.T3$6X<XRZ9DX\C4>I)O +0(1Q0QOB0O_6);I9I\9\%&YA;'D1JJE)-8
M(3,S3[0L._<=Y="NAD[>Q68%]$4;.Q(QU"*C=ZZ; /-;B,F*9@4H4L(]=898
MV',^>61R8V'.:5W8,LRBMF4+Q<F]_O_4+-V2QZ61OPQ4BI<"#3&&T;E8Z)KR
M=KJ83'Y'TE[UARO)W]_L0(D*N/1OCU $\109L7BQ'<KQ]RQ(BM+TIIF*A%!=
M YHP%X14;AM=H.GO%EFYZ)BVFXNA,.?\<"?NXN"99JWHNKXZA(Y'^*S*7@X@
M"*F'S.S*2A,:\7/Q' ]WU;V8U+A?T3B[$OM/:?F/'07;F//3C8>MN A&QJ_9
MC(QLRYTWZWOC^6P,0 /^#G?(<?U"U'55X=="UB:PHC9W&WEOE*7M<0O(^I#*
MZ=BZYN"U!+,Q$OIZ@LRG8"PC?BZ?&P_W@/RCE':"P_O0(D/$\MCP"%.<N',B
MF?'KG1Z<.GSU,$7*-Q&DW+DM%!=SK1?!_U+-^!8 K^^BE!-OHRBLGMY^R&'4
MABE.=K/% !9B=SU_NT/\7J@/%ZKEWVS5]RH"9RQ!N1XD;T_B/%K&0RG%?3MA
M)$3(9/+8U]=SY_H7:R['B$+,_MFY3N]5+QOT%379V4#?%H JMO9VO<1W3[&P
MSY6U_E/GE3)UT;H*F;'$Y&P#BNHBAZ2O.EQY6]_RF^-$=%E^L-#R'E'LF.L9
M5E";<3F& T#ZJ ,XNNSU$$P[_O]@X_,NG,F'JY43F]BI> '/8@L+8&@>N*$X
M\_\ ;G*M41>APT[/3^;O99;1XV]02P,$%     @ &8@,51GRM"+J)@  N$$"
M !4   !A=&YM+3(P,C(P-C,P7V1E9BYX;6SM75MSVSBR?M]?X?5Y.:>V/+YD
M,YFD)KLEW[*>L2V/Y"2;V=I*T20D<4*1"DC*UOSZ X 7\8H; 8&,4[5;DS@F
MNO%UH]%H=#=^_N?3TMM; QBZ@?]V__B'H_T]X-N!X_KSM_OOIP>CZ=G5U?X_
M_[&W]Y>?_WIPL/<.^ !:$7#V'C9[9\%R-;7=O7MH^>$L@,N]_XV6_[=WL+>(
MHM6;P\/'Q\<?;/0[H>U"$ 8QM$&(?[!W<( &S(8\@P /^&;O$KI[HWB^=WRR
M=W3RYOCEFQ?'>^_OS_9.CDY.DD_^\K/G^E\>K!#L(;[]\.U^@=+3 _1^".#\
M\.3HZ,5A]HO[R6^^><(_*/W^XPORV\>O7[\^)/^:_VKH-OTB&O;X\-\WUU-[
M 9;6@>N'D>7;F$#HO@G)#Z\#VXH(DDR^]EI_ __M(/NU _RC@^.3@Q?'/SR%
M3LXB^ATGRLD4!WAYF/SC/L9K;^]G&'A@ F9[9(IOHLT*O-T/W>7*PYR3GRT@
MF+W=MR)_>8"A/OKQQ1&F]3_X)Y_AY[/ #P//=;"03BT/SWFZ "#:W\-#OY]<
MY6Q8=N3Z;KQ<+2RXM&P01ZYM>43DA_AW#UN'.OR'7EX_WUD0^-$")!PI9+TZ
MLHZ97*$5N033"/UYB6AUY+XZVJ$.1:D048L_8W!E$YHB9L B\!QD'R^^QFZT
MN4>#G 3PA<0$*(,=$FNH7@AG5KBX](+'CG#GPQ ^E7!Y#D(;NBML*X/9:1RZ
M/@A#RW>F\7)IP4TPF[ISWYTAIOQH9-M!["-^YW>((]L%,NK3D:#"-;)<NA'6
M6DP=H8S)H!U7;E:TT92Q? W0/B3#7?JA2NT>HU4.)V -_!A(<%3Z7!E R6J6
M8"?]4"5 T_@A!%]CI!$7:[FMHCJ"ND5?7U>G&_(G&>PH@ZG$LYO=N+<>/ /F
M*B6;X*#0!DA/I_2YXG4GS53I<W4^ SH(.+$'@IF-MDW\?[28W+7EI48:'80B
MZ-IH6\7_1JC++%()*DK-3$[?<;T8D?%!Y 5AN$+.#?9SD%JZY%_<->@^1UX:
MJGSO KKH]!KX&-1@YF$E!D\KX(<*YD0?6?U,PGB%/L.N@N5AG9@AA\[U\:&=
MG%@A\+"K%P7>=JEVFI\,/3T:^@C<^0+1LM8 6G, T3D=3<*?$\H1@$L%L^6E
MH5ZN%<J.&Y+= ,=HU,^K872%F\R6+-*1&+H1VLK2Q>&YUH/KD9]TGQ1[="V3
M"J/ _A*0/1TSN\XVGV[+K&U0#9IF08AL;DI&B21:AMS%:>L<1)8K&8E@#JH*
M_,1ODF>U_+U"K2X>I.39:QI%%72)=R?/6_E[E0:A?+Z2Y[!EH.Z+YSRP8ZS>
M(]^Y0,H=;:ZV^[;,688V7,:M!6U>AEL"YUG<&T?,7Y)Y."XBBR\V#APPLV(/
MG893,D7^\S%</SI$GQRFOW-8_SS53<V\!MAWD&8U^7JKKSJ87: AH!T_@(.<
ML!B_30,4G#\M !-@#I9@^0"@(+JE3_-XB XN+<\3XPU_D'.$]!0M1;RNKA'M
M$E?@*0*^ YR,+_RQ@GN;3,T0<2^P2Q0]?!<6P(R@9ST [^U^'![,+6OU.0_>
MCV>7KH\&="WO+@@)\Z,'='A%/-4Q##,H9E;X0/!(QSO$!NP0>%&8_828-(*I
M$,EDB0M/9Q0B-S\\BR&^B-#$?S.-G.&M\$>PS#K2E8R55&U$=3[]>@:#I9P(
MHX")50 = -_N'Z%/R*)X8Z/#/G#>[D<P+AX-A66#KR_0WH/_<[$-DHRB,^1\
M;I#K]L'RXH;UVDE6?#2SA6M">E2-+8J+$SZF^&1$-\G#6)A\RJQB4373,+>L
MN 73 DXJB&/EZV@*;'QL1C[Q"J]RU=:Y,OIA86OIKPQJF*3HG]#0EP'_#H*5
MY3H729 0K4=R=BKQJ5@@/!2'(20N[%+!O5 M.)TB:A*&*6D(*&BK,Z!I%[F#
M 3IN1)L[STI.H6@;6V''Y1:H7S044H,4$!T\YF8C(Z_4F(8);[>!;VM9/:UD
MTIC$@(34CAA[/Y*1T'B%DT"1\T<"C!-\1S">O4<,8_J*Q42G-3Q9,;!C[T,R
M DL.:& 'XJ)1,GG>D906%;A45G]7[FHG;&GQ%@R>;#JY"#G:+U5[:-?;VS^]
M 1P*H>%%<6BH:3N"W@81".^L#;XEU.-2-U$PN,>P=;,HDT9X..)J4BX 7KMU
M]E1O_BU4S+K28E)I18J]3+K[9AG=C2;YT(D9C0\(2HD!FZ[ 3M'!T"PL*JDA
MK2@Z9GH\:.VFKG=6CD<SZ1X!WZ6.7(A@!A ))R\%4!P9*(]NU(R)BJ$&C988
M32-7VD(U+&KFW&=1Z3!Q4QNP(3E'UX$_QSFH1=KC!\^=DQ2<U@!;2P83_VC]
MEXHH/+HN"0JF4]^N,@!Y-.+!CK)(905LLSA'M4(\I2*@43(9$1,5"A4QCN",
M7)I08'\I%<UJ2PYJ)32\V P--9YSC.P-=>)X$.HZDFJ:*!B,S;!ULW()78='
M4VP&K]3 UR:'VO F5XB(#.JX:(M4CAR'X( 6K.4Z5_Z9M7(CRU,=TF^A8O;@
M*":45J3T7%U.<)J\#YP+"^("K7!DV_$R)L5HZ.3DVLH3FS@(#L:(\8#'X2.K
M\02T>P"&EQ&_IM+W?HVIM04_';F$VD7$)&?2G983%QM!GBT*)_\?EK/_M]44
M.Z\*J/;C^5XDD.YT18U808#&QL.B/WN C.\[HV4 (_=/\O/6S"O53H0JMDRN
M/NEB!&4RT92Z6#PUH'4UAF2F#O%?[P D7:6TGK-:B9IV,N4$SHNHGLO9,G5"
M*AS%T2* [I];,ZQ%CC5B1F\UU(BO#J#&_/L:W:LPC'<BM)30\ )1--1X8NG*
M1#6.(]RM$[<UW8&\BM2^#:&5\-.6]EB(S^QHJ^.A.$@[R06EKHS* G'-6QR-
MTA#=42IRJ;A^5.IAUBAJV=7:J S3AVS%+)70*_57E25R^G8S*JEO1%A->]E/
M5(D9CJU4&S9+JE%E&$T!E#8J'=R"-),IU,1Q;7AS+AM#1.50?!44=I2W _B7
MB$]\Y8])?72CQ5D<1HA5B#CV8KR4<)4&^I]S;SWID8\0!^9$V*:L#;(3PU1;
M$'\:/Y N>(GRJ8ZGE@<W>-/%(Y@J%!RQ]RX&39,A,WYOQ;T"0EVWO'DV?UIL
MIFOO:*=C]-0HL(]0D-*2.#P!(4 SP2UESI$2> $)GZ?$E2\(&BV#MHBIGI4^
M+S3$]&S[R3L_'K[^<)8(',P>;K2L1U L:N:V<R%),4'CO,OM;NYTFSFCP14A
MF31 HRT%,J>5V-_K(-0FB (%@W9,9I\I8J--$K>!'Y0)9E7G>OP -CVS/IF
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MO9"/VK50IZ=.!"2;>TC0Y&\=)3VXIB74W%]*A5RWSZ!(X[GS6HXMO_6R"YI
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MH&UWX=KLE>:D$AKG(+2A2];<>#8)-I:7]Z&^#R; LR*\/&&TX8*>?[2ARD0
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M" 7];2N0\EB:-A45=JPR:<Z I3BF_(U)>%#=02L2J@%J5)42G/Q]1[K@R6=
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M $C=<X75YCDU/K?J!Q)!VV5CQ4/1!L2!;F."D5YCIW[*J.?%X 5>5@YH#G^
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M2F!4SX/P[QK]P$?]#5)FC P394:/J*O,E*&O6>2DO3:$AZ\%@<J,*X-_?8D
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M!9?JE>*I6_8F?;9L]V;W8L%>U=GU>=$E'Z[4D:H:$]'<=SU13USK;C27M "
M&"&"\G>3?B3TI2UL>&2U>N!':4BJ5$JQV4^Y3T_+;&^%JKW Q6<2BMEIJ^Z\
M\.IQ?X<38FO&]#8/-U'"VK[1Q$5#@5 YC6M!K8G5&TJ0NJT!*1D#K>C@^0.W
MS988DX)"/M9;S#HA@*I(MJB.22J!;=?)'S<JKYB<^RS/'9Y#YNNP'W#O>NG8
MC9;Y'K(1;>EI.IAL/E/%K/UA)D_8(@JH#6HQH/O++5GL,9TQ(^\Q?0EE=UV"
MC#DTY<3U?!&V4M,L$_" /[06R#(&2'#R7[[8J=V[(CIH%JWH@\;D%T07:O]
M&,GC;'TG4:GSGCZM[JEA2;N@GJ[76)TV2=?=0_VBR&9GQ(=03;/SP_8,#A*2
M^.]$BZ6"C+6E11PVV,O2+Q^D<6X 2?"BAM$\OI-TQ>KOFD2^,_(3I<.P&MY*
M6V0S($Y^#0(B(XUX^HQ_:W+]G=,4R@J)=I8"H ]!A]^ /(4N43RGMX_K9W*T
MH>$ Y6T\3=N9/<2W@;[-IR"55 N8C@=>.V">;G!V1R!YEZ6/Q3V%,4A,?3"K
M.8A/0N4L\!<1I+ATCU<CVOX2\3DH-\'3>4C.>]9UC$I'\WJRA@=D%FI/ZSU4
M#<,$!3IR-FAQ]Z99<%B.PI LFE^F>1'$?XVVNB;L)1/**31'F4Y"9%:W*SL,
M$V2XR#F@QMI'L$S4=V[(RD9EC@X"Z[HK0JK2VAHL@%-\];UT9>F]>TMHEZO
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MV_F5T,RPV5R17P"2.#\]2672-1_K/-K"[0//T("Y=]PO('M'BH#Y:(=OL<S
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MR7!UI+X([>@?&A2E@ 26_RW P18T9<20A>=8S.Q=? GM8'/'@)QX])7" AJ
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MJW9:GPH^/1KZ0.SY@N$RUH0:<T+9]9LMPIU'F -"EP"K%<4!+]<"9LOVH].
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MK%7'[7<@LL6.9!7;C2M'P N -,6LZK!T.,^2O$!?$\4E\)@N:(N0\H\N1;;
MO5=W$-,E6P]/9N$D?;*#Q5GH!VQ)E*W,"?G^Y.5C['_6G?&H1Y)2%& *NTZQ
M*Z0LQU7,?DK3\#YJ"AEK,G1$/ \<]8E41'I%9L %YSI94DT6%-V=D-A0?J=
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M_M31DD!6S&V-73E@:]F%%&2_7]*8=F(Z]F".,?/A2%PBU>S1 KS_U&,:4JI
M(\? AG&HR#()Y?-N:W/7UN\1M>,;EELDP#^HB1RJWJ[#?N+QPO0U&?%)7?/H
MV"DZZ>">KR#:8=EM869B%1Z^YZ/8$J54B38T?3\$B]NX?L!"0:DT!-ODW>.4
M7H;KOAV&E:Q=.>KP"^9G$;92[F&=,\H<+^K6D/3XTV(-13 .RA *L;!+-5OW
M>TVFO>\M<:(Y!;PF7'? 1PSK .ZLTHSL4(@&-&K>H"Y;%"^\C-H"Z!5U&[;^
MQ^6%^=:A0*S#%66WB&AXBD$MGQ)VG@3.QH[&8*TB.@-&Y[WP>2H-=!@'K3RO
MP&J_U#HF/&3613V7_=&,HV'[>'R11C\,)5#G;JH,$"&E018G10D321'"<WF<
MWJ8AF MBA0Z)JTL+,4=>G;+P:'!'Z#)N<Q4W/XO&DNE*[NA.T' .7PCN0[V?
M=].>$5NS93LACXTDG;/9VB\>>;\+8O'^/=R5#-.BJ*+7H5^;P @<0B!$IWS
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MY5X\F@O>MO;2H_D#1I?Q[D()RJYNT?5<&\PN7,8M(! AO;+4%T$]JNG \?2
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MBU;'FU1L,*D.U84Y/QQQ@NX-G_"__3]02P,$%     @ &8@,53UE-06'G0$
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MW:56$SCO@-BP*' M[_L]3%G@_6\E0X6!#Z^U%26!BY+ &RZH* EL%26!BY+
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MIOAY9/,LW#U3VT<RFM<R,@^(^25_B-'\S'G8XQ&7FYNQ[JH5,N06GDQY_/3
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MB04 -(Y><*I171:ZOH.0SBGAW5C:K?W"Z;8\O!!>*"AK51*4OP<%^+!RG(&
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M8[4%2J.<E3J5*9<&ZH5<RMS@LV^&*"^#6AS5;0L<($*%BW627^%=B"EI0Z7
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MY*A7/WW]Z^7#)?U>^_0>^YGU? -$H#^AG#G^8MB^H%C;>K;)%1!/$Y9>HPD
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MX E>[%H#&W2:$ONBCQS= #Q>3B>.#XB\?IY.O!*[<1"Y\/-/^.DZ.C=+[&_
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MDH-SK\Z/LID6ULQ9#!)0%0#D6":(G/N"WO7!"RYO$/$\X+F6F\6+B8VAMMZ
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M>[)TV(!2^&I\=,92\X)M+JFEDC2P$U'T'+QEP3S;$]Q.N)W7GJW0G*W;TQ[
M!F).GH>P%J"_ZPT9V*1:.2-VGDQF49Y6<W1)CK #VKK0BO1LLN0XA.>HO]QQ
MB93S: )KD13)*N#O,72!=9V(U.))ZEB?K+-;O>&^:YU)$54$(K W<!19K I
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M=X<=Z:9]N8D.4)H^R:*EC;G9:8#7)*T5'589!$T?S&%-]2;V-+:P9%/^!.\
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M3^?O3Z.)=FR2EI-F3A^EI=1T4TP8<_EX+\B\N^FDU2:-OYB0>A+HDDZ;FJ:
M/9'8:7)CV1=H^686,,]S6*8)>QW?Y<4-M5 F".OQ!%_S_N.?Z35##B;>2_2\
M*'4%;[ S,Q #!9@!!/A(-8+;DW4AX?UJ#U FTYX0V>/ S?-?J..I3!9M'\RV
MVS+1N&B422PJRR7^> UGF-LJZ'#@+[3L,NI87H!=B11/G(0%#I&))<J@]#8?
MAB=NQKVMRT.;*MZ?$WUTMYJ!M-'^"(7*N.AW2YHASE+D:2:+>%*S$UG?A$^
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M#</7IS\<OQ;K^?35V4\_7'R.==JJ/1\QII^*_!ZUTXZK:E.\4L\W_^P<#SG
M&GY_?'+Y]OQ^S\UG6Z5'G#),YL-9'B!9:OF[\VC/%YR;N2P: X<V[%NHZYY,
MF\S4"K4U6CGHHG7G!YWB?1ZQGB2+^<X"DY 4F*S-_VTB,LV!+=:RUUKP6I9@
MM+OSO\/P>[_ _41Z&''I*R\U+!''@Y1BGSC#)FI7=W=L,D65<')5 Y^!C=S8
M(3+)V43<.%Q>E8;%O ;P:[CWHG$A171QZ^_M?O?&&OS6@?!*'C;.N6-,/]<3
MF3I;#6!^=>_CF7/GWW]K_?O\A=%WFKKE50P/_V3%\/ 4?!=:FG#=(IN2*)GR
MZM?1.Q#)Z=(/=%VB&"1UB;76.N$,#5:P_T%&R'Z5U2#'(/#F?*519KPP46"&
MF8/_0BL$^+M:D'48B'S)<=[!]>1*N8\3N$M,Z)&W+LKD,ILEZHI$S!$;&_XY
M;;$=IGR7HY:ED-Y9JGZ=/GZ4QB[TNLKJP]XV*3G:XOGCMM5_9),LF'H$+)KP
M6T5957"T$M#YM&P]V0YXWV.UDPT!.#V$85RP/W();_8Y#I4*M <_KL=Z3RH,
M07SA)J3J7PV\G)8^UI.3?!]%KBPF> E:,KHEG3FQ>A:90LFH;FO(LM752P<Z
ME=^84(CW-3]_66I!Y22%2[@#<)D##&'O[S*Y3I,;12=DV1_OM!: 2$O.J2X3
MZBOCDYUP].][YW 6<@<-=T_]&UTSLGND>.7"!'#1&Y+3 D2AU;NE@8^OD^]Z
MUP](-CKB]2R=I^*@'W1JPCS<H_@!PZ(6&E>Z31=8IOSJ?[[:_8K_32],S+\_
M>HPW:5S/\.CN-U_!.?7WNOSX1NAFKP&?,+-3%XNOU--5QW^X3P?/%^_O<8+K
M^,]W<>]@\?XS;(P7SXY>?**.WW-?2>BB:YPC85$U.U4-<:;J')]Q#H(*7*?F
M\NKM8C->)0LA"H=90$^V)H'^4V[*EOV\LF&3=\"#[NKF;*F_[)(\.%G'HLRP
MWG*Z),IIBN\";.]+L=NKE!/W.>QI2@5)410%][@"FIQ=+1PJ@OWFUCM-.XCJ
MAN[@K:1Y)%W=G"WUEUV2AR,4SZ;<-?:WI1E[P,9,SNC9ENHJS*]<%9DQ2EF8
M@A-6]$E-,\X25KB5E"/MEIR"H<S-*.0$L#7NQI(K2+&)ZUFF&[J[MU+HD71U
M<[;47W9)'H[ ]"SF67HU8Z0GBM)#MFG>7-6P#Q&NRC-J<[SSTO+879R=GI\?
M:]H*H\:%2$>25D(G456*,B.BJ;/GTEX\@<J]*20<X<O99#HMRKJRK3NV);1)
MQGGD-2Q\3HD4,UJI4KBAAV4KU!Y)5S=G2_UEE^3AR-^W3<E]\\C)M ![-V)M
M$-$FV8(%\BR)LGH6)HLT3N;II/(S!#C'.RO& '>__??9JYW1BY"ZS0]NZ(;=
M"I9'TM7-V5)_V25Y.#+0]V1"MR,))>69:TU08Q9'C5VK$2XUKJIH*FQ8+O^,
M \DYDJYCCP)[U:G)Q0-BAFC5<()&&7>B3N>&7ZNBSP$$AA)=/9IJ*%A]OV\*
MY('^:FI[JLM@ A*L6.@JU.&0T'RFAIKK^U?'5C\=<$?2*;MO-_14;:7?(^GJ
MYFRIO^R2/!Q!;9353D%$-LJ-O]43WJ3")K^!HC>S>BN]-9$0/$1WW97JGIPT
M'$;"[K/@^#Q+UCC)HB5WH\>V#TT2K83OM<3BAN[XK62ZCZYNY>4CWR@/1U[^
M7": "N91N12E[DRXS*4JK*+]:1/LH$"*@>:S+Y-A2*Q2=D2M"=)'>5XT'-(G
MX=F,L[2:R4NLP(*P#?\+P>SJ<LU)7>5N@,LCD?*3$:FB7,$ENB8!+EP-@ 64
MEL.*"] T<2JQKFL,U2C6'@N$EU?A7+,6J]EAGD,$3M1M]&#8?\"^9<CAIRUQ
M\H"2Y+[ZR*3LO6U2]DI2]O[N-BG[2YZ!+6AXDR[F!PH:_F-RYO."YW]D-SPR
M)7B4=_V_++E**TU(*"%DYJ9DBY"[<JZ= /! ;))PKI<A@^5:[LK8SK& Q2PJ
MY]$D:7A??U1'K%-M$:6FBE[X)H$'#2ROY4!2T6[2*AGX"733)&8*6;7$/&(N
MYI*=_;%I41X9T2:ZG*X:%K'<KFVJ0_&Z*9B;BX)R7JHZ]) M^%$]:7$C^G).
M-O/&[\M5^;RU83; +GA(-HPZY\N$<UF1V57&P@F85(J68\]-C[$R#,]8&%1)
MYS6E-55@B227D91 .EQ3:V:8J7[%-38;O&:@(7/4GH3[GF.B<1+%,)\J"]=;
M2@ZYYQWR*Y$.UF!4%"?8YU."/)3&K5M))J7?<[6A_H('Y,+9=G7K@MKH)7EP
MXMM1# B\CTOC(2GD*E/AO /AC$($>8/,V@;%"X7+D]5,$77)CA7Q/;S5<=D@
ML9G++:)*0KY$=G'9<+:)!#7%_^/Q37<BI^NZ,G!T".L>J5P5OZM("@6X)!7E
MEA"LXVW\$KZJN$[]>T1>JJV%ODERZX%:Z)\M[MB#IF /-Q/Y@..W2DO>T& >
M<C"Y4HQ($1^@N$U4>W4^ZQD9JD;Q[,%Z#$P 4C B_%R/IC@09@"KP=HLXD6!
MBJTIGK#,^Q!0/F=+CB)QJ9 S5^JIW.J2F[\Y'W17-V=+_667Y &*X8CK3]MB
M26EE<D<L=XH2C%T7V752:?['>_@[57.<JF5/8J[J%%;:J%VYE1Z/I*N;LZ7^
MLDOR< 3=Y4RL9N:'G))R^'M4QD7CJ.=;>19E%*=%).ACR+9Q6F3%%:N0K>>%
M>BNIDJB<S/C)O@2W=(Y*920S19"*]0[YF3+'%]>&@O7>B*D*_=< -80/D!Y4
M_B_X+2=9E*+@1)ER_2F!B)!9K-27\[3208J?UG9X0P_/5L@]DJYNSI;ZRR[)
MPY'''TA2AEQ]ERQ!CEH5>9YD YN@'"=SK;H3UEQ9U+@%24C7R6260U1SL@CU
MFBQYI\I"YB8U"JHFWYF$#"U3U(Y=H<6HYE@5)*SX#R&Z\2]M[#?2=:4XD-?'
M_CA4*RB60F^>"_"9.R%U?I*VRU+0UE?+#3U@6T'X2+JZ.5OJ+[LD#T=FGWCZ
M*Y/@5GZ\!W\5'#$KGV?YI"@7A41:6(2^7&;1C:BXKQ+Z$7*7_D>(7M.:L<Q,
MU9Y.X$OEK#\/9< <$-&$P_ZDZ\KUP>HR>&*9>)PK4G6:\;@J!DB_RR'UN2(?
MO5-&>15-M%Y=:0O3574Q>3<KLI@DN_*UVPK53+2^F4=H*^H>25<W9TO]99?D
MX4AEX\(U+@*4&JA3 )I8EH'CT=57 -NCX+)(O)($CD4>&Q>OAN.C]ZS^<OT,
M6_]<&;+[O;KW$3-_S%3U]W"NQO] $8$J.'=%[U'(_J6:%(]BC ^V_[0Z?T]-
M 8'[X+$>AE+5X[Y++7%1A<\T76;1[WE<7[*6Q,I6&*=%&_1O-X=44;*%"IQ,
MGZ45( M<ZD$)-SQ*#<8Q).(OZ6P>[+? 4G2X/8>OM3:= 6ET=MRO2K7)]26@
M'GLE%ZP"#E3&M&3P [!J /F6*8 0S'V41&6VE*$',E"IT!"6T2*-\3SBC>SF
M1@:5X(]O$@,WCN(8Z1/JZ9:O^]Z60=NKPKVM&A2#NN>Z<9_GF#P:J?C%&:^'
M7T;*;&7F'Y"97#2K+*9I;7.;V_O'VSNH8*8UJ'LVSS \9O?%/YL\"?=WN>[9
MWD ]%)UR:.S<G478;(%7XCV,$Y)S:8UFOMY[]GSX+*3!969G?KUW>#@\,K\:
M(%:X$%:C3 2V+4(?V;W)38WVAB_:+8UVA_OV-R3-N2Q;E;X/YS1/LTK+N/4,
M17J_\F5)MVBQ(R-G@J\5FM7:[Q%77?-8E+VH9[ FZCEH-6M22KJY[][+'O*7
MB9SYLAE@V[U+K!L^IKN.[1),PB1:B-$#;'(@=<PGM-?&? 5&2*O3(DJ1Y+;9
M6Q' PC89J=1>,T1.K5N3KTJ5%K_D?/E>U(Q4I#\F697<X,O#\/NFA/D$_],
MBW-;;XP/JD5]9;[*%8B6MC/MG!H_8R5N,ZI(7EW>R:<+-)QB;T'Z"&\%FMR>
M$GMKT=+W=V-^A##QDJV_F#S[J!S^_6T._VH._VB;P[\9-^KC4"#/IL&7KP[
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M-C#%-A]FV!M\6*VL,ZY8Y%: /=0@(R!OVQK]$EPXI]3HQ;^B.,B02%F^B5\
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M)L*2N(WA^;=??#$A6IKPH24%U!\;]HXX*903)[?F^=1H39!]G=ZE?/HBY2/
M(J?:59O;D<Y:;+97JU9SCMK/>J.U1(*4!C@":("'\M=*5E,[B@>4=CG/('\Z
M@Z_SI]/ODJG24K7@5HI$FEMXA(QZI9A"FN<UF<\=,D$<"$$""*SH5.Q193M@
M$PGTG7S754CCZ0:)"IIN;];27%*!Z6A9P2YBCJA8U$EIIBJQQ]Q1FB[YG?2B
M%'OOG(<9QI#U',V<:?HNIN0")EPZV#*R-%F,6@"1@:E$*UR,N2I]L49]L2I8
M$\W%L24)3:NK/KZM"*"WD$_<R+1A1>Q!BN63AR)",;K=MY ?"5A:L'0R=MLA
MI&7P'B0]DQW&<NR[?5Q9BC$9O7>6R@)!/$Q%)Q!#[.^:91P#W.[)6$E#HDY[
M;4[&Z^!"(7=51BA;F4C7W]:M+,3@D,:^D[*\.PLE#)UDBPSH*X6"B#99ZP0=
M338"U2@6L&6J4 C@BN9-=W@7I'?NUU)8]++E6>#='DY.&/F!'F0VP3PK18EB
MTX4J19:)?/A&_+ND-=(YM(-;B6QLZ:U,Q)YR- V @A/5LMW2>($_T(+.,/K4
M]V56?0"PE3,6O6&1B7'5E UYP7,:)J?E#=O/<[NBC/^!@KG<WR<ISK(4X)A<
M5*6UR,_+Z6YL0:V4P79_T:8''HY2W_USO&O2QS_K0'S^&8$!GCSZYL7/SX"[
M?_+XF\^K-PPBO3BF/;8<!*%_B-%O/XH+] <$'4D!V]Z0_4N'2-*E :5%Z>[:
M%&),&JH[Q>@4*261NIYB'LG!W3(WT-H%(>R>3\M]_%LLS!A17 @06G;,18C%
M$BC2!1Q&&^?0?/C*ZMC15R_Y9P#.2M@6LNI?<.8QC.*PN)G"5%<<JB/N&+;*
M+&!>20S<5'E[.XR&,-"P&@& 6 5.>=B6Z:LVWH=Q%$?B-WS;$F2?K!V+L+B8
M0G>@U9TY"_'WX\T6EAUJWPD83>>$_-9%6.E#0ZP'"?<HQ2B_E0FL2:,2EUJ2
M"W"Y]G0Y-L>Q95&'U'.R0":.+ZK(AE+X,!!JF\@FDIY!PSYJ_H:+&6$=BC D
M?42?S66 2C"K6 C.VOX7460ED?31>V45=1"47/4I4O'PZE/2AW'A'^D.GLW.
M-H-UMZ03]G1#W@#*K--Q00S>GV1B]:=1R+JW/8"L0R@0FTU+Y@U;X45I+;2"
MF9R_;*@V?F BIID[DHEX&@Z1B@F&H4MBFI.<?E4RJWO [VE@E $]# S;/]3+
MUT.AE&_[[EX3$"" FM=LM.MW/&AXF!2,;X8Z#8G.6;*FDU9(QJJ\HN*^)DE,
MDHY)YRMKL/6A8GU&/^\W4B2<UF%[#ZC>*E+"@/!\3'F[.:956^#9FK6D3JQ+
MF7CCLF?L7Z[DUYGJHY7^Q15ECXG!@T WZ5\4&%[!'SGNDXFZHD3/SSQYHPEF
MO7&0!7I@EO[C-]\$4K<3M]L].3#M[?_]OQ[]+_P\)#VH/[_SD.Z;U6%#ES[Z
M/RV"AE+*_1#_8Z'_^E^C-DAOU=Q('OT0![]^[$QC'[O[R?NA\']CIZ%_\0BP
MAZ1Q, SR=.:;@X\BGC?UIGJK17G79?B?OOXW'??')"]$"%\AA:&9YC.R0]X8
MW.<C!UK2Z4;X'"-7X<LC,6!5!JM!,(@8(M!4%18A_WK=2$5B/L@^\X":_9Y"
MH(XD SX[08S5M:)??'Z1Y8LLYQ&4^ %FX_)  *T7G/'NV-9B-#Z KRM*R%_$
MZR)>3KSJ'26F)&Z9#,0CAWS8!D0LTP+@R@!1E;F(##NXB-9%M/((?"J)$.ZW
M$*RW:4Y[D9-/24XTD,:$.8,@4>]0[^]H1&'"08KBR/EGC.)OWO7S PC1/-T>
M-@C#WT?KL$J1U>XXA&P!Y(!_M\5TV[PRXW'>MB"5H-A*-9IR#:DX B'$700N
MBDI#!>DIP89Q=ER''[L>G;"%<)\; LJ(%FB1S=G2!R-"3) LK;>%*I*R[)I_
MGZ3[P&$J5CAG_P*3I+FP*U\D;Q" 7TN!0"TK.[;H'SZBQ@ $>\F559S4KA=E
M)$J@!;==FHNV2VI"V-042PL P$<:9'U#!7 A64TKD-* D'>=:8 A6R0P4DSF
M0K0BX_-"6BTVCO-7Z@1BRS*.>M2#:V3E*40P JZ (A%;'K=UKZW;I%8K W^9
MN5BRB9TTS\* 9!Q<E#4K%6]$8R*I^]90YPF7WJ>=_'TW[-WO+]B[*?;NRPOV
M[M]F$R"EQ3%]UVC[9\8')(7@&XI__.P3^G*"_GW_[5-MH%4S8< 4PA$<A ,:
MGO(]U# D>\0.[T&@P,%3CHQ:?,T0$CQ0M?M!$'-\  K[)\<&*175>M2'OKGM
M4+'7FT K )&6%YDZ+>ICRW0=5T325G$52P&:*<$$>>$GQ>)#C*^9+S?+B:XG
M6B\ -"]M'&ZZU0D$=!@=L>[__0CS6I><^,$G!>575E .T[2B'#^)'"@\%"K!
M=2*,B,438M">LE66,!!LD!5]RW#!2%F^%U:?3O9/65S.THJ7-.@P<$98AUP"
MD"8[%ZS3RX)CVM%&W44EE/;KUA*4FZCH(= P$[7+J#XK6UV5+7"Z8D<UN8Z?
MP'=<#3"]J2[HK5:B:P'R)<J7>O'L+T^%&"5?0.6^0C2R8@$S/A(2$;I%Q00T
MR\.! &;;V-X>-B<N(&ZIC@A\"U:_RZ8@WH=^9:ZUJQ([PQC=2^==:D/^ZT$$
MAI($#D+#55FTIDJV>.@J]I?(^ZD\'+(: 0.36[>).YJ^4S4BHRU\1,6A/?_Q
MN<+0<,&V)HPW5?5A3",J&"EC2[-FG#;,3,[X-^X./$,6HW A60):D@8IZ /W
M0CL.D6=?ICE+JRX%F@&GR:RY,93S/@U]JRSYBF=EL*T:T"4&$SB96AH&/:C;
MLRZ85_%E-URW.[;,F1W*DL99>UY03](A=P3;=4RL]Y&=>.TV:80X\WA%!K\R
M@49XF,V#5F0=[PF,*NV,5/22(C>< MH=W#/3:QP.E;'PR$M<*X3[**L+5; !
MOHKZ1WO5P_??]H NZGPSI./6T80)L+86-YQWY&*?_G?E:#<FH8'>?S[Z.HR^
M.N#XKUGDV6]<=7' !VD/,12&Z998;NMFYYF.4/XY-&9X>%:SDE#(P=?QHLE@
MA&:(]PD=9BC^7@S)$2!/6/DE7#46"-D9CF]ZTV1(:=WG;9)/)R(!HM6Q+N'H
M0RC;:DOELG)G:ZGLN&;AV&I]AU1FY-.08YV,_%9EBU910+P#LF]:TX#F>%\P
M "YK035[Q-J9 24KT%>J6X;7TA !P3"I#D!L[ ;,#:AE45QY2^>F3UA7&F<+
MO@?,J!P#K:5N)7@C8*'"QM%N =AZC<9!A@9E$&E13LKG8[BGLXHNC!3<O!+6
MA9SV1Y^NH_#,9B4C9"W)@NE>"WR*;_%HTZ EUVE43M]PEM^=BX,>>FFNCSP$
MA 2(D\C32/@F-DK-P- W-B+2$S8$8J/RU$ULS40*;G2SBAYV1II_;Q-F:BV9
MS9(C<8[MOAKA1\M0U+(>-F%-E 5:??T0:6UE>6Q7VD 8/0.[\XW8=NDY3,N!
MW\GCC;:@A/J3F 0^#_^)<_ -K%9O?0Y2V#+(.<B;]CG3-ML6-RGUO)7*9F6'
M1=(EI#^FCP?FKVPW,#EN''G?+!^44F!C_C]2O>\XY8R[P6W-E<RFK7HHW="T
M;]54Y7W*(?SVY%:$HP'C6D9X:V57OVGY$-DP<Z0/@0-G7AJ5+CSWUYF13V,O
M2W/0J!AX)P:P='+>+J&'G)3P+4!KOV*!O#'7L$))&\P;3XH'^37+8*7C_T :
M8G&*=9_7@TO)5E)5-J;V,$"ONF $#X-PWC1 49.[,LOYYBA@2DQ0IOQ3"OA-
MK.\:+N\;F:%N1-5(6&;;=P3+=4R\'(L-&,6G?Q[);D%S-^:>RWTEBMN:[)&S
M+M62PRH<(F9NY,M69I17[F.(CL_Q1E9*I6&A!%V//.MS>XS)5G7+,U-7%5QN
M*CONYR-6#Q[7LW:+2[QFJX4R4&PQ498UF0_@U\^+#TL"\9.#M@R5N-6[Z979
M$:51-%OV]Z9K'3XCZZ9>;CXG.GO<[4(G:1F5'TSSP8?[[LR;9UEQ:#I4H5^=
MXH%M67QFCNL0=9A^IEM BK6A+Z^U4?"2+*29JA00F&$*I&Y@:\<:F.@Q3;IZ
MB%':O=(D5A*)Z"4 )P'*X#X!M:IQ+^?YCMK5WWAV9#D"I,/*GD#]/1\?_*G\
MG?^Z8_O]JNK_5@;O#Y<,WC2#]]4E@_=AB/;;6"$O9A0L_+M 2E7.B?3B/85U
MZF4\PD&"-GCXM.)>,WST/']J\,V77 WY _-EOI*J_*?I7HW\OOSAU5.K0 YE
M?+6!'[P7B]BXTUR^A/UW4)1E@[J=H^F%?@05G3M"Y_(XC-_9=ESD7Q^.>BH6
MKQRE<7*>8\ZAS;68F5^22Z\03>0 H)401!M0D %A,%618#HW,FU_-1@)B!B/
MC!R9<1**.DT?_M'/TX9:P=D6ZC<P75PW:\N8>TZF0%S-'^ZYT1&3K\G K6W]
M^ZH!>[<=>ZD+^[B1HV(=B:WN:3^L-RRU%A]$V]1MLW.4( VZ/*7ER[O;IZIN
MNV[EG[,';0-YZ:H3__27ET.1#LO&=]%NUPQ#%'92-UIL<_=L'IGKZEP\R;3&
M!5]_P4WG$>1PO<NT GK:+EX8.P_'Y^FIW](98(PB__EM)A01;YU]#F K<X!+
MCA"N21Z'^6?/"CY0DB*_B.M%7/,(1HE9:[C"X*GM]DK0!H2'."MM#RGL)-)>
M65:+/SU_*21/Y-F[;-6L<B:>+6&\)-HPC,#(K,08-1,QF;Q"+N] ZE79F>3-
M\ 9.%\W89'.0A_G=]*^H;_@(#:HO_[C_]9^VIYY\>?;FCVF#GC]/+(*6$10Y
MV8IP540GX#/F#^CQ!&[OB=%Y<U2+/>#ZO%-1;3C% &G?*/'.X!C*)32V&Y0/
M&5?M,#8')2X\QP)W.:0NAY3; XI/(ZN\="_2&V@_-"U'.A2>$T>XN?0OP9CU
M^F_DW!'\I<MGU'VC^5]*A#,#(C>)*6,/RS_]^%(\F2%7K\ /MQ=5:2\>-MUJ
M5.2%J(J>N%Q@1R0\YT9D9RH3&]#F' X]T'85,4UME=^+M^YE#UWVD#/TK& <
M&:#D;)NN;KNV8.8\S6ADY<@DV58<,8?E *2AIGV,BW4'P*6H^"*$Y0@X3@XN
M38G,2-H7L)@6V.<L/[]Q[? 'FX=XQLY_-I].#V(0:'/"<5+FQLD%2',-\L>I
M?09V\.O%R]&?C'[,Q\PB-1%@5R_ W)-W94#[H?NU6>I)15Z:MFSR^/!14#"?
MOABCJ3+GR&D?K[&-ZM"YO["=RR4&Z]G/'3C>XHF?)9]0Y DX;^",Z4PH1.%'
MH30?*5!J:M/U 2^0[/"!<1)J',^.B&;L%K24/)[2L"D<W3JYT:>#PX3"P[ZK
MFRU[B!XP2GC$9#"0(C]*RKK.WJ]=JCS7E?<^Z@%%(#KDY.)?+UY1@&I.>HI^
M+(".<&6'W!F8UI%A 3QQ%#*HCX>./HL1AAS_&EP [(M'Z2M.@SP+X(:TBW*2
MI5H<VZT*#-1.W0Q<C<Z$H^GS ?R3O,]M#8Q.*&( XU ';"OBZALR9SSY-W6^
M<M-MF:D/0;AT6'[QZ"H-E#-&7%,.R"P0#35ZZ50Z%2HBR*'IN"$NE%S:*O#Q
M>+#B(_L:B0<>IF)'N 3$_3(LV?I*20.L8O #?]"#"D7 >/@F>3,I<);(,QSP
MLE7]_ /$;-8T<*_ZU3RRP<ULH,%5^E#%8Q(%ZVX7U1@G#EDV;P#4^4>&_J4'
MMUQ7),G6" 9)N2[3Y:>[1Y"M7)T.6%0? ];5^>42W$T+*&@CWX$<PY%\W&1N
M %RY1?=42$LE<:]N$#>"2]"WU-=%8%AH9H5O"%38QKLAO;M2;QSH90P$51U]
MH\\:C@/S!?/74Q.]R')XH2/'$)Y/(IM(JB+#7Z_2A#7 HSHG\Z&T/BTN1R-/
MU'>(N$'ID"5(;RT\33GOGXQG2N^K.,&96S?(^WI"_Y SOM:9G(M=A*P.<DS5
M"_;DXO#)7<S9!;U>C+^Y[NV,5#G+O0Z2C7;@@JLJG&.<[A &H@[@UOIK5-RV
MZ@:T5C?FD\J"1T/<BA?/Z,UTJ&)*EGT#F+IO#M#7R:=.,QH8_84NHH[7VQXI
MX2Q'^9=L=?3LZH];=6G$=:_'VM,8*.@>+B*P9I_*!@%RE3!L4(\ NI'KQ7<U
M@RHP;SG8G;;ORJ)O&M[&)0HMRPBY-YRWXX63!X2\>*CHY-E@ ,$X3#\N _06
M#NEE7B>ZZD_/7Q;VSI@KW/T-\QEJUH.C,+TTE!"C)7)U3;K']28A-.)X$71N
MV'.0+S,8_@W9?T4WC*;@[A=_XX:X^^%HO/CY645'& D),#7T%7BONS&3C,^<
MJ2H5-M=4.4K/1;4I"N6$KE?3%V)9)/-VK0#!GKJ[\";IE<>MH>XQRN!&D\/M
M-Z"D&R%<5I)RGG@0"H"G.6G+9G4D4; G'=A"+#XAN(U.*FV'TP\SVM,4U\2>
MR829W/E0(L^$?,$S@7ILX[HYB)U+WPUS0I9$02C]+F.E6Q->7?L@:U\B*ZD6
M2RIK9P3!8LS4=H.[;Z1YV";CC:0-T;.6B/*D?AL/=3S_X\<!&QL,S'F]^&$V
MP47S<CCMQ13-^PL32Q0$@DK"(F[ /<_?E&P4PIQOZ[V JM.K;HC]^8++N>!R
MWG_PY27)YN(Q;]KY>'<2_$,C@+*#Q+[IG]F2X0QLF7A-!HJ40_%A"P<'^ZUF
M3,W OJ&2%4#QWD7V&I*=$Z^8SQRM' GL'[G#*-"+/!PJI2O<>L''';K.E_(C
MMH#,%O5:D:HV-MQB/V^05:*5\.'R>>JZDHY)_F5;;GK]^)GP5!F<FNQMV[%O
M8>ZZ:]\-9_W'"\YZBK/^_<>,LWX+L?KWT^VSQYE7^.\:27=W/^'RA8].MS]Y
M2+=+9%9< :N)U8YT^VY_S-:>4*>#HF% D6))?E>P6,,(K22!2<\ENH.MQ8*C
M<N2<Y1&Q"MH#F<XT*CT$^("A@CP.643R'ID:>1M!2)A,^OT!P6+Y"PK&V'49
MEIOD86[C^TLD?$P[\&)=O?L._&(^HH(XRJ%^'5MN#<5]QVU_L.2Z%@2Z62I%
MWE1^O]'^;:D\H08*;68'(TG+34'%#$H;BCHC3#NE(J\+O3&,'23M)B1HMPF,
M#DR@Y.BG_<^A3+B%"\3(QOM<"DO@_Z.QML >;NJA89M0K]2RT$OZ;WX(+XG%
M(M-@C$AS AG;![RYC^M('&2</ENPA'XYI=D16]I%CI!449MX"B][2%PD#A=N
M.49FZ$Y'R6IL90>R^K7(VJ*B$K#(<I?V2KU'-94KZ*\<#UF2;Q*@;=?>7M$Y
MH1N%"V&NCOM//K3]U%)N)7QJ'!4"KG!J/U2C$G%%'VK8ABNX<CVLHS/*TG,V
M9FZD;9P;U:QR@1IDU5!4P1>5&N,Z$NW7I3+N6:NENCXG4J/U\Y+JX5 JKRJG
M!(U(RA>(;Y,F1]S1WE$FVY@>:X7MB*:E73_*'W&Z%N7=6VYC0\*=UN6^;KC%
M(#W/ R;'C$C1:LWF*]4<1R&7/'-BD"B^$?Q&6-B@:S1R(:19QOTA**03W"J-
M3D#F^P%A7I5Y.FQT&BK%%# :M%8Z0ZA^UX/Q>B'(!KX;+Z&W9@X=/$VP?B.(
M71FP=7:O6^957I:<("MHS_@N21TWAVQW#GENB@1\R-,//(,;#\[.6;A@B1W
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M$^_V-3KJ.5J1)- _/J_FVB\671>_NXMM:$:XEUP>Z-;$OE]YI;2ARTQ?1%>
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MD-)D'TX^N9.AS4$3_DD/$G,@F6/H.H)Z)& ;7D?X$/C-QWN$OV-%Z>L(" @
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M<W-D(IP7<^TF9"M8U0:%$$\JD;POEC7U)&&4C)]X5'ORY#9#?NE!"!9-LK)
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M;V78,P$[7KFSCG"'=/$:59[.A%9Q <N WHZR?)\&\B\_^*>1T)"=2VBYY@
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MQT3C_\87OUNB[\M+HF^:Z'MR2?1]. +_8,KOQ1IJJ04B,#)#"=6,0F\P(D%
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M&-)<;4:5>.%0EKY"8*2O5Y'II68^D/"05VR?;+BK;/5Y6 1_!'W/4.ER2Z@
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M3">3C) A%JS<01928RZ5IEDH%_;DT3?Y&;K"%?[R^!MNJI[L8)T-QPK#F4G
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M?LI[EMV3Q0M+5+WL>J7)P)9ZND3-COY*TDN/O_[Z]]@//[QX^?0IX'\*6M+
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MAGY7(UU1E2F,43W# R#!$2S0%9"NCTC#S+&:_1. P!*,Z-@#,G_8N*DN#64
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M+ *C#"?QW"]D%&U^V9U3Y+\YY>BUTH20ZSF2!1:?N<#B";JV/'7+&.;-&X\
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MQI=1FL3PH@  U"4+;$RB2KN %$*,=G,P3-0A(*N(PKI47Z!>-.X.R+16%F@
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MA >,7.I!A=<4T=+#GA/'DQLU9!1K'ER[7=I>NJE*I0?8CLJ-[,.Y9>7F[.D
M<&A=Y2LG<+FQF4.R(#]7P]^[!]_) %FS5T<;T$Y01[>B;YAG29/IFM,MX3 2
MH4Y@R-ZG"5&()O=53R>SE"':CW]++H XB+L2S"&F;W395=4:?E66C0E94"/1
MZ):&ULJ.AQ:W^F!3F!)^XO%-'$0,>I^NWC8)"(%*"S>'_0N!MVOE>EK7DTU,
M><_&P*+=X=HW)B6&^B)JBJQN,X(C:\\3CE!7YQ;@$@0Q&(:FH1Y6S(=QE)2C
M<5=]Y7!<31 J>(B7.V%.4[JKR\[H,<;-8,NYZFE<))SY%A(U-+;:V#AH+B.5
MTBY=K)**L'1+78"C04!T(THZH\Y7@#51@!S6!=TA+G;@O!=Y3^9*"9EU*2Z\
MSFYL-%H.UU<8ZU/!A8G(\"F1=AX61&BCQ]"")&W8"*+',)4WXG7Y\V3Q#&#Z
M(?17U&SI/I79$"X:OK]W\NO1_NO&&Q_BO! T6///X// ?4 ?*:0D3/UE%%M&
M/)*N$-<*JR^=$"6QH6B7Q/)U0=\$$@J>(K;"5BX0[B@;<FR(K'F[FL8C1$HM
M2#3V@;;A(B3?G.H[U??':8S8Q)39>Y51&3MY9TC; 4\7M6M@.IO20CAH 4,G
MIASR8=!)$^79Q0DT 8?@#9:^(L,G,0+>Q('ZD_-LO6R:R42'<NV\T<&US9[L
M'ZX";<HPF00H54\D?DP^7?NM\ #=W]&E A/QW1#NYX@<;%D^7]TT5W>/KHPC
M%PJ-9<+0I<^P%WTU0QQDMORJ-Z,<$Y6&<\X3#Q @+T&&7@]@-EAGK&ZDH6!<
MT>P4?*^@!XB& I:;X8JJ5[$-/DFT&+J*BU6CTZX\!?1'0KNVNGEMS8V :[*Z
M$AM;V'4T@2O%-1\!:L!,\S7"6!_^O58EVL#2A%^.XAZ%"":)LV?%F>77KY1?
M--Y<>9]P[HUTWZX).>]'FM"3F Y1!2M_/8C40>]BWUHEA$'65P9^<O62K+!9
MH"BW5RC*,HIR<X6B7/)#("Q9-ET)7$'69.:QP26N-X)L]Y3VYAN3<!-4PWN!
M^I8O&2*04/H<(D3DO$+#AM?6/9%)<P-<J=F;4B0VU*7G9G6A_H]N/2RN&T1?
MD5LL\3O(&2;SPIHUCFUO!*B@X51$GY3M7_-(4.)$3:'?WR.XB,U$ Z-QJG/^
M!N8AH59(D3X@9%[T%]Z[LJ$T\;):-CX*%D ^.*Q*!=LD9S9N0S5OX'\XWN6D
M-""L9%!-[<]%$'-HC;+B;-(BEHQLPX)-!>NJ+AW'?%[S/UK:"MY5=:&YB!O/
MXFNN0@/0T84"\, *%Y5NO#+CFPV#F8Q-C8A)D,(.5Q%32Z,T@?)Y<DD"?Y
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M\J3SE0A3LO_ZVTZSL?W. W+/-.M'(U'OS@J=T=$K=2YB#:6DHK:),H_D0#"
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MYA_\^^>C#T?*GGF,BXG$;"%4TEXRBD+C9EG2% ,A\S"-3-ES -7ZX36CKS&
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M@0X<FP$?']:&66)E:8V<;33TI]SN1R$-;=VVL%_'92J1XR%(HH^!"3;1Y^0
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MWCKHUV+QGDNO-MA;3?X?Q6_!:WFPTMZR"^[VP-HGD_C2FA2Z4V"C.<V8(27
ML1?;D#+F3\",)?1UX[<P 1/%I#G TB%,T@P.B:0V3;'I2;H$P=#5FE0.TZ+8
M9%Q#&7MBYA322$M==!B;$#5B6H;OBS<4F"4]=F$>I#5=0\6(]>'@,":PRO3
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MUZ J>=DT/,'$,G3Q#C\SIB T_J[?F*ZD6='+G!9(#X"D[O1*-BXR#!?3/N=
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M8C5C8MY3B[KS>(?*'O/^FP/W2SAPGW]AE4_W5^<XL,ZY-4%_TMJG12_[YZ^
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M *=%DD\&Q1-BT^K>RYEC"?M7"AFR,&#0)NJ?,(%FO+ZSX.52_$PPMH.]U01
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M9&]DR17U8.AD)#@#.GA9KL+@^HV5=Y^5MP*>8*DFMBF.D'P[W=@J*68(*M!
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M!>/R'.H7<QDMD:L9$BZR;_\IZ1H:CCUY83'49:N;QKT;52#8--:',1R;%U,
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MPKZLBNNB;98?Q7QM-&956_][JE22@7\KF2D"ZW)N"_4(4&-=I;&E'L4BIF?
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ME.+LP7]!HEG2?")4<YYAYZAD'/=1F:1<E+-D(O(:F(,"M!D4$W.KX8-K;YA
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M+K'\FGYD=Y^/8[-9*2"?R5;Z"X\+:2DVIO' =_; >[?RP-"Y#R)_HOG4QEX
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MGAENU>:_E]Y, J9YQLF<?\-Y$MM:6P2NMDN&&\C4^2*5Y@F+*!XFV$-N'G8
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M A<L'3K>,9 U.*OQ)A]K7:0$-S8!T@1*>>X(6K6B-XT5W=**^NM9T;4)I,0
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ML= "+J3- KE?$Q!2_9=2U, $162JBEJ Y6.(H<_2>2^)&EN$;*1+18$KQ;I
M&Z(1=Q(R9B23:9RR-#Q%P:):BF,(P<'>.*D7DO5+\+9^\-NDI^XC05))4-V8
M!)'>!$J!V Z3%0D0W3'5)#Z^I]M<.QV&, -8SYE%NB)U,K6/.'5.9@;'U0ZG
M6-P,,5&=>B28D@>C1I*\8!+-S0T'LHJ@.X#A'O_(\FML%23"<NBUY[R[U7%6
M-[X3\;2&LU--@5A:'-NT<#^7%='1I-)NP0Z*>IZ[BD<:KD\TTJ<$X,7RB$+X
M[$3M$O+T0XLZ[8E*,;PL38MG9Z3.POI%_F0!/DP9"/]VZCV8*2#<$?QN1DV6
MN)'AVYA,I<,8IQQB)>!L+V G@6\1\2EB9:1$:]^XU0C/(HO/<3P%V' =4RE%
MMW^8VRU(!8Q4Q0'<XY0G\&&@WYFV#"ZDP/.Q00;#/K-5.I[.#+8:[$\N"$S-
MK-]*FATY%UQQC% 37EH.:8#RJ1DT&0YW.[>0)5PU:J9"V\KD]S@"]V[<ANB%
MG!C$*DD:FNM44$$Q/'Y)]-K<_5T2HH,N14\(37L8AT###84E&)H"EVUSNGD(
MM[IF'K'N5EOBW%HK':S6,Z_R#SM2>S(9W1F,S?[,2,3^#._EJRB3:ZUZ-%E%
M(2W'D*QY8VD/86GK9E!J&RGA0N&0,; [1:VODP0,W.?P^T<?\FM[>EFVSUIX
MZDTJ#UHFC_;7E@WQS<_]G7:]+=6'S39F^!!FN"YV4JFVM$&U!3IM2FZU 0[J
MN6AYF? CF8' :#EC=86Z=>ZSO)9#CCAMQ!HK^^K3AKG6%=?CV##="=UZVDNF
MF,:Z#Z$=:]6>BX)C*3GE4!AIL9&('3'QPABIG)."\)+P3Q-QF6F01BSN)F \
M#(8I;.)5/PMXM$&1]BELK,TP/T>^N<')4,EI5:ZY5!'C<13WS>0TZ^@AUM$M
MTEB>68(#-0=NXSGGI8G;T0H3RHI;?"N9)B)J279.;"PGO1OHA -+(,[!V"Z$
MS8V@_P?O7EV2+2$S$U8BQJ=SVV$J/8XN1=6BXP!!DY(BO\"U:B51N=41:9KP
M5N:,* ^G4PFA7LC&8A_"8M>$/P;#"^MAZ_9EXN(1 .=Q-QB#^AGO N/4?+5%
M<3!T8@GN6RRX1-]/*=LD&\PG_8+:*C@T^))FM"Z&-PLX>,O,T?Y23\Q:$=/F
MAGTD3 XCF(Z&E0C#OAG4C0\5!9^ITDS"VYO3I<9%-Z"LZ] LLRPM+P/JPK4U
M5F-LJ,IPT[;1++"'6& OOF)+@'R#,03%_>*KJCOC9/>LL+9%,DZN8B:^JQH-
MT(%D&+_#LK*-YN&>=+/:6C;CYU/9]+S<G@[R[-!<6D7Y^[1$]["YP3J%T%/&
MTEMI9D*9N3G9F/$T%OH0%OKRCA;J<>FZJH"Q O4RM5:-TZ"<H0C,*.$6J 12
MG !B%W)M.5U:(FZ2_O./!+\R$FFW02()$FFW02+]ZDBD)SNO[NC#J+DF&;K6
MF@J];LN50'"?"C/;4BCG\"7"" 3A'+)EM725PG%E)9G4SI<%V,MV7B\9F$%C
M&5\D+<NYN82+8.W%D :&X%;&E\XSA:YJ-MH'J=8^OK.58K &^'1!"&NF'Z;'
M$<DPJA;IWT 9RWSN<8/9H ^DJ/V=V:;0G.GCQY=P2NEVN]&^,6G4;#PK4-(Q
MD'^JLE2K0F*E1/?^\ 2>8'/C_?Y)8X</8H=KP@:R),4SJV>/V3*^>W PF$"R
M.#K S/=C%(VGSK7_F9M;(): #\Z.'W!S0R@'%XBZ\WR:+I8%[RW,FE93#[ZI
MEPA(-:#,NO& ^?C*:9DOKX"L S7XJD>.W!,W9O\09K]^6=>>8*I8P?!IEL5
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M[,-__ :F^IM^^=_98E^\W'GYC+)G09O=>[[S%/^^%:\G1NW9QC(KLH>)45H
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MHO95N_I.=#[-L[ +C:KOJ^:V59N6]R*D:Q+!SDX(K)1'<7CA%;S2+=YZB@0
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M>*%S ^CQXPFLYM)LHHG^&VI@L[-/;*PLG:;+!Z%R=S:]>]N+-.O](8QN371
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M8+S#F/HF3-2"W:N.2'"4HG#>.,^'YBK)U#R!V4_-?T[-$N+__)]Y#)S#)L8
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M])N8[S[6[<OU4_52A.:P#ZM393#3:$V@3]T80GD/*QG"0CZU]TW,/TIG%2=
M&J^8=1O:$X-MGBO]451KI<U)X%ZLXM7:5G&$A74V@S8%WO!!2W 3F-7 TP(Y
MCIS3QI/)/+,'T6!E<6)N(S!9'0U+D<:Y?L1,8O@\G(\7'$-##R)A><S9' 9
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MZ0.QCW* $E!E,C'6Z1N1=20M>E1MQ^0)BX1UL<@W)BB+NVASK&2"H&6C+?C
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MFF"N?24$B!;W-4YJ,'0"2$4H^U'-HD;<=@%4,/^D+T9(&EZ1^BUNW@1/3B(
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M%ICIO(/#6\H**K,NN%VLSA&847SE2X[V8#3 \+;8;$:4Q-;1"SW-V9Y$>#
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M0Q(\)2[$V[?$B3'PC!*1>:.Y5LRWY%4)<QD8BG$'#QW#PVOB[*55*?HWV/A
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M#UA,S&6A[/O#9-;?E,MKZ\[E)2ZOK<T[G]??$9YK#"P&BLEET#I*8\1\S44
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M*DN?=^& U@>TKL4%'4S"[Y]1V7AUY+$)+_*U@$--TGZ$]SN&=W!@,\B!\Q2
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M/Q5BZ(@T(WQS),NG$T#?YT*F"+OU 2(ARR 9PA0A4![2$'XI.(5^U\3T]GI
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M]PSJAF?ZOL@Y?I_95!9GCS/ZYHU.=UC]L]#N=R+]<](_4$L! A0#%     @
M&8@,5;"WAQ\H#P  %)D  !$              ( !     &%T;FTM,C R,C V
M,S N>'-D4$L! A0#%     @ &8@,58K#(XTF"0  %EL  !4
M ( !5P\  &%T;FTM,C R,C V,S!?8V%L+GAM;%!+ 0(4 Q0    ( !F(#%49
M\K0BZB8  +A! @ 5              "  ; 8  !A=&YM+3(P,C(P-C,P7V1E
M9BYX;6Q02P$"% ,4    "  9B Q5]SDPTE%B  "P-P4 %0
M@ '-/P  871N;2TR,#(R,#8S,%]L86(N>&UL4$L! A0#%     @ &8@,56OK
ME<=?)P  L6\" !4              ( !4:(  &%T;FTM,C R,C V,S!?<')E
M+GAM;%!+ 0(4 Q0    ( !F(#%4]934%AYT! $5L#  ;              "
M >/)  !F,3!Q,#8R,E]A8W1I;FEU;7!H87)M82YH=&U02P$"% ,4    "  9
MB Q5F0Q'S"?B  "P504 &P              @ &C9P( 9C$P<3 V,C)E>#$P
M+3%?86-T:6YI=6TN:'1M4$L! A0#%     @ &8@,55#SK4-&/0  ?SP! !L
M             ( ! TH# &8Q,'$P-C(R97@Q,"TR7V%C=&EN:75M+FAT;5!+
M 0(4 Q0    ( !F(#%5$*^#;HP<  *HI   ;              "  8*' P!F
M,3!Q,#8R,F5X,S$M,5]A8W1I;FEU;2YH=&U02P$"% ,4    "  9B Q5\FC4
M\KL'  "T*P  &P              @ %>CP, 9C$P<3 V,C)E>#,Q+3)?86-T
M:6YI=6TN:'1M4$L! A0#%     @ &8@,57NKI3T=!   ]!   !L
M     ( !4I<# &8Q,'$P-C(R97@S,BTQ7V%C=&EN:75M+FAT;5!+ 0(4 Q0
M   ( !F(#%4W&.0_,P0  %42   ;              "  :B; P!F,3!Q,#8R
J,F5X,S(M,E]A8W1I;FEU;2YH=&U02P4&      P # !* P  %* #

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
